Document:

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Directors and Shareholders of Elan Corporation, plc

We have audited the accompanying consolidated balance sheets of Elan
Corporation, plc and subsidiaries ("the Company") as of 3l December 2003 and
2002, and the related consolidated profit and loss accounts, statements of cash
flows, statements of changes in shareholders' funds and statements of total
recognised gains and losses for each of the years in the three year period ended
31 December 2003, all prepared in accordance with Irish generally accepted
accounting principles. These consolidated financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on the consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States) . Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of the Company as of 31
December 2003 and 2002, and the results of their operations and their cashflows
for each of the years in the three year period ended 31 December 2003 in
conformity with generally accepted accounting principles in Ireland.

Accounting principles generally accepted in Ireland vary in certain significant
respects from accounting principles generally accepted in the United States of
America. Information relating to the nature and effect of such differences is
presented in Note 33 to the consolidated financial statements. As discussed in
Note 34 to the consolidated financial statements, net income and earnings per
share data under US GAAP for the year ended 31 December 2003 have been restated.

/s/ KPMG
KPMG
Chartered Accountants
Dublin, Ireland
23 April 2004, except for Note 34, which is as of 28 October, 2004CONSENT OF INDEPENDENT ACCOUNTANTS

The Board of Directors
Elan Corporation, plc

Dear Sirs:

We consent to incorporation by reference in the Post-Effective Amendments on
Forms F-3 and S-8 to the Registration Statement on Form F-4 (No. 333-12756) of
Elan Corporation, plc, the Registration Statements on Form S-8 (Nos. 333-13996,
333-12344, 333-11940, 333-09644, 333-09284, 333-09048, 333-08384, 333-07361,
333-07136, 333-14240, 33-27506 and 333-100252) of Elan Corporation, plc, and the
Registration Statement on Form F-3 (No. 333-13130) of Elan Corporation, plc and
Athena Neurosciences Finance, LLC, of our report dated

April 23, 2004, (except for Note 34, which is as of 28 October, 2004) relating
to the consolidated balance sheets of Elan Corporation, plc as of December 31,
2003 and 2002 and the related consolidated profit and loss accounts, statements
of cash flows, statements of changes in shareholders' funds and statements of
total recognised gains and losses for each of the years in the three year period
ended December 31, 2003, all prepared in accordance with Irish generally
accepted accounting principles, which report appears in the Annual Report on
Form 20-F/A1 of Elan Corporation, plc for the fiscal year ended December 31,
2003.

/s/ KPMG

KPMG
Chartered Accountants
Dublin, Ireland

October 28, 2004--------------------------------------------------------------------------------

TABLE OF CONTENTS

Statement from the Chairman                                                  2

Statement from the President and CEO                                         3

Operating Review                                                             4

Financial Review                                                            31

Directors' Report                                                           70

Corporate Governance                                                        79

Independent Auditors' Report                                                83

Financial Statements                                                        85

    Notes Relating to Financial Statements                                  91

Selected Financial Data                                                    179

    Group Financial Record-Irish GAAP                                      179

    Group Financial Record-U.S. GAAP                                       180

Shareholders' Information                                                  181

Risk Factors                                                               186

Additional Information                                                     194

Cross Reference to Form 20-F                                               199

TERMS

In this Annual Report and Form 20-F, Elan Corporation, plc and its consolidated
subsidiaries are referred to as "Elan", "the Company", "the Group", "we", "our"
and "us".

FINANCIAL STATEMENTS

We prepare our financial statements in accordance with Irish generally accepted
accounting principles ("Irish GAAP"), which differ in certain significant
respects from U.S. generally accepted accounting principles ("U.S. GAAP"). For
a discussion of the significant differences between Irish GAAP and U.S. GAAP,
please refer to Note 33 to the Consolidated Financial Statements.

STATEMENTS OF COMPETITIVE POSITION

Except as otherwise stated, market information in this Annual Report and Form
20-F regarding the position of Elan's business or products relative to its or
their competition is based upon published statistical data obtained from IMS
Health Incorporated ("IMS Health" or "IMS") (noted as "1" in text. Source: IMS
Health, Copyright 2003. All Rights Reserved) and Verispan, L.L.C. ("Verispan")
(noted as "2" in text. Source (Trade Mark)  Prescription Audit (SPA) January
2003 to December 2003). IMS Health and Verispan are leading suppliers of
statistical data to the pharmaceutical industry. Except as otherwise stated,
this market share and industry data from IMS Health and Verispan has been
derived by comparing Elan's sales revenue to competitors' and total market
sales revenue.

TRADEMARKS

All product names appearing in italics are trademarks owned by or licensed to
Elan.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

(Cautionary Statements Under the United States Private Securities Litigation
Reform Act of 1995)

Our disclosure and analysis in this Annual Report and Form 20-F contain some
forward-looking statements that set forth anticipated results based on
management's plans and assumptions. From time to time, we also provide
forward-looking statements in other materials we release to the public as well
as oral forward-looking statements. Such statements give our current
expectations or forecasts of future events; they do not relate strictly to
historical or current facts. We have tried, wherever possible, to identify such
statements by using words such as "anticipate", "estimate", "expect",
"project", "intend", "plan", "believe", "strategy" and similar expressions in
connection with any discussion of future operating or financial performance. In
particular, these include statements relating to future actions, our ability to
meet our future financial obligations, prospective products or product
approvals, future performance or results of current and anticipated products,
sales efforts, expenses, interest rates, the outcome of contingencies, such as
legal proceedings and governmental investigations, and financial results.

We cannot guarantee that any forward-looking statements will be realised.
Achievement of future results is subject to risks, uncertainties and
potentially inaccurate assumptions. Should known or unknown risks or
uncertainties materialise, or should underlying assumptions prove inaccurate,
actual results could vary materially from past results and those anticipated,
estimated or projected. Investors should bear this in mind as they consider
forward-looking statements.

We undertake no obligation to publicly update forward-looking statements,
whether as a result of new information, future events or otherwise. You are
advised, however, to consult any further disclosures we make on related
subjects in our Form 6-K reports submitted to the United States Securities and
Exchange Commission ("SEC"). Also note that we provide the following cautionary
discussion of risks, uncertainties and possibly inaccurate assumptions related
to our business. This discussion, together with the discussion under "Risk
Factors" located elsewhere in this Annual Report and Form 20-F, describe the
factors that, individually or in the aggregate, we think could cause our actual
results to differ materially from expected and historical results. We note
these factors for investors as permitted by the United States Private
Securities Litigation Reform Act of 1995. You should understand that it is not
possible to predict or identify all such factors. Consequently, you should not
consider these factors to be a complete discussion of all potential risks or
uncertainties. These factors include those set forth under the heading "Risk
Factors" located elsewhere in this Annual Report and Form 20-F and the
following:

 o   the timing and outcome of the ongoing SEC investigation and the putative
     shareholder class action;

 o   the success of our development and commercialisation efforts with respect
     to Antegren and our other product development candidates and the speed
     with which necessary product approvals may be achieved;

 o   our ability to maintain financial flexibility and maintain sufficient
     cash, liquid resources and investments and other assets capable of being
     monetised to meet our liquidity requirements;

 o   the continued acceptance of our currently marketed products, including, in
     particular, Maxipime and Azactam, and competitive developments affecting
     those products;

 o   the high cost and uncertainty of research, clinical trials and other
     development activities involving pharmaceutical products;

 o   our ability to protect our intellectual property;

 o   our ability to successfully market both new and existing products;

 o   difficulties or delays in manufacturing;

 o   our ability to meet generic and branded competition after the expiration
     of our patents or our regulatory exclusivity;

 o   our future capital expenditure requirements;

 o   the trend towards managed care and health care cost containment;

 o   possible legislation affecting pharmaceutical pricing;

 o   exposure to product liability and other types of lawsuits;

 o   interest rate and foreign currency exchange rate fluctuations;

 o   governmental laws and regulations affecting domestic and foreign
     operations, including tax obligations;

 o   general changes in Irish and U.S. GAAP;

 o   our ability to reduce costs and expenses;

 o   changes in product mix; and

 o   the impact of acquisitions, divestitures, restructurings, product
     withdrawals and other unusual items.

--------------------------------------------------------------------------------

[ELAN LOGO]

2003 was an important year for Elan. The company focused on continuing the
successful execution of its recovery plan, communicating the value of its
research and development programme accurately and consistently, and delivering
against clear expectations. As a result, Elan experienced renewed stakeholder
interest in its science and business plans and a greater appreciation of its
accomplishments and goals.

--------------------------------------------------------------------------------

                                                               [GRAPHIC OMITTED]

STATEMENT FROM THE CHAIRMAN

Garo Armen

Dear Shareholders:

     2003 was a pivotal year for Elan, marked by a number of key events,
decisions and milestones that ultimately reshaped both the Company and its
future. It was also a year where the Company focused intensely on executing
against well-defined goals and delivering on previous commitments. Successes in
our scientific and business plans, and our transparent articulation of each,
helped set the stage for a return of confidence in the Company and a renewed
interest in our pipeline, our science and our future.

     By year's end, we had completed almost all of the elements of the recovery
plan announced in July 2002, and we formally concluded the plan in February
2004. We achieved or exceeded all of the plan's goals, raising aggregate
consideration of $2.7 billion, including $0.6 billion from an equity and
convertible notes offering, reducing headcount and related costs by more than
50 percent, simplifying our business model and balance sheet, and strengthening
our liquidity position. Other elements from 2002 and 2003 are as yet
unresolved, including the timing and outcome of the ongoing SEC investigation
and the putative shareholder class action.

     Throughout 2003, we made steady progress in the research and development
of novel treatments in our core therapeutic focus areas of neurology,
autoimmune diseases and severe pain, bringing the Company to a new threshold in
each.

     In neurodegenerative diseases, our Alzheimer's programme saw a return to
the clinic with a Phase I immunotherapy study evaluating a monoclonal antibody
directed against A-beta as a potential treatment of mild-to-moderate
Alzheimer's disease. In autoimmune diseases, we earned the interest -- and
admiration -- of the entire industry with our news concerning Antegren, whose
unique inflammatory-inhibiting characteristics were reported in announcements
concerning Crohn's disease, multiple sclerosis and rheumatoid arthritis. And
our advances with Prialt, our first-in-class therapy for severe pain, have
reached the point where it is appropriate for us to prepare arduously for
potential product launches.

     Today, our financial and scientific accomplishments speak clearly of a
company that has been successfully transformed. This transformation encompassed
more than our business and scientific ventures; equally important was how we
executed against our plans, delivered on our pledge of transparency, and were
guided by strong principles and strong leaders.

     I thank CEO Kelly Martin for articulating Elan's vision in a manner that
resonates deeply within and outside the Company, and for strengthening the
business processes that will make that vision a reality. I appreciate the
tireless efforts of our board of directors, as they engaged fully in guiding
and supporting difficult decisions and in helping to set Elan's new course.

     Most importantly, I want to acknowledge our shareholders and express my
gratitude for the extraordinary efforts of our employees. Neither our
accomplishments of the last year nor the promise of what is yet to come would
exist without their support and commitment. Their understanding of our
Company's priorities and our purpose reflects the true measure of its value.

/s/ Garo Armen

--------------------------------------------------------------------------------
2

                                                               [GRAPHIC OMITTED]

STATEMENT FROM THE PRESIDENT AND CEO

G. Kelly Martin

Dear Shareholders:

     A dispassionate assessment of Elan's performance in 2003 would accurately
report that we were required to respond rapidly to a series of difficult
challenges and important opportunities, and that we did so successfully.
Throughout the year, we continued to focus our energies on the transformation
of our Company.

     I would suggest, however, that Elan's transformation into a world-class,
neuroscience-based biotechnology company -- rooted in Ireland and focused on
neurology, autoimmune disease and severe pain -- cannot be assessed
dispassionately. Our identity, our strategy and alignment, and our commitment
to creating value cannot be understood unless you understand our passion.

     And our passion starts with patients.

     Everything we do at Elan is predicated on the possibility of bringing our
products and moving our research toward the millions of patients who
desperately need our help. Our employees know this, and our scientific approach
embodies it. Our commitment to patients reflects even more than how we work; it
says who we are.

     We are passionate about our potential to lead -- to create a new industry
model for taking science from the lab to the marketplace -- and in neurology,
autoimmune disease and severe pain, we are absolutely clear and purposeful
about our strategic direction and focus. Last year, this clarity was
self-evident, culminating in a stunning accomplishment: three groundbreaking
clinical milestones in a single six-week period.

     This year, our next steps with Antegren and Prialt, as well as our
continued clinical development in Alzheimer's disease, will be closely watched
by the industry, our competitors and, of course, by you, our shareholders. We
welcome that attention, and the opportunity to demonstrate that a well-executed
science-to-market continuum is more than just a new phrase; it is a new way of
doing business and helping patients.

     We also look forward to showing the importance of all our operations and
the organisational alignments that support them.

     We will have some key opportunities this year, as we prepare to leverage
the value of a strategically aligned, hospital-based specialty sales and
marketing group, and as we extend the value of our biologic supply chain
business and our recently integrated manufacturing services unit. In these
areas, we will be driven by the same forces that cut across all of Elan: the
knowledge that our work is important, and the desire to make a difference.

     We will demonstrate that knowledge and desire in everything we do, every
day. We will continue our execution momentum across all the dimensions of our
Company, prioritising, planning and working strategically with others to extend
the progress of last year. We will continue to set identifiable goals -- such
as filing two to three U.S. NDAs and two European MAAs by the end of 2004, as
well as two INDs in the next one to two years. We will deliver against these
goals with an operating discipline that is efficient and measurable. And we
will maintain our focus on value creation -- delivering the work and the
results that the market and our shareholders expect.

     Most of all, however, we will continue our commitment to patients. In some
ways, this commitment will be large and visible, such as our premier
sponsorship, in July, of the Alzheimer's Association's 9th International
Conference on Alzheimer's Disease and Related Disorders, or the announcements
we may make concerning regulatory filings or trial results. In other ways, it
will be small or quiet, but no less important.

     Our passion for patients reminds us -- and the world -- that we are more
than a company with great people, strategies, science, or execution. We're a
company with a great purpose.

/s/ G. Kelly Martin

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                       3

--------------------------------------------------------------------------------

Operating Review

COMPANY OVERVIEW

Elan, an Irish public limited company, is a neuroscience-based biotechnology
company headquartered in Dublin, Ireland that is focused on discovering,
developing, manufacturing and marketing advanced therapies in neurology,
autoimmune diseases and severe pain.

     Elan was incorporated as a private limited company in Ireland on 18
December 1969 and became a public limited company on 3 January 1984. Elan's
principal executive offices are located at Lincoln House, Lincoln Place, Dublin
2, Ireland and its telephone number is 353-1-709-4000. Elan's principal
research and development, manufacturing and marketing facilities are located in
Ireland, the United States and the United Kingdom.

     In the early months of 2002, the Company suffered a number of setbacks in
rapid succession, including the cessation of dosing in a Phase IIA clinical
trial of AN-1792, an experimental immunotherapeutic that was under development
for the treatment of Alzheimer's disease ("AD"), the announcement of a profit
warning and an investigation by the SEC. These disappointments ultimately led
to a loss of confidence in the Company. To address these issues, Elan announced
a recovery plan on 31 July 2002 to restructure Elan's business, assets and
balance sheet in order to enable it to meet its financial commitments. The
principal elements and outcomes of the recovery plan are set out in the
Operating Review on page 16 under the heading "Completion of Recovery Plan". As
a result of this recovery plan, Elan's business has now been transformed, and
the Company is now focused clearly on three core therapeutic areas: neurology,
autoimmune diseases and severe pain. One significant result of the number of
product and business divestments since the beginning of 2002 is that Elan's
financial performance in historical years is of limited relevance to an
understanding of its future prospects. Near term, Elan is focusing its
development, sales and marketing efforts to enable it to focus resources on the
anticipated launch of its late stage pipeline candidates, Antegren for multiple
sclerosis ("MS") and Crohn's disease, and Prialt for severe pain. In research,
Elan is focused on neurology, in which it is continuing its research and
advances in neurodegenerative diseases, including multiple sclerosis,
Alzheimer's disease and Parkinson's disease. On 12 February 2004, Elan
announced the formal completion of its recovery plan. With the completion of
the recovery plan, Elan announced the end of operations for its Elan
Enterprises business unit.

     In February 2004, the Company's operations were reorganised into two
business units: Biopharmaceuticals and Global Services and Operations ("GS&O").
The remaining businesses in Elan Enterprises comprising principally of drug
delivery businesses were amalgamated with the drug delivery business from Core
Elan to form "GS&O". Biopharmaceuticals engages in biopharmaceutical research
and development activities, and pharmaceutical commercial activities.
Biopharmaceutical research and development activities include the discovery and
development of products in the therapeutic areas of neurology, autoimmune
diseases and severe pain. Elan's pharmaceutical commercial activities include
the marketing of neurology and pain management products and hospital and
specialty products. GS&O focuses on product development and manufacturing to
provide technology platforms that address the drug delivery challenges of the
pharmaceutical industry. In this amendment, all prior period financial
information has been recast to reflect the Company's new basis of segmentation,
as presented in our Form 20-F as originally filed for 2003.

     Elan's biopharmaceutical product pipeline includes innovative products in
research and development in neurology, autoimmune diseases and severe pain. In
neurology, Elan has an Alzheimer's disease immunotherapy programme, in
collaboration with Wyeth, which currently includes a Phase I development
project. Other efforts in neurology include a number of AD research projects
and work in neuropathology-based disorders such as Parkinson's disease.

     In autoimmune diseases, Elan, in collaboration with Biogen Idec, Inc.
("Biogen Idec") (formerly Biogen Inc.), is developing Antegren, which is
currently in Phase III clinical trials in multiple sclerosis and Crohn's
disease, and Phase II studies in rheumatoid arthritis ("RA"). Elan's primary
autoimmune research emphasis is studying cell trafficking to discover ways to
provide disease-modifying therapies for a wide range of autoimmune diseases. In
severe pain, Elan's filing of a European Market Authorisation Application
("MAA") for Prialt, a late-stage development product for severe chronic pain,
is under regulatory review. Elan also expects to file an amendment to its New
Drug Application ("NDA") for Prialt, with the U.S. Food and Drug Administration
("FDA"), in the second quarter of 2004. Research efforts in severe pain focus
on inflammatory and neuropathic pain.

     Elan expects to file two to three U.S. NDAs and two European MAAs by the
end of 2004. Elan also expects to file two Investigational New Drug
Applications ("INDs") in the next one to two years, based on its current
research efforts.-

--------------------------------------------------------------------------------
4

                               [GRAPHIC OMITTED]

OPERATING REVIEW

Elan is comprised of biopharmaceutical research and development activities,
pharmaceutical commercial activities and pharmaceutical manufacturing
activities. Biopharmaceutical research and development activities include the
discovery and development of products in the therapeutic areas of neurology,
autoimmune diseases and severe pain. Elan's pharmaceutical commercial
activities include the marketing of neurology/pain management products and
hospital/specialty products. The Company's initiatives in product development,
optimisation and manufacturing are encompassed by Global Services & Operations,
which is focused on providing technology platforms that address the drug
delivery challenges of the pharmaceutical industry.

Biopharmaceuticals

Research and Development

     Elan's biotechnology research and development activities include the
discovery and development of products in the therapeutic areas of neurology,
autoimmune diseases and severe pain. Elan's focus on improving the health of
patients suffering from chronic and debilitating conditions is exemplified by
its breakthrough research and development programmes in Alzheimer's disease.
Other neurology research and development efforts include work in the areas of
Parkinson's disease and epilepsy. In autoimmune diseases, products in mid- or
late-stage development efforts include Antegren (natalizumab), being developed
for multiple sclerosis, Crohn's disease and rheumatoid arthritis; and research
efforts centre on Elan's cell trafficking programme and new disease-modifying
approaches to treat autoimmune diseases such as MS, Crohn's, inflammatory bowel
disease ("IBD") and RA. In severe pain, Prialt (ziconotide) is in late stage
development and research efforts focus on inflammatory and neuropathic pain.

Antegren (natalizumab)

     Antegren, a humanised monoclonal antibody, is the first alpha 4-integrin
antagonist in a new class of potential therapeutics known as selective adhesion
molecule ("SAM") inhibitors. SAM inhibitors are designed to selectively inhibit
immune cells from leaving the bloodstream and to prevent these cells from
migrating into chronically inflamed tissue -- the brain in MS, the
gastrointestinal tract in Crohn's disease, and the joints in RA -- where they
may cause or maintain inflammation.

     Since August 2000, Elan and Biogen Idec have engaged in a worldwide,
exclusive, mutually beneficial agreement to develop, manufacture and
commercialise Antegren and together are investigating its use as a potential
treatment in patients with MS, Crohn's disease, and RA. Under the terms of the
agreement, Elan and Biogen Idec share costs for ongoing development activities.
In 2000, Biogen Idec paid a one-time, non-refundable license fee of $15.0
million to Elan. In 2001 and 2002, Biogen Idec paid $16.0 million and $7.0
million, respectively, to Elan for the achievement of certain milestones in
those years. Biogen Idec is obligated to pay Elan additional amounts upon the
completion of certain future milestones. If all future milestones were
achieved, Biogen Idec would be required to pay up to an additional $14.0
million over the remaining life of the agreement.

     To date, approximately 2,800 patients have been treated with Antegren in
clinical trials. Elan and Biogen Idec are encouraged by results thus far and
believe that, due to its unique mechanism of action, Antegren may provide a
meaningful advancement for patients with debilitating autoimmune diseases.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                       5

--------------------------------------------------------------------------------
OPERATING REVIEW

Autoimmune Diseases

     In autoimmune diseases, the immune system targets the cells, tissues, and
organs of a person's own body. Inflammation is a response of body tissues to
trauma, infection, chemical or physical injury, allergic reaction or other
factors and is usually characterised by a collection of immune system cells and
molecules at a target site. Different autoimmune diseases affect the body in
different ways. For example, in MS the autoimmune reaction is directed against
the brain; in Crohn's disease it is directed against the gastrointestinal tract;
and in RA, it is directed against the joints. Autoimmune diseases afflict
millions of people worldwide and some, including MS, strike women --
particularly those of working age and in their childbearing years -- more often
than men. Autoimmune diseases are often chronic, with patients requiring
life-long care, and most autoimmune diseases cannot currently be reversed or
cured. The social, economic, and health impacts from autoimmune diseases are
far-reaching.

[GRAPHIC OMITTED]

     In autoimmune diseases, Elan has earned the interest and admiration of the
entire industry with its announcements concerning the unique
inflammatory-inhibiting characteristics of Antegren.

                                   TED YEDNOCK
                            Senior Research Director

     MS is the most common neurological autoimmune disorder among young adults;
approximately one million people are thought to be affected worldwide. MS is a
disorder involving repeated episodes of inflammation of nervous tissue in the
central nervous system ("CNS"). This inflammation destroys the myelin sheath or
covering of the nerve cells, leaving multiple areas of scar tissue and
impacting the CNS function. The cause or causes of the inflammation associated
with MS have not been scientifically determined or proven.

     Crohn's disease is a chronic inflammatory relapsing-remitting disease of
the gastrointestinal tract characterised by abdominal pain and diarrhoea; other
symptoms include rectal bleeding, weight loss and fever. Crohn's disease
affects men and women equally, and evidence indicates that it may have a
hereditary component. Approximately one million people worldwide have Crohn's
disease. Crohn's disease is an IBD, the general name for diseases that cause
inflammation in the intestines. Crohn's disease can result in frequent
hospitalisations for patients and may necessitate surgery.
     RA is a chronic progressive autoimmune disease affecting approximately six
million people worldwide. RA often begins with pain, swelling and stiffness in
the small joints of the hands and feet, and can progress to involve other
joints, sometimes with severe disability and disfigurement. Although a number
of medicines are approved to treat symptoms of RA, the disease itself cannot
currently be cured nor reversed.

Evaluating Antegren in MS

     Elan and Biogen Idec are conducting two, two-year Phase III trials
evaluating Antegren in MS patients with relapsing-remitting forms of the
disease. The AFFIRM (natalizumab safety and efficacy in relapsing-remitting MS)
Phase III trial is a two-year, randomised, multi-centre, placebo-controlled,
double-blind study of approximately 900 patients, evaluating the ability of
natalizumab to slow the progression of disability in MS and reduce the rate of
clinical relapses. The SENTINEL (safety and efficacy of natalizumab in
combination with Avonex in patients with relapsing-remitting MS) Phase III
trial is a two-year, randomised, multi-centre, placebo-controlled, double-blind
study of approximately 1,200 patients with relapsing-remitting MS, evaluating
the effect of the combination of natalizumab and Avonex compared to treatment
with Avonex alone in slowing the progression of disability and reducing the
rate of clinical relapses. The primary endpoints for both trials are based on
Expanded Disability Status Scale scores and relapse rates. The pre-specified
primary endpoint of the one-year analysis was relapse rates. Both studies are
fully enrolled.

     Elan and Biogen Idec plan to submit an application for approval to market
Antegren as a treatment for MS to the FDA and European regulatory agencies
around mid-year 2004. The decision to file a Biologics License Application
("BLA") was made after discussions with the FDA and the European Rapporteur and
Co-Rapporteur based on one-year data from the two ongoing Phase III trials. To
protect the integrity of the trials, the companies are not disclosing the
one-year data at this time. It is important to note that no other MS therapy
currently on the market has been approved with less than two years of data.

     In January 2003, Antegren was the focus of two separate publications in
the New England Journal of Medicine ("NEJM") regarding Phase II studies with
Antegren in both MS and Crohn's disease. The first publication reported on the
results of the Phase II MS study and noted a greater

--------------------------------------------------------------------------------
6

--------------------------------------------------------------------------------

than 90% reduction in the volume of new inflammatory brain lesions in
Antegren-treated patients. For patients with relapsing forms of MS, the study
showed an approximate 50% reduction in the number of patients experiencing
relapse in the natalizumab group compared to placebo. The second publication
reported the results of the Antegren Phase II Crohn's disease study. That study
showed promising data on patient response rate, disease remission, and quality
of life for patients with Crohn's disease, as determined by the Crohn's Disease
Activity Index ("CDAI") and the Inflammatory Bowel Disease Questionnaire
("IBDQ").

Evaluating Antegren in Crohn's Disease

     The safety and efficacy of Antegren in Crohn's disease is the subject of
two key Phase III trials conducted by Elan and Biogen Idec: ENACT-1 and
ENACT-2.

     Evaluation of Natalizumab in Active Crohn's Disease Trial-1 ("ENACT-1"),
the largest-ever study in Crohn's disease conducted to date, was fully enrolled
with more than 900 patients. This trial evaluated clinical response and ability
to induce remission. This Phase III, double-blind, placebo-controlled trial
randomised patients to one of two treatment groups: 300 mg natalizumab or
placebo in a 4:1 ratio (active to placebo) dosed at weeks 0, 4 and 8. The
primary endpoint of inducing a "response" was defined as a 70-point decrease in
the CDAI score and inducing a "remission" was defined as a CDAI score of less
than or equal to 150, both at week 10. Secondary and tertiary endpoints
included response and remission at other time points through week 12, "time to
remission and response," mean changes in CDAI, as well as quality of life
measurements and inflammatory markers (for example, C-reactive protein). In
this study, the primary endpoint of "response" as defined by a 70-point
decrease in the CDAI at week 10 was not met, and this result appears to be due
to a larger than expected placebo response rate. Data from the study indicated
evidence of a consistent clinical effect similar to the biological activity of
natalizumab seen in the Phase II study published in the NEJM earlier in 2003.
The week 12 response and remission endpoints were statistically significant
compared to placebo, as was a secondary endpoint of IBDQ, a validated quality
of life measurement, at week 10. Over the course of the study, the time to
remission and, at weeks 6 through 12, mean changes in CDAI, were also
statistically significant in natalizumab treated patients compared to those
treated with placebo. The most common adverse events seen in the trial were
headache, nausea and abdominal pain across both groups. Patients who achieved a
70-point decrease in the CDAI following three months of treatment in ENACT-1
were designated as responders and allowed to enter the Evaluation of
Natalizumab As Continuous Therapy-2 ("ENACT-2") trial, where they were
re-randomised equally to receive either Antegren at 300 mg or placebo for a
further 12-month period. The ENACT-2 trial was designed to evaluate the ability
of Antegren to maintain efficacy following the induction of an initial response
from the first trial, ENACT-1.

     In January 2004, Elan and Biogen Idec announced that the second of the two
Phase III studies in Crohn's disease, ENACT-2 met its primary endpoint. The
primary endpoint for ENACT-2 was defined as the maintenance of response, or a
sustained CDAI score of less than 220, in addition to no use of rescue
medication throughout the first six months of the ENACT-2 study comparing
Antegren to placebo. A significant treatment difference of greater than 30% in
favour of Antegren as compared to placebo was seen, and no difference in the
overall rates of side effects between natalizumab and placebo treatment groups
were observed through month six. In addition to the clear evidence of efficacy
observed in ENACT-2, which is further supported by ENACT-1, it is also
noteworthy that there were no differences in the overall rates of side effects
between Antegren and placebo in these two pivotal trials. Based on the clinical
data from ENACT-2, Elan is currently working with both the U.S. and European
regulatory agencies to determine the path forward for Antegren in Crohn's
disease. A further three-month Phase III Crohn's disease "induction" trial was
initiated in the first quarter of 2004.

[GRAPHIC OMITTED]

     We are passionate about our potential to lead -- to create a new industry
model for taking science from the lab to the marketplace in neurology,
autoimmune disease, and pain.

                                 ALLISON HULME
                   Senior Vice President, Global Development

Evaluating Antegren in Rheumatoid Arthritis

     In February 2004, Elan and Biogen Idec announced that they had filed an
IND for Antegren for the treatment of RA and planned to initiate a Phase II
clinical trial in the first half of 2004 to evaluate Antegren in patients with

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                       7

--------------------------------------------------------------------------------

OPERATING REVIEW

RA. The Phase II study will be a multi-centre, double-blind, placebo-controlled
study of the efficacy, safety and tolerability of intravenous natalizumab (300
mg) in patients with moderate-to-severe RA receiving concomitant treatment with
methotrexate.

Prialt (ziconotide)

     Prialt is the first in a new class of non-opioid analgesics known as
N-type calcium channel blockers. N-type calcium channel blockers are a new
class of drugs that are believed to selectively block the nerve channels
responsible for transmission of pain signals. Elan is developing Prialt, which
is the synthetic equivalent of a naturally occurring conopeptide found in a
marine snail, as a potential intrathecal treatment for patients suffering from
severe chronic pain.

About Severe Pain

     There are many different ways to classify pain, including: duration or
time (acute or chronic), disease base (malignant or non-malignant) and whether
physiologically the pain is based in nerves that sense and respond to damage to
parts of the body (nociceptive) or if the pain is the result of an injury or
malfunction in the peripheral or central nervous system (neuropathic). Chronic
pain can be defined as pain that has lasted over six months and is not relieved
by medical and/or surgical care. Chronic pain may result from a previous injury
long since healed; or, it may be from an ongoing condition, such as back and/or
leg pain, cancer pain, complex regional pain syndromes, or painful neuropathy.
Pain severity is often measured by the Visual Analog Scale of Pain Intensity
("VASPI"). The VASPI uses a 0-100 millimetres scale with 0=no pain to
100=worst-ever pain.

Evaluating Prialt for Severe Chronic Pain

     In June 2000, Elan received an approvable letter from the FDA for its
application to market Prialt as a treatment for patients with severe chronic
pain. Following discussions with the FDA, Elan agreed to conduct an additional
Phase III clinical trial. In January 2004, Elan announced that this additional
Phase III trial for Prialt had met its primary endpoint in patients with severe
chronic pain who had not achieved pain relief with other therapies, including
intrathecally delivered morphine. In the double-blind, placebo controlled
trial, patients treated with Prialt displayed a statistically significant
improvement at week three in the VASPI score, as compared to placebo. Based on
these positive results, Elan expects to file an amendment to its NDA in the
second quarter of 2004. Additionally, the FDA granted Elan approval to initiate
a treatment IND programme. In Europe, Elan has received orphan drug designation
for treatment of patients with severe chronic pain with Prialt, and Elan filed
an MAA with the European regulatory authorities in 2003. Regulatory review of
this submission is ongoing. Additionally, results of an earlier Phase III study
were published in the January 2004 issue of the Journal of the American Medical
Association in an article entitled "Intrathecal Ziconotide in the Treatment of
Refractory Pain in Patients with Cancer or AIDS: A Controlled Clinical Trial."

Alzheimer's Immunotherapy in Development

About Alzheimer's Disease

     Approximately four million people in the United States presently have AD,
according to the Alzheimer's Association. Most of these people are over age 65
and almost half of all Americans over age 85 are thought to have AD. AD is a
degenerative brain disorder that primarily affects older persons. AD can begin
with forgetfulness and progress into more advanced symptoms, including
confusion, language disturbances, personality and behaviour changes, impaired
judgement and profound dementia. As the disease advances, patients will
eventually need complete skilled nursing care, and in the absence of other
illnesses, the progressive loss of brain function itself will cause death.

     Today, the leading scientific approach to develop therapeutic treatments
for AD focuses on strategies that block the generation or enhance the clearance
of neurotoxic forms of the beta-amyloid peptide in the brain. The beta-amyloid
peptide -- A-beta -- is the main building block of amyloid plaques, which are a
hallmark of AD neuropathology and are found in the brain tissue of affected
patients.

Evaluating AAB-001 in Mild-to-Moderate Alzheimer's Disease

     In March 2000, Elan and Wyeth formed one of the broadest research and
development alliances in the pharmaceutical industry to discover and develop
immunotherapeutic approaches to treat and prevent AD. These approaches
encompass both passive and active immunisation therapies. Elan and Wyeth are
currently conducting Phase I safety studies with an antibody (AAB-001) directed
against the A-beta peptide in patients with mild-to-moderate AD. AAB-001 is a
humanised monoclonal antibody specifically designed and engineered to
neutralise the neurotoxic beta-amyloid peptide that accumulates in the brains
of patients with AD. The rate and extent to which A-beta is removed by
immunotherapy is believed to be controlled by the amount of antibody delivered.
In essence, the antibody AAB-001 is designed to provide

--------------------------------------------------------------------------------
8

--------------------------------------------------------------------------------

the necessary highly specific component of the immune response (antibody) for
the patient, while avoiding the activation of non-essential components. In this
way, Elan hopes to reverse beta-amyloid accumulation while minimising side
effects such as inflammation of the CNS. Additionally, Elan and Wyeth continue
to use Wyeth's innovative conjugate technology to evaluate a novel
immunotherapeutic A-beta peptide conjugate in preclinical studies.

Collaboration to Develop Alzheimer's Immunotherapies

     The Elan and Wyeth collaboration was originally formed to use the early
preclinical research demonstrating that Elan's original AD immunotherapy
project, AN-1792, reduced and prevented the development of amyloid plaque in
mice, and to develop additional products based upon an immunotherapeutic
approach. The potential impact of this novel immunotherapeutic approach to
treating AD was highlighted in 2002 in two publications in Nature Medicine. In
one of these papers, an independent group of investigators at the University of
Zurich studied a subset of patients in the Phase IIa study of AN-1792 carried
out by Elan and Wyeth, in which dosing was suspended early in 2002 following
reports of inflammation within the CNS. The authors concluded that most of the
patients developed antibodies against beta-amyloid, which is thought to be a
critical step in plaque clearance in humans. The investigators found that the
antibodies in the cerebrospinal fluid had unique specificity for the targeted
pathogenic structures containing beta amyloid. In another independent study from
the University of Toronto, the study authors demonstrated in transgenic mice
over-expressing the beta amyloid peptide that an immune response directed to the
amino terminus of that peptide can prevent the precipitous cognitive decline
typically observed in these mice.

[GRAPHIC OMITTED]

Everything Elan does is predicated on the possibility of bringing our products
and moving our research toward the millions of patients who desperately need
our help. Our employees know this, and our scientific approach embodies it.

                                  DALE SCHENK
               Senior Vice President and Chief Scientific Officer

     In March 2003, a report published in Nature Medicine summarised the
neuropathology of one patient with AD who participated in the AN-1792 Phase I
study. The paper provides the first evidence that the immune response generated
against the A-beta peptide may elicit clearance of A-beta plaques in humans.
The report also identifies the accumulation of inflammatory cells as the likely
cause of the CNS inflammation reported in approximately 6% of patients in the
Phase IIa study.

[GRAPHIC OMITTED]

In neurology, our Alzheimer's programme saw a return to the clinic with a Phase
I immunotherapy study evaluating a monoclonal antibody directed against A-beta
as a potential treatment of mild-to-moderate Alzheimer's disease

                                  JIM CALLAWAY
               Senior Vice President, Pharmaceutical Development

Elan's Research Programmes

     For almost two decades, Elan has been discovering novel,
disease-modifying, and potentially life-changing therapies in neurology,
autoimmune diseases and severe pain. In the past year, Elan has made important
progress in its key research programmes in Alzheimer's disease, as well as in
its programmes for Parkinson's disease, autoimmune diseases and severe pain.

Alzheimer's Disease Research Programmes

     Elan currently has one of the largest research efforts dedicated to
developing disease-modifying therapies which are neuropathology-based
approaches to the treatment of AD. Elan scientists have researched approaches
to the detection, prevention and treatment of AD since 1987. These research
advances have been discussed in distinguished scientific publications, such as
Nature, and by scientific organisations such as the American Academy of
Neurology.

     Elan's extensive knowledge of the processes of beta-amyloid peptide
formation has led to identification of new disease targets and the development
of one of the first animal models of the disease. As a result of this work,
Elan has developed several new therapeutic approaches for the treatment of AD
based on the beta-amyloid hypothesis. These include two distinct enzyme
inhibitor programmes, one focused on beta secretase inhibitors

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                       9

--------------------------------------------------------------------------------
OPERATING REVIEW

and a second focused on gamma secretase inhibitors, as well as an
immunotherapeutic approach.

Beta Secretase Programme

     Beta secretase is a discrete, attractive therapeutic target for a
disease-modifying therapy for AD, because it is believed to initiate and be the
rate-limiting step in the formation of A-beta.  Elan has been an industry
leader in beta secretase research for more than 10 years, and its 1999
publication concerning the role beta secretase plays in A-beta production is
considered a landmark discovery. Today, Elan continues to be at the centre of
understanding the complexities of beta secretase and advancing potential
disease-modifying agents that inhibit its role in AD pathology. Elan has been
collaborating with Pfizer Inc. ("Pfizer") (formerly Pharmacia Corporation)
since July 2000, focusing on the discovery of inhibitors of beta secretase. On
11 December 2003, Elan commenced AAA arbitration proceedings against Pfizer in
connection with certain alleged breaches of the agreement governing the
collaboration. As a result of these breaches, Elan believes it holds an
exclusive worldwide licence of all of Pfizer's interest in the subject matter
of the parties' collaboration. While Elan believes that it holds the exclusive
worldwide licence to the intellectual property developed in connection with the
Pfizer collaboration, Pfizer disputes this. There can be no assurance that the
arbitral tribunal or court will ultimately accept Elan's position.

Gamma Secretase Programme

     Gamma secretase is an unusual multi-protein complex, and its role in the
formation of A-beta was both unknown and un-assumed until the early 1990s, when
discoveries about A-beta production showed that earlier explanations regarding
it were incorrect. Since then, Elan has played a critical leadership role in the
increased awareness of how gamma secretase may affect AD pathology. Elan's
finding, published in 2001, that functional gamma secretase inhibitors appear to
reduce A-beta levels in the brain, was a breakthrough in this area of AD
research. That research continues today, as does Elan's position as a world
leader in the discovery and development of disease-modifying therapies for AD.

[GRAPHIC OMITTED]

     Elan's research progress in Alzheimer's disease, Parkinson's disease,
autoimmune diseases and severe pain represents decades of dedication and
perseverance in the Discovery arena.

                                STEPHEN FREEDMAN
                     Senior Vice President, Global Research

Alzheimer's Immunotherapy Programme

     In addition to its monoclonal antibody immunotherapy approach, Elan is
exploring, with Wyeth, a novel A-beta immunoconjugate that leverages the
innovative conjugate technology that Wyeth uses in some of its other products.
This research project is in the pre-clinical research and development phase.

Cell Trafficking Research Programme

     Elan's Cell Trafficking research programme is focused on discovering
disease-modifying approaches to treat autoimmune diseases such as MS, Crohn's,
IBD and RA. Antegren emerged from this research programme, and Elan scientists
continue to make progress in the discovery of novel disease-modifying
therapeutics.

Pain Research Programme

     In severe pain, Elan's research efforts focus on inflammatory and
neuropathic pain. In March 2003, Elan formed a strategic research alliance with
Ingenium Pharmaceuticals AG ("Ingenium") to develop novel therapeutics for pain
management. Elan and Ingenium are funding a four-year research programme
leading to the identification of clinical candidates. In October 2003, Elan
expanded the scope of its strategic alliance with Ingenium to increase the use
of specific Ingenium technologies for drug target validation.

Parkinson's Disease Research Programme

     Elan's research programme in Parkinson's disease is focused on the
discovery of disease-modifying approaches to potentially treat this devastating
disease. Much of this effort is based upon analysis of genes known to be
involved in early forms of the disease, such as synuclein and parkin.

     Parkinson's disease is a slowly progressive disease of the nervous system
and the second most common degenerative neurological disorder after Alzheimer's
disease. It affects an estimated four million people worldwide. The disease
typically occurs at a late age, affecting approximately 1% of the population
over the age of 65. In the United States, Japan, and the five major European
markets (France, Germany, Italy, Spain and the United Kingdom), about 2.7
million people suffer from Parkinson's disease. Of this group, approximately
85% are over 65 years of age.

--------------------------------------------------------------------------------
10

--------------------------------------------------------------------------------

[GRAPHIC OMITTED]

Pipeline and Products

Discovery

Preclinical

Phase I

Phase II

Phase III

Registration

Launched

Neurology

     Alzheimer's Disease

          Beta Secretase Research

          Gamma Secretase Research

     Alzheimer's Immunotherapies*

          AAB-001 Monoclonal Antibody

          ACC-001 Immunoconjugate

     Parkinson's Disease

          Parkinson's Research

Autoimmune Diseases

     Multiple Sclerosis

          Antegren (natalizumab)**

     Crohn's Disease

          Antegren (natalizumab)**

     Rheumatoid Arthritis

          Antegren (natalizumab)**

     Autoimmune Diseases

          Autoimmune Research

Severe Pain

     Severe Pain

          Prialt (ziconotide)(U.S.)

          Prialt (ziconotide)(EU)

          Pain Research

Hospital/Specialty Products

     Infectious Diseases

          Azactam (aztreonam for injection, USP)(Marketed in U.S.)

          Maxpime (cefepime hydrochloride) for Injection (Marketed in U.S.)

*Developed in collaboration with Wyeth.

**Developed in collaboration with Biogen Idec.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      11

--------------------------------------------------------------------------------

OPERATING REVIEW

Therapeutic Markets

     Elan's pharmaceutical commercial activities included the marketing of
neurology/pain management products and hospital/specialty products. Elan has
divested all of its previously marketed neurology/pain management products.

The following table sets forth Elan's aggregate U.S. revenue from its main
product lines.
------------------------------------------------------------------------------
                                                       2003         2002
                                                        $M           $M
------------------------------------------------------------------------------

    Neurology/Pain Management Products                 304.4        428.3
    Hospital/Specialty Products                        155.3        176.8
------------------------------------------------------------------------------
                                                       459.7        605.1

     Product revenue from Elan's main product lines, including divested
products, decreased by 24% to $459.7 million for 2003 from $605.1 million for
2002. The decline in product revenue in 2003 is due mainly to the divestment of
a number of products and businesses as part of the recovery plan and the impact
of generic competition on sales of Zanaflex, which was compensated for, in
part, by the growth in sales of those products retained. Divested products are
products or businesses which have been sold or which are subject to an
agreement to divest.

     Please refer to the Financial Review for further information on product
revenue.

         U.S NEUROLOGY/PAIN MANAGEMENT PRODUCTS REVENUE
-----------------------------------------------------------------
                                           2003         2002
                                            $M           $M
-----------------------------------------------------------------

  Total Neurology/Pain Management          304.4       428.3

  DIVESTED PRODUCTS(1)
  Pain Portfolio(2)                         68.0        59.8
  Skelaxin(3)                               60.2       145.3
  Sonata(3)                                 48.2        92.5
  Zonegran(4)                               80.7        43.1
  Frova(4)(5)                               37.5        11.2
  Myobloc(6)                                14.9        19.6
  Zanaflex(7)                             ( 5.1)        56.8
                                          ------       -----
                                           304.4       428.3
-----------------------------------------------------------------

(1)  Products described as "Divested Products" include products or businesses
     divested since the beginning of 2001, and products or businesses subject to
     divestment agreements.

(2)  Sold to aaiPharma Inc. ("aaiPharma") in December 2003.

(3)  Sold to King Pharmaceuticals Inc. ("King") in June 2003.

(4)  On 30 March 2004, Elan announced an agreement to divest this product. This
     divestment closed during the end of the second quarter of 2004.

(5)  Launched in the United States in May 2002.

(6)  Sold to Solstice Neurosciences, Inc. ("Solstice") in July 2004.

(7)  Sold to Acorda Therapeutics, Inc. ("Acorda") in July 2004.

Neurology/Pain Management Products

     Neurological diseases and disorders affect the body's central nervous
system, which is made up of the brain and spinal chord. CNS diseases and
disorders can be classified into two types: neurological, which includes
Alzheimer's disease and other dementia disorders, Parkinson's disease and
epilepsy, and psychiatric disorders, including depression, anxiety disorders
and schizophrenia. Elan's focus is on neurological conditions.

Myobloc

     Myobloc (Neurobloc in Europe) was developed by Elan. It is a sterile liquid
formulation of a purified neurotoxin that acts at the neuromuscular junction to
produce flaccid paralysis. Myobloc was approved by the FDA for the treatment of
patients with cervical dystonia to reduce the severity of abnormal head position
and neck pain. Myobloc was launched in the United States in December 2000 and
Neurobloc was launched in the European Union ("EU") in March 2001. Revenue for
Myobloc amounted to $14.9 million for 2003. Elan recorded an impairment charge
of $37.1 million in 2003 related to the Myobloc intangible assets based on
revised estimates of its future prospects. The product was sold to Solstice in
July 2004. See Note 6 to Elan's Consolidated Financial Statements.

--------------------------------------------------------------------------------
12

--------------------------------------------------------------------------------

Zanaflex

     In June 2002, Elan announced that Eon Labs. Inc. ("Eon") received FDA
approval to market a generic alternative for Zanaflex. A number of other
generic applications for Zanaflex have since received approval from the FDA.
Arising from the approval of generic alternatives for Zanaflex, Elan has
experienced a significant decline in the sales and profitability of this
product. Product returns of Zanaflex during 2003 exceeded the Company's best
estimate of returns at 31 December 2002, resulting in net negative revenues of
$(5.1) million for 2003. Zanaflex was sold to Acorda in July 2004. See Note 6 to
Elan's Consolidated Financial Statements. (see Note 6 to Elan's Consolidated
Financial Statements.)

Pain Portfolio

     In September 2001, Elan acquired a portfolio of pain products (the "Pain
Portfolio") from Roxane Laboratories, Inc. ("Roxane"). In December 2003, Elan
sold the Pain Portfolio to aaiPharma. The Pain Portfolio was comprised of
Roxicodone, Oramorph, Roxanol and Duraclon. These products were marketed in the
United States. Elan's revenue from the Pain Portfolio for 2003 amounted to
$68.0 million.

Skelaxin

     Elan acquired Skelaxin through its acquisition of GWC Health, Inc.
("Carnrick") in 1998. Skelaxin is approved by the FDA as an adjunctive
treatment for the relief of discomfort associated with acute, painful
musculoskeletal conditions. On 12 June 2003, Elan sold Skelaxin to King as part
of the divestment of Elan's primary care franchise. Product revenue from
Skelaxin during 2003 amounted to $60.2 million.

Sonata

     In December 2001, Elan entered into a strategic alliance with Wyeth
pursuant to which Elan assumed responsibility for the U.S. marketing of Sonata,
a non-benzodiazepine hypnotic for the treatment of sleep disorders, which was
launched by Wyeth in 1999. Sonata was also part of Elan's primary care
franchise which was sold to King on 12 June 2003. Product revenue from Sonata
was $48.2 million for 2003.

Zonegran

     Elan licensed Zonegran for the United States and Europe from Dainippon
Pharmaceuticals Co., Ltd. ("Dainippon"). Zonegran was launched in the United
States in May 2000 as an adjunctive therapy in the treatment of partial
epileptic seizures in adults. U.S. revenue for Zonegran for 2003 amounted to
$80.7 million. Zonegran has been marketed by Dainippon in Japan since 1989. A
European MAA filing for Zonegran was submitted in November 2003. In August 2003,
Elan received approval from the FDA to market two new additional dosage
strengths of Zonegran, 25 mg and 50 mg capsules; this is in addition to the
original 100 mg capsule which was previously approved. In 2003, Zonegran
prescription demand increased by 57%2. Zonegran demand continues to grow as a
result of increased promotional efforts as well as the increased interest in
this product following the approval of the 25 mg and 50 mg capsules. On 30 March
2004, Elan announced an agreement with Eisai Co. Ltd. ("Eisai") for the sale of
Elan's interests in Zonegran in North America and Europe. The transaction closed
in the second quarter of 2004 (see Note 6 and Note 34 to Elan's Consolidated
Financial Statements).

Frova

     Elan licensed exclusive North American sales and distribution rights for
Frova in October 1998 from Vernalis plc ("Vernalis"). Frova is a 5HT1B/1D
agonist used as an anti-migraine therapy. In November 2001, the FDA approved
Frova for the acute treatment of migraine. In March 2002, Elan and UCB Pharma,
Inc. ("UCB") entered into an agreement to co-promote Frova. The companies
launched Frova during the second quarter of 2002. Revenue from Frova for 2003
amounted to $37.5 million. On 30 March 2004, Elan announced an agreement with
Vernalis for the termination of the development and licence agreements between
Elan and Vernalis regarding Frova. Vernalis agreed to purchase Elan's
commercialisation rights in North America for Frova. The transaction closed in
the second quarter of 2004 (see Note 6 and Note 34 to Elan's Consolidated
Financial Statement).

[GRAPHIC OMITTED]

Elan is prepared to leverage the value of a strategically aligned,
hospital-based specialty sales and marketing group. The company's Therapeutic
Markets organisation represents an important operational asset.

                           JUAN CARLOS AGUILERA, M.D.
                             Senior Vice President,
                 Global Sales and Marketing and Medical Affairs

Hospital/Specialty Products

     Severe bacterial infections remain a major concern, even more so with the
rise in resistance seen to many available therapies. Currently Elan markets two
products that treat severe infections; each designed to address specific
medical needs within the hospital market. As distinct from the community or
home

[GRAPHIC OMITTED]

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      13

--------------------------------------------------------------------------------
OPERATING REVIEW

       U.S. HOSPITAL/SPECIALTY PRODUCTS REVENUE
-------------------------------------------------------
                                 2003         2002
                                  $M           $M
-------------------------------------------------------

   Total Hospital/Specialty     155.3        176.8
   RETAINED PRODUCTS(1)
   Maxipime                     109.1         79.2
   Azactam                       45.1         33.0
                                -----        -----
                                154.2        112.2
   DIVESTED PRODUCTS(2)
   Abelcet(3)                     1.1         64.6
-------------------------------------------------------

(1)  Products described as "Retained Products" include products or businesses
     not divested and not subject to divestment agreements.

(2)  Products described as "Divested Products" include products or businesses
     divested since the beginning of 2001, and products or businesses subject to
     divestment agreements.

(3)  Divested in November 2002 to Enzon Pharmaceuticals, Inc. ("Enzon")

settings markets, the hospital market is highly specialised and often relies on
a team of healthcare professionals that influence the decision- making process.
Elan is committed to meeting the needs of the infectious disease-community
within the hospital market.

Maxipime

     Elan licensed the U.S. marketing rights to Maxipime from Bristol-Myers
Squibb Company ("Bristol-Myers") in January 1999. Maxipime is a
fourth-generation injectable cephalosporin antibiotic used to treat patients
with serious and/or life-threatening infections. Pulmonologists, infectious
disease specialists, urologists, internal medicine physicians, haematologists
and oncologists prescribe Maxipime for patients with severe hospital-based
respiratory and non-respiratory conditions such as pneumonia, urinary tract
infection and febrile neutropenia. An important attribute of Maxipime is its
broad spectrum of activity, including activity against many pathogens resistant
to other antibiotics. U.S. revenue for Maxipime amounted to $109.1 million for
2003.

SALES AND MARKETING

In 2003, Elan marketed its products through two focused sales forces in the
United States. The U.S. sales forces promoted the following products:

----------------------------------------------------------------------------------------
SALES FORCE                                                 PRIMARY CARE     SPECIALTY
----------------------------------------------------------------------------------------

 Approximate Average Number of U.S. Sales Representatives   390              270
 Products                                                   Skelaxin         Maxipime
                                                            Sonata           Azactam
                                                                             Zonegran
                                                                             Frova
                                                                             Roxicodone
----------------------------------------------------------------------------------------

In June 2003, Elan sold its primary care franchise to King. This divestment
included Elan's primary care sales force of approximately 390 representatives.
In December 2003, Elan sold the Pain Portfolio, including Roxicodone, to
aaiPharma. In March 2004, Elan agreed to sell Zonegran to Eisai, including the
associated sales team of approximately 115 employees, and also agreed to sell
Frova to Vernalis. Going forward, Elan's sales forces will continue to be
re-configured to optimise the products in the portfolio and to prepare for the
launch of the pipeline products.

Azactam

     Elan licensed the U.S. marketing rights to this injectable product from
Bristol-Myers in January 1999. Azactam is a monobactam and is principally used
by surgeons, infectious disease specialists and internal medicine physicians to
treat pneumonia, post-surgical infections and septicemia. U.S. revenue for
Azactam was $45.1 million for 2003.

Abelcet

     Elan acquired Abelcet when it acquired The Liposome Company, Inc.
("Liposome") in May 2000. Abelcet, which is an amphotericin B lipid complex, is
used for the treatment of systemic fungal infections. These infections mainly
occur in immuno-compromised patients such as those undergoing cancer
chemotherapy. On 22 November 2002, Elan announced the completion of the sale of
its U.S., Canadian and any Japanese rights to Abelcet, and certain related
assets, to Enzon. In February 2004, Elan sold its remaining marketing rights to
Abelcet to Medeus Pharma Limited ("Medeus") as part of the sale of its European
sales and marketing business.

Commercial--Non-U.S.

     On 12 February 2004, Elan announced the sale of its European sales and
marketing business to Medeus. Product revenue from Elan's European business
amounted to $112.4 million for 2003.

--------------------------------------------------------------------------------
14

--------------------------------------------------------------------------------

Global Services & Operations

     GS&O encompasses the Company's initiatives in product development,
optimisation and manufacturing and is focused on providing superior technology
platforms that can offer innovative, high-value, quality technologies to
address the drug delivery challenges of the pharmaceutical industry. Elan's
drug delivery businesses engage in the development and commercialisation of
pharmaceutical products for clients through the application of drug delivery
technologies. Drug delivery technologies can improve the performance of
existing marketed drugs or drugs under development and can improve the efficacy
of research and development processes. Elan has a long and established history
in the manufacture and development of pharmaceutical dosage forms for
pharmaceutical markets worldwide, with dozens of products successfully launched
in more than 40 countries in North America, Asia and Europe. Elan's GS&O unit
assists companies with their pharmaceutical manufacturing, scale-up and
development requirements.

     Elan has a fully compliant FDA/European Agency for the Evaluation of
Medicinal Products ("EMEA")-approved site in Athlone, Ireland, where it recently
completed an investment of approximately $178 million in its key strategic
pharmaceutical manufacturing and development facilities. The Athlone campus now
comprises 138,000 square feet of dedicated, fully-equipped current Good
Manufacturing Practices ("cGMP") manufacturing capacity to manufacture two
billion units annually.

[GRAPHIC OMITTED]

GS&O encompasses the Company's initiatives in product development, optimisation,
and manufacturing, and is focused on providing superior platforms that offer
innovative technologies and address the industry's drug delivery challenges.

                                   PAUL BREEN
             Executive Vice President, Global Services & Operations

     Elan also has a manufacturing, scale-up and development facility approved
for the manufacture of controlled substances (through Schedule II), in
Gainesville, Georgia. The Company's development and scale-up facility in King
of Prussia, Pennsylvania is home to its proprietary NanoCrystal technology for
delivery of poorly water-soluble compounds. Prior to the completion of the
Company's recovery plan, Elan's King of Prussia and Gainesville drug delivery
businesses were included within Elan Enterprises.

                               [GRAPHIC OMITTED]

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      15

                               [GRAPHIC OMITTED]

OPERATING REVIEW

COMPLETION OF RECOVERY PLAN

On 12 February 2004, Elan announced the formal completion of its recovery plan.
The recovery plan, which was announced on 31 July 2002, involved the
restructuring of the Company's businesses, assets and balance sheet; and
resulted in gross consideration of $2.1 billion, ahead of the target of $1.5
billion.

The principal elements and outcomes of the recovery plan were:

o    A focus on three core therapeutic areas: neurology, autoimmune diseases and
     severe pain. For additional information on Elan's therapeutic areas, please
     refer to pages 5 to 14.

o    The divestment of financial assets, non-core businesses, products and
     assets targeting proceeds of $1.0 billion in the first nine months of the
     recovery plan and a further $500.0 million by the end of 2003. The total
     target of $1.5 billion was exceeded six months ahead of schedule, and by
     the end of the recovery plan gross consideration of $2.1 billion was
     achieved. For additional information on recovery plan divestments since the
     beginning of 2003, please refer to pages 17 to 18;

o    To enable Elan to meet its financial obligations. Contractual and potential
     future payments have been reduced by $2.5 billion since 31 December 2001 to
     $2.2 billion at 31 December 2003. For additional information on the impact
     of the recovery plan on Elan's financial commitments and contingencies
     during 2003, please refer to pages 19 to 20;

o    The implementation of a cost reduction programme through headcount and
     infrastructure reductions and business rationalisations. At the completion
     of the recovery plan, headcount had been reduced to less than 2,000 from
     approximately 4,700 in July 2002; and

o    A review of Elan's business venture portfolio to conserve cash and reflect
     the reduced scope of Elan's activities. As a result, Elan decided to
     restructure or terminate substantially all of its business ventures with
     the aim of substantially reducing or eliminating future cash outlays by
     Elan. All business ventures have been terminated, restructured or are now
     inactive. As a consequence, Elan does not expect to provide any additional
     financing to the business ventures and business venture parents. For
     additional infor mation on the business ventures, please refer to pages 20
     to 23.

--------------------------------------------------------------------------------
16

--------------------------------------------------------------------------------

ELAN ENTERPRISES

     The conclusion of Elan's recovery plan marked the end of operations for
the Company's Elan Enterprises business unit. Elan Enterprises was mainly
comprised of Elan's drug delivery businesses and other assets such as business
ventures and non-core pharmaceutical products. Elan Enterprises divested many
of these businesses and assets. Following the completion of the recovery plan,
Elan's King of Prussia and Gainesville drug delivery businesses are now
included within Global Services & Operations. In February 2004, the Company's
operations were reorganised into two business units: Biopharmaceuticals and
GS&O. Biopharmaceuticals engages in biopharmaceutical research and development
activities, and pharmaceutical commercial activities. Biopharmaceutical
research and development activities include the discovery and development of
products in the therapeutic areas of neurology, autoimmune diseases and severe
pain. Elan's pharmaceutical commercial activities include the marketing of
neurology and pain management products and hospital and specialty products.
GS&O focuses on product development and manufacturing to provide technology
platforms that address the drug delivery challenges of the pharmaceutical
industry.

     The business venture programme was included within Elan Enterprises. For
additional information on the business venture programme, please refer to pages
20 to 23.

RECOVERY PLAN -- DIVESTMENT PROGRAMME

     A key element of the recovery plan was the divestment of businesses,
products, investments and other assets. The objective was to complete $1.5
billion in asset divestments by the end of 2003. From its commencement in
August 2002 to its completion in February 2004, the divestment programme
generated gross consideration from asset divestments of $2.1 billion.

     The divestment programme evolved over the period and the Company sold more
products and businesses than initially envisaged due to market demand for
non-core assets. The following is a summary of the principal divestments
resulting from the recovery plan that occurred since the beginning of 2003:

European Sales and Marketing Business

     On 12 February 2004, Elan announced the completion of the sale of its
European sales and marketing business to Medeus, a new U.K. pharmaceutical
company backed by Apax Partners Funds. Elan realised total consideration of
approximately $120 million from this transaction (subject to adjustment for
certain movements in indebtedness and working capital in the period to
completion), which was previously announced on 23 December 2003. Approximately
180 employees of Elan's European sales and marketing business have transferred
their employment to Medeus. Separately, Elan completed the sale of certain
rights to two products in the U.K. and Ireland for approximately $10 million
during the first quarter of 2004.

Pain Portfolio

     On 2 December 2003, Elan announced the completion of the sale of the Pain
Portfolio, acquired from Roxane in September 2001, and related assets to
aaiPharma. These products included the rights to Roxicodone tablets and oral
solution, Oramorph SR tablets, Roxanol and Duraclon. The total consideration
was $101.8 million, comprising a cash payment to Elan of $50.4 million and the
assumption, by aaiPharma, of $51.4 million of Elan's product payment
obligations to Roxane.

Xcel

     On 1 April 2003, Elan announced that it received $89.5 million in cash
from Xcel Pharmaceuticals, Inc. ("Xcel") in exchange for all of Elan's
shareholding in, and loans to, Xcel.

Skelaxin & Sonata

     On 30 January 2003, Elan announced that it had agreed to sell its primary
care franchise, principally consisting of its U.S. and Puerto Rican rights to
Sonata and Skelaxin, related inventory and related rights to enhanced
formulations of these products, to King.

     On 17 March 2003, Elan commenced a lawsuit against King to compel King to
complete its purchase of the primary care franchise. On 19 May 2003, Elan and
King agreed to proceed with the transaction on amended terms and on 12 June
2003 the transaction was completed. Effective upon the closing of the
transaction, all claims under the pending litigation were released and Elan and
King dismissed the litigation with prejudice.

     Under the terms of the amended transaction, King paid gross consideration
on closing of $749.8 million, which included the transfer to King of Sonata and
Skelaxin inventory with a value of approximately $40 million and obligations
related to Sonata of $218.8 million that were assumed by King at closing. In
addition, Elan received an additional $25.0 million payment in January 2004
which was contingent on the ongoing patent exclusivity of Skelaxin through 31
December 2003. Elan will also receive payments of 5% of net sales of the
current formulation of Skelaxin through 31 December 2005 and, thereafter,
beginning in 2006 and continuing through December 2021, Elan will receive
payments of 10% of net sales of the current formulation of Skelaxin in excess
of $50.0 million of net sales annually. Finally, Elan may receive up to an
additional $61.0 million in milestone payments (comprised of up to $86.0
million in clinical, regulatory and sales milestones less up to $25.0 million
in milestones that Elan would be obligated to pay to a third party) relating to
the development of enhanced formulations of Sonata, contingent on the
achievement of certain clinical and regulatory events. Elan received the first
of these milestone payments, for $11.0 million, in March 2004.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      17

--------------------------------------------------------------------------------

OPERATING REVIEW -- COMPLETION OF RECOVERY PLAN

Ligand Common Stock

     On 12 November 2002, Elan announced that Ligand Pharmaceuticals, Inc.
("Ligand") had agreed to repurchase from Elan approximately 2.2 million shares
of Ligand common stock for a cash purchase price of $20.0 million. This share
sale closed in February 2003.

     On 28 May 2003, Elan sold an additional 6.4 million shares of Ligand
common stock in the open market for net cash proceeds of $73.0 million. On 11
July 2003, Elan sold its remaining 5.8 million shares of Ligand common stock to
a number of qualifying institutional investors for net cash proceeds of $65.1
million.

Other Divestments

     In July 2003, Elan sold a transdermal technology business located in
Miramar, Florida, United States to Nitto Americas, Inc. ("Nitto Americas"), the
U.S. subsidiary of Nitto Denko Corporation.

     In July 2003, Elan also sold an oral controlled-release and pulmonary
technologies business located in Nottingham, United Kingdom to a company
managed by former employees of the business.

     On 29 April 2003, Elan completed the sale of the assets of Elan
Diagnostics, Inc. ("Elan Diagnostics") to Novitron International, Inc.

Zonegran & Frova

     On 30 March 2004, Elan announced an agreement with Eisai for the purchase
of Elan's interests in Zonegran in North America and Europe. On closing, Eisai
paid Elan consideration of $129.6 million for these interests, including
inventory and the associated sales team of approximately 115 employees. In
addition, Elan may earn future deferred purchase payments of up to $110.0
million, primarily contingent on when generic zonisamide is introduced in the
U.S., and including up to $25.0 million contingent on receiving marketing
approval for Zonegran in Europe. Elan will also receive additional deferred
purchase payments on net sales of Zonegran in North America and Europe if
certain additional conditions are met. Elan was required to pay $17.0 million
to Dainippon on closing for the assignment of the Zonegran North American and
European licence agreements to Eisai. Elan realised a gain of $41.3 million on
the sale of Zonegran. Elan will continue to manufacture Zonegran in all three
dosage strengths of 25 mg, 50 mg, and 100 mg capsules in
Athlone, Ireland.

     Also on 30 March 2004, Elan announced an agreement with Vernalis for the
termination of the development and licence agreements between Elan and Vernalis
regarding Frova. Vernalis agreed to purchase Elan's commercialisation rights in
North America for Frova. Vernalis agreed to pay Elan a total of approximately
$55 million for rights to Frova in North America, comprising $5.0 million
received on closing in the second quarter of 2004; $20.0 million and $25.0
million on 31 December 2004 and 31 December 2005, respectively; and, no later
than 31 December 2004, Elan was to receive a payment for its Frova inventory,
estimated at approximately $5 million. In August, Elan and Vernalis agreed to
settle the remaining consideration for approximately $44 million as a full
payment for Frova. Elan's co-promotion agreement with UCB was terminated at
closing, and Elan paid UCB approximately $10 million as a result of the
termination. Elan realised a gain of $6.6 million on the sale of Frova.

     While the divestments of Zonegran and Frova did not form part of the
recovery plan, and are not included in the $2.1 billion of gross consideration
from recovery plan asset divestments described above, they further align Elan's
strategy in research, development, sales and marketing with the Company's core
therapeutic areas. They enable Elan to focus its resources on the anticipated
launch of the Company's late-stage pipeline candidates, Antegren for multiple
sclerosis and Crohn's disease, and Prialt for severe pain.

     For further information on these disposals, including the impact of these
disposals on Elan's financial results, please refer to the Financial Review.

Future Transactions

     Neither the completion of the recovery plan nor the dissolution of Elan
Enterprises preclude the Company from considering future, specifically-targeted
divestment and acquisition opportunities. For example, as described above, on
30 March 2004 Elan announced agreements to sell Zonegran and Frova.

--------------------------------------------------------------------------------
18

--------------------------------------------------------------------------------

RECOVERY PLAN -- FINANCIAL COMMITMENTS AND CONTINGENCIES

     A key objective of the recovery plan was to enable Elan to meet its
financial obligations.

During 2003, contractual and potential future payments have been reduced by
approximately $1.2 billion, from $3.4 billion at 31 December 2002 to $2.2
billion at 31 December 2003. The main elements of this reduction were:

-------------------------------------------------------------
                                                        $M
-------------------------------------------------------------

   Contractual and potential future payments at
     31 December 2002 -- as previously reported      3,124.1
   Inclusion of operating and capital lease
     obligations (1)                                   251.3
                                                     -------
   Contractual and potential future payments at
     31 December 2002 -- revised                     3,375.4
   Net reduction during 2003:
   Risk-sharing arrangements                        ( 335.0)
   Repurchase of 3.25% zero coupon subordinated
     exchangeable notes ("LYONs")                   ( 816.0)
   Reduction of fixed, contingent and potential
     product payment obligations                    ( 451.6)
   Operating and capital lease obligations          (   8.3)
   Issuance of 6.5% convertible guaranteed notes
     due 2008 ("6.5% Convertible Notes")               460.0
-------------------------------------------------   --------
   Contractual and potential future payments at
     31 December 2003                                2,224.5
-------------------------------------------------------------

(1) In accordance with SEC Release No 34-47264 "Disclosure in Management's
Discussion and Analysis about Off-Balance Sheet Arrangements and Aggregate
Contractual Obligations," which is effective for financial statements ending on
or after 15 December 2003, operating and capital lease obligations have been
included in the table of contractual and potential future payments at 31
December 2003 on page 61. The table above has also been revised to include the
amounts for these items at 31 December 2002 for comparative purposes. For
additional information on operating and capital leases, please refer to Note 23
to the Consolidated Financial Statements.

Risk-Sharing Arrangements

     Elan's risk-sharing arrangement with Pharma Marketing Ltd. (together with
its subsidiary, "Pharma Marketing") was restructured in January 2003, such that
effective upon the sale of Sonata to King on 12 June 2003, (i) Elan paid Pharma
Operating Ltd. ("Pharma Operating") $196.4 million in cash (representing $225.0
million less royalty payments on all related products paid or due to Pharma
Operating from 1 January 2003 through 12 June 2003) to acquire Pharma
Operating's royalty rights with respect to Sonata and Prialt and (ii) Elan's
maximum purchase price for the remaining products in the arrangement, Zonegran,
Frova and Zanaflex, was reduced to $110.0 million, which increased at a rate of
15% per annum from 12 June 2003 (less royalty payments made for periods after
12 June 2003). The parties also agreed to extend Elan's purchase option
termination date to 3 January 2005, from the original termination date of 30
June 2003. Elan exercised that option and, on 20 November 2003, announced the
completion of the purchase of royalty rights in respect of Zonegran, Frova and
Zanaflex from Pharma Operating for $101.2 million. As a result, all of Elan's
agreements with Pharma Marketing were terminated.

     For additional information on Pharma Marketing, please refer to Note 24 to
the Consolidated Financial Statements.

LYONs

     In December 1998, Elan Finance Corporation Limited ("EFC"), a wholly owned
subsidiary of Elan, issued in a private placement, at a substantial discount,
LYONs due 2018 in the principal amount of $1,643.5 million at maturity. The
issue price of the LYONs was $524.78 per $1,000 principal amount at maturity
and the gross proceeds to the Company amounted to $862.5 million.

     In December 2002, Elan repurchased $318.6 million in principal amount at
maturity of the LYONs.

     Through 3 June 2003, Elan repurchased an additional $523.7 million in
principal amount at maturity of the LYONs (representing approximately 32% of
the originally issued LYONs) in separate privately negotiated purchases. The
aggregate cost was $310.3 million. This was a discount of approximately 4% to
the accreted value of such LYONs at 14 December 2003 of $322.9 million.

     On 14 November 2003, Elan announced that holders of the remaining
outstanding LYONs had the right to surrender their LYONs for purchase during
the period that began on that date and ended on 15 December 2003. Pursuant to
the indenture under which the LYONs were issued in December 1998, each holder
of LYONs had the right to require Elan to purchase, until 5:00 p.m., New York
time, on 15 December 2003, such holder's LYONs at a price equal to $616.57 per
$1,000 principal amount at maturity of the LYONs.

     Under the terms of the LYONs, Elan had the option to pay for the LYONs in
cash, in American Depositary Shares ("ADSs"), representing Ordinary Shares of
Elan, or in any combination of cash and ADSs. Elan elected to pay for the LYONs
in cash. The aggregate principal amount due at maturity for all outstanding
LYONs was approximately $801.3 million.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      19

--------------------------------------------------------------------------------

OPERATING REVIEW -- COMPLETION OF RECOVERY PLAN

     On 16 December 2003, Elan announced that LYONs with an aggregate principal
amount at maturity of approximately $799.7 million were validly surrendered for
repurchase and not withdrawn, and Elan had repurchased all such LYONs.
Approximately $1.6 million in aggregate principal amount at maturity of LYONs
remain outstanding following the completion of the repurchase. The aggregate
purchase price for all LYONs validly surrendered for repurchase and not
withdrawn was approximately $493.1 million. The accreted value of the remaining
LYONs was $0.9 million at 31 December 2003.

     For additional information on the LYONs, please refer to Note 15 to the
Consolidated Financial Statements.

Fixed, Contingent and Potential Product Payment Obligations

     The net reduction of $451.6 million in fixed, contingent and potential
product payment obligations from 31 December 2002 to 31 December 2003 primarily
reflects product payments made during 2003 of $212.4 million and product
payment obligations assumed by King and aaiPharma of $218.8 million and $51.4
million respectively.

Issuance of Ordinary Shares and 6.5% Convertible Notes

     On 5 November 2003, Elan announced that it had successfully completed a
private offering of 35 million Ordinary Shares at a price of $4.95 per share
and, on 10 November 2003, Elan announced that it had successfully completed a
private offering of $460.0 million in aggregate principal amount of 6.5%
Convertible Notes. The offerings resulted in aggregate net proceeds (after
giving effect to the payment of commissions and concessions and the expenses of
the offerings, including a waiver fee of $16.8 million paid to the holders of
Elan Pharmaceutical Investments II, Ltd ("EPIL II") 9.56% guaranteed senior
notes (the "EPIL II Notes") and Elan Pharmaceutical Investments III, Ltd ("EPIL
III") Series B guaranteed senior notes (the "Series B Guaranteed Notes") and
Series C guaranteed senior notes (the "Series C Guaranteed Notes") (together
with the Series A guaranteed senior notes (the "Series A Guaranteed Notes")
which matured and were repaid on 29 June 2002, the "EPIL III Notes")) of $592.6
million. The net proceeds from the offering were used to repurchase outstanding
LYONs, including LYONs surrendered for purchase by the holders on 15 December
2003, pursuant to the indenture under which the LYONs were issued, and for the
repurchase of royalty rights from Pharma Operating.

BUSINESS VENTURES

     Since 1996, Elan has pursued collaborations with biotechnology, drug
delivery and pharmaceutical companies in order to leverage Elan's drug delivery
technologies and its proprietary neurological and oncology research, and to
access complementary or synergistic research and development programmes in
Elan's areas of expertise. Elan has historically referred to this programme in
a number of ways, including as a joint venture programme, a business venture
programme, and a strategic licensing programme. For the purposes of this
discussion, this programme will be referred to as the "business venture
programme". Elan has not entered into any new business ventures under the
business venture programme since mid-2001.

     In 2002, as part of the recovery plan, Elan completed a review of its
business venture portfolio to conserve cash and reflect the reduced scope of
Elan's activities. As a result, Elan decided to restructure or terminate
substantially all of its business ventures with the aim of substantially
reducing or eliminating future cash outlays by Elan. The restructuring process
and any terms agreed have been the result of negotiations between Elan and the
respective business venture parents. As such, the agreed terms arising from the
restructuring process vary between different business venture relationships.
Typically, as part of the termination of a business venture, the technologies
contributed by the business venture parent and Elan are returned, the
technology developed in the business venture is transferred to the business
venture parent and/or Elan, and Elan transfers its interest in the business
venture to the business venture parent in exchange for a continuing interest in
the product or technology previously in the business venture, such as a
royalty. There were approximately 55 business ventures in place prior to the
announcement of the recovery plan on 31 July 2002. All business ventures have
been terminated, restructured or are now inactive. As a consequence, Elan does
not expect to provide any additional financing to the business ventures and
business venture parents.

     As all business ventures have been terminated, restructured or are now
inactive, the description of the business venture programme below is described
in the past tense.

     The business venture programme generally involved licensing drug delivery
technologies and know-how, or pharmaceutical research and development assets,
to a

--------------------------------------------------------------------------------
20

--------------------------------------------------------------------------------

newly formed subsidiary ("the business venture") of an emerging biotechnology;
drug delivery or pharmaceutical company ("the business venture parent") and the
establishment of a joint development collaboration.

     Contemporaneously with the licensing and collaborative transaction, Elan
typically made an investment in the business venture. Investments in business
ventures were in various forms. Prior to mid 1999, those investments were
generally in the form of voting common stock. Subsequently, these investments
were in the form of non-voting preferred stock convertible into common stock
after a period of two years. Elan typically held an initial fully diluted
equity interest of 19.9% in the business venture. Elan also typically made a
contemporaneous investment in the business venture parent in the form of common
equity and convertible/exchangeable preferred stock and/or convertible/
exchangeable debt. The convertible/exchangeable securities in the business
venture parent were generally convertible, at Elan's option, into common equity
of the business venture parent or exchangeable for up to 30.1% of the common
equity in the business venture, potentially bringing Elan's fully diluted equity
interest in the business venture up to 50%. In many transactions, if Elan chose
to exchange the convertible/exchangeable securities in the business venture
parent into common equity of the business venture, then it would be required to
pay the business venture parent an amount equal to 30.1% of the cumulative
operating funding of the business venture to the date of exchange such that Elan
and the business venture parent would have shared equally (on a cumulative
basis) in such funding. Elan sold certain of its investments in the business
ventures and the business venture parents to EPIL II in June 2000 and to EPIL
III in March 2001. EPIL II and EPIL III are securitisation entities and the
investments are held by EPIL II and EPIL III as security for outstanding
indebtedness issued by the entities. For additional information regarding these
special purpose entities, please refer to Notes 15 and 33 to the Consolidated
Financial Statements.

     The business venture generally conducted research and development
activities using its technologies and proprietary know-how in an agreed
research field. Elan's partner, the business venture parent, principally
managed the business venture. The technologies and proprietary know-how of the
business venture were in-licensed by the business venture from Elan and the
business venture parent. On formation, a number of contracts were entered into
to govern the in-licensing of intellectual property assets to the business
venture from Elan and the business venture parent.

     Development of products and technologies for pharmaceutical applications
involves risk. The nature of pharmaceutical development, with stringent
regulatory constraints and guidelines designed to protect the health and safety
of patients and those working with the products, means that development
activities are costly and time consuming. Elan's portfolio of business ventures
allowed it to diversify the risks associated with product development.
Individual development programmes within the business ventures had varying
degrees of success and failure. Elan and the business venture parent would
typically work together using commercially reasonable efforts and their
combined technical, regulatory and clinical expertise to increase the
likelihood of success of the business ventures. This could lead to changes in
the direction of a development programme, adding or substituting technologies
or products and redirection of clinical programmes as deemed necessary.

     The business venture, the business venture parent and Elan continually
reviewed the progress of the research and development activities in the
business venture. As part of this review, the parties could decide that it was
not commercially or technically practical to continue to support the business
venture.

     Elan received and recorded initial revenue from the business ventures of
$Nil, $Nil and $172.5 million for 2003, 2002 and 2001, respectively, and Elan's
initial investments in the business ventures and the business venture parents
were $Nil, $Nil and $229.2 million for 2003, 2002 and 2001, respectively. These
amounts for 2001 are set out in the table on page 23.
     The business ventures typically had the following operational structure.
The board of directors of a business venture was generally comprised of a
majority of directors from the business venture parent and one director
nominated by Elan. For a quorum, the presence of the Elan nominated director
was required. The business plan required the approval of the board of directors
of the business venture, including the Elan nominated director. This approval
was subject to the directors' fiduciary duty to the business venture. The
contracts of establishment provided for subsequent reviews, either annually or
more frequently, of the business plan and required the continuing approval by
the Elan nominated director. The business

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      21

--------------------------------------------------------------------------------

OPERATING REVIEW -- COMPLETION OF RECOVERY PLAN

ventures also typically had a management committee and/or research and
development committee. These committees generally provided for equal
representation by Elan and the business venture parent. The committees had
responsibility for day to day activities of the business venture and for the
implementation of the business plan. At their inception, the business ventures
typically had no funds after payment of the initial fee to Elan. The operating
funding of the business venture was provided by the business venture parent and
Elan, subject to the approval of both parties. Funding was generally utilised
to pay for research and development activities. Typically, such subsequent
financial support was provided in proportion to the respective fully diluted
ownership of the business venture by the business venture parent and Elan
(typically 80.1% and 19.9%, respectively). Elan expensed the subsequent funding
it provided directly to the business venture. This was expensed within the
interest and other expense line. Elan expensed $3.0 million, $23.9 million and
$24.6 million of subsequent business venture funding in 2003, 2002 and 2001,
respectively. If both Elan and the business venture parent agreed to provide
subsequent financial support to the business venture through their ongoing
approval of a business plan, then, if requested by the business venture parent,
Elan was required to make additional investments in the business venture
parent, typically in the form of convertible debt, in an amount equal to the
business venture parent's proportion of such subsequent financial support, the
proceeds of which the business venture parent was required to use to fund its
proportion of the subsequent support of the business venture. This amount was
recorded by Elan as a financial asset. Elan provided additional financing of
$7.1 million, $83.4 million and $92.2 million to business venture parents in
2003, 2002 and 2001, respectively. All business ventures have been terminated,
restructured or are now inactive. As a consequence, Elan does not expect to
provide any additional financing to the business ventures and business venture
parents.

     The business ventures incurred research and development expenditures of
approximately $17 million, $125 million and $125 million in 2003, 2002 and
2001, respectively. While the business ventures and the business venture
parents were generally responsible for ongoing research and development
activities, they could request that Elan conduct research and development on
their behalf. If Elan undertook such work, the work was typically charged to
the business venture at pre-determined rates, which were set to recover Elan's
costs plus a mark-up. Elan received research revenue from the business ventures
of $3.7 million, $13.4 million and $15.0 million in 2003, 2002 and 2001,
respectively. Elan does not expect to receive any future research revenues from
the business ventures.

     Investments in the business ventures and the business venture parents were
made at fair value. The fair value of investments was typically initially
determined by Elan using established financial methodologies, including quoted
market prices for quoted equity securities. Unquoted equity investments and
non-traded securities of public entities were assessed using methodologies
including the Black-Scholes option-pricing model, the valuation achieved in the
most recent private placement by an investee, an assessment of the impact of
general private equity market conditions, and discounted projected future cash
flow models.

     Subsequent to Elan's investment in a business venture and business venture
parent, the fair values of the investments have been typically determined
periodically, but not less frequently than yearly, by an independent financial
institution using methodologies similar to those described above.

     The table on page 23 sets forth certain information regarding the 12
business ventures that were formed in 2001. No new business ventures were
formed in 2003 or 2002. Of all of the business ventures formed since the
commencement of the business venture programme in 1996, approximately 55 were
still in place prior to the announcement of the recovery plan on 31 July 2002.
All business ventures have been terminated, restructured or are now inactive.
As a consequence, Elan does not expect to provide any additional financing to
the business ventures and business venture parents.

     Elan recognised exceptional charges in its profit and loss account for
2003 to reflect impairments to the Group's investment portfolio, including
investments held by EPIL II and EPIL III. This includes impairment charges
relating to investments in business ventures and business venture parent
companies of $4.0 million (2002: $114.4 million; 2001: $13.4 million) and
$106.0 million (2002: $880.0 million; 2001: $NiL), respectively.

--------------------------------------------------------------------------------
22

--------------------------------------------------------------------------------

BUSINESS VENTURES--2001
-----------------------------------------------------------------------------------------------------------------------------
                                     AGGREGATE INITIAL
                                     AMOUNT INVESTED
                                     (IN BOTH BUSINESS                                                        INITIAL FEE
                                     VENTURE AND BUSINESS                                                     RECEIVED
BUSINESS VENTURE PARENT              VENTURE PARENT)          FIELD OF RESEARCH AND DEVELOPMENT               BY ELAN
-----------------------------------------------------------------------------------------------------------------------------

Allergy Therapeutics Ltd.            $20.7 million            Development of anti-histamine                   $15.0 million
                                                              formulations

Applied Genetics                     $19.0 million            Topical treatments of skin disease              $15.0 million
Incorporated Dermatics                                        including skin cancer
                                                              (Dimericine (Trade Mark) --liposomal T4N5)

Beyond Genomics, Inc.                $15.0 million            Research into Alzheimer's disease and/or        $10.0 million
                                                              mild cognitive impairment

CeNeS Limited                        $21.0 million            Treatment of pain                               $15.0 million
                                                              (morphine-6-glucuronide)

ChemGenex                            $20.0 million            Treatment of cancer                             $15.0 million
Therapeutics, Inc.

Cogent Neuroscience, Inc.            $17.5 million            Treatment of CNS diseases                       $12.5 million

Curis, Inc.                          $19.0 million            Treatment of neurological disorders             $15.0 million

eNOS Pharmaceuticals, Inc.           $17.0 million            Treatment of neurological and                   $15.0 million
                                                              cardiovascular diseases in
                                                              non-hypercholesterolemic humans
                                                              (EN-110)

GlycoGenesys, Inc.                   $20.0 million            Treatment of cancer (GCS-100, formerly          $15.0 million
                                                              known as GBC-590)

Inex Pharmaceuticals Corporation     $20.0 million            Treatment of cancer (VSLI (Trade Mark))         $15.0 million

Lipocine Inc.                        $20.0 million            Oral hormone replacement therapy                $15.0 million
                                                              combination product

Nobex Corporation                    $20.0 million            Treatment of post-menopausal                    $15.0 million
                                                              osteoporosis or Paget's disease
                                                              (Oratonin (Trade Mark) )
-----------------------------------------------------------------------------------------------------------------------------
Total                                $229.2 million                                                           $172.5 million
-----------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      23

                               [GRAPHIC OMITTED]

OPERATING REVIEW

ENVIRONMENT

Many factors and elements contribute to the environment in which the Company
conducts its activities. Key factors and elements include the world
pharmaceutical market, government regulation, the product approval process,
manufacturing, patents and intellectual property rights, competition,
distribution, raw materials and product supply, employees and principal
properties.

WORLD PHARMACEUTICAL MARKET

     IMS audited global pharmaceutical sales increased by 9% from 2002 to
$466.3 billion in 20031. In 2002, IMS audited global pharmaceutical sales
increased by 8% over 20011. Sales increased due to ageing of the global
population and an increasingly robust drug development pipeline, among other
factors.

     North America, Japan and Europe accounted for approximately 88%1 of global
pharmaceutical sales in 2003. North America's pharmaceutical sales grew 11% to
$229.51 billion, representing almost half of all global pharmaceutical sales in
2003.

     The U.S. market is Elan's most important market. Please refer to Note 2 to
the Consolidated Financial Statements for an analysis of revenue by geographic
region. For this reason, the factors discussed below, such as "Government
Regulation" and "Product Approval Process", place emphasis on requirements in
the United States.

GOVERNMENT REGULATION

     The pharmaceutical industry is subject to significant regulation by
international, national, state and local governmental regulatory agencies.
Pharmaceutical product registration is primarily concerned with the safety,
efficacy and quality of new drugs and devices, and, in some countries, their
pricing. A product must generally undergo extensive clinical trials before it
can be approved for marketing. The process of developing a new pharmaceutical
product, from idea to commercialisation, can take in excess of ten years. This
period varies considerably from case to case and from country to country.

     An application for registration includes specific details concerning not
only the chemical composition, but also the manufacturing plant and procedures
involved in the production of the product. The time from submission of an
application to commercialisation of the product is typically two years or
longer. After a product has been approved by the regulatory authorities and has
been launched, it is a condition of the product approval that all aspects
relating to its safety, efficacy and quality remain under review.

     Governmental authorities, including the FDA and comparable regulatory
authorities in other countries, regulate the design, development, testing,
manufacturing and marketing of pharmaceutical products. For example, the
Federal Food, Drug and Cosmetic Act ("FDCA"), the Public Health Service Act,
the Controlled Substances Act and other federal statutes and regulations impose
requirements on the clinical and non-clinical testing, safety, effectiveness,
manufacturing, labelling, storage, record-keeping, reporting, advertising,
marketing, import, export, distribution and approval of Elan's products in the
United States. Non-compliance with applicable requirements can result in fines
and other judicially imposed sanctions, including product seizures, import
restrictions, injunctive actions and criminal prosecutions. In addition,
administrative remedies can involve requests to recall violative products, the
refusal of the government to enter into supply contracts and/or the refusal to
approve pending product approval applications (such as NDAs and Abbreviated New

--------------------------------------------------------------------------------
24

--------------------------------------------------------------------------------

Drug Applications ("ANDAs") for drugs, BLAs for biological products, or
Premarket Approval Applications and "510(k)s" for medical devices), until
manufacturing or other alleged deficiencies are brought into compliance. The
FDA also has the authority to cause the withdrawal of approval of a marketed
product or to impose labelling restrictions.

     In addition, the U.S. Centers for Disease Control and Prevention regulate
select biologics and toxins. This includes registration and inspection of
facilities involved in the transfer or receipt of select agents. Select agents
are subject to specific regulations for packaging, labelling and transport.
Non-compliance with applicable requirements could result in criminal penalties
and the disallowance of research and manufacturing of clinical products. Exemp-
tions are provided for select agents used for a legitimate medical purpose or
for biomedical research, such as toxins for medical use and vaccines.

[GRAPHIC OMITTED]

     Elan expects to file two to three U.S. NDAs and two European MAAs by the
end of 2004. Elan also expects to file two Investigational New Drug Applications
in the next one to two years, based on current research efforts.

LARS EKMAN, M.D. Executive Vice President & President, Global R&D and Corporate
Strategy

     Certain in vitro diagnostic products and certain delivery systems, such as
MEDIPAD, are regulated or potentially regulated in the United States under the
FDCA as medical devices. These products are subject to pre-marketing and
post-marketing requirements. Among other things, medical devices are subject to
quality system requirements, including design control and good manufacturing
practices, and to requirements for adverse event reporting by manufacturers,
distributors and user facilities. The failure to adhere to these requirements
can result in a refusal of permission to market and the imposition of sanctions,
including seizure, recall notification, replacement or refund, injunction, and
civil and criminal penalties. Additionally, as a condition to marketing or
continued marketing, the FDA could impose certain post-market surveillance
and/or tracking requirements, which could significantly increase the regulatory
costs associated with a product. Under the FDCA, it is also possible for a given
product to be regulated both as a drug and a medical device or as a biologic and
medical device. In vitro diagnostic products are also subject to certain
requirements under the Clinical Laboratory Improvement Act of 1988, as amended,
relating to test complexity and risk.

     The pricing of pharmaceutical products is regulated in many countries. The
mechanism of price regulation varies. For example, certain countries regulate
the price of individual products while in other countries prices are controlled
by limiting overall company profitability. In the United States, while there
are limited indirect federal government price controls over private sector
purchases of drugs, there have been ongoing discussions on potential reforms of
the healthcare system, including the pricing of pharmaceuticals, which could
result, directly or indirectly, in the implementation of price controls on a
larger number of pharmaceutical products. Certain states are attempting to
impose requirements, processes, or systems that would result in indirect price
controls. It is not possible to predict future regulatory action on the pricing
of pharmaceutical products.

     In June 2002, Elan entered into a settlement with the U.S. Federal Trade
Commission ("FTC") resolving the FTC's investigation of a licensing arrangement
between Elan and Biovail Corporation ("Biovail") relating to nifedipine, a
generic version of the hypertension drug Adalat CC. The settlement is reflected
in a consent order which, by its terms, does not constitute an admission by
Elan that any law had been violated, and does not provide for monetary fines or
penalties. Elan continues to satisfy all of the terms of the consent order.

     In June 2001, Elan received a letter from the FTC stating that the FTC was
conducting a non-public investigation to determine "whether Brightstone Pharma,
Inc., Elan Corporation or others may have engaged in an effort to restrain
trade by entering into an agreement which may restrict the ability of
Brightstone or others to market a bioequivalent or generic version of
Naprelan." In October 2001, counsel for Elan met informally with the FTC staff
to discuss the matter. No further communication from the FTC was received until
December 2002, when Elan was served with a subpoena duces tecum from the FTC
for the production of documents related to Naprelan. Elan has voluntarily
provided documents and witness testimony in response to the subpoena and
continues to cooperate with the FTC relating to this investigation. Elan does
not believe that it is feasible to predict or determine the outcome of the
investigation and any possible effect on Elan's business, or reasonably to
estimate the amounts or potential range of loss, if any, with respect to the
resolution of the investigation.

     On 13 March 2003, Elan received notification from the FTC that the FTC's
Bureau of Competition was conducting an investigation to determine whether
Elan, King or any

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      25

--------------------------------------------------------------------------------

OPERATING REVIEW -- ENVIRONMENT

other person was engaging in unfair methods of competition in violation of
Section 5 of the Federal Trade Commission Act, including, among other things,
by preventing or slowing generic competition to Skelaxin. The FTC's stated
focus of the investigation was Elan's listing in the FDA's Approved Drug
Products with Therapeutic Equivalence Evaluations ("Orange Book") of at least
one patent for Skelaxin, and other actions with regard to the FDA regulatory
process. On 8 May 2003, Elan received notification from the FTC that it had
discontinued that portion of its investigation concerning whether Elan
wrongfully listed its patent for Skelaxin in the Orange Book. Elan does not
believe that it is feasible to predict or determine the outcome of the
remaining portion of the investigation and any possible effect on the Group's
business or reasonably estimate the amounts or potential range of loss, if any,
with respect to the resolution of the investigation.

PRODUCT APPROVAL PROCESS

     Preclinical tests assess the potential safety and efficacy of a product
candidate in animal models. The results of these studies must be submitted to
the FDA as part of an IND before human testing may proceed.

     For ethical, scientific and legal reasons, animal studies are required in
the discovery and safety evaluation of new medicines. Elan's policy is to seek
alternatives to animal studies through the replacement of animal models with
non-animal models. Alternatives used include various in vitro cell culture
assays. If animal studies are unavoidable, Elan seeks to refine the animal
models used to either reduce the number of animals utilised or to eliminate or
lessen animal discomfort.

     Under U.S. law, an IND must be submitted to the FDA and become effective
before human clinical trials may commence. U.S. law further requires that
studies conducted to support approval for product marketing be "adequate and
well controlled." In general, this means that either a placebo or a product
already approved for the treatment of the disease or condition under study

PRODUCT APPROVAL PROCESS

The stages of testing required before a pharmaceutical product can be marketed in the United States are generally as follows:
-------------------------------------------------------------------------------------------------------------------------------
PHASE OF DEVELOPMENT   DESCRIPTION
---------------------- --------------------------------------------------------------------------------------------------------

Preclinical            Animal studies and laboratory tests to evaluate safety and efficacy, demonstrate activity of a product
                       candidate and identify its chemical and physical properties

Phase I                Clinical studies to test safety profile of drug in humans

Phase II               Clinical studies conducted with groups of patients to determine preliminary efficacy, dosage and
                       expanded evidence of safety

Phase III              Larger scale clinical studies conducted in patients to provide sufficient data for statistical proof of
                       efficacy and safety

must be used as a reference control. Studies must also be conducted in
compliance with good clinical practice ("GCP") requirements, and adverse event
and other reporting requirements must be followed.

     The clinical trial process can take three to ten years or more to
complete, and there can be no assurance that the data collected will be in
compliance with GCP regulations, will demonstrate that the product is safe or
effective, or, in the case of a biologic product, pure and potent, or will
provide sufficient data to support FDA approval of the product. The FDA may
place clinical trials on hold at any point in this process if, among other
reasons, it concludes that clinical subjects are being exposed to an
unacceptable health risk. Trials may also be terminated by institutional review
boards, who must review and approve all research involving human subjects. Side
effects or adverse events that are reported during clinical trials can delay,
impede, or prevent marketing authorisation.

     The results of the preclinical and clinical testing (described in the
table below), along with information regarding the manufacturing of the product
and proposed product labelling, are evaluated and, if determined appropriate,
submitted to the FDA through a licence application such as an NDA. In certain
cases an ANDA can be filed in lieu of filing an NDA. An ANDA relies on
bioequivalency tests that compare the applicant's drug with an already approved
reference drug rather than on clinical safety and efficacy studies. An ANDA
might be available to Elan for a new formulation of a drug for which
bioequivalent forms have already been approved by the FDA. In responding to
applications for approval, the FDA could grant marketing approval, approve the
product for a narrower indication, impose labelling or distribution
restrictions, request additional information, require post-approval studies or
deny the application. Applications are often referred to an outside FDA
advisory committee of independent experts prior to the FDA acting on the
application. Similar systems are in place for the testing and approval of
biologics and medical devices.

--------------------------------------------------------------------------------
26

--------------------------------------------------------------------------------

     There can be no marketing in the United States of any drug, biologic or
device for which a marketing application is required until the application is
approved by the FDA. Until an application is actually approved, there can be no
assurance that the information requested and submitted will be considered
adequate by the FDA. Additionally, any significant change in the approved
product or in how it is manufactured, including changes in formulation or the
site of manufacture, generally require prior FDA approval. The packaging and
labelling of all products developed by Elan are also subject to FDA approval
and ongoing regulation.

     In the United States, under the Prescription Drug User Fee Act and the
Medical Device User Fee and Modernization Act, the FDA receives fees for
reviewing product applications and supplements thereto, as well as annual fees
for commercial manufacturing establishments and for approved products. These
fees can be significant. For example, the NDA or BLA review fee alone can
exceed $500,000, although certain deferrals, waivers and reductions may be
available. Even when user fees are significant, they do not generally
constitute a major expense relative to the overall cost associated with product
development and regulatory approval.

     Whether or not FDA approval has been obtained, approval of a
pharmaceutical product by comparable regulatory authorities in other countries
outside the United States must be obtained prior to the marketing of the
product in those countries. The approval procedure varies from country to
country. It can involve additional testing and the time required can differ
from that required for FDA approval. Although there are procedures for unified
filings for EU countries, in general, most other countries have their own
procedures and requirements.

     Once a product has been approved, significant legal and regulatory
requirements apply in order to market a product. In the United States these
include, among other things, requirements related to adverse event and other
reporting, product advertising and promotion, and ongoing adherence to cGMP
requirements, as well as the need to submit appropriate new or supplemental
applications and obtain FDA approval for certain changes to the approved
product, product labelling or manufacturing process. Adverse events that are
reported after marketing authorisation can result in additional limitations
being placed on a product's use and, potentially, withdrawal of the product
from the market. Any adverse event, either before or after marketing
authorisation, can result in product liability claims against the Company.

     The FDA also enforces the requirements of the Prescription Drug Marketing
Act, which, among other things, imposes various requirements in connection with
the distribution of product samples to physicians.

[GRAPHIC OMITTED]

     Sales, marketing and scientific/educational grant programmes must comply
with the Medicare-Medicaid Anti-Fraud and Abuse Act, as amended, the False
Claims Act, as amended, and similar state laws. Pricing and rebate programmes
must comply with the Medicaid rebate requirements of the Omnibus Budget
Reconciliation Act of 1990, as amended. If products are made available to
authorised users of the Federal Supply Schedule of the General Services
Administration, additional laws and requirements apply.

MANUFACTURING

     Each manufacturing establishment, including any contract manufacturers,
used to manufacture a product must be listed in the product application for
such product. In the United States, this means that each manufacturing
establishment must be listed in the drug, biologic, or device application, and
must be registered with the FDA. The application will not be approved until the
FDA conducts a manufacturing inspection, approves the applicable manufacturing
process for the product, and determines that the facility is in compliance with
cGMP requirements. If the manufacturing facilities and processes fail to pass
the FDA inspection, the FDA will not grant approval to market the product. All
facilities are also subject to periodic regulatory inspections to ensure
ongoing compliance with cGMP.

     At 31 December 2003, Elan had manufacturing facilities in Ireland, the
United States and Switzerland. The Switzerland facility was sold in February
2004.

     At 31 December 2003, Elan employed 617 people in its manufacturing and
supply activities, over half of these in Athlone, Ireland. This facility is the
primary location for the manufacture of oral solid dosage products, including
instant, controlled-release and oral microparticulate products. Additional
dosage capabilities may be added as required to support future product
introductions. Elan's facility in Gainesville, Georgia, United States, provides
additional oral controlled-release dosage product manufacturing capability and
is registered with the U.S. Drug

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      27

--------------------------------------------------------------------------------
OPERATING REVIEW -- ENVIRONMENT

Enforcement Administration for the manufacture, packaging and distribution of
Schedule II controlled drugs. Elan also manufactures Myobloc in the United
States. Elan's former facility in Switzerland was the primary location for the
manufacture of effervescent and fast melt oral dosage products. Elan sold this
facility in February 2004. Elan sold a transdermal dosage products manufacturing
facility in Miramar, Florida, United States in July 2003 to Nitto Americas, as
part of the divestment of a transdermal technology business. Capital
expenditures at Elan's manufacturing sites amounted to approximately $22 million
in 2003, mainly at the Athlone facility, where a new building was completed.

[GRAPHIC OMITTED]

Capital expenditures at Elan's manufacturing sites amounted to approximately
$22 million, mainly at the Athlone facility, where a new building was completed.

     All facilities and manufacturing techniques used for the manufacture of
products and devices for clinical use or for sale in the United States must be
operated in conformity with cGMP regulations. There are FDA regulations
governing the production of pharmaceutical products. Elan's facilities are also
subject to periodic regulatory inspections to ensure ongoing compliance with
cGMP regulations. In May 2001, Elan Holdings, Inc. ("Elan Holdings"), a wholly
owned subsidiary of Elan, Donal J. Geaney, then chairman and chief executive
officer of Elan, William C. Clark, then president, operations, and two then
employees of Elan Holdings, Hal Herring and Cheryl Schuster, entered into a
consent decree of permanent injunction with the U.S. Attorney for the Northern
District of Georgia, on behalf of the FDA, relating to alleged violations of
cGMP at Elan's Gainesville facility. The facility manufactured, and continues
to manufacture, verapamil hydrochloride controlled-release capsules used in the
treatment of high blood pressure. The consent decree does not represent an
admission by Elan Holdings of any of the allegations set forth in the decree.
Under the terms of the consent decree, which will continue in effect until at
least May 2006, Elan Holdings is permanently enjoined from violating cGMP
regulations. In addition, Elan Holdings is required to engage an independent
expert, subject to FDA approval, to conduct inspections of the facility at
least annually through May 2004, in order to ensure the facility's compliance
with cGMP. The first of these inspections was completed and reported upon by
the independent expert to the FDA on 3 September 2002. A corrective action plan
was prepared and sent to the FDA in response to this inspection. A second
independent consultant audit occurred in May 2003 and was reported upon by the
independent expert to the FDA on 14 August 2003. In response to this inspection
a corrective action plan was prepared and sent to the FDA. During the term of
the consent decree, Elan expects that the facility will be subject to increased
FDA inspections and, under the terms of the consent decree, Elan will be
required to reimburse the FDA for its costs related to these inspections. Elan
believes that, during the term of the consent decree, the FDA will continue to
process approvals for products to be manufactured at the facility. For example,
during 2002 the FDA approved Avinza and Ritalin LA, which are being
manufactured at the Gainesville facility.

PATENTS AND INTELLECTUAL PROPERTY RIGHTS

     Intellectual property is a vital asset for Elan. Elan's competitive
position depends on its ability to obtain patents on its current and future
technologies and products, to defend its patents, to protect its trade secrets
and to operate without infringing the valid patents or trade secrets of others.
In addition, under a number of licence agreements for its drug delivery
products, Elan's failure to obtain patents on the drug delivery product would
reduce the royalty rate that Elan receives on sales of such product.

     Elan's products are sold around the world under brand-name, logo and
certain product design trademarks that Elan considers in the aggregate to be of
material importance. Trademark protection continues in some countries for as
long as the mark is used and, in other countries, for as long as it is
registered. Registrations generally are for fixed, but renewable, terms.

     Elan owns or licenses a number of U.S. and foreign patents. These patents
cover:

     o    Pharmaceuticals and other products and their uses;

     o    Pharmaceutical formulations; and

     o    Product manufacturing processes.

     Patents for individual products extend for varying periods according to
the date of patent filing or grant and the legal term of patents in various
countries. The actual protection afforded by a patent, which can vary from
country to country, depends upon the type of patent, the scope of its coverage
and the availability of legal remedies in the country.

--------------------------------------------------------------------------------
28

--------------------------------------------------------------------------------

The following are the basic U.S. patent expiration dates for various Elan
products and products under development:
-------------------------------------------------------------------------
                                   BASIC U.S. PATENT     U.S. REGULATORY
DRUG                               EXPIRATION YEAR       EXCLUSIVITY (1)
-------------------------------------------------------------------------

A. Antegren                        See text              --
B. Azactam                         2005                  --
C. Maxipime                        See text              --
D. Prialt                          See text              See text

(1) Five years of regulatory exclusivity is provided by U.S. laws upon FDA
approval of a product incorporating a previously unapproved active ingredient,
which prevents the FDA from approving a generic version which relies on data
from the original FDA approval.

     In some instances, there are later-expiring patents relating to these
products directed to particular forms or compositions of the drug or to methods
of manufacturing or using the drug in the treatment of further diseases or
conditions. Although such patents may provide some additional exclusivity, they
may not protect Elan's drug from generic drug competition after the expiration
of the basic patent.

     Elan has a basic U.S. patent for its developmental product Antegren which
covers the humanised antibody and its use to treat MS which expires in 2015.
Additional U.S. patents covering the use of Antegren to treat irritable bowel
disease and to inhibit brain inflammation expire in 2012 and 2017,
respectively. In the event that Antegren is approved by the FDA, one of the
patents would qualify for a patent term extension of up to 5 years.

     The basic U.S. patent for Maxipime expires in 2007. However, two
formulation U.S. patents covering Maxipime expire in 2008.

     For the developmental product Prialt, the fundamental U.S. patent covering
the use of Prialt to produce analgesia expires in 2011. Two further U.S.
patents covering (i) the planned commercial, stabilised formulation of Prialt
and (ii) a method for preventing progression of neuropathic pain expire in
2015. If Prialt is approved by the FDA, it will be subject to five years of
U.S. regulatory exclusivity and a U.S. patent term extension of up to five
years.

     Elan has proactive programmes to maximise global patent and exclusivity
protection for its key commercial and developmental products. As part of its
normal business activity, Elan monitors competitor activity carefully and will
enforce its intellectual property rights whenever appropriate.

COMPETITION

     The pharmaceutical industry is highly competitive. Our principal
pharmaceutical competitors consist of major international companies, many of
which are larger and have greater financial resources, technical staff,
manufacturing, research and development and marketing capabilities than Elan.
Other competitors consist of smaller research companies and generic drug
manufacturers.

     A drug may be subject to competition from alternative therapies during the
period of patent protection or regulatory exclusivity and, thereafter, it may
be subject to further competition from generic products. The price of
pharmaceutical products typically declines as competition increases. Elan's
basic U.S. patent for Maxipime expires in 2007. However, two formulation U.S.
patents covering Maxipime expire in 2008. Elan's basic U.S. patent for Azactam
expires in 2005.

     Generic competitors may also challenge existing patent protection or
regulatory exclusivity. Generic competitors do not have to bear the same level
of research and development and other expenses associated with bringing a new
branded product to market. As a result, they can charge much less for a
competing version of our product. Managed care organisations typically favour
generics over brand name drugs, and governments encourage, or under some
circumstances mandate, the use of generic products, thereby reducing the sales
of branded products that are no longer patent protected. Governmental and other
pressures toward the dispensing of generic products may rapidly and
significantly reduce, slow, or reverse the growth in, sales and profitability
of any of our products not protected by patents or regulatory exclusivity, and
may adversely affect our future results and financial condition. For example,
generic forms of Zanaflex were launched in the second quarter of 2002. As a
result, product revenue from Zanaflex declined from $53.7 million in the first
quarter of 2002 to $0.8 million in the first quarter of 2003. Product returns
of Zanaflex during 2003 exceeded the Company's best estimate of returns at 31
December 2002, resulting in net negative revenues of $(5.1) million for 2003.
The launch of competitor products, including generic versions of Elan's
products, may

[GRAPHIC OMITTED]

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      29

--------------------------------------------------------------------------------

OPERATING REVIEW -- ENVIRONMENT

materially adversely affect our business, financial condition and results of
operations.

     Our competitive position depends, in part, upon our continuing ability to
discover, acquire and develop innovative, cost-effective new products, as well
as new indications and product improvements protected by patents and other
intellectual property rights. We also compete on the basis of price and product
differentiation and through our sales and marketing organisation that provides
information to medical professionals and launches new products. If we fail to
maintain our competitive position, our business, financial condition and
results of operations may be materially adversely affected.

DISTRIBUTION

     Elan sells its pharmaceutical products primarily to drug wholesalers.
Elan's revenue reflects the demand from these wholesalers to meet the in-market
consumption of Elan's products and to reflect the level of inventory that
wholesalers of Elan's products carry. Changes in the levels of inventory can
directly impact Elan's revenue and could result in Elan's revenue not
reflecting in-market consumption of its products.

     Elan generally manufactures its drug delivery products for licencees and
distributors but does not usually engage in any direct sales of drug delivery
products.

RAW MATERIALS AND PRODUCT SUPPLY

     Raw materials and supplies are generally available in quantities adequate
to meet the needs of Elan's business. However, Elan does not have dual sourcing
or manufacturing for many of its raw materials or products. Elan is also
dependent on third party manufacturers for most of the pharmaceutical products
that Elan markets and for raw materials. An inability to obtain raw materials or
product supply could have a material adverse impact on Elan's business,
financial condition and results of operations.

PRINCIPAL PROPERTIES
The following table lists the location, ownership interest, use and size of Elan's principal properties.
-------------------------------------------------------------------------------------------------------------------------------
LOCATION AND OWNERSHIP INTEREST                   USE                                                          SIZE
------------------------------------------------- ------------------------------------------------------------ ----------------

 Dublin, Ireland                                  Corporate administration                                     21,600 Sq. Ft.
 Leased

 Athlone, Ireland                                 Research and development, manufacturing and administration   402,000 Sq. Ft.
 Owned

 San Diego, California, United States             Product development, sales and administration                274,800 Sq. Ft.
 Leased

 South San Francisco, California, United States   Research and development and administration                  255,000 Sq. Ft.
 Leased

 Gainesville, Georgia, United States              Manufacturing and administration                             71,200 Sq. Ft.
 Owned

 King of Prussia, Pennsylvania, United States     Research and development, sales and administration           47,000 Sq. Ft.
 Leased

 Stevenage, United Kingdom                        Product development and administration                       35,800 Sq. Ft.
 Leased

EMPLOYEES

     On 31 December 2003, Elan had 2,159 employees worldwide, of whom 606 were
engaged in research and development activities, 617 were engaged in
manufacturing and supply activities, 498 were engaged in sales and marketing
activities and the remainder worked in general and administrative areas. The
number of employees has been reduced from approximately 3,600 employees at 31
December 2002 as a result of the implementation of the recovery plan.

PRINCIPAL PROPERTIES

     Elan considers that its properties are in good operating condition and
that its machinery and equipment has been well maintained. Facilities for the
manufacture of products are suitable for their intended purposes and have
capacities and projected capacities adequate for current and projected needs.

     For additional information, please refer to Note 11 to the Consolidated
Financial Statements, which discloses amounts invested in land and buildings
and plant and equipment, Note 23 to the Consolidated Financial Statements,
which discloses future minimum rental commitments, capital commitments for the
purchase of property, plant and equipment and dispositions of plant and
equipment, and "Financial Review--Capital Expenditures and Investment" on pages
62 to 63, which discloses Elan's capital expenditures.

--------------------------------------------------------------------------------
30

FINANCIAL REVIEW

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

This financial review discusses Elan's financial performance as prepared under
Irish GAAP. It also includes an overview of its results presented in accordance
with U.S. GAAP on pages 63 to 67 of this Annual Report and Form 20-F. The
reconciliation of Elan's performance under Irish GAAP to U.S. GAAP is set out
on pages 167 to 168.

INTRODUCTION

This financial review primarily discusses:

o    Recovery plan (page 31)

o    Critical accounting policies (pages 31 to 34);

o    The results of operations for the year ended 31 December 2003 compared to
     the year ended 31 December 2002 (pages 34 to 47);

o    The results of operations for the year ended 31 December 2002 compared to
     the year ended 31 December 2001 (pages 34, 47 to 55);

o    Segmental analysis (page 55);

o    Risk-sharing arrangements (pages 56 to 57);

o    Elan's financial position, including its capitalisation and liquidity
     (pages 58 to 63);

o    Post balance sheet events (page 63); and

o    U.S. GAAP (pages 63 to 67)

Elan's operating results can be affected by a number of factors, including
those described under "Cautionary Factors That May Affect Future Results" and
"Risk Factors".

RECOVERY PLAN

In the early months of 2002, the Company suffered a number of setbacks in rapid
succession, including the cessation of dosing in a Phase IIA clinical trial of
AN-1792, an experimental immunotherapeutic that was under development for the
treatment of AD, the announcement of a profit warning and an investigation by
the SEC. These disappointments ultimately led to a loss of confidence in the
Company. To address these issues, Elan announced a recovery plan on 31 July
2002 to restructure Elan's business, assets and balance sheet in order to
enable it to meet its financial commitments. The principal elements and
outcomes of the recovery plan are set out in the Operating Review on page 16
under the heading "Completion of Recovery Plan". As a result of this recovery
plan, Elan's business has now been transformed, and the Company is now focused
clearly on three core therapeutic areas: neurology, autoimmune diseases and
severe pain. One significant result of the number of product and business
divestments since the beginning of 2002 is that Elan's financial performance in
historical years is of limited relevance to an understanding of its future
prospects. Near term, Elan is focusing its development, sales and marketing
efforts to enable it to focus resources on the anticipated launch of its late
stage pipeline candidates, Antegren for multiple sclerosis and Crohn's disease,
and Prialt for severe pain. In research, Elan is focused on neurology, in which
it is continuing its research and advances in neurodegenerative diseases,
including multiple sclerosis, Alzheimer's disease and Parkinson's disease. On
12 February 2004, Elan announced the formal completion of its recovery plan.

CRITICAL ACCOUNTING POLICIES

The Consolidated Financial Statements include certain amounts that are based on
management's best estimates and judgements. Estimates and judgements are used
in determining items such as the carrying values of intangible assets, the
carrying values of financial assets, the accounting for contingencies and
estimating sales rebates and discounts, among other items. Because of the
judgements and uncertainties inherent in such estimates, actual results may
differ from these estimates.

IRISH GAAP

INTANGIBLE ASSETS AND IMPAIRMENT

The principal judgements and uncertainties affecting Elan's accounting for
intangible assets relate to the determination of carrying values. The carrying
values of intangible assets are assessed annually, using discounted cash flows
and net realisable values (estimated

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      31

FINANCIAL REVIEW
--------------------------------------------------------------------------------

sales proceeds less costs to sell). The estimates and judgements used to assess
carrying values include those relating to research and development risk,
commercial risk, revenue and cost projections, the intention of the Group with
respect to the intangible asset, such as the sales and marketing support for a
product or the continued focus or level of resources for a particular
development project or technology, the impact of competition, including generic
competition, the impact of any reorganisation or change of business focus of
the Group, the level of third party interest in Elan's intangible assets and
market conditions.

In July 2002, Elan announced a recovery plan. This resulted in material
impairment charges in Elan's profit and loss account of $189.5 million and
$1,614.6 million in 2003 and 2002, respectively. For additional information on
these impairment charges, please refer to Note 3 to the Consolidated Financial
Statements. Where the carrying value of intangible assets exceeds their
recoverable amounts, the carrying values of those intangible assets have been
written down to their recoverable amounts. If Elan were to use different
estimates or judgements, particularly with respect to expected proceeds from
divestments, the likelihood of research and development success, the likelihood
and date of commencement of generic competition or the impact of any
reorganisation or change of business focus, an additional material impairment
charge to the profit and loss account could arise. For example, a 10% decrease
in the carrying value of intangible assets at 31 December 2003 would have
resulted in an additional impairment charge of $125.2 million. Intangible
assets amounted to $1,252.4 million and $2,079.5 million at 31 December 2003
and 31 December 2002, respectively. Elan believes that it has used reasonable
estimates and judgements in assessing the carrying values of its intangible
assets.

FINANCIAL ASSETS AND IMPAIRMENT

The principal judgements and uncertainties affecting Elan's accounting for
financial assets relate to carrying values. In general, Elan's accounting
policy for financial assets is to carry such assets at cost less provision for
impairment in value. The carrying values of financial assets are assessed using
established financial methodologies, including quoted market prices for quoted
equity securities. Unquoted equity investments and non-traded securities of
public entities are typically assessed using methodologies such as the
Black-Scholes option-pricing model, the valuation achieved in the most recent
private placement by an investee, and an assessment of the impact of general
private equity market conditions. The factors affecting carrying values include
both general financial market conditions for pharmaceutical and biotechnology
companies and factors specific to a particular company. Different market
conditions, negative developments or news affecting a specific investee could
result in a material impairment charge for the applicable investment.
Additionally, many of Elan's investments are in emerging drug delivery,
pharmaceutical and biotechnology companies. In assessing the carrying values of
these investments, Elan has assumed that it holds the investments for the
medium to long-term and that no liquidity discount is required. If Elan were to
dispose of investments in a forced sale or in an accelerated manner, it is
likely that material impairment charges would arise. For example, a 10%
decrease in the carrying values of financial assets at 31 December 2003 would
have resulted in an additional impairment charge of $49.5 million. Fixed and
current financial assets amounted to $494.5 million and $809.4 million at 31
December 2003 and 31 December 2002, respectively. The investments held by EPIL
II will be sold to meet the maturity of the EPIL II Notes in June 2004. The
financial markets for emerging biotechnology, drug delivery and pharmaceutical
companies declined significantly in 2002. In 2003, Elan incurred a charge,
arising from impairments to its investment portfolio, including those
investments held by EPIL II and EPIL III, in its profit and loss account of
$120.4 million (2002: $1,262.9 million). Elan also recorded a net gain on
financial assets of $106.3 million (2002: net loss of $10.0 million). For
additional information on these investment charges, gains and losses, please
refer to Note 3 to the Consolidated Financial Statements. Elan believes that it
has used reasonable estimates and judgements in assessing the carrying values
of its financial assets.

EXCEPTIONAL ITEMS

Exceptional items are those items that in management's judgement are material
items which derive from events or transactions that fall within the ordinary
activities of the Group and which individually or, if of a similar type, in
aggregate, need to be disclosed by virtue of their size or incidence. Elan
believes that it has used reasonable judgements in determining exceptional
items.

The principal items classified as exceptional items include exceptional
revenues recorded on the disposal of products and gains or losses recorded on
the disposal of businesses, tangible and intangible asset impairments, purchase
of royalty rights, severance and relocation costs, losses from litigation or
regulatory actions including shareholders litigation and SEC investigation, and
investment gains, losses and impairments (including those related to
investments in business ventures and business venture parents). These items
have been treated consistently from period to period. Management believes that
disclosure of exceptional items is meaningful because it provides additional
information in relation to these material items.

--------------------------------------------------------------------------------
32

--------------------------------------------------------------------------------

CONTINGENCIES

The principal judgements used by Elan in accounting for contingencies include
the likelihood of the contingency occurring and the ability to estimate the
financial impact, including the minimum loss, or range of losses, that will
ultimately be incurred to resolve the matter. Elan's contingencies include
shareholder litigation and an investigation by the SEC. For additional
information on these and other contingencies and litigation, please refer to
Notes 23 and 25 to the Consolidated Financial Statements. As discussed in Note
25 to the Consolidated Financial Statements, the Group is unable to ascertain
the ultimate aggregate amount of monetary liability or financial impact, if
any, of the shareholder litigation, which seeks damages of material or
indeterminate amounts, or the SEC investigation. The principal judgements and
estimates in accounting for the litigation contingency relate to the Group's
assessment of the outcome of the litigation and the SEC investigation, which
can evolve over time.

REVENUE--DISCOUNTS, SALES RETURNS, REBATES AND CHARGE-BACKS

Estimated sales returns, pursuant to rights of return granted to the Company's
customers, are reflected as a reduction of revenue in the same period that the
related sales are recorded. The sales returns provisions are based on actual
experience, although in certain situations, for example, a new product launch
or at patent expiry, further judgement may be required. Additionally, revenue
is also recorded net of provision, made at the time of sale for estimated cash
discounts, rebates and charge-backs. These amounts are included in other
current liabilities (rebates) or deducted from trade debtors (other discounts).
Discounts, sales returns, rebates and charge-backs that require the use of
judgement in the establishment of the accrual include Medicaid, managed care,
long-term care, hospital and various other government programmes. The Company
enters into contracts with certain managed care organisations to provide access
to the Company's products. Based on a managed care organisation's market share
performance and utilisation of the Company's products, the organisation
receives rebates from the Company. In addition, the Company is bound by certain
laws and regulations to provide product at a discounted rate to Medicaid
recipients. Medicaid rebates are paid to each state in the United States based
on claims filed by pharmacies that provide the Company's products to Medicaid
recipients at the reduced rate. Charge-backs are amounts paid to reimburse
wholesalers for sales to third parties at reduced prices based on contracts the
Company negotiates. Cash discounts are provided to customers that pay their
invoice within a certain time period. Discounts, sales returns, rebates and
charge-backs are primarily based upon historical rebate/discount payments made
to the Company's customer segment groups. These amounts are calculated based
upon a percentage of sales for each of the Company's products as defined by the
statutory rates and the contracts with Elan's various customer groups.

The largest of the discounts, sales returns, rebates and charge-backs amounts
are rebates associated with the Medicaid rebate programme in the United States.
Although Elan generally accrues a liability for Medicaid rebates at the time
the product is shipped, there is typically up to a six-month difference between
the time in which Elan records sales of products and the payment of the
Medicaid rebate amounts to the state government. In determining the appropriate
Medicaid rebate accrual amount, the assumptions consider historical Medicaid
rebate payments by product as a percentage of historical sales as well as any
significant changes in sales trends, evaluation of the current Medicaid rebate
laws and interpretations, the percentage of the products that are sold to
Medicaid recipients, and Elan's product pricing and current rebate/discount
contracts. Elan believes that it has used reasonable judgements in assessing
discounts, sales returns, rebates and charge-backs.

EQUITY ACCOUNTING

Investments in associated undertakings are accounted for under the equity
method where the Company holds voting equity in the investee and exercises
significant influence over the operating and financial policies of the
investee. Significant influence may exist even if the Company owns less than
20% of the investee's equity depending on the existence of factors such as
representation on the board of directors, participation in policy making
processes, material intercompany transactions, interchange of managerial
personnel or technological dependency. Certain circumstances, such as majority
ownership by another company, can offset the impact of such factors. The
determination to use cost or equity accounting requires a significant degree of
judgement on the facts and circumstances of a particular investment. Financial
asset investments which are accounted for under the equity method are stated at
cost, adjusted for the Company's share of the earnings or losses of the
investee after the date of investment, less any provision for impairment in
value.

For additional information regarding Elan's significant accounting policies,
please refer to Note 1 to the Consolidated Financial Statements.

U.S. GAAP

REVENUE RECOGNITION

Under U.S. GAAP, the accounting treatment for non-refundable up-front fees was
similar to Irish GAAP prior to 2000. In December 1999, the SEC issued Staff
Accounting Bulletin No. 101 ("SAB 101") which provides guidance on revenue
recognition under U.S. GAAP,

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      33

FINANCIAL REVIEW
--------------------------------------------------------------------------------

and which was adopted by the Company in 2000. In December 2003, the SEC issued
Staff Accounting Bulletin No. 104 ("SAB 104") which updates the guidance in SAB
101. SAB 104 generally requires the deferral and amortisation of up-front fees
when there is a continuing involvement (such as an ongoing product
manufacturing contract) by the seller with the asset disposed of. SAB 104 does
not apply under Irish GAAP. Elan defers and amortises up-front licence fees to
the income statement over the "performance period". The performance period is
the period over which Elan expects to provide services to the licencee. It is
determined by the provisions, facts and circumstances, such as the research and
development period, of the relevant contract. Additionally, under Irish GAAP,
revenue from the sale of product rights and related inventory is recognised
when earned and non-refundable. The same accounting is generally applicable
under U.S. GAAP. In certain circumstances, however, when Elan has continuing
involvement with the product, deferral and amortisation of such revenue may be
appropriate.

For additional information on the significant differences between Irish and
U.S. GAAP, please refer to Note 33 to the Consolidated Financial Statements.

RESULTS OF OPERATIONS FOR THE YEARS ENDED 31 DECEMBER 2003, 2002 AND 2001
-------------------------------------------------------------------------------------------
                                                    YEAR ENDED 31 DECEMBER
-------------------------------------------------------------------------------------------
                                            2003                                     2002
                                              $M          2003                         $M
                                          BEFORE            $M         2003        BEFORE
                                     EXCEPTIONAL   EXCEPTIONAL           $M   EXCEPTIONAL
                                           ITEMS         ITEMS        TOTAL         ITEMS
-------------------------------------------------------------------------------------------

 Revenue--continuing
  operations(1)                         309.6             --          309.6         414.5
 Revenue--discontinued(1)               452.5             --          452.5         746.0
-------------------------------------------------------------------------------------------
 Total revenue                          762.1             --          762.1       1,160.5
 Cost of sales                          342.6            6.9          349.5         417.0
-------------------------------------------------------------------------------------------
 Gross profit/(loss)                    419.5           (6.9)         412.6         743.5
 Selling, general and
  administrative expenses               470.3          546.0        1,016.3         835.4
 Research and development
  expenses                              307.6           23.8          331.4         402.6
-------------------------------------------------------------------------------------------
 Operating (loss)/profit--
  continuing operations(1)             (353.6)        (384.4)        (738.0)       (438.5)
 Operating (loss)--acquisitions            --             --             --            --
 Operating profit/(loss)--
  discontinued(1)                        (4.8)        (192.3)        (197.1)        (56.0)
-------------------------------------------------------------------------------------------
 Operating (loss)/profit               (358.4)        (576.7)        (935.1)       (494.5)
 Share of (losses)/profits of
  associates                             (8.1)            --           (8.1)          6.0
 Loss on sale of securities/
  guarantee                                --             --             --            --
 Gain on disposal of businesses            --          293.3          293.3            --
-------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before interest and
  tax                                  (366.5)        (283.4)        (649.9)       (488.5)
 Net interest and other expense        (153.8)         (33.7)        (187.5)       (156.7)
-------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before tax                (520.3)        (317.1)        (837.4)       (645.2)
 Tax on (loss)/profit on ordinary
  activities                             22.0             --           22.0         (19.8)
-------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities after tax                 (498.3)        (317.1)        (815.4)       (665.0)
 Minority interest                         --             --             --          (0.7)
-------------------------------------------------------------------------------------------
 Retained (loss)/profit for the
  year                                 (498.3)        (317.1)        (815.4)       (665.7)
-------------------------------------------------------------------------------------------
 Basic (loss)/earnings per
  Ordinary Share                      $ (1.40)      $  (0.89)     $   (2.29)     $  (1.90)
 Diluted (loss)/earnings per
  Ordinary Share                      $ (1.40)      $  (0.89)     $   (2.29)     $  (1.90)
 Weighted average number of
  Ordinary Shares
  outstanding (millions)                356.0          356.0          356.0         349.7
-------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------
                                                          YEAR ENDED 31 DECEMBER
----------------------------------------------------------------------------------------------------------
                                                                         2001
                                           2002                            $M          2001
                                             $M            2002        BEFORE            $M           2001
                                    EXCEPTIONAL              $M   EXCEPTIONAL   EXCEPTIONAL             $M
                                          ITEMS           TOTAL         ITEMS         ITEMS          TOTAL
----------------------------------------------------------------------------------------------------------

 Revenue--continuing
  operations(1)                           172.5           587.0        824.8          233.4        1,058.2
 Revenue--discontinued(1)                    --           746.0        688.1           (5.6)         682.5
-----------------------------------------------------------------------------------------------------------
 Total revenue                            172.5         1,333.0      1,512.9          227.8        1,740.7
 Cost of sales                             66.1           483.1        364.0           22.8          386.8
-----------------------------------------------------------------------------------------------------------
 Gross profit/(loss)                      106.4           849.9      1,148.9          205.0        1,353.9
 Selling, general and
  administrative expenses               1,788.0         2,623.4        697.5        1,084.2        1,781.7
 Research and development
  expenses                                114.7           517.3        323.3           78.6          401.9
-----------------------------------------------------------------------------------------------------------
 Operating (loss)/profit--
  continuing operations(1)             (1,120.4)       (1,558.9)        58.9         (510.1)        (451.2)
 Operating (loss)--acquisitions              --              --         (3.3)            --           (3.3)
 Operating profit/(loss)--
  discontinued(1)                        (675.9)         (731.9)        72.5         (447.7)        (375.2)
-----------------------------------------------------------------------------------------------------------
 Operating (loss)/profit               (1,796.3)       (2,290.8)       128.1         (957.8)        (829.7)
 Share of (losses)/profits of
  associates                                 --             6.0         10.3             --           10.3
 Loss on sale of securities/
  guarantee                              (217.0)         (217.0)          --             --             --
 Gain on disposal of businesses            77.9            77.9           --             --             --
-----------------------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before interest and
  tax                                  (1,935.4)       (2,423.9)       138.4         (957.8)        (819.4)
 Net interest and other expense        (1,014.0)       (1,170.7)       (76.3)          25.9          (50.4)
-----------------------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before tax                (2,949.4)       (3,594.6)        62.1         (931.9)        (869.8)
 Tax on (loss)/profit on ordinary
  activities                                 --           (19.8)       (17.4)            --          (17.4)
-----------------------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities after tax                 (2,949.4)       (3,614.4)        44.7         (931.9)        (887.2)
 Minority interest                           --            (0.7)          --             --             --
-----------------------------------------------------------------------------------------------------------
 Retained (loss)/profit for the
  year                                 (2,949.4)       (3,615.1)        44.7         (931.9)        (887.2)
-----------------------------------------------------------------------------------------------------------
 Basic (loss)/earnings per
  Ordinary Share                     $    (8.44)    $    (10.34)   $    0.13      $   (2.77)     $   (2.64)
 Diluted (loss)/earnings per
  Ordinary Share                     $    (8.44)    $    (10.34)   $    0.12      $   (2.77)     $   (2.64)
 Weighted average number of
  Ordinary Shares
  outstanding (millions)                  349.7           349.7        336.0          336.0          336.0
-----------------------------------------------------------------------------------------------------------

A reconciliation between Elan's Irish GAAP financial results and Elan's
financial results determined in accordance with U.S. GAAP is provided in Note
33 to the Consolidated Financial Statements.

(1)   Amounts have been recast to reflect disposals subsequent to 31 December
      2003 as discontinued operations. See Note 34 to Elan's consolidated
      financial statements.

--------------------------------------------------------------------------------
34

--------------------------------------------------------------------------------

2003 COMPARED TO 2002

REVENUE

Total revenue decreased 43% to $762.1 million for 2003 from $1,333.0 million
for 2002.

------------------------------------------------------------------------
                                                      2003          2002
PRODUCT REVENUE                                         $M            $M
------------------------------------------------------------------------

 (A) Revenue from Retained Products(1)
------------------------------------------------------------------------
 U.S. Promoted Products
 Maxipime                                           109.1          79.2
 Azactam                                             45.1          33.0
------------------------------------------------------------------------
                                                    154.2         112.2
------------------------------------------------------------------------
 Contract manufacturing and royalties               112.0         109.3
------------------------------------------------------------------------
 TOTAL REVENUE FROM RETAINED PRODUCTS               266.2         221.5
------------------------------------------------------------------------
 (B) Revenue from Divested Products(2)
------------------------------------------------------------------------
 Skelaxin(3)                                         60.2         145.3
 Sonata(3)                                           48.2          92.5
 Abelcet(4)                                           1.1          64.6
 Dermatology                                          --           47.6
 Diagnostics                                          9.0          70.6
 Pain Portfolio(5)                                   68.0          59.8
 Avinza(6)                                            --           75.6
 Actiq/nifedipine(6)                                  --           79.1
 European business                                  112.4         102.6
 Zonegran(7)                                         80.7          43.1
 Frova(7)(8)                                         37.5          11.2
 Myobloc(9)                                          14.9          19.6
 Zanaflex(10)                                      ( 5.1)          56.8
 Other                                               10.2           2.0
 Product rationalisations(6)                          9.3          17.8
 Product sales of rationalised products               --           32.0
------------------------------------------------------------------------
                                                    446.4         920.2
------------------------------------------------------------------------
 (C) Co-promotion Fees
------------------------------------------------------------------------
 Autoimmune Diseases Research & Development
 Corp. Ltd. ("Autoimmune")                            --           38.8
 Pharma Marketing                                     --           24.0
------------------------------------------------------------------------
                                                      --           62.8
------------------------------------------------------------------------
 TOTAL PRODUCT REVENUE                              712.6       1,204.5
------------------------------------------------------------------------

------------------------------------------------------------
                                          2003          2002
                                            $M            $M
------------------------------------------------------------

 CONTRACT REVENUE
------------------------------------------------------------
 Licence fees                             --            7.1
 Pharma Marketing / Autoimmune            --           37.2
 Research revenue and milestones         49.5          84.2
------------------------------------------------------------
 TOTAL CONTRACT REVENUE                  49.5         128.5
------------------------------------------------------------
 TOTAL REVENUE                          762.1       1,333.0
------------------------------------------------------------

(1)  Products described as "Retained Products" include products or businesses
     not divested and not subject to divestment agreements.

(2)  Products described as "Divested Products" include products or businesses
     divested since the beginning of 2001, and products or businesses subject to
     divestment agreements.

(3)  Sold to King in June 2003.

(4)  Sold to Enzon in November 2002.

(5)  Sold to aaiPharma in December 2003.

(6)  Exceptional product revenue in 2002.

(7)  On 30 March 2004, Elan announced an agreement to divest this product. This
     divestment closed during the second quarter of 2004.

(8)  Launched in the United States in May 2002.

(9)  Sold to Solstice in July 2004.

(10) Sold to Acorda in July 2004.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      35

FINANCIAL REVIEW
--------------------------------------------------------------------------------

PRODUCT REVENUE

Total product revenue decreased by 41% to $712.6 million for 2003 from $1,204.5
million for 2002.

(A) Revenue from Retained Products

Revenue from retained products was $266.2 million for 2003 compared with $221.5
million for 2002. Combined revenue from Maxipime and Azactam was $154.2 million
for 2003 compared to $112.2 million for 2002, an increase of 37%. This increase
was due to stronger demand in 2003 and the negative impact on the sales of
these products in 2002 due to a change in Elan's discounting strategy and
short-term supply issues resulting from third party manufacturing constraints.

(B) Revenue from Divested Products

On 30 January 2003, Elan announced that it had agreed to sell its primary care
franchise, principally consisting of its U.S. and Puerto Rican rights to
Skelaxin and Sonata, related inventory and related rights to enhanced
formulations of these products, to King. On 17 March 2003, Elan commenced a
lawsuit against King to compel King to complete its purchase of the primary
care franchise. On 19 May 2003, Elan and King agreed to proceed with the
transaction on amended terms and on 12 June 2003 the transaction was completed.
Effective upon the closing of the transaction, all claims under the pending
litigation were released and Elan and King dismissed the litigation with
prejudice. During 2003, product revenue from Skelaxin and Sonata was $108.4
million (2002: $237.8 million).

During 2002, Elan divested its dermatology and Athena Diagnostics Inc. ("Athena
Diagnostics") businesses and its U.S., Canadian and any Japanese rights to
Abelcet. On 29 April 2003, Elan completed the sale of Elan Diagnostics. These
businesses contributed $10.1 million to product revenue for 2003, representing
revenues before they were divested (2002: $182.8 million).

On 2 December 2003, Elan announced the completion of the sale of the Pain
Portfolio to aaiPharma. Revenue from the Pain Portfolio was $68.0 million for
2003 compared to $59.8 million for 2002.

On 9 December 2002, Elan announced the amendment of the terms of its
development, licence and supply agreement with Ligand regarding Avinza. Elan
received a cash payment of $100.0 million from Ligand in return for a reduction
in the ongoing royalty rate from the previous level of 30% of net sales of
Avinza in the United States and Canada to approximately 10%. In addition, Elan
agreed to forego its option to negotiate a co-promotion agreement with Ligand
for Avinza in the United States and Canada. Elan will continue to manufacture
the product in its Gainesville facility. Net of the write-off of the related
intangible assets, Elan recorded exceptional product revenue of $75.6 million
on the closing of this transaction.

On 3 October 2002, Elan announced that it sold its rights to Actiq in twelve
territories, principally in Europe, to Anesta Corp. ("Anesta"). At the date of
disposal, Actiq was marketed by Elan in the United Kingdom, Ireland and
Germany. Net of the write-off of the related intangible assets, Elan recorded
exceptional product revenue of $40.3 million on the closing of this
transaction.

On 23 August 2002, Elan announced a licensing agreement with Watson for
exclusive marketing rights to the 30 mg and 60 mg dosage strengths of Elan's
extended-release nifedipine tablets in the United States. Elan received $45.0
million in cash from Watson. Elan will continue to manufacture the products in
its Athlone facility. Net of the write-off of the related intangible assets,
Elan recorded exceptional product revenue of $38.8 million on the closing of
this transaction.

On 12 February 2004, Elan announced the sale of its European sales and
marketing business to Medeus. Separately, Elan completed the sale of certain
rights to two products in the U.K. and Ireland for approximately $10 million
during the first quarter of 2004. During 2003, revenue from the European
business was $112.4 million (2002: $102.6 million).

On 30 March 2004, Elan announced that it had agreed to sell its interests in
North America and Europe for Zonegran to Eisai. The transaction closed in the
second quarter of 2004. Zonegran revenue was $80.7 million for 2003 compared to
$43.1 million for 2002, an increase of 87%. This increase was as a result of
Elan's promotional efforts as well as the increased interest in the product
following the approval of the 25 mg and 50 mg strengths in late 2003.

On 30 March 2004, Elan announced that it had agreed to sell its
commercialisation rights in North America for Frova to Vernalis. The
transaction closed in the second quarter of 2004. Frova, which was launched in
the United States in May 2002 under a co-promotion agreement between Elan and
UCB, generated revenue of $37.5 million for 2003 compared to $11.2 million for
2002.

Elan sold Myobloc to Solstice in July 2004, and also sold Zanaflex to Acorda in
the same month. Myobloc product revenue decreased 24% for 2003 to $14.9 million
from $19.6 million for 2002. Generic competitor products to Zanaflex were
launched in the United States during 2002. Product returns of Zanaflex during
2003 exceeded the Company's best estimate of returns at 31 December 2002,
resulting in net negative revenues of $(5.1) million for 2003 compared to
revenues of $56.8 million for 2002.

--------------------------------------------------------------------------------
36

--------------------------------------------------------------------------------

Product rationalisation revenue, which represents ongoing royalties from
products divested during 2002 and 2001 under the 2001 product rationalisation
programme, was $9.3 million for 2003 compared to $17.8 million for 2002.

Product sales of rationalised products, which represents revenue prior to
rationalisation, was $32.0 million for 2002. As the product rationalisation
programme initiated in 2001 was completed in 2002, Elan did not record any
product sales of rationalised products in 2003.

(C) Co-promotion Fees

Product revenue from product co-promotion and marketing activities, which
resulted from Elan's risk-sharing arrangements with Pharma Marketing and
Autoimmune, was $Nil for 2003 compared to $62.8 million for 2002. Elan will not
receive any future revenue from either Pharma Marketing or Autoimmune.

CONTRACT REVENUE

Contract revenue decreased by 61% to $49.5 million for 2003 from $128.5 million
for 2002, primarily as no revenue was received from either Pharma Marketing or
Autoimmune compared to $37.2 million for 2002, and reduced research revenue and
milestones. Elan will not receive any future revenue from either Pharma
Marketing or Autoimmune. Research revenue and milestones amounted to $49.5
million in 2003 compared to $84.2 million in 2002, reflecting a lower level of
activity in 2003 coupled with the timing of the receipt of milestone payments.

MAJOR CUSTOMERS

Cardinal Health, Inc. ("Cardinal Health"), Amerisource Bergen Corporation
("Amerisource Bergen") and McKesson Corporation ("McKesson"), all of which are
drug wholesalers, accounted for approximately 20%, 16% and 16%, respectively,
of Elan's total revenue for 2003. Cardinal Health, Amerisource Bergen and
McKesson accounted for approximately 13%, 13% and 12%, respectively, of Elan's
total revenue for 2002. No other customer accounted for more than 10% of total
revenue for 2003 or 2002.

COST OF SALES

Cost of sales, after exceptional items, decreased by 28% to $349.5 million for
2003 from $483.1 million for 2002. The decrease was 18% before exceptional
items of $6.9 million for 2003 and $66.1 million for 2002. Gross margin on
total revenue, before exceptional items, was 55% for 2003 compared to 64% for
2002. Gross margin on total revenue, after exceptional items, was 54% for 2003
compared to 64% for 2002. Gross margin on product revenue, before exceptional
items, decreased to 52% for 2003 from 60% for 2002. Gross margin on product
revenue, after exceptional items, decreased to 51% in 2003 from 60% in 2002.
The reduction in gross margin on product revenue reflects changes in the mix of
product revenue, including the divestment of a number of products and
businesses under the recovery plan and decreased revenues from risk-sharing
arrangements, under-utilisation of capacity at Elan's manufacturing facility in
Athlone and the payment of royalties to Pharma Marketing. The reduction in
gross margin on total revenue reflects changes in the mix of revenue, in
particular the decrease in revenue from risk-sharing arrangements.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses, after exceptional items,
decreased by 61% to $1,016.3 million for 2003 from $2,623.4 million for 2002.
The decrease was 44% before exceptional items of $546.0 million for 2003 and
$1,788.0 million for 2002, reflecting the implementation of the recovery plan
and related cost reduction initiatives.

RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses, after exceptional items, decreased by 36% to
$331.4 million for 2003 from $517.3 million for 2002. The decrease was 24%
before exceptional items of $23.8 million for 2003 and $114.7 million for 2002,
principally reflecting a refocus of research and development efforts, including
increased spending on key programmes including Antegren, Prialt and the
Alzheimer's programmes. For additional information on our research and
development programmes, please refer to pages 5 to 11.

EXCEPTIONAL ITEMS

Exceptional items are those items that in management's judgement are material
items which derive from events or transactions that fall within the ordinary
activities of the Group and which individually or, if of a similar type, in
aggregate, need to be disclosed by virtue of their size or incidence.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      37

FINANCIAL REVIEW
--------------------------------------------------------------------------------

The principal items classified as exceptional items include exceptional
revenues recorded on the disposal of products and gains or losses recorded on
the disposal of businesses, tangible and intangible assets impairments,
purchase of royalty rights, severance and relocation costs, losses from
litigation or regulatory actions including shareholders litigation and SEC
investigation, and investment gains, losses and impairments (including those
related to investments in business ventures and business venture parents).
These items have been treated consistently from period to period. Management
believes that disclosure of exceptional items is meaningful because it provides
additional information in relation to these material items.

2003

In 2003, Elan incurred net exceptional charges of $317.1 million.

The exceptional items for 2003 mainly relate to the implementation of Elan's
recovery plan and investment impairments. On 31 July 2002, Elan announced a
recovery plan to restructure its businesses, assets and balance sheet. Elan
decided to focus on three core therapeutic areas. These are neurology,
autoimmune diseases and severe pain. A key element of the recovery plan was the
divestment of businesses and products.

The exceptional charges and revenue in 2003 mainly relate to the:

o    Sale of businesses. The carrying value of these assets have been written
     down, where applicable, to their estimated recoverable amounts;

o    Discontinuance of businesses;

o    Rationalisation and restructuring expenses incurred from a reduction in the
     scope of Elan's activities, a reduction in employee numbers and related
     write-downs in the carrying value of assets;

o    Simplification of Elan's business such as the termination of the Pharma
     Marketing risk-sharing arrangement; and

o    Termination, restructuring or cessation of activity in all of Elan's
     business ventures.

These exceptional costs have been included under the statutory format headings
to which they relate analysed as follows:

                                                            SELLING,      RESEARCH         OTHER
                                                COST     GENERAL AND           AND      ORDINARY          NET
                                            OF SALES  ADMINISTRATIVE   DEVELOPMENT    ACTIVITIES     INTEREST
                                                 (A)             (B)           (C)           (D)          (E)        TOTAL
                                                  $M              $M            $M            $M           $M           $M
--------------------------------------------------------------------------------------------------------------------------

 Acquired intellectual property ("acquired
  IP") and goodwill impairment:
  Europe                                          --           108.2            --             --           --       108.2
  Dura Pharmaceuticals Inc ("Dura")               --            16.2            --             --           --        16.2
  Nanosystems LLC ("Nanosystems")                 --            11.7            --             --           --        11.7
--------------------------------------------------------------------------------------------------------------------------
 Total acquired IP and goodwill impairment        --           136.1            --             --           --       136.1
--------------------------------------------------------------------------------------------------------------------------
 Product impairments:
  Myobloc                                         --            37.1            --             --           --        37.1
  All others                                      --             9.2           7.1             --           --        16.3
--------------------------------------------------------------------------------------------------------------------------
 Total product impairments                        --            46.3           7.1             --           --        53.4
--------------------------------------------------------------------------------------------------------------------------
 Purchase of Pharma Operating royalty
  rights                                          --           297.6            --             --           --       297.6
 Severance/relocation costs                      4.1            25.1           8.2             --           --        37.4
 Tangible fixed asset write-downs                3.4             9.3           1.7             --           --        14.4
 Gain on disposal of businesses                   --              --            --         (293.3)          --      (293.3)
 Waiver fee to EPIL II/III noteholders            --              --            --             --         16.8        16.8
 Investment impairments                           --              --            --             --        120.4       120.4
 Net gain on financial assets                     --              --            --             --       (106.3)     (106.3)
 Profit on repurchase of LYONs                    --              --            --             --         (1.6)     (  1.6)
 Other                                          (0.6)           31.6           6.8             --          4.4        42.2
--------------------------------------------------------------------------------------------------------------------------
 Net exceptional charges                         6.9           546.0          23.8         (293.3)        33.7       317.1
--------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
38

--------------------------------------------------------------------------------

(A) COST OF SALES

Exceptional cost of sales include $3.4 million on the impairment of certain
manufacturing fixed assets, severance/relocation costs of $4.1 million and
other exceptional cost of sales of $(0.6) million.

(B) SELLING, GENERAL AND ADMINISTRATIVE

Exceptional selling, general and administrative expenses were $546.0 million.
$182.4 million of the exceptional expenses relate to impairment charges arising
on write-downs of intangible assets. $297.6 million relates to the purchase of
royalty rights from Pharma Operating. For additional information on the
purchase of royalty rights from Pharma Operating, please refer to pages 56 to
57. Other exceptional selling, general and administrative expenses were $66.0
million. These include tangible fixed asset write-downs of $9.3 million,
severence/relocation costs of $25.1 million and similar costs arising from the
restructuring of the Group as part of the recovery plan. They also include
legal costs related to the SEC investigation, shareholder litigation and
litigation provisions.

In February 2004, Elan completed the sale of its European sales and marketing
business to Medeus. As a result, the related intangibles were written down to
their net realisable value at 31 December 2003. This resulted in an impairment
to goodwill of $108.2 million. The other goodwill impairment charge of $16.2
million related to Dura. Impairment charges to acquired IP arising from the
acquisition of Nanosystems was $11.7 million. Impairment charges to patents and
licences arising on write-downs of the product intangibles for Myobloc amounted
to $37.1 million. Other impairments to patents and licences totalled $9.2
million. Each of these impairments arose due to changed expectations for the
related products.

(C) RESEARCH AND DEVELOPMENT

Exceptional research and development expenses were $23.8 million. These mainly
relate to product impairments of $7.1 million, severance/relocation costs of
$8.2 million and similar costs arising from the restructuring of the Group as
part of the recovery plan.

(D) OTHER ORDINARY ACTIVITIES

Elan recognised a gain of $293.3 million on the sale of certain businesses as
part of the Group's recovery plan. In June 2003, Elan completed the sale of its
primary care franchise, comprising of Skelaxin and Sonata, to King. On
completion, Elan received a net cash payment of $510.9 million from King,
representing the total consideration, before agreed price adjustments and
expenses. The gain amounted to $284.8 million. In July 2003, Elan sold a
transdermal technology business to Nitto Americas for a cash consideration of
$45.0 million before expenses. The loss amounted to $30.3 million. In December
2003, Elan completed the sale of the Pain Portfolio business to aaiPharma. The
total consideration was $101.8 million, comprising a cash payment to Elan of
$50.4 million and the assumption, by aaiPharma, of $51.4 million of Elan's
product payment obligations to Roxane. Elan recorded a net gain of $40.2
million on the transaction. Other businesses divested by Elan in 2003 were its
operations in the Philippines and Taiwan, a Spanish primary care business, a
U.K. drug delivery business and an Italian manufacturing business. The total
net loss on these divestments amounted to $1.4 million.

(E) NET INTEREST

Exceptional net interest and other expense amounted to $33.7 million.

This includes a net gain of $1.6 million on the repurchase of $1,323.4 million
in principal amount at maturity of LYONs. These LYONs, having an accreted value
of $810.5 million at the date of purchase, were purchased at an aggregate cost
of $803.4 million, resulting in the net gain of $1.6 million after related
costs. For further information regarding the LYONs, please refer to Note 15 to
the Consolidated Financial Statements.

During 2003 the Company recognised a $120.4 million charge in relation to
investment impairments arising from Elan's investment portfolio, primarily
relating to investments in business ventures and business venture parents of
$4.0 million and $106.0 million, respectively.

During 2003 the Company recognised a net gain on financial assets of $106.3
million, primarily reflecting gains of $72.3 million on the disposal of Elan's
investment in Ligand.

On 10 November 2003, Elan announced that it had successfully completed a
private offering of $460.0 million in aggregate principal amount of 6.5%
Convertible Notes. In connection with this offering a waiver fee of $16.8
million was paid to the holders of the EPIL II Notes and EPIL III Notes.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      39

FINANCIAL REVIEW
--------------------------------------------------------------------------------

2002

In 2002, Elan incurred net exceptional charges of $2,949.4 million.

The exceptional items for 2002 mainly relate to the implementation of Elan's
recovery plan, a significant decline during 2002 in the financial markets for
investments in emerging biotechnology, drug delivery and pharmaceutical
companies, and the introduction of generic competitors to some of Elan's
products. On 31 July 2002, Elan announced a recovery plan to restructure its
businesses, assets and balance sheet. Elan decided to focus on three core
therapeutic areas. These are neurology, autoimmune diseases and severe pain. A
key element of the recovery plan was the divestment of businesses and products.

The exceptional charges and revenue in 2002 mainly relate to the:

o    Sale of businesses and products. The carrying value of these assets have
     been written down, where applicable, to their estimated recoverable
     amounts. Exceptional revenue arises from the proceeds received on the
     disposal of products;

o    Discontinuance of businesses or the decision not to exercise an option to
     acquire a product, such as Elan's decision not to exercise its option to
     acquire certain dermatology products from GlaxoSmithKline, plc ("GSK")

o    Rationalisation and restructuring expenses incurred from a reduction in the
     scope of Elan's activities, a reduction in employee numbers and related
     write-downs in the carrying value of assets;

o    Simplification of Elan's business such as the termination of the Autoimmune
     risk-sharing arrangement; and

o    Termination, restructuring or cessation of activity in Elan's business
     ventures.

--------------------------------------------------------------------------------
40

--------------------------------------------------------------------------------

These exceptional revenues and costs have been included under the statutory
format headings to which they relate analysed as follows:

                                                                     SELLING,         RESEARCH       OTHER
                                                          COST    GENERAL AND              AND    ORDINARY          NET
                                              REVENUE OF SALES ADMINISTRATIVE      DEVELOPMENT  ACTIVITIES     INTEREST
                                                  (A)      (B)            (C)              (D)         (E)          (F)     TOTAL
                                                   $M       $M             $M               $M          $M           $M        $M
------------------------------------------------------------------------------------------------------------------------------------

 Product disposals and product
  rationalisations                            (172.5)       --             --               --          --           --     (172.5)
 Zanaflex inventory -- generic competition        --      43.3             --               --          --           --       43.3
 Acquired IP and goodwill impairment:
  Dura                                            --        --          854.9               --          --           --      854.9
  Liposome                                        --        --          111.8               --          --           --      111.8
  Sano Corporation ("Sano")                       --        --           89.8               --          --           --       89.8
  Quadrant Healthcare, plc ("Quadrant")           --        --           78.2               --          --           --       78.2
  Axogen Limited ("Axogen")                       --        --           28.4               --          --           --       28.4
  Others                                          --        --           19.1             10.6          --           --       29.7
------------------------------------------------------------------------------------------------------------------------------------
 Total acquired IP and goodwill impairment        --        --        1,182.2             10.6          --           --    1,192.8
------------------------------------------------------------------------------------------------------------------------------------
 Product impairments:
  Pain Portfolio                                  --        --           86.3               --          --           --       86.3
  Myobloc                                         --        --           77.7               --          --           --       77.7
  Naprelan                                        --        --           35.7               --          --           --       35.7
  Myambutol                                       --        --           32.7               --          --           --       32.7
  Dermatology products                            --        --           29.8               --          --           --       29.8
  Frova                                           --        --           29.4               --          --           --       29.4
  Delsys                                          --        --             --             45.7          --           --       45.7
  All others                                      --       8.0           62.9             13.6          --           --       84.5
------------------------------------------------------------------------------------------------------------------------------------
 Total product impairments                        --       8.0          354.5             59.3          --           --      421.8
------------------------------------------------------------------------------------------------------------------------------------
 Purchase of Autoimmune royalty rights            --        --          121.0               --          --           --      121.0
 Severance/relocation costs                       --       8.4           23.2             19.7          --           --       51.3
 Litigation provisions                            --        --           19.0               --          --           --       19.0
 Tangible fixed asset write-downs                 --       5.7           28.3             11.6          --           --       45.6
 Gain on disposal of businesses                   --        --             --               --       (77.9)          --      (77.9)
 Loss on sale of securities/guarantee             --        --             --               --       217.0           --      217.0
 Investment impairments                           --        --             --               --          --      1,045.9    1,045.9
 Net loss on financial assets                     --        --             --               --          --         10.0       10.0
 Profit on redemption of LYONs                    --        --             --               --          --        (37.7)     (37.7)
 Other                                            --       0.7           59.8             13.5          --         (4.2)      69.8
------------------------------------------------------------------------------------------------------------------------------------
 Net exceptional charges                      (172.5)     66.1        1,788.0            114.7       139.1      1,014.0    2,949.4
------------------------------------------------------------------------------------------------------------------------------------

(A) REVENUE

Exceptional product revenue of $172.5 million for 2002 includes $154.7 million
from product disposals arising from Elan's recovery plan, as well as $17.8
million relating to product rationalisations. For additional information on
product rationalisations, please refer to pages 50 to 53.

On 9 December 2002, Elan announced the amendment of the terms of its
development, licence and supply agreement with Ligand regarding Avinza. Elan
received a cash payment of $100.0 million from Ligand, in return for a
reduction in the ongoing royalty rate from the previous level of 30% of net
sales of Avinza in the United States and Canada to approximately 10%. In
addition, Elan agreed to forego its option to negotiate a co-promotion
agreement with Ligand for Avinza in the United States and Canada. Elan will
continue to manufacture the product in its Gainesville facility. Net of the
write-off of the related intangible assets, Elan recorded exceptional product
revenue of $75.6 million on the closing of this transaction.

On 3 October 2002, Elan announced that it sold its rights to Actiq in twelve
territories, principally in Europe, to Anesta. At the date of disposal, Actiq
was marketed by Elan in the United Kingdom, Ireland and Germany. Net of the
write-off of the related intangible assets, Elan recorded exceptional product
revenue of $40.3 million on the closing of this transaction.

On 23 August 2002, Elan announced a licensing agreement with Watson for
exclusive marketing rights to the 30 mg and 60 mg dosage strengths of Elan's
extended-release nifedipine tablets in the United States. Elan received $45.0
million in cash from Watson. Elan will

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      41

FINANCIAL REVIEW
--------------------------------------------------------------------------------

continue to manufacture the products in its Athlone facility. Net of the
write-off of the related intangible assets, Elan recorded exceptional product
revenue of $38.8 million on the closing of this transaction.

(B) COST OF SALES

Exceptional cost of sales were $66.1 million in 2002, including a charge of
$43.3 million related to the write-off of Zanaflex inventories due to the
impact of generic competition during 2002. Other exceptional cost of sales
includes $8.0 million on the write down of the intangible asset for Mysoline,
following generic competition for this product, severance/relocation costs of
$8.4 million, $5.7 million on the impairment of tangible fixed assets and other
exceptional cost of sales of $0.7 million.

(C) SELLING, GENERAL AND ADMINISTRATIVE

Exceptional selling, general and administrative expenses were $1,788.0 million.
$1,536.7 million of the exceptional expenses relate to impairment charges
arising on write-downs of intangible assets. Other exceptional selling, general
and administrative expenses were $251.3 million. These include the purchase of
royalty rights from Autoimmune, fixed asset write-downs and similar costs
arising from the restructuring of the Group as part of the recovery plan. They
also include legal costs related to the SEC investigation, shareholder
litigation and litigation provisions.

Impairment charges to goodwill relating to the acquisitions of Dura, Liposome,
Quadrant and Sano were $854.9 million, $111.8 million, $78.2 million and $2.4
million, respectively. Impairment charges to acquired IP arising from the
acquisitions of Sano and Axogen Limited ("Axogen") were $87.4 million and $28.4
million, respectively. Other impairments to goodwill totalled $19.1 million.
Impairment charges to patents and licences arising on write-downs of the
product intangibles for the Pain Portfolio, Myobloc, Naprelan, Myambutol,
dermatology products and Frova were $86.3 million, $77.7 million, $35.7
million, $32.7 million, $29.8 million and $29.4 million, respectively. Other
impairments to patents and licences totalled $62.9 million.

Dura

Elan acquired Dura in November 2000 for $1,590.7 million. Dura was a specialty
pharmaceutical company engaged in the marketing and sale of prescription
products for the treatment of infectious diseases and respiratory conditions.
The Dura acquisition added over 500 hospital and primary care sales
representatives to Elan's sales and marketing infrastructure and broadened
Elan's portfolio of marketed products. The purchase price was primarily
allocated to goodwill and patents and licences. In 2002, Elan wrote down
goodwill relating to the acquisition of Dura by $854.9 million. Elan acquired
Dura in order to significantly expand its sales and marketing infrastructure.
Elan's recovery plan aimed to create a research and development based
biopharmaceutical company focused in neurology, autoimmune diseases and severe
pain. Therefore, Elan decided to significantly reduce its sales and marketing
infrastructure. For example, during 2002, Elan decided to dispose of its
primary care franchise and related infrastructure. As a result of such
reductions in Elan's sales and marketing capability, the carrying value of the
Dura goodwill was impaired.

Liposome

Elan acquired Liposome in May 2000 for $731.8 million, which included a
milestone payment of $54.0 million paid on the receipt of marketing and pricing
approval for Myocet in certain countries of the EU. Liposome was a
biotechnology company engaged in the development, manufacturing and marketing
of therapeutic products to treat cancer and related diseases. The purchase
price was primarily allocated to goodwill and patents and licences. In 2002,
under its recovery plan, Elan disposed of its U.S., Canadian and any Japanese
rights to Abelcet, and certain related assets, and allocated $119.0 million of
goodwill to the sale of the Abelcet business based on the estimated relative
fair value of the Abelcet rights disposed. In 2002, Elan wrote down the
remaining goodwill arising from the acquisition of Liposome by $111.8 million,
as under its recovery plan Elan decided to close its oncology research and
development business. The residual value for goodwill of $86.8 million was
supported by European rights to Abelcet and Myocet.

Sano

Elan acquired Sano in February 1998 for $434.6 million. Sano was developing
transdermal drug delivery products. The purchase price was primarily allocated
to acquired IP. In 2002, Elan wrote down acquired IP and goodwill arising from
the acquisition of Sano by $87.4 million and $2.4 million, respectively, as
under its recovery plan Elan decided to dispose of its transdermal business.
This business was sold to Nitto Americas in July 2003.

--------------------------------------------------------------------------------
42

--------------------------------------------------------------------------------

Quadrant

Elan acquired Quadrant in December 2000 for $86.0 million. Quadrant was a drug
delivery company with proprietary formulation technology applicable to
pulmonary, oral and parenteral routes of administration. The purchase price was
primarily allocated to goodwill. In 2002, Elan wrote down goodwill arising from
the acquisition of Quadrant by $78.2 million to $Nil, as under its recovery
plan Elan decided to dispose of or close the Quadrant business. This business
was sold to a company managed by former employees of the business in July 2003.

Axogen

Elan acquired Axogen in December 1999 for $268.4 million. The purchase price
was primarily allocated to patents and licences and acquired IP. In 2002, Elan
wrote down acquired IP relating to Myobloc, arising from the acquisition of
Axogen, by $28.4 million. Elan also wrote down $77.7 million in respect of
other Myobloc intangible assets. The carrying value of Myobloc was written down
due to lower than expected revenue from this product for 2002 and changed
expectations for this product.

Other products

The intangible asset for the Pain Portfolio was written down due to supply
difficulties since its acquisition in 2001, leading to diminished selling
support from Elan as well as changed commercial expectations related to generic
competition. Naprelan and Myambutol have been written down due to the impact of
generic competition on these products in 2002 and reduced projected revenue and
profitability from these products. Frova was written down to reflect reduced
projected revenue and profitability from this product. In June 2002, Elan
elected not to exercise its purchase option to acquire certain dermatology
products from GSK. This resulted in rights to all products reverting to GSK at
the end of 2002. As a result of this decision, Elan wrote down the related
product intangible by $29.8 million to $Nil.

Autoimmune

In July 2002, Elan announced the termination of all agreements relating to the
risk-sharing arrangement with Autoimmune. The royalty obligations to Autoimmune
were terminated. The total consideration for the royalty rights was $121.0
million which, after taking account of the redemption of Elan's investment of
$38.5 million in Autoimmune, resulted in a net cash cost of $82.5 million. Elan
expensed $121.0 million as an exceptional selling, general and administration
expense arising from the acquisition of Autoimmune.

Litigation

Elan recorded a provision during 2002 of $19.0 million relating to litigation
with Schwarz Pharma, Inc. ("Schwarz"), Allergan, Inc. and Allergan Sales, LLC
(collectively, "Allergan") and shareholder derivative actions. For additional
information on these litigations, please refer to Note 25 to the Consolidated
Financial Statements.

(D) RESEARCH AND DEVELOPMENT

Exceptional research and development expenses were $114.7 million. These mainly
relate to product and goodwill impairments of $59.3 million and $10.6 million,
respectively, together with fixed asset write-downs of $11.6 million and
severance/relocation costs.

In September 2001, Elan acquired Delsys, for $50.0 million. Delsys was formed
in 1995 and was engaged in developing novel manufacturing technology. During
2002, Elan recorded an impairment charge for the intangible assets relating to
Delsys of $45.7 million, as under its recovery plan, Elan decided to close
Delsys.

(E) OTHER ORDINARY ACTIVITIES

Elan recognised a gain of $77.9 million on the disposal of Athena Diagnostics
and the Abelcet business. In November 2002, Elan completed the sale of its
U.S., Canadian and any Japanese rights to Abelcet, and certain related assets,
to Enzon. Elan received a net cash payment of $360.0 million from Enzon,
representing the total consideration, after agreed price adjustments. The gain
amounted to $12.7 million. In December 2002, Elan together with the other
stockholders of Elan's subsidiary, Athena Diagnostics, completed the sale of
all of the outstanding stock of Athena Diagnostics to Behrman Capital and
certain of its affiliated investment funds ("Behrman"). Elan realised net cash
proceeds of $81.8 million and a net gain of $65.2 million.

In its 2002 Annual Report and Form 20-F, Elan restated its U.S. GAAP financial
results as of and for the fiscal year ended 31 December 2001 to consolidate
EPIL III from its date of establishment on 15 March 2001. Under U.S. GAAP, EPIL
III had been historically accounted

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      43

FINANCIAL REVIEW
--------------------------------------------------------------------------------

for by Elan as a qualifying special purpose entity and was not, therefore,
consolidated. In addition, in its 2002 Annual Report and Form 20-F, Elan
adjusted its previously announced unaudited U.S. GAAP financial information as
of and for the fiscal year ended 31 December 2002 to give effect to the
consolidation of EPIL III and to consolidate Shelly Bay Holdings Ltd. ("Shelly
Bay"), an entity established by Elan, from 29 June 2002 through 30 September
2002. Shelly Bay acquired certain financial assets from EPIL III on 29 June
2002. Under Irish GAAP, EPIL III had been accounted for as a consolidated
subsidiary since its date of establishment in accordance with the requirements
of FRS 5, "Reporting the Substance of Transactions" ("FRS 5"). Therefore, the
2001 restatement did not affect Elan's Irish GAAP financial information,
including the Irish GAAP financial information contained in this Annual Report
and Form 20-F. For additional information regarding the restatement and the
adjustments, please refer to Note 33 to the Consolidated Financial Statements.

In March 2001, Elan transferred a portfolio of equity and debt securities to
EPIL III, a wholly owned subsidiary of Elan. EPIL III issued $160.0 million in
aggregate principal amount of Series A Guaranteed Notes, $190.0 million in
aggregate principal amount of Series B Guaranteed Notes and $200.0 million in
aggregate principal amount of Series C Guaranteed Notes. The Series A
Guaranteed Notes matured on 29 June 2002. To fund the repayment of the notes,
on 29 June 2002 EPIL III transferred certain financial assets, consisting of
certain of the securities included in the portfolio transferred to EPIL III, to
Shelly Bay and Shelly Bay made a $148.0 million cash payment to EPIL III. EPIL
III used the proceeds from the payment by Shelly Bay, together with existing
cash of $12.0 million, to repay the Series A Guaranteed Notes. The assets
transferred by EPIL III to Shelly Bay had a carrying value under Irish GAAP of
$223.4 million.

The documents that established EPIL III required that EPIL III dispose of
financial assets in order to repay the Series A Guaranteed Notes at maturity.
The documents also mandated the order in which the assets were to be sold prior
to the maturity date for the Series A Guaranteed Notes. However, due to a
number of factors, including the inability of Elan and EPIL III to locate the
list mandating the order of disposal of the financial assets, the disposal
process was commenced and completed over the one-week period ending on 29 June
2002. Although Elan, as servicing agent for EPIL III, contacted a number of
third parties regarding their potential interest in purchasing financial assets
from EPIL III, each of those parties indicated that they would not be able to
complete a due diligence analysis of the issuers of the financial assets to be
sold, or to receive all necessary internal approvals to complete the purchase,
on a timely basis.

Therefore, in an effort to enable EPIL III to dispose of the financial assets,
Elan determined that it would be necessary to provide non-recourse credit
support to third parties who would agree to purchase financial assets from EPIL
III. Credit support was offered to a number of potential purchasers of the
financial assets. However, ultimately, only Shelly Bay possessed the ability to
complete the transaction on a timely basis.

Elan established Shelly Bay specifically for the purpose of acquiring financial
assets from EPIL III. All of the capital stock of Shelly Bay was issued to its
sole shareholder. Elan did not own any capital stock of Shelly Bay and did not
have a representative on Shelly Bay's board of directors. In addition, the sole
shareholder of Shelly Bay had no previous contact with Elan. However, as
further described below, Elan possessed all of the financial risk of the Shelly
Bay transaction. Similar to all other potential purchasers contacted by Elan,
the sole shareholder of Shelly Bay was unwilling to invest capital to acquire
the financial assets until a due diligence analysis of the issuers of the
financial assets had been completed. Therefore, the sole shareholder of Shelly
Bay made no substantive capital investment in Shelly Bay and, although Shelly
Bay possessed all of the potential financial benefits of the transaction,
neither Shelly Bay nor its sole shareholder had any financial risk in the
transaction.

Elan believed that any failure by EPIL III to dispose of financial assets prior
to 29 June 2002 could potentially adversely impact the non-consolidated
accounting status of EPIL III under U.S. GAAP and could result in defaults
under Elan's debt instruments.

Under the terms of the transaction, Shelly Bay acquired certain financial
assets from EPIL III on 29 June 2002 and made a cash payment to EPIL III of
$148.0 million. Shelly Bay financed the entire purchase price of the financial
assets, together with the funds necessary to pay interest and other costs on
the loan to its maturity date, through borrowings under a $153.0 million
non-recourse bank loan facility maturing on 30 September 2002. Elan provided a
full and unconditional guarantee to the bank to support Shelly Bay's obligation
to repay the loan and provided $153.0 million in cash collateral to the bank to
secure Elan's obligations under its guarantee. Upon the closing of the
transaction, Elan paid to Shelly Bay approximately $1 million to reimburse
Shelly Bay for the expenses expected to be incurred by it in connection with
the transaction. In addition, Elan irrevocably waived all rights of recourse
against Shelly Bay in the event that it failed to repay the bank loan at
maturity.

The cash payment made by Shelly Bay in connection with its acquisition of the
financial assets was based upon a valuation conducted by Elan. The valuation
utilised customary, widely-accepted valuation methodologies and required that
Elan make certain judgements and assumptions regarding the financial assets.
Elan did not receive any independent verification of the valuation at the time
of the transaction. In addition, EPIL III did not receive any bids for the
financial assets to be disposed of.

--------------------------------------------------------------------------------
44

--------------------------------------------------------------------------------

Upon the closing of the transaction, Shelly Bay's assets consisted solely of
the financial assets purchased from EPIL III. Under the terms of the
transaction, Shelly Bay was required to complete a due diligence analysis of
the issuers of the securities prior to 15 September 2002. Shelly Bay had the
right to either elect, on or prior to 15 September 2002, to retain the
financial assets on a long-term basis or to dispose of the financial assets
prior to 30 September 2002.

In the event that Shelly Bay elected to retain the financial assets, it was
required, within 15 days of the election, to obtain alternative financing in an
amount equal to the value, as of 29 June 2002, of the assets being retained, as
determined by an independent appraiser engaged by Shelly Bay. The net cash
proceeds received by Shelly Bay from any alternative financing were required to
be applied to repay amounts outstanding under Shelly Bay's bank loan.

In the event that Shelly Bay elected to dispose of the financial assets prior
to 30 September 2002, Shelly Bay was required to apply the net proceeds from
the dispositions to repay amounts outstanding under its bank loan. The
transaction agreements contained no limitation on the price at which any
financial asset could be sold by Shelly Bay or the party to whom any financial
asset could be sold. In addition, Elan agreed that it had no right to object to
the disposition of any financial asset, the party to whom it was disposed or
the price obtained for the disposition.

Given the non-recourse nature of the Shelly Bay bank loan, Elan possessed all
of the financial risk of the transaction under its guarantee of the bank loan,
and the cash collateral provided by Elan to secure the guarantee, in the event
of any shortfall in the aggregate proceeds received by Shelly Bay from the
refinancing or disposition of the financial assets. Although Shelly Bay
possessed all of the potential financial benefits of the transaction, neither
Shelly Bay nor its sole shareholder had any financial risk in the transaction.

As required by the terms of the transaction, Shelly Bay engaged an independent
appraiser to value the financial assets as of 29 June 2002. The appraisal,
which was prepared in early September 2002, valued the financial assets at $8.2
million.

Shelly Bay did not elect, under the terms of the transaction, to retain any of
the financial assets and obtain alternative financing in an amount equal to the
independent appraiser's valuation. Rather, by 30 September 2002, Shelly Bay had
disposed of all of the financial assets for aggregate net proceeds of $9.3
million. A number of the financial assets were disposed of, for net proceeds of
$1.8 million, to an affiliate of Shelly Bay. The remainder of the financial
assets were sold to third parties and in open market transactions. As described
above, the transaction agreements contained no limitation on the price at which
any financial asset could be sold by Shelly Bay or the party to whom any
financial asset could be sold, including to an affiliate of Shelly Bay. In
addition, Elan agreed that it had no right to object to the disposition of any
financial asset, the party to whom it was disposed or the price obtained for
the disposition.

As a result of the disposition of the financial assets by Shelly Bay for
aggregate net proceeds of $9.3 million, on 30 September 2002, Elan made a cash
payment of $141.6 million to satisfy its obligation under its guarantee. Under
the terms of the transaction agreements, Elan has no further obligation under
the guarantee and has no recourse to Shelly Bay or to its sole shareholder
arising from Elan's payment under the guarantee. The loss on the sale of the
securities was $217.0 million under Irish GAAP including the $141.6 million
under the guarantee.

(F) NET INTEREST

Exceptional net interest and other expenses were $1,014.0 million.

This includes a charge of $1,045.9 million relating to investments in Elan's
investment portfolio, including the investments held by EPIL II and EPIL III.
The financial markets for emerging biotechnology, drug delivery and
pharmaceutical companies declined significantly during 2002. The investment
impairment charge mainly reflects this significant decline in the financial
markets and also the impact of weak financial markets on the ability of
emerging biotechnology, drug delivery and pharmaceutical companies to raise
finance. The charge also includes impairments relating to investments in
business ventures and business venture parents. The investment impairments
comprise $215.4 million, $575.4 million and $255.1 million in relation to
quoted investments, unquoted investments and loans, and securitised
investments, respectively. In addition, during 2003 the Company recognised a
net loss on financial assets of $10.0 million.

Offsetting these charges was a net gain of $37.7 million on the repurchase of
$318.6 million in principal amount at maturity of LYONs. These LYONs, having an
accreted value of $190.1 million at the date of purchase, were purchased at an
aggregate cost of $149.8 million, resulting in the net gain of $37.7 million
after related costs. For further information regarding the LYONs, please refer
to Note 15 to the Consolidated Financial Statements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      45

FINANCIAL REVIEW
--------------------------------------------------------------------------------

NET INTEREST AND OTHER EXPENSES

Net interest and other expense was $187.5 million for 2003 compared to $1,170.7
million for 2002.

Interest payable and similar charges decreased by 74% to $331.7 million for
2003 from $1,297.1 million for 2002, primarily reflecting investment related
charges of $120.4 million and debt interest charges of $124.1 million in 2003
compared with $1,045.9 million and $128.5 million, respectively, in 2002. The
investment related charges are specific to individual investments, and were
impacted adversely by the significant decline in biotechnology markets during
2002. Interest payable for 2003 includes $4.1 million (2002: $Nil) on the 6.5%
Convertible Notes, issued by Elan Capital Corp. Ltd ("ECC"), an indirect wholly
owned subsidiary of Elan, in November 2003; $47.1 million (2002: $47.1 million)
on the 7.25% senior notes due 2008 (the "7.25% Senior Notes"), issued by Athena
Neurosciences Finance, LLC, ("Athena Finance"), an indirect wholly owned
subsidiary of Elan, in February 2001; $29.9 million (2002: $37.2 million) on
the EPIL III Notes issued in March 2001; and $43.0 million (2002: $43.0
million) on the EPIL II Notes issued in June 2000. Elan expensed the subsequent
funding it provides directly to business ventures. This is expensed within the
interest and other expense line. Elan expensed $3.0 million and $23.9 million
for this subsequent funding in 2003 and 2002, respectively.

Income from financial assets increased by 14% to $144.2 million for 2003 from
$126.4 million for 2002. Interest and other income decreased to $32.1 million
for 2003 from $86.3 million in 2002, reflecting lower cash balances and reduced
investment income during 2003. Net gains on financial assets amounted to $106.3
million in 2003 primarily reflecting gains of $72.3 million on the disposal of
Elan's investment in Ligand. Income from financial assets for 2003 also
included a gain of $1.6 million (2002: $37.7 million) on the repurchase of
LYONs. Foreign exchange gains amounted to $4.2 million in 2003 and $2.4 million
in 2002.

For additional information regarding net interest and other expense, please
refer to Note 4 to the Consolidated Financial Statements.

For additional information regarding indebtedness, please refer to Note 15 to
the Consolidated Financial Statements and to "Debt Facilities" in this
Financial Review.

TAXATION

Tax on profit on ordinary activities decreased to a tax credit of $22.0 million
for 2003 from a tax charge of $19.8 million for 2002. The tax credit for 2003
includes the utilisation of prior stock option tax deductions of $26.7 million
offset in part by tax charges of $4.7 million. The tax charges reflected tax at
standard rates in the jurisdictions in which Elan operates, income derived from
Irish patents, which is exempt from tax, foreign withholding tax and the
availability of tax losses. Elan's Irish patent derived income was exempt from
taxation pursuant to Irish legislation, which exempts from Irish taxation
income derived from qualifying patents. Currently, there is no termination date
in effect for such exemption.

For additional information regarding taxation, please refer to Note 7 to the
Consolidated Financial Statements.

DISCONTINUED OPERATIONS

Under Irish GAAP, a discontinued operation is classified as an operation of the
business which is (i) sold or terminated and the sale or termination has been
completed during the year or within three months following the year end, (ii)
the former activities have ceased permanently, (iii) the operation had a
material effect on the nature and focus of the business and (iv) its financial
results are clearly distinguishable.

In the first quarter of 2004, Elan concluded its recovery plan with the sale of
its European sales and marketing infrastructure. Subsequently, Elan sold
several pharmaceutical products and businesses, including Frova, Zonegran,
Myobloc, Zanaflex, Naprelan and other non-promoted pharmaceutical products. The
results of these operations together with those of other business divestments
and closures made during the recovery plan have been reported separately as
discontinued operations for 2003 and for comparative years. Other divestments
and closures include the sale of Elan's diagnostic businesses, the return of
the dermatology products to GSK, the Abelcet business, the sale of the primary
care franchise to King, the sale of the Pain Portfolio to aaiPharma and the
sale or closure of a number of drug delivery businesses including the sale of a
transdermal technology business, the closure of Elan's medipad business and
Elan's research facility in Princeton and the sale of a U.K. drug delivery
business.

For additional information on discontinued operations, please refer to Note 6
to the Consolidated Financial Statements.

RETAINED LOSS

Retained loss for the year, after exceptional items, was $815.4 million for
2003 compared to a retained loss of $3,615.1 million for 2002. Before
exceptional items, retained loss was $498.3 million for 2003 compared to a
retained loss of $665.7 million for 2002. Basic loss

--------------------------------------------------------------------------------
46

--------------------------------------------------------------------------------

per share, after exceptional items, was $2.29 for 2003, compared to $10.34 per
share for 2002. Basic loss per share, before exceptional items, was $1.40 for
2003 compared to $1.90 per share for 2002. Diluted loss per share, after
exceptional items, was $2.29 for 2003, compared to $10.34 per share for 2002.
Diluted loss per share, before exceptional items was $1.40 for 2003 compared to
$1.90 per share for 2002.

2002 COMPARED TO 2001

The previously reported analysis of revenue has been restated to reflect
additional product divestments in 2003 and 2004.

REVENUE

Total revenue decreased 23% to $1,333.0 million for 2002 from $1,740.7 million
for 2001.

-------------------------------------------------------------------------
                                                       2002          2001
PRODUCT REVENUE                                          $M            $M
-------------------------------------------------------------------------

 (A) Revenue from Retained Products(1)
-------------------------------------------------------------------------
 U.S. Promoted Products
 Maxipime                                             79.2          86.3
 Azactam                                              33.0          46.4
-------------------------------------------------------------------------
                                                     112.2         132.7
-------------------------------------------------------------------------
 Contract manufacturing and royalties                109.3         113.4
-------------------------------------------------------------------------

 TOTAL REVENUE FROM RETAINED PRODUCTS                221.5         246.1
-------------------------------------------------------------------------

 (B) Revenue from Divested Products(2)
-------------------------------------------------------------------------
 Skelaxin(3)                                         145.3         117.9
 Sonata(3)                                            92.5           2.3
 Abelcet(4)                                           64.6          72.0
 Dermatology                                          47.6          61.8
 Diagnostics                                          70.6          51.7
 Pain Portfolio(5)                                    59.8          15.4
 Avinza(6)                                            75.6            -
 Actiq/nifedipine(6)                                  79.1            -
 European business                                   102.6          90.9
 Zonegran(7)                                          43.1          37.8
 Frova(7)(8)                                          11.2           --
 Myobloc(9)                                           19.6          11.6
 Zanaflex(10)                                         56.8         161.7
 Other                                                 2.0          47.0
 Product rationalisations(6)                          17.8         231.4
 Product sales of rationalised products               32.0         101.7
-------------------------------------------------------------------------
                                                     920.2       1,003.2
-------------------------------------------------------------------------
 (C) Co-promotion Fees
-------------------------------------------------------------------------
 Autoimmune                                           38.8          15.9
 Pharma Marketing                                     24.0         141.8
-------------------------------------------------------------------------
                                                      62.8         157.7
-------------------------------------------------------------------------
 TOTAL PRODUCT REVENUE                             1,204.5       1,407.0
-------------------------------------------------------------------------

 CONTRACT REVENUE
-------------------------------------------------------------------------
 Licence fees                                          7.1         173.6
 Pharma Marketing / Autoimmune                        37.2          58.7
 Research revenue and milestones                      84.2         101.4
-------------------------------------------------------------------------
 TOTAL CONTRACT REVENUE                              128.5         333.7
-------------------------------------------------------------------------
 TOTAL REVENUE                                     1,333.0       1,740.7
-------------------------------------------------------------------------

(1)  Products described as "Retained Products" include products or businesses
     not divested and not subject to divestment agreements.

(2)  Products described as "Divested Products" include products or businesses
     divested since the beginning of 2001, and products or businesses subject to
     divestment agreements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      47

FINANCIAL REVIEW
--------------------------------------------------------------------------------

(3)  Sold to King in June 2003.

(4)  Sold to Enzon in November 2002.

(5)  Acquired from Roxane in September 2001. Sold to aaiPharma in December 2003.

(6)  Exceptional product revenue.

(7)  On 30 March 2004, Elan announced an agreement to divest this product. This
     divestment closed during the second quarter of 2004.

(8)  Launched in the United States in May 2002.

(9)  Sold to Solstice in July 2004.

(10) Sold to Acorda in July 2004.

PRODUCT REVENUE

Product revenue decreased by 14% to $1,204.5 million for 2002 from $1,407.0
million for 2001.

(A) Revenue from Retained Products

Revenue from retained products was $221.5 million for 2002 compared with $246.1
million for 2001. Combined revenue from Maxipime and Azactam was $112.2 million
for 2002 compared to $132.7 million for 2001, a decrease of 15%. This decrease
was due to supply issues during 2002, which have since been resolved, together
with a change in Elan's discounting strategy, which resulted in reduced
wholesaler inventories.

(B) Revenue from Divested Products

On 30 January 2003, Elan announced that it had agreed to sell its primary care
franchise, principally consisting of its U.S. and Puerto Rican rights to
Skelaxin and Sonata, related inventory and related rights to enhanced
formulations of these products, to King. On 17 March 2003, Elan commenced a
lawsuit against King to compel King to complete its purchase of the primary
care franchise. On 19 May 2003, Elan and King agreed to proceed with the
transaction on amended terms and on 12 June 2003 the transaction was completed.
Effective upon the closing of the transaction, all claims under the pending
litigation were released and Elan and King dismissed the litigation with
prejudice. During 2002, product revenue from Skelaxin and Sonata was $237.8
million (2001: $120.2 million).

During 2002, Elan divested its dermatology and Athena Diagnostics businesses
and its U.S., Canadian and any Japanese rights to Abelcet. On 29 April 2003,
Elan completed the sale of Elan Diagnostics. These businesses contributed
$182.8 million to product revenue for 2002 (2001: $185.5 million), representing
revenues before they were divested.

On 2 December 2003, Elan announced the completion of the sale of the Pain
Portfolio to aaiPharma. Revenue from the Pain Portfolio was $59.8 million for
2002 compared to $15.4 million for 2001.

On 9 December 2002, Elan announced the amendment of the terms of its
development, licence and supply agreement with Ligand regarding Avinza. Elan
received a cash payment of $100.0 million from Ligand in return for a reduction
in the ongoing royalty rate from the previous level of 30% of net sales of
Avinza in the United States and Canada to approximately 10%. In addition, Elan
agreed to forego its option to negotiate a co-promotion agreement with Ligand
for Avinza in the United States and Canada. Elan will continue to manufacture
the product in its Gainesville facility. Net of the write-off of the related
intangible assets, Elan recorded net revenue of $75.6 million on the closing of
this transaction.

On 3 October 2002, Elan announced that it sold its rights to Actiq in twelve
territories, principally in Europe, to Anesta. At the date of disposal, Actiq
was marketed by Elan in the United Kingdom, Ireland and Germany. Net of the
write-off of the related intangible assets, Elan recorded revenue of $40.3
million on the closing of this transaction.

On 23 August 2002, Elan announced a licensing agreement with Watson for
exclusive marketing rights to the 30 mg and 60 mg dosage strengths of Elan's
extended-release nifedipine tablets in the United States. Elan received $45.0
million in cash from Watson. Elan will continue to manufacture the products in
its Athlone facility. Net of the write-off of the related intangible assets,
Elan recorded revenue of $38.8 million on the closing of this transaction.

On 12 February 2004, Elan announced the sale of its European sales and
marketing business to Medeus. Separately, Elan completed the sale of certain
rights to two products in the U.K. and Ireland for approximately $10 million
during the first quarter of 2004. During 2002, revenue from these European
products was $102.6 million (2001: $90.9 million).

On 30 March 2004, Elan announced that it had agreed to sell its interests in
North America and Europe for Zonegran to Eisai. The transaction closed in the
second quarter of 2004. Zonogran revenue was $43.1 million for 2002 compared to
$37.8 million for 2001, an

--------------------------------------------------------------------------------
48

--------------------------------------------------------------------------------

increase of 14%. The percentage increase in prescription demand for this
product in 2002 over 2001 was higher than the percentage increase in product
revenue, due to a change in Elan's discounting strategy, which resulted in
reduced wholesaler inventories.

On 30 March 2004, Elan announced that it had agreed to sell its
commercialisation rights in North America for Frova to Vernalis. The
transaction closed in the second quarter of 2004. Frova, which was launched in
the United States in May 2002 under a co-promotion agreement between Elan and
UCB, generated revenue of $11.2 million for 2002.

Elan sold Myobloc to Solstice in July 2004, and sold Zanaflex to Acorda in the
same month. Myobloc product revenue increased 69% for 2002 to $19.6 million
from $11.6 million for 2001 as a result of increased promotion. Generic
competitor products to Zanaflex were launched in the United States during 2002.
This resulted in a decrease in Zanaflex revenue to $56.8 million for 2002
compared to $161.7 million for 2001.

Product rationalisation revenue was $17.8 million for 2002 compared to $231.4
million for 2001. For additional information on product rationalisations,
please refer to pages 50 to 53.

Product sales of rationalised products, which represents revenue prior to
rationalisation, decreased by 69% to $32.0 million for 2002 from $101.7 million
for 2001.

(C) Co-promotion Fees

Product revenue from product co-promotion and marketing activities, which
resulted from Elan's risk-sharing arrangements with Pharma Marketing and
Autoimmune, decreased by 60% to $62.8 million for 2002 from $157.7 million for
2001. Elan will not receive any future revenue from either Pharma Marketing or
Autoimmune.

CONTRACT REVENUE

Contract revenue decreased by 61% to $128.5 million for 2002 from $333.7
million for 2001, primarily as no licence fees were received from business
ventures in 2002. Elan received up front licence fees of $7.1 million in 2002
compared to $173.6 million for 2001. Contract revenue from Pharma Marketing and
Autoimmune decreased by 37% to $37.2 million for 2002 from $58.7 million for
2001. Elan will not receive any future revenue from either Pharma Marketing or
Autoimmune. Research revenue and milestones amounted to $84.2 million in 2002
compared to $101.4 million in 2001.

MAJOR CUSTOMERS

Cardinal Health, Amerisource Bergen and McKesson, all of which are drug
wholesalers, accounted for approximately 13%, 13% and 12%, respectively, of
Elan's total revenue for 2002. Cardinal Health and Pharma Marketing accounted
for approximately 14% and 11%, respectively, of Elan's total revenue for 2001.
No other customer accounted for more than 10% of total revenue for 2002 or
2001.

COST OF SALES

Cost of sales, after exceptional items, increased by 25% to $483.1 million for
2002 from $386.8 million for 2001. The increase was 15% before exceptional
items of $66.1 million for 2002 and $22.8 million for 2001. Gross margin on
total revenue, before exceptional items, was approximately 64% for 2002 and 76%
for 2001. Gross margin on total revenue, after exceptional items, was 64% for
2002 and 78% for 2001. Gross margin on product revenue, before exceptional
items, decreased to 60% for 2002 from 69% for 2001. Gross margin on product
revenue, after exceptional items, decreased to 60% in 2002 from 73% in 2001.
The reduction in gross margin on product revenue reflects changes in the mix of
product revenue, in particular the decrease in product revenue from
risk-sharing arrangements and from Zanaflex. The reduction in gross margin on
total revenue reflects changes in the mix of revenue, in particular the
decrease in licence fees and in revenue from risk-sharing arrangements.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses, after exceptional items,
increased by 47% to $2,623.4 million for 2002 from $1,781.7 million for 2001.
The increase was 20% before exceptional items of $1,788.0 million for 2002 and
$1,084.2 million for 2001, principally reflecting increased sales and marketing
costs arising from the inclusion of a full year's sales and marketing costs for
2002 for Sonata (Elan assumed marketing responsibility for this product in
December 2001) and the Pain Portfolio (Elan acquired these products in
September 2001), together with the launch of Frova during 2002.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      49

FINANCIAL REVIEW
--------------------------------------------------------------------------------

RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses, after exceptional items, increased by 29% to
$517.3 million for 2002 from $401.9 million for 2001. The increase was 25%
before exceptional items of $114.7 million for 2002 and $78.6 million for 2001,
principally reflecting increased expenditure on Elan's research and development
projects, including Antegren.

EXCEPTIONAL ITEMS

Exceptional items are those items that in management's judgement are material
items which derive from events or transactions that fall within the ordinary
activities of the Group and which individually or, if of a similar type, in
aggregate, need to be disclosed by virtue of their size or incidence.

2002

In 2002, Elan incurred net exceptional charges of $2,949.4 million. For
additional information on these exceptional charges, please refer to pages 40
to 45.

2001

In 2001, Elan incurred net exceptional charges of $931.9 million. These
exceptional revenues and costs have been included under the statutory format
headings to which they relate analysed as follows:

---------------------------------------------------------------------------------------------------------------------------
                                                                           SELLING,       RESEARCH
                                                                COST    GENERAL AND            AND        NET
                                                   REVENUE  OF SALES ADMINISTRATIVE    DEVELOPMENT   INTEREST
                                                       (A)       (B)            (C)            (D)         (E)       TOTAL
                                                        $M        $M             $M             $M          $M          $M
---------------------------------------------------------------------------------------------------------------------------

 Product rationalisations                          (231.4)      15.6             --             --          --      (215.8)
 Rationalisation of research and
  development activities                             (2.0)        --             --           60.5          --        58.5
 Pharmaceutical division reorganisation costs          --        0.4           55.7             --          --        56.1
 Acquired IP and product impairment                    --         --        1,009.8             --          --     1,009.8
 Investment impairments                                --         --             --             --        24.1        24.1
 Net gain on financial assets                          --         --             --             --       (56.8)      (56.8)
 Asset write-downs and other                          5.6        6.8           18.7           18.1         6.8        56.0
---------------------------------------------------------------------------------------------------------------------------
 Net exceptional charges                           (227.8)      22.8        1,084.2           78.6       (25.9)      931.9
---------------------------------------------------------------------------------------------------------------------------

(A) REVENUE

Exceptional revenue in 2001 primarily relates to product rationalisation
revenue of $231.4 million.

During 2001, Elan reorganised its sales force into five groups, consisting of
primary care, hospital, neurology, specialty/dermatology and clinical sales
consultants. Sales force activity was redirected to promote Zanaflex, Skelaxin,
Abelcet, Azactam, Maxipime, Myobloc, Zonegran and Cutivate. Elan also commenced
a product acquisition and marketing alliance strategy to access brands meeting
certain commercial criteria established by Elan. Conversely, pursuant to its
rationalisation programme, Elan rationalised certain of its products that did
not meet its commercial criteria. This rationalisation programme generated
product revenue and profits for Elan. The commercial criteria on which the
promoted products were chosen, and against which product acquisitions or
marketing alliances were evaluated, included potential future revenue from the
product; whether the product was in a therapeutic area in which Elan marketed
products or had pipeline products; whether the product was a niche product; and
whether Elan's drug delivery technologies could be utilised to enhance the
value of the product. For example, Elan assumed responsibility for the U.S.
marketing rights of Sonata in December 2001 pursuant to its marketing alliance
with Wyeth and acquired the Pain Portfolio from Roxane in September 2001.

In 2001, Elan rationalised Diastat, Entex, Furadantin, Midrin, Mysoline,
Nasalide, Nasarel and Permax. These rationalisations were accomplished through
outright sales or pursuant to distribution and royalty arrangements. The
rationalised products did not fit with Elan's commercial criteria. Some of
these products would also have suffered over time from the withdrawal of
promotional support by Elan. In certain cases, the products were also facing
other challenges such as the potential for generic competition.

--------------------------------------------------------------------------------
50

--------------------------------------------------------------------------------

Revenue generated from product rationalisations is recorded as product revenue.
Elan recorded net product revenue of $231.4 million from product
rationalisations in 2001. This is recorded as exceptional product revenue. The
rationalised products generated revenue prior to rationalisation of $101.7
million for 2001.

The following table lists each product rationalised in 2001, the company to
which the product was rationalised and the net revenue recorded by Elan in 2001
from the rationalisation. Net income from product rationalisations in 2001
amounted to $215.8 million.

----------------------------------------------------------------------------------------------
                                                                                   NET REVENUE
PRODUCT RATIONALISED      COMPANY                                                           $M
----------------------------------------------------------------------------------------------

 (a) Diastat              Xcel                                                            97.0
----------------------------------------------------------------------------------------------
 (a) Mysoline             Xcel                                                            23.5
----------------------------------------------------------------------------------------------
 (b) Nasarel/Nasalide     IVAX Corporation ("IVAX")                                       62.6
----------------------------------------------------------------------------------------------
 (c) Permax               Amarin Corporation, plc ("Amarin")                              10.7
----------------------------------------------------------------------------------------------
 (d) Entex                Andrx Corporation ("Andrx")                                     12.8
----------------------------------------------------------------------------------------------
 (d) Midrin               Women First Healthcare, Inc. ("WFHC")                           13.6
----------------------------------------------------------------------------------------------
 (d) Furadantin           First Horizon Pharmaceutical Corporation ("First Horizon")      11.2
----------------------------------------------------------------------------------------------
                                                                                         231.4
----------------------------------------------------------------------------------------------

(a) Diastat/Mysoline

Xcel was formed in January 2001. Xcel is a specialty pharmaceutical company
with an initial focus on neurology. Mr Cam Garner, Mr Michael Borer and Mr John
Cook, founders of Xcel, were previously employed by Dura, a company Elan
acquired in November 2000. Mr James Fares, a founder of Xcel, was previously
employed by Elan.

Elan rationalised the product rights and related inventory of Diastat to Xcel
on 31 March 2001. Elan subsequently rationalised the product rights and related
inventory of Mysoline to Xcel. Both these products fall within Xcel's focus on
neurology. Diastat and Mysoline are products used for the treatment of
epilepsy. Under the product agreements, Xcel acquired worldwide rights to
Diastat and exclusive rights to Mysoline in the United States. Elan received
aggregate cash consideration of $160.0 million for Diastat and Mysoline. Elan
also had a royalty right of between 5% and 20% on net sales of Mysoline by
Xcel. After reducing the carrying value of the related intangible assets, Elan
recorded net revenue of $97.0 million and $23.5 million on the rationalisation
of Diastat and Mysoline, respectively, in 2001.

On 30 March 2001, Xcel raised net proceeds of $69.6 million from issuing
convertible preferred stock. Elan purchased $15.0 million of this convertible
preferred stock, representing approximately 16% of Xcel's equity on a fully
diluted basis. On this date, two venture capital funds and their affiliates
purchased 54% of Xcel's equity on a fully diluted basis.

On 31 March 2001, Elan provided a loan of $99.0 million to Xcel. Elan also
provided a $10.0 million line of credit to Xcel, which was drawn down in June
2002.

Mr Erle Mast, who, at the time, was an Elan employee, became a member of Xcel's
board of directors in February 2002.

On 1 April 2003, Elan announced that it received $89.5 million in cash from
Xcel in exchange for all of Elan's shareholding in, and loans to, Xcel. In
addition, the royalty right on net sales of Mysoline was terminated. The net
carrying value of the shares and loan notes was written down during 2002 by
$34.5 million.

(b) Nasarel/Nasalide

IVAX is engaged in the research, development, manufacturing and marketing of
branded and brand equivalent (generic) pharmaceuticals and veterinary products
in the United States and international markets. In September 2001, Elan
rationalised the product rights and related inventory of Nasarel and Nasalide
to IVAX. Elan received cash consideration of approximately $120.0 million for
Nasarel and Nasalide and retained a royalty right of between 5% and 10% on net
sales of Nasarel and Nasalide by IVAX. After reducing the carrying value of the
related intangible assets, Elan recorded net revenue of $62.6 million on the
rationalisation of Nasarel and Nasalide in 2001.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      51

FINANCIAL REVIEW
--------------------------------------------------------------------------------

(c) Permax

Amarin is a specialty pharmaceutical company focused on neurology and pain
management. Mr Thomas Lynch, an employee of Elan and formerly its executive
vice chairman, and Mr John Groom, a director of Elan, serve on Amarin's board
of directors. Mr Lynch is non-executive chairman of Amarin.

In May 2001, Elan and Amarin entered into a distribution and option agreement,
whereby Amarin agreed to market and distribute Permax in the United States, and
was granted an option to acquire rights to the product from Elan. Permax is
used for the treatment of Parkinson's disease and falls within Amarin's focus
on neurology. In September 2001, this agreement was amended, whereby Amarin was
appointed the sole distributor of Permax in the United States until August
2002. Elan recorded consideration of $45.0 million under the terms of the
amended distribution and option agreement and retained a royalty right of 3.5%
on net sales of Permax by Amarin from 1 January 2002 through the date on which
Amarin exercised or terminated its option to acquire Permax. In 2001, Elan also
recorded a net amount of $6.2 million from Amarin for distribution fees and
royalties on sales of Permax. After reducing the carrying value of the Permax
intangible and equity accounting, Elan recorded net revenue from Amarin of
$16.9 million in 2001 which includes the distribution revenue. Amarin's option
to purchase Permax was exercisable between September 2001 and May 2002 for an
exercise price of $37.5 million, payable $7.5 million on exercise of the option
and $2.5 million in quarterly instalments thereafter, and a royalty of between
7% and 10% on future net sales of Permax by Amarin. On 11 March 2002, Amarin
exercised its option to acquire Permax and paid Elan the first instalment of
the exercise price of $7.5 million. Elan did not recognise the unpaid option
exercise price, but rather intended to record such consideration as it was
received due to uncertainties surrounding its ultimate collectibility.

In connection with the amended distribution and option agreement, Elan provided
a loan of $45.0 million to Amarin. The loan bore interest at a rate equal to
LIBOR plus a margin of 2%. Amarin repaid $2.5 million of this loan in July
2002. In January 2003, $19.9 million of this loan, including interest of $2.4
million, was repaid by Amarin and the maturity of the remaining amount of the
loan was amended to $10.0 million payable in September 2004 and $15.0 million
payable in September 2005.

During 2001, Elan granted Amarin a purchase option to acquire Zelapar. Zelapar
is a fast melt formulation of selegiline for the treatment of Parkinson's
disease.

In August 2003, Elan and Amarin agreed to amend certain terms of their
agreements whereby Amarin had until 31 December 2003 to pay $30.0 million to
Elan. If Amarin did so, all loans referred to above and outstanding deferred
payments due in connection with the purchase of Permax would have been
discharged in full, and Amarin would have been deemed to have exercised its
option to acquire Zelapar. Elan would additionally receive a royalty of 12.5%
of net sales of Zelapar by Amarin, and may have received a future
revenue-contingent milestone payment of $10.0 million in ordinary shares of
Amarin if annual sales of Zelapar exceeded $20.0 million. All quarterly
payments due in connection with the purchase of Permax and all loan interest
payments due were subject to a moratorium that expired on 31 December 2003.

In December 2003, Elan agreed to further amendments of those terms, by
increasing the amount Amarin could pay to discharge its indebtedness and
acquire Zelapar, from $30.0 million to $31.5 million, and extending the time
for doing so to 31 March 2004. Consequently, the times for exercise of the
Zelapar option and the moratorium on payments due in connection with the
purchase of Permax and all loan interest payments due were also extended to 31
March 2004.

Additionally, Elan agreed to a loan facility to Amarin of up to $6.0 million to
finance Amarin's cash requirements through 31 March 2004 and repayable on 31
March 2004. Amarin drew down $4.0 million of this facility through February
2004. Amarin agreed to pay Elan a monthly fee for this facility. In February
2004, Amarin paid $0.3 million to Elan, representing the amount of this fee for
January 2004.

Amarin repaid $11.1 million to Elan in December 2003. In February 2004, Elan
and Amarin agreed to further amend their contractual arrangements subject to
the sale by Amarin of certain of its U.S. assets, including its rights to
Zelapar and Permax, to Valeant Pharmaceuticals International ("Valeant"). On 25
February 2004, Amarin's sale of assets to Valeant closed and the amendments
became effective. The amendments required, in full settlement of all previous
liabilities owed by Amarin to Elan and as a deemed exercise of Amarin's option
to acquire Zelapar, the payment by Amarin of $17.2 million to Elan and the
issuance of a $5.0 million five-year 8% loan note and warrants to purchase
500,000 ordinary shares in Amarin to Elan. Under the amendments, Elan is also
entitled to receive a $1.0 million milestone payment from Amarin upon the
successful completion of certain Zelapar safety studies. Elan is also entitled
to receive from Valeant a revenue contingent milestone on Zelapar of $10.0
million if annual sales of Zelapar exceed $20.0 million, and royalties on
future net sales by Valeant of 12.5% for Zelapar and 10% for Permax. As a
consequence of these amendments Amarin paid $17.2 million to Elan in February
2004.

--------------------------------------------------------------------------------
52

--------------------------------------------------------------------------------

At 31 December 2003, Elan held approximately 26% of the outstanding ordinary
shares of Amarin. As described above, in February 2004 Elan received warrants
to purchase 500,000 ordinary shares in Amarin. As a result, Elan's share
ownership in Amarin is now approximately 28% on a fully diluted basis.

Under Irish GAAP Elan accounted for Amarin using the equity method, based on
Elan's fully diluted equity investment in Amarin in 2003 and 2002. Amarin is a
related party to Elan. Elan recorded net revenue from Amarin of $0.3 million in
2003 (2002: $4.8 million; 2001: $16.9 million). Elan's total investment in
Amarin at 31 December 2003 amounted to $23.9 million, consisting of loans,
including interest, of $20.9 million and a net equity investment of $3.0
million. In addition, Elan had trading balances due from Amarin of $Nil at 31
December 2003 (2002: $13.7 million). As described above, Amarin paid a net
$13.5 million to Elan during January/February 2004, and now owes Elan $5.0
million under a five-year loan note and a potential $1.0 million milestone
payment on Zelapar. Aside from the $5.0 million five-year loan note and the
potential $1.0 million milestone payment on Zelapar, Amarin has no remaining
debt obligations to Elan.

(d) Other Product Rationalisations

In June 2001, Elan rationalised the product rights and related inventory of
Entex to Andrx. Andrx is a corporation that commercialises controlled-release
oral pharmaceuticals using its proprietary drug delivery technologies. Elan
received cash consideration of $14.7 million and retained a royalty of 10% on
sales of Entex for 10 years from 2002. If annual sales of Entex exceed $10.0
million, Andrx will make additional royalty payments to Elan of 5% on sales in
excess of $8.0 million. Elan recorded net revenue of $12.8 million on the
rationalisation of Entex in 2001. The royalties are subject to a cap of $0.8
million per annum if Andrx reformulates the product.

In June 2001, Elan rationalised the product rights and related inventory of
Midrin to WFHC. WFHC is a specialty pharmaceutical company dedicated to
improving the health and well-being of midlife women. Elan received cash
consideration of $15.0 million and retained a royalty right of 10% on net sales
of Midrin by WFHC for 10 years from 2002. Elan recorded net revenue of $13.6
million on the rationalisation of Midrin in 2001. The maximum annual royalty
receivable is $0.5 million from 2003. Elan provided a loan to WFHC in the form
of an $11.0 million convertible promissory note. Elan will earn interest on the
note at a rate of 7% per annum. The note matures in June 2008. In addition,
Elan purchased 400,000 shares of WFHC common stock for $4.0 million.

In December 2001, Elan rationalised the product rights and related inventory of
Furadantin to First Horizon for cash consideration of $16.0 million. First
Horizon is a specialty pharmaceutical company that markets and sells brand name
prescription products. After reducing the carrying value of the Furadantin
intangible, Elan recorded net revenue of $11.2 million on the rationalisation
of Furadantin in 2001.

(B) COST OF SALES

The exceptional cost of sales is primarily comprised of $15.6 million relating
to product rationalisation revenue.

(C) SELLING, GENERAL AND ADMINISTRATIVE

Exceptional selling, general and administrative expenses were $1,084.2 million.
$1,009.8 million of the exceptional charges relate to impairment charges
arising on write-downs of intangible assets. Impairment charges to acquired IP
arising from the acquisitions of Neurex and Sano were $500.0 million and $285.2
million, respectively. Impairment charges to patents and licences arising on
write-downs of the product intangibles for Naprelan, Ceclor CD and Myambutol
were $81.0 million, $94.2 million and $44.4 million, respectively. Other
impairments to patents and licences amounted to $5.0 million. Other exceptional
selling, general and administrative expenses were $74.4 million. These mainly
relate to severance, integration, relocation and similar costs and asset
write-downs arising from the integration of Elan's U.S. biopharmaceuticals
businesses.

Elan acquired Neurex Corporation ("Neurex") in August 1998 for $810.0 million.
Neurex was developing Prialt. The purchase price was primarily allocated to
acquired IP. In 2001, Elan wrote down acquired IP arising from the acquisition
of Neurex by $500.0 million. This write-down was due to delays in the product
launch schedule and reduced revenue projections for Prialt.

Elan acquired Sano in February 1998 for $434.6 million. Sano was developing
transdermal drug delivery products. The purchase price was primarily allocated
to acquired IP. In 2001, Elan wrote down acquired IP arising from the
acquisition of Sano by $285.2 million. The write-down was due to reduced
revenue projections from products under development and to Elan's decision to
focus its research and development efforts in other areas.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      53

FINANCIAL REVIEW
--------------------------------------------------------------------------------

Ceclor CD and Myambutol were written down due to the impact of generic
competition on these products during 2001. Generic versions of each of these
products were approved and launched in 2001, which reduced projected revenues
and profitability from these products. Revenue from Ceclor CD declined by $26.0
million in 2001, from $39.4 million in 2000 to $13.4 million in 2001. Naprelan
was written down due to lower than forecasted revenues in 2001 and reduced
projected revenue and profitability from this product. Revenue from Naprelan
declined by $33.6 million in 2001, from $41.8 million in 2000 to $8.2 million
in 2001.

(D) RESEARCH AND DEVELOPMENT

Exceptional research and development expenses were $78.6 million in 2001. These
mainly relate to severance, integration and similar costs and asset write-downs
arising from the re-organisation, closure or scaling back of various drug
delivery programmes and sites. Also included were costs of certain research
programmes that Elan does not intend to complete. These were the estimated
costs incurred pending closure or sale.

(E) NET INTEREST

Exceptional net interest and other expenses amounted to a net gain of $25.9
million in 2001. This mainly relates to net gains on financial assets of $56.8
million, offset by investment impairments of $24.1 million and costs of $6.8
million associated with the redemption in March 2001 of the 4.75% Exchangeable
Notes (the "4.75% Exchangeable Notes") of Athena Neurosciences, Inc., a wholly
owned subsidiary of Elan ("Athena Neurosciences").

NET INTEREST AND OTHER EXPENSE

Net interest and other expense was $1,170.7 million for 2002 compared to $50.4
million for 2001.

Interest payable and similar charges increased by 384% to $1,297.1 million for
2002 from $268.2 million for 2001, primarily reflecting investment related
charges of $1,045.9 million in 2002 compared with $24.1 million in 2001.
Interest payable for 2002 includes $47.1 million (2001: $40.3 million) on the
7.25% Senior Notes, issued by Athena Finance in February 2001; $37.2 million
(2001: $35.4 million) on the EPIL III Notes issued in March 2001; and $43.0
million (2001: $43.0 million) on the EPIL II Notes issued in June 2000. Elan
expenses the subsequent funding it provides directly to business ventures. This
is expensed within the interest and other expense line. Elan expensed $23.9
million and $24.6 million for this subsequent funding, in 2002 and 2001,
respectively.

Income from financial assets decreased by 42% to $126.4 million for 2002 from
$217.8 million for 2001. Interest and other income decreased to $86.3 million
for 2002 from $159.2 million in 2001, reflecting lower cash balances and
reduced investment income during 2002. Net gains on financial assets were $Nil
in 2002 compared to $56.8 million in 2001. Gains on financial assets in 2001
includes $31.5 million for the sale of approximately 20% of Athena Diagnostics
in December 2001. Income from financial assets for 2002 also included a gain of
$37.7 million on the repurchase of LYONs. Foreign exchange gains amounted to
$2.4 million in 2002 and $1.8 million in 2001.

For additional information regarding net interest and other expense, please
refer to Note 4 to the Consolidated Financial Statements.

For additional information regarding indebtedness, please refer to Note 15 to
the Consolidated Financial Statements and to "Debt Facilities" in this
Financial Review.

TAXATION

Tax on profit on ordinary activities increased by 14% to $19.8 million for 2002
from $17.4 million for 2001. The tax charges reflected tax at standard rates in
the jurisdictions in which Elan operates, income derived from Irish patents,
which is exempt from tax, foreign withholding tax and the availability of tax
losses. Elan's Irish patent derived income was exempt from taxation pursuant to
Irish legislation, which exempts from Irish taxation income derived from
qualifying patents. Currently, there is no termination date in effect for such
exemption.

For additional information regarding taxation, please refer to Note 7 to the
Consolidated Financial Statements.

RETAINED LOSS

Retained loss for the year, after exceptional items, was $3,615.1 million for
2002 compared to a loss of $887.2 million for 2001. Before exceptional items,
retained loss was $665.7 million for 2002 compared to a retained profit of
$44.7 million for 2001. Basic loss per

--------------------------------------------------------------------------------
54

--------------------------------------------------------------------------------

share, after exceptional items, was $10.34 for 2002, compared to $2.64 for
2001. Basic loss per share, before exceptional items, was $1.90 for 2002
compared to basic earnings per share of $0.13 for 2001. Diluted loss per share,
after exceptional items, was $10.34 for 2002, compared to $2.64 for 2001.
Diluted loss per share, before exceptional items, was $1.90 for 2002 compared
to diluted earnings of $0.12 per share for 2001.

SEGMENTAL ANALYSIS

On 12 February 2004, Elan announced the formal completion of its recovery plan.
The recovery plan had been announced on 31 July 2002 to restructure Elan's
businesses, assets and balance sheet in order to enable it to meet its
financial commitments. As a cornerstone of the recovery plan, Elan turned its
focus to three core therapeutic areas: neurology, autoimmune diseases and
severe pain. During the course of the recovery plan, Elan was reorganised and
two business units were created: Core Elan and Elan Enterprises. With the
completion of the recovery plan, Elan announced the end of operations for its
Elan Enterprises business unit.

In February 2004, the Company's operations were reorganised into two business
units: Biopharmaceuticals and GS&O. In this reorganization, the Company's Core
Elan business, with the exception of its drug delivery businesses, now forms
the Biopharmaceuticals business unit. The remaining businesses in Elan
Enterprises comprising principally of drug delivery businesses and the drug
delivery business from Core Elan now form GS&O. Biopharmaceuticals engages in
biopharmaceutical research and development activities, and pharmaceutical
commercial activities. Biopharmaceutical research and development activities
include the discovery and development of products in the therapeutic areas of
neurology, autoimmune diseases and severe pain. Elan's pharmaceutical commercial
activities include the marketing of neurology and pain management products and
hospital and specialty products. GS&O focuses on product development and
manufacturing to provide technology platforms that address the drug delivery
challenges of the pharmaceutical industry. In this amendment prior period
financial information as presented in our Form 20-F as previously filed for
2003, has been recast to reflect the new basis of segmentation.

The Group's total revenue of $762.1 million (2002: $1,333.0 million) is
comprised of revenue within Biopharmaceuticals and GS&O of $612.6 million
(2002: $1,024.5 million) and $149.5 million (2002: $308.5 million),
respectively. Elan's operating loss of $935.1 million (2002: $2,290.8 million)
primarily comprises operating losses incurred by Biopharmaceuticals and GS&O of
$820.9 million (2002: $2,020.7 million) and $108.9 million (2002: $262.1
million), respectively.

Biopharmaceuticals' revenue decreased by 40% to $612.6 million for 2003 from
$1,024.5 million for 2002. The decrease in revenue from Skelaxin/Sonata,
risk-sharing arrangements (Pharma Marketing/Autoimmune), Abelcet, Dermatology
and Zanaflex was $129.4 million, $100.0 million, $63.5 million, $47.6 million
and $61.9 million, respectively, for 2003 compared to 2002. The declines were
due principally to the fact that these products were sold during 2002 or 2003,
other than Zanaflex, which was as a result of generic competition, and the
risk-sharing arrangements, which were terminated. Partly offsetting this was
increased revenue for Maxipime, Zonegran and Frova of $29.9 million, $37.6
million and $26.3 million, respectively, for 2003 compared to 2002.
Biopharmaceuticals incurred an operating loss of $820.9 million for 2003,
compared with an operating loss of $2,020.7 million for 2002, primarily due to
exceptional charges in 2003 of $539.7 million compared to $1,659.2 million for
2002. Exceptional charges in 2003 relate primarily to the purchase of royalty
rights from Pharma Operating of $297.6 million and impairment charges to
goodwill relating to the European business and Dura of $108.2 million and $16.2
million, respectively, and, in 2002 relate primarily to the impairment of
intangible assets arising from Elan's recovery plan initiated during 2002.
Biopharmaceuticals' operating loss before exceptional items decreased to $281.2
million for 2003 from $361.5 million for 2002, primarily due to lower operating
expenses reflecting the successful implementation of the recovery plan and
related cost reduction initiatives, including reduced goodwill amortisation and
patent and licence amortisation. This has been partly offset by lower revenue
due to product and business disposals.

GS&O's revenue decreased by 52% to $149.5 million for 2003 from $308.5 million
for 2002 mainly due to the reduction in revenue following product and business
disposals. GS&O incurred an operating loss of $108.9 million in 2003, compared
with an operating loss of $262.1 million in 2002, primarily due to exceptional
charges in 2003 of $37.0 million compared to $137.1 million for 2002.
Exceptional charges in 2003 relate primarily to impairment charges to acquired
IP arising from the acquisition of Nanosystems of $11.7 million and severance
and restructuring costs of $19.3 million and in 2002 relate primarily to the
impairment of intangible assets arising from Elan's recovery plan initiated
during 2002. GS&O's operating loss before exceptional items decreased by 42% to
$71.9 million for 2003 from $125.0 million for 2002.

For additional information regarding Elan's reportable segments, please refer
to Note 2 to the Consolidated Financial Statements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      55

FINANCIAL REVIEW
--------------------------------------------------------------------------------

RISK-SHARING ARRANGEMENTS

PHARMA MARKETING

In June 2000, Elan disposed of royalty rights on certain products and
development projects to Pharma Marketing. Pharma Marketing completed a private
placement of its common shares to a group of institutional investors, resulting
in gross proceeds of $275.0 million. Elan held no investment in Pharma
Marketing and had no representative on its board of directors. Concurrent with
the private placement, Pharma Marketing entered into a Program Agreement with
Elan. The Program Agreement, which substantially regulated the relationship
between Elan and Pharma Marketing, represented a risk-sharing arrangement
between Elan and Pharma Marketing. Under the terms of the Program Agreement,
Pharma Marketing acquired certain royalty rights to each of the following
products for the designated indications (including any other product which
contained the active ingredient included in such product for any other
designation): (i) Frova, for the treatment of migraine; (ii) Myobloc, for the
treatment of cervical dystonia; (iii) Prialt, for the treatment of acute pain
and severe chronic pain; (iv) Zanaflex, for the treatment of spasticity and
painful spasm; and (v) Zonegran, for the treatment of epilepsy. Pharma
Marketing agreed to make payments to Elan in amounts equal to expenditures made
by Elan in connection with the commercialisation and development of these
products, subject to certain limitations. These payments were made on a
quarterly basis based on the actual costs incurred by Elan. Elan did not
receive a margin on these payments.

Elan received no revenue from Pharma Marketing during 2003. Elan's revenue from
Pharma Marketing was $31.3 million for 2002, consisting of $24.0 million for
commercialisation expenditures, which has been recorded as product revenue, and
$7.3 million for development expenditures, which has been recorded as contract
revenue. Pursuant to the Program Agreement, Pharma Marketing utilised all of
its available funding by mid-2002. Elan will not receive any future revenue
from Pharma Marketing. Elan's revenue from Pharma Marketing was $189.8 million
for 2001, consisting of $141.8 million for commercialisation expenditures, and
$48.0 million for development expenditures. In 2003, the royalty rate on net
sales of all designated products was 27.71% on the first $122.9 million of net
sales and 52.5% for net sales above $122.9 million. In 2002, the royalty rate
on net sales of all designated products was 15.79% on the first $122.9 million
of net sales and 3.51% for net sales above $122.9 million. In 2001, the royalty
rate on net sales of Zanaflex was 8.44% on the first $38.0 million of net sales
and 1.88% for net sales of Zanaflex above $38.0 million. No royalties were
payable on the other products in 2001. Elan paid aggregate royalties of $43.3
million for 2003 (2002: $24.1 million; 2001: $5.6 million). This was recorded
as a cost of sales.

In December 2001, the Program Agreement was amended such that Elan re-acquired
the royalty rights to Myobloc and disposed of royalty rights on Sonata to
Pharma Marketing. The amendment was transacted at estimated fair value. The
board of directors and shareholders of Pharma Marketing approved this
amendment. The estimated difference in relative fair value between the royalty
rights on Sonata and the royalty rights on Myobloc was $60.0 million. This
amount was paid to Pharma Marketing by Elan in cash and was capitalised by Elan
as an intangible asset.

Under the original agreements, Elan could have, at its option at any time prior
to 30 June 2003, acquired the royalty rights by initiating an auction process.
This date was extended to 3 January 2005 under the settlement with Pharma
Marketing and Pharma Operating described below. In addition, the holders of
Pharma Marketing common shares were entitled to initiate the auction process
earlier upon the occurrence of certain events. Pursuant to the auction process,
the parties were to negotiate in good faith to agree on a purchase price,
subject to Elan's right to re-acquire the royalty rights at a maximum purchase
price. The maximum purchase price was approximately $413 million at 31 December
2002 and increased by approximately 25% annually (less royalty payments). The
purchase price was reduced under the settlement with Pharma Marketing and
Pharma Operating described below.

On 17 January 2003, Elan announced that Pharma Operating had filed a lawsuit in
the Supreme Court of the State of New York against Elan and certain of its
subsidiaries in connection with the risk-sharing arrangement between the
parties. The lawsuit sought, among other things, a court determination that
Pharma Operating's approval would be required in the event of a sale by Elan of
its interest in Sonata to a third party. On 30 January 2003, Elan, Pharma
Operating and its parent Pharma Marketing, agreed to settle the lawsuit and,
under the terms of the settlement agreement, Pharma Operating dismissed the
litigation between the parties without prejudice. Pursuant to the settlement
agreement, effective upon the sale of Sonata to King on 12 June 2003, (i) Elan
paid Pharma Operating $196.4 million in cash (representing $225.0 million less
royalty payments on all related products paid or due to Pharma Operating from 1
January 2003 through 12 June 2003) to acquire Pharma Operating's royalty rights
with respect to Sonata and Prialt and (ii) Elan's maximum purchase price for
the remaining products in the arrangement, Zonegran, Frova and Zanaflex, was
reduced to $110.0 million, which increased at a rate of 15% per annum from 12
June 2003 (less royalty payments made for periods after 12 June 2003). The
parties also agreed to extend Elan's purchase option termination date to 3
January 2005 from the original termination date of 30 June 2003.

--------------------------------------------------------------------------------
56

--------------------------------------------------------------------------------

In connection with the settlement agreement, Elan agreed that it would cause
certain subsidiaries in the United States, Ireland, the United Kingdom,
Germany, France, Spain and Italy to pledge their accounts receivable from
commercial sales of pharmaceutical products and services to Pharma Operating as
collateral to secure Elan's obligations in relation to royalty payments under
the Pharma Marketing arrangement and the settlement agreement. Elan also agreed
that, following the closing of a sale of Sonata, it would grant Pharma
Operating additional collateral to the extent that the aggregate value of the
collateral package, which was to be tested on a quarterly basis, was less than
the maximum purchase price for the royalty rights on Zonegran, Frova and
Zanaflex. On 6 March 2003, Elan Pharmaceuticals, Inc. ("EPI") and Pharma
Operating entered into a security agreement pursuant to which EPI granted
Pharma Operating a first priority security interest in its accounts receivable
from commercial sales of pharmaceutical products in the United States. On that
same date, Elan and Pharma Operating agreed to the terms of the additional
collateral mechanism. On 20 May 2003, Elan Pharma Limited ("EPL") and Pharma
Operating entered into a security agreement pursuant to which EPL granted
Pharma Operating a security interest in its accounts receivable from commercial
sales of pharmaceutical products and services in the United Kingdom. A similar
agreement was entered into in relation to Ireland by Elan Pharma Limited
(Ireland) on 10 June 2003.

In November 2003, Elan exercised its option to purchase the remaining royalty
rights in respect of Zonegran, Frova and Zanaflex from Pharma Operating for
$101.2 million. As a result, all of Elan's agreements with Pharma Marketing
were terminated. During 2003, Elan expensed $297.6 million as an exceptional
selling, general and administrative expense arising from the acquisition of
royalty rights from Pharma Operating.

AUTOIMMUNE

In December 2001, Autoimmune, in an initial tranche, completed a private
placement of its common shares to a group of institutional investors, resulting
in gross proceeds to Autoimmune of $95.0 million. In the same initial tranche,
Elan purchased non-voting preferred shares of Autoimmune's subsidiary for an
aggregate purchase price of $37.5 million. Elan had no representative on the
board of directors of Autoimmune. The existing group of institutional investors
and Elan also committed to a second investment tranche in the same amounts to
be completed in April 2003, subject to certain conditions. Autoimmune entered
into a Program Agreement with Elan. The Program Agreement, which substantially
regulated the relationship between Elan and Autoimmune, represented a
risk-sharing arrangement among the companies. Under the terms of the Program
Agreement, Autoimmune acquired royalty rights to each of the following products
and development projects for the designated indications: (i) Antegren, for the
treatment of relapsing forms of MS, moderate-to-severe inflammatory bowel
disease, including Crohn's disease and ulcerative colitis, and
moderate-to-severe rheumatoid arthritis; (ii) Maxipime, for the treatment of
infection; (iii) Azactam, for the treatment of infection; and (iv) Abelcet, for
the treatment of severe fungal infection. Autoimmune also acquired royalty
rights on certain development projects, as well as any other product
subsequently developed or acquired by Elan that had an indication substantially
the same as Maxipime, Azactam or Abelcet and that would be in direct
competition with Maxipime, Azactam or Abelcet. Autoimmune agreed to make
payments to Elan in amounts equal to expenditures made by Elan in connection
with the commercialisation and development of these products, subject to
certain limitations. These payments were to be made on a quarterly basis based
on actual costs incurred by Elan. Elan did not receive a margin on these
payments. Elan's revenue from Autoimmune was $68.7 million for 2002 (2001:
$26.6 million), consisting of $38.8 million (2001: $15.9 million) for
commercialisation expenditures, which has been recorded as product revenue, and
$29.9 million (2001: $10.7 million) for development expenditures, which has
been recorded as contract revenue. Elan has received no revenue from Autoimmune
since June 2002. Elan will not receive any future revenue from Autoimmune. No
royalties were payable to Autoimmune by Elan in 2003, 2002 or 2001.

Under the original agreement, Elan could, at its option at any time prior to
April 2005, acquire the royalty rights by initiating an auction process. In
addition, the holders of the Autoimmune common shares could initiate the
auction process earlier upon the occurrence of certain events. If the auction
process had not been initiated prior to October 2004, it would have
automatically commenced. Pursuant to the auction process, Elan and Autoimmune
would have negotiated in good faith to agree on a purchase price, subject to
Elan's right to re-acquire the royalty rights at a maximum purchase price. This
maximum purchase price increased at various rates, approximately 25% annually,
subject to certain conditions.

In July 2002, Elan announced the termination of all agreements relating to the
risk-sharing arrangement with Autoimmune. The royalty obligations to Autoimmune
were terminated. The total consideration for the royalty rights was $121.0
million which, after taking account of the redemption of Elan's investment of
$38.5 million in Autoimmune, resulted in a net cash cost of $82.5 million. Elan
expensed $121.0 million as an exceptional selling, general and administrative
expense arising from the acquisition of royalty rights from Autoimmune.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      57

FINANCIAL REVIEW
--------------------------------------------------------------------------------

CAPITALISATION AND LIQUIDITY

Elan had net debt of $1,146.9 million at 31 December 2003, consisting of
outstanding debt of $1,974.9 million, less cash and liquid resources, excluding
managed funds, of $828.0 million. For additional information regarding Elan's
net debt, please refer to Note 30c to the Consolidated Financial Statements.

CASH FLOW

------------------------------------------------------------------------------------------------------------
                                                                                     YEAR ENDED 31 DECEMBER
------------------------------------------------------------------------------------------------------------
                                                                                          2003         2002
                                                                                            $M           $M
------------------------------------------------------------------------------------------------------------

 CASH FLOW FROM OPERATING ACTIVITIES                                                   (322.3)        259.6
------------------------------------------------------------------------------------------------------------
 RETURNS ON INVESTMENTS AND SERVICING OF FINANCE
 Interest received                                                                       24.2          44.8
 Interest paid                                                                         (281.9)       (176.5)
------------------------------------------------------------------------------------------------------------
 Cash outflow from returns on investments and servicing of finance                     (257.7)       (131.7)
------------------------------------------------------------------------------------------------------------
 TAXATION                                                                                (8.9)        (18.6)
------------------------------------------------------------------------------------------------------------
 CAPITAL EXPENDITURE AND FINANCIAL INVESTMENT
 Additions to property, plant and equipment                                             (33.7)       (170.2)
 Receipts from disposal of property, plant and equipment                                 27.9           8.6
 Payments to acquire intangible assets                                                 (144.8)       (315.5)
 Receipts from disposal of intangible assets                                              0.5           9.4
 Payments to acquire Pharma Marketing/Autoimmune product royalty rights                (297.6)       (121.0)
 Redemption of investment in Autoimmune                                                    --          38.5
 Sale of EPIL III investments in connection with the repayment of EPIL III debt            --         148.0
 Payment under guarantee in connection with EPIL III sale of investments                   --        (141.6)
 Payments to acquire financial current assets                                              --          (1.0)
 Sale and maturity of financial current assets                                             --          83.9
 Payments to acquire financial fixed assets                                             (13.9)       (191.2)
 Receipts from disposal of financial fixed assets                                       329.3          36.6
------------------------------------------------------------------------------------------------------------
 Cash outflow from capital expenditure and financial investment                        (132.3)       (615.5)
------------------------------------------------------------------------------------------------------------
 ACQUISITIONS AND DISPOSALS
 Cash received on disposal of businesses                                                546.9         361.3
 Cash received on disposal of subsidiaries                                               46.1          81.8
------------------------------------------------------------------------------------------------------------
 Cash inflow from acquisitions and disposals                                            593.0         443.1
------------------------------------------------------------------------------------------------------------
 Cash outflow before use of liquid resources and financing                             (128.2)        (63.1)
------------------------------------------------------------------------------------------------------------
 MANAGEMENT OF LIQUID RESOURCES                                                          14.5         225.5
------------------------------------------------------------------------------------------------------------
 FINANCING
 Proceeds from issue of share capital                                                   167.9           5.7
 Issue of loan notes                                                                    460.0            --
 Repurchase of LYONs                                                                   (687.5)       (126.9)
 Repayment of EPIL III debt                                                                --        (160.0)
 Repayment of loans                                                                     (83.2)       (399.9)
------------------------------------------------------------------------------------------------------------
 Cash outflow from financing                                                           (142.8)       (681.1)
------------------------------------------------------------------------------------------------------------
 Net decrease in cash                                                                  (256.5)       (518.7)
------------------------------------------------------------------------------------------------------------

Cash outflows from operating activities amounted to $322.3 million for 2003
compared to cash inflows of $259.6 million for 2002. The movement in cash flows
from operating activities is principally due to cash flows in 2003 including an
outflow from working capital of $102.4 million while 2002 includes an inflow of
$283.9 million. Cash outflows from working capital in 2003 primarily relate to
a decrease in accruals as a result of business and product disposals and the
completion of the recovery plan. Working capital cash inflows in 2002 mainly
relate to a decrease in trade debtors during 2002, reflecting the impact of
decreased revenue and the termination of the

--------------------------------------------------------------------------------
58

--------------------------------------------------------------------------------

Pharma Marketing and Autoimmune agreements. Also cash flow from operating
activities for 2002 included $195.0 million from proceeds of the product
disposal programme entered into as part of the recovery plan, consisting of
$100.0 million received from Ligand in relation to Avinza, $45.0 million
received from Watson in relation to nifedipine, and $50.0 million received from
Anesta in relation to Actiq.

Cash outflows from returns on investment and servicing of finance were $257.7
million for 2003 compared to $131.7 million for 2002. The 2003 outflows consist
primarily of interest payments of $115.9 million related to LYONs repurchases,
$47.1 million on the 7.25% Senior Notes, $43.0 million on EPIL II Notes and
$29.9 million on the EPIL III Notes. A payment of $16.1 million for financing
costs associated with the issuance of the 6.5% Convertible Notes was made,
together with a waiver fee of $16.8 million to the holders of the EPIL II and
EPIL III Notes in connection with the debt offering. These outflows were offset
by interest receipts of $24.2 million in 2003, which principally comprises bank
and investment interest income.

In 2002 interest payments included $47.1 million for the 7.25% Senior Notes,
$46.6 million on EPIL III Notes, $43.0 million on EPIL II Notes and a payment
of $22.9 million related to LYONs repurchases. Interest receipts of $44.8
million related primarily to bank and investment interest income received.

Cash outflow from capital expenditure and financial investment amounted to
$132.3 million for 2003 compared to $615.5 million in 2002. This comprised net
cash expended to acquire tangible and intangible fixed assets of $150.1 million
(2002: $467.7 million), net cash received/(expended) in relation to the
sale/(purchase) of financial assets of $315.4 million (2002: ($71.7) million)
and payments of $297.6 million made to acquire product royalty rights from
Pharma Operating. In 2002 a payment of $121.0 million was made to acquire
product royalty rights held by Autoimmune and $38.5 million was received on
disposal of an investment in Autoimmune.

Cash paid for acquisitions was $Nil in 2003 and 2002. Cash of $546.9 million
was received in 2003, primarily from the disposal of the primary care franchise
to King. Cash received from the disposal of subsidiaries in 2003 was $46.1
million. Cash of $361.3 million was received in 2002, primarily from the
disposal of the Abelcet business. Proceeds of $81.8 million for the disposal of
the remaining holding in Athena Diagnostics (approximately 80%) was received in
2002.

Elan's initial investment in business ventures and business venture parents,
arising from the formation of business ventures, was $Nil in 2003 and 2002.
Elan invested $7.1 million and $83.4 million in 2003 and 2002, respectively, in
business venture parents, apart from such initial investment.

During 2003, Elan had net cash ouflows from financing activities of $142.8
million, primarily reflecting the repurchase of LYONs of $687.5 million (a
further $115.9 million payment related to this LYONs repurchase is included as
interest paid within returns on investments and servicing of finance),
repayment of loans of $83.2 million, offset by proceeds received of $460.0
million from the issuance of the 6.5% Convertible Notes, and $167.9 million
from the issuance of share capital.

During 2002, Elan had cash outflows from financing activities of $681.1
million, primarily reflecting an outflow of $325.0 million for the repayment of
borrowings under the revolving credit facility, a cash outflow of $160.0
million in connection with the maturity of the EPIL III Series A Guaranteed
Notes, and repayment of the 3.5% convertible subordinated notes ("3.5%
Convertible Notes") in the amount of $62.6 million. In December 2002, Elan
repurchased approximately 19% of the LYONs for $149.8 million. This is included
in the Consolidated Statement of Cash Flows as $126.9 million within financing
activities and $22.9 million within returns on investments and servicing of
finance.

CASH, LIQUID RESOURCES AND FINANCIAL ASSETS

Cash and liquid resources amounted to $828.0 million at 31 December 2003. This
includes restricted cash of $21.1 million, consisting of the cash held by EPIL
II and EPIL III. Elan also holds other financial assets of $494.5 million,
consisting primarily of $197.9 million in unquoted investments and loans,
$150.3 million in securitised investments, other marketable securities of $86.6
million and $35.8 million in quoted investments.

DEBT FACILITIES

At 31 December 2003, Elan had the following amounts outstanding under borrowing
facilities, which are unsecured and exchangeable or convertible into Ordinary
Shares:

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      59

FINANCIAL REVIEW
--------------------------------------------------------------------------------

o    6.5% Convertible Notes due 2008 - $460.0 million; and

o    LYONs due 2018 - $0.9 million (accreted value at 31 December 2003);

At 31 December 2003, Elan had the following principal amounts outstanding under
other borrowing facilities:

o    EPIL II Notes due 28 June 2004         -- $450.0 million;

o    EPIL III Notes due 2005                -- $390.0 million; and

o    7.25% Senior Notes due 2008            -- $650.0 million.

For additional information regarding Elan's outstanding debt, please refer to
Note 15 to the Consolidated Financial Statements.

PRODUCT ACQUISITIONS AND ALLIANCES

At 31 December 2003, Elan included in creditors $30.6 million relating to
future payments and/or future potential payments on products. Of the $30.6
million, $19.4 million is owing at 31 December 2003 and $11.2 million is
potentially payable, contingent on future events. Elan is a party to certain
product acquisition or alliance agreements that contain staged or option
payments which may be uncertain in amount, which may be paid at Elan's
discretion, such as upon the exercise of an option to acquire the product, or
which must be paid upon the occurrence of future events, such as the attainment
of pre-determined product revenue targets or other milestones. Elan has accrued
$19.4 million within creditors (within one year), including $15.6 million for
Maxipime/Azactam, and $11.2 million within creditors (after one year) for
Frova.

At 31 December 2002, Elan included in creditors $482.2 million relating to
future payments and/or future potential payments on products. The reduction of
$451.6 million from December 2002 to December 2003 primarily reflects product
payments made during the year of $212.4 million and product payment obligations
assumed by King and aaiPharma of $218.8 million and $51.4 million,
respectively.

For additional information regarding future payments and potential future
payments on the acquisition of products, please refer to Note 16 to the
Consolidated Financial Statements.

COMMITMENTS AND CONTINGENCIES

At 31 December 2003, Elan had commitments to invest $3.8 million in healthcare
managed funds, compared to $3.2 million in 2002.

At 31 December 2003, the Company had deferred purchase arrangements for certain
products, which amounted to $4.5 million (2002: $4.5 million). These payments
are dependent on various approvals and milestones being met. These deferred
purchase arrangements were transferred to Medeus upon disposal of the European
sales and marketing business in 2004.

For additional information regarding commitments and contingencies, including
those related to Autoimmune, Pharma Marketing, lease commitments, capital
expenditures, litigation and asset divestitures, please refer to Note 23, Note
24 and Note 25 to the Consolidated Financial Statements.

LIQUIDITY

The following table sets out, at 31 December 2003, the main contractual and
potential future payments due by period for debt repayments and contractual and
potential product acquisition and alliance payments. These represent the major
contractual and potential future payments that may be made by Elan. The table
does not include items such as expected capital expenditures on plant and
equipment or future investments in financial assets.

--------------------------------------------------------------------------------
60

--------------------------------------------------------------------------------

                                                                                      LESS THAN       1-3          4-5   AFTER 5
CONTRACTUAL AND                                                               TOTAL      1 YEAR     YEARS        YEARS     YEARS
POTENTIAL FUTURE PAYMENTS                                                        $M          $M        $M           $M        $M
--------------------------------------------------------------------------------------------------------------------------------

 Contractual fixed future payments (composed of : $650.0 million
  relating to the 7.25% Senior Notes (2008); $460.0 million
  relating to 6.5% Convertible Notes (2008); $0.9 million relating
  to the LYONs (2008); remaining amounts are payments for
  product acquisitions and alliances of $19.4 million)                       1,130.3       19.4        --       1,110.9      --
 Potential future payments (for product acquisitions and alliances)(1)          11.2        --        11.2          --       --
 Capital lease obligations(2)                                                   85.4       10.3       21.3          7.7     46.1
 Securitised debt (EPIL II and EPIL III Notes)                                 840.0      450.0      390.0          --       --
--------------------------------------------------------------------------------------------------------------------------------
                                                                             2,066.9      479.7      422.5      1,118.6     46.1
 Operating lease obligations (2)                                               157.6       19.8       36.5         12.7     88.6
--------------------------------------------------------------------------------------------------------------------------------
 Total                                                                       2,224.5      499.5      459.0      1,131.3    134.7
--------------------------------------------------------------------------------------------------------------------------------

As of 28 October 2004, the company intends to raise additional long term debt
of $817 million, after expenses, which will be used to finance a tender offer
for $351 million of the EPIL III Notes and for general corporate purposes.

(1)   Related to Frova. Was cancelled upon the closing of the sale of Frova to
      Vernalis in the second quarter of 2004.

(2)   In accordance with SEC Release No. 34-47264 "Disclosure in Management's
      Discussion and Analysis about Off-Balance Sheet Arrangements and
      Aggregate Contractual Obligations," which is effective for financial
      statements ending on or after 15 December 2003, operating and capital
      lease obligations have been included in the table of contractual and
      potential future payments at 31 December 2003. For additional information
      on operating and capital leases, please refer to Note 23 to the
      Consolidated Financial Statements.

The two major rating agencies covering Elan's debt rate Elan's debt as
sub-investment grade debt. None of Elan's debt has a rating trigger that would
accelerate the repayment date upon a change in rating.

Elan's current debt ratings are as follows:

------------------------------------------------------------
                              STANDARD & POOR'S      MOODY'S
                                         RATING    INVESTORS
                                       SERVICES      SERVICE
------------------------------------------------------------

 7.25% Senior Notes                          B-        Caa2
 6.5% Convertible Notes                     CCC          Ca
 LYONs                                      CCC          Ca
 EPIL II Notes                              CCC          Ca
 EPIL III Notes                             CCC        Caa2
------------------------------------------------------------

The agreements governing certain of Elan's outstanding indebtedness contain
various restrictive covenants that restrict the Group's ability to, among other
things, incur additional indebtedness (including intercompany indebtedness),
create liens and other encumbrances, enter into transactions with related
parties, sell or otherwise dispose of assets and merge or consolidate with
another entity. In addition, some of these agreements require Elan to maintain
certain financial ratios. Elan does not currently, and does not expect in the
foreseeable future to have the ability to incur any additional indebtedness
under certain of these covenants, unless it receives a waiver from a majority
of the holders of the applicable indebtedness. This inability to incur
additional indebtedness (including intercompany indebtedness) has adversely
affected Elan's financial flexibility. As a result, Elan's ability to meet its
liquidity requirements and capital needs may be adversely impacted. These
events may have a material adverse impact on Elan's business, results of
operations, liquidity and financial condition. For additional information on
the shareholder litigation and SEC investigation, please refer to Note 25 to
the Consolidated Financial Statements.

As a result of Elan's failure to timely complete and file with the SEC Elan's
Annual Report on Form 20-F for its fiscal year ended 31 December 2002, on 30
June 2003, Elan defaulted under certain covenants contained in the agreements
governing the EPIL II Notes and the Series B and Series C Guaranteed Notes
issued by EPIL III. The covenants required that Elan provide to each of the
holders of such notes Elan's audited consolidated financial statements,
together with an officer's certificate relating thereto, on or prior to 29 June
2003.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      61

FINANCIAL REVIEW
--------------------------------------------------------------------------------

On 15 July 2003, Elan also defaulted under a covenant contained in the
indenture governing the 7.25% Senior Notes that required Elan to file its 2002
Annual Report on Form 20-F with the SEC on or prior to 15 July 2003.

Commencing on 29 July 2003, Elan received a series of separate agreements from
a majority of the holders of the EPIL II Notes and the holders of the Series B
and Series C Guaranteed Notes waiving compliance by Elan with the applicable
covenants described above. The series of waivers was effective through 5
September 2003. With the completion and filing with the SEC of Elan's 2002
Annual Report on Form 20-F, the defaults described above were cured in all
respects. In the absence of the waivers, the defaults under the EPIL II Notes
and the Series B and Series C Guaranteed Notes would have become events of
default on 30 July 2003. In the absence of the completion and filing with the
SEC of Elan's 2002 Annual Report on Form 20-F, the default under the indenture
governing the 7.25% Senior Notes would have become an event of default on 16
September 2003.

Elan believes that it has sufficient current cash, liquid resources and
realisable assets and investments to meet its near-term liquidity requirements.
Longer-term liquidity requirements will need to be met out of future operating
cash flows, financial and other asset realisations and future financing.
However, certain events, including material adverse legal judgements, fines,
penalties or settlements arising from Elan's pending litigation or governmental
investigations, a material deterioration in Elan's operating performance as a
result of Elan's inability to timely receive marketing approval for products
under development or otherwise or the occurrence of other circumstances or
events described under "Risk Factors", could materially adversely affect its
ability to meet its liquidity requirements.

The Company commits substantial resources to its research and development
activities, including collaborations with third parties such as Biogen Idec for
the development of Antegren. The Company expects to commit significant cash
resources to the development and commercialisation of Antegren and to the other
products in the Company's development pipeline. The Company and Biogen Idec are
conducting two, two-year Phase III trials evaluating Antegren in MS patients
with relapsing-remitting forms of the disease. The Company and Biogen Idec have
announced that they plan to file a BLA with the FDA and an application with the
EMEA, in each case for approval to market Antegren as a treatment for MS. These
plans and the receipt of necessary regulatory approvals could fail if
unexpected data arises from the clinical trials or if other difficulties,
delays or failures occur. In the event of the Company's failure to successfully
develop and commercialise Antegren, our business, financial condition, results
of operations and prospects, including our ability to meet our liquidity
requirements, could be materially adversely affected.

Elan continually evaluates its liquidity requirements, capital needs and
availability of resources in view of, among other things, its alternative uses
of capital, its debt service requirements, the cost of debt and equity capital
and estimated future operating cash flow. As a result of this process, Elan has
in the past and may in the future seek to raise additional capital, restructure
or refinance its outstanding debt, repurchase Ordinary Shares or ADSs,
repurchase its outstanding debt, consider the sale of interests in
subsidiaries, marketable investment securities or other assets or the
rationalisation of products, or take a combination of such steps or other steps
to increase or manage its liquidity and capital resources. Any such actions or
steps could be material. In the normal course of business, Elan may
investigate, evaluate, discuss and engage in future company or product
acquisitions, capital expenditures, investments and other business
opportunities. In the event of any future acquisitions, capital expenditures,
investments or other business opportunities, Elan may consider using available
cash or raising additional capital, including the issuance of additional debt.

SHAREHOLDERS' FUNDS

Shareholders' funds at 31 December 2003 decreased to $825.4 million from
$1,460.0 million at 31 December 2002, a decrease of $634.6 million. This
decrease was comprised principally of $815.4 million in retained loss for the
year offset in part by the net proceeds of $165.4 million resulting from the
completion of a private offering of 35 million Ordinary Shares in November
2003.

CAPITAL EXPENDITURES AND INVESTMENT

The decrease in intangible fixed assets to $1,252.4 million at 31 December 2003
from $2,079.5 million at 31 December 2002 primarily reflects disposals of
$495.2 million, impairments of $189.5 million and amortisation charges of
$159.3 million. The decrease in tangible fixed assets to $372.2 million at 31
December 2003 from $459.3 million at 31 December 2002 primarily reflects the
disposal of and impairments to assets as part of Elan's recovery plan, along
with the depreciation charge for the year. The decrease in non-current
financial fixed assets to $407.9 million at 31 December 2003 from $734.6
million at 31 December 2002 primarily reflects impairment charges of $120.4
million and disposals/repayments of $250.1 million, offset by additions of
$43.7 million. Elan's capital expenditures during 2003 amounted to $34.8
million.

--------------------------------------------------------------------------------
62

--------------------------------------------------------------------------------

Elan believes that its current and planned manufacturing, research, product
development and corporate facilities are adequate for its current and projected
needs. Elan will use its resources to make such capital expenditures as are
necessary from time to time and also to make investments in the purchase or
licensing of products and technologies and in marketing and other alliances
with third parties to support Elan's long term strategic objectives.

POST BALANCE SHEET EVENTS

SALE OF EUROPEAN BUSINESS

On 12 February 2004, Elan announced the completion of the sale of its European
sales and marketing business to Medeus, a new U.K. pharmaceutical company
backed by Apax Partners Funds. Elan realised total consideration of
approximately $120 million from this transaction (subject to adjustment for
certain movements in indebtedness and working capital in the period to
completion), which was previously announced on 23 December 2003. Approximately
180 employees of Elan's European sales and marketing business have transferred
their employment to Medeus. Separately, Elan completed the sale of certain
rights to two products in the U.K. and Ireland for approximately $10 million
during the first quarter of 2004.

ZONEGRAN & Frova

On 30 March 2004, Elan announced an agreement with Eisai for the purchase of
Elan's interests in Zonegran in North America and Europe. On closing, Eisai
paid Elan consideration of $129.6 million for these interests, including
inventory and the associated sales team of approximately 115 employees. In
addition, Elan may earn future deferred purchase payments of up to $110.0
million, primarily contingent on when generic zonisamide is introduced in the
U.S., and including up to $25.0 million contingent on receiving marketing
approval for Zonegran in Europe. Elan will also receive additional deferred
purchase payments on net sales of Zonegran in North America and Europe if
certain additional conditions are met. Elan was required to pay $17.0 million
to Dainippon on closing for the assignment of the Zonegran North American and
European licence agreements to Eisai. Elan will continue to manufacture
Zonegran in all three dosage strengths of 25 mg, 50 mg, and 100 mg capsules in
Athlone, Ireland.

Also on 30 March 2004, Elan announced an agreement with Vernalis for the
termination of the development and licence agreements between Elan and Vernalis
regarding Frova. Vernalis agreed to purchase Elan's commercialisation rights in
North America for Frova. Vernalis agreed to pay Elan a total of approximately
$55 million for rights to Frova in North America, comprising $5.0 million
received on closing in the second quarter of 2004; $20.0 million and $25.0
million on 31 December 2004 and 31 December 2005, respectively; and, no later
than 31 December 2004, Elan was to receive a payment for its Frova inventory,
estimated at approximately $5 million. In August, Elan and Vernalis agreed to
settle the remaining consideration for approximately $44 million as a full
payment for Frova. Elan's co-promotion agreement with UCB was terminated at
closing, and Elan paid UCB approximately $10 million as a result of the
termination.

Subsequent Events

Please refer to Note 34 of Elan's Consolidated Financial Statements for a
description of the restatements and other matters that have occurred subsequent
to the initial filing of this Form 20-F.

U.S. GAAP

Elan's financial statements have been prepared under Irish GAAP, which differs
in certain significant respects from U.S. GAAP. The primary differences between
Elan's financial results under Irish and U.S. GAAP arise due to:

o    The accounting for the acquisition of Dura using acquisition (purchase)
     accounting under Irish GAAP and using pooling of interests (merger)
     accounting under U.S. GAAP;

o    The implementation of SAB 104 under U.S. GAAP which results in differences
     in the accounting for revenue between Irish and U.S. GAAP. SAB 104 does not
     apply under Irish GAAP;

o    The expensing of acquired in-process research and development ("IPR&D")
     costs under U.S. GAAP, which amounts were capitalised under Irish GAAP; and

o    The consolidation of Elan Pharmaceutical Investments Ltd. ("EPIL") and EPIL
     II under Irish GAAP. Under U.S. GAAP, EPIL (prior to March 2001) and EPIL
     II have not been consolidated, as they are qualifying special purpose
     entities within the meaning of SFAS No. 125 "Accounting for Transfers and
     Servicing of Financial Assets and Extinguishment of Liabilities" ("SFAS No.
     125"), as grandfathered under

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      63

FINANCIAL REVIEW
--------------------------------------------------------------------------------

     SFAS No. 140 "Accounting for Transfers and Servicing of Financial Assets
     and Extinguishments of Liabilities" ("SFAS No. 140"). EPIL was a qualifying
     special purpose entity and was not consolidated under U.S. GAAP prior to
     March 2001. In March 2001, its qualifying status was terminated.

Net loss under Irish GAAP was $815.4 million for 2003 compared to a net loss of
$508.7 million for 2003 under U.S. GAAP. This difference of $306.7 million
primarily reflects:

o    Impairment charges of $112.8 million arising under Irish GAAP. These
     impairment charges did not arise under U.S. GAAP as such amounts were
     previously expensed as acquired IPR&D costs under U.S. GAAP in 1998 and
     2000; and

o    Revenue of $100.9 million being recognised under U.S. GAAP which was
     previously recognised under Irish GAAP.

Shareholders' equity at 31 December 2003 amounted to $825.4 million under Irish
GAAP compared to $599.1 million under U.S. GAAP, primarily reflecting the
carrying value under Irish GAAP of intangible assets that were previously
expensed as acquired IPR&D costs under U.S. GAAP, and the deferral of revenue
under U.S. GAAP due to the implementation of SAB 104.

For additional information regarding the material differences between Irish
GAAP and U.S. GAAP, please refer to Note 33 to the Consolidated Financial
Statements.

RESTATEMENT

In this 2003 Annual Report and Form 20-F/A, Elan has restated its U.S. GAAP
financial results as of and for the year ended 31 December 2003 following a
reassessment of the amount of net operating loss carryforwards expected to be
realised on a probable basis. This correction has the impact of reducing the
previously reported tax charge and net loss reported under U.S. GAAP by $26.7
million resulting in a net loss of $508.7 million. For additional information
regarding the restatement and the adjustments please refer to Note 33 and 34 to
the company's consolidated financial statements.

In its 2002 Annual Report and Form 20-F, Elan restated its U.S. GAAP financial
results as of and for the fiscal year ended 31 December 2001 to consolidate
EPIL III from its date of establishment on 15 March 2001. Under U.S. GAAP, EPIL
III had been historically accounted for by Elan as a qualifying special purpose
entity and was not, therefore, consolidated. In addition, in its 2002 Annual
Report and Form 20-F, Elan adjusted its previously announced unaudited U.S.
GAAP financial information as of and for the fiscal year ended 31 December 2002
to give effect to the consolidation of EPIL III and to consolidate Shelly Bay,
an entity established by Elan, from 29 June 2002 through 30 September 2002.
Shelly Bay acquired certain financial assets from EPIL III on 29 June 2002.
Under Irish GAAP, EPIL III had been accounted for as a consolidated subsidiary
since its date of establishment in accordance with the requirements of FRS 5.
Therefore, the 2001 restatement did not affect Elan's Irish GAAP financial
information, including the Irish GAAP financial information contained in this
Annual Report and Form 20-F. For additional information regarding the
restatement and the adjustments, please refer to Note 33 to the Consolidated
Financial Statements.

As required by US GAAP, U.S. GAAP financial information for all periods has been
restated as discontinued operations the results of business disposals subsequent
to the original filing of the Company's Form 20-F that constitute discontinued
operations under US GAAP to reflect certain products sold by Elan in 2004 which
meet the U.S. GAAP definition of discontinued operations. Please refer to Note
33.

2003 COMPARED TO 2002 (U.S. GAAP)

Total revenue for 2003 decreased by 37% to $685.6 million from $1,093.1 million
for 2002.

Total revenue under U.S. GAAP was lower than under Irish GAAP by $76.5 million
for 2003 and by $239.9 million for 2002. Product revenue under U.S. GAAP was
$587.7 million for 2003 (2002: $743.6 million), compared to $712.6 million
(2002: $1,204.5 million) under Irish GAAP. Contract revenue under U.S. GAAP was
$97.9 million (2002: $349.5 million), compared to $49.5 million (2002: $128.5
million) under Irish GAAP.

For 2003, the $124.9 million difference between product revenue under Irish
GAAP and U.S. GAAP arose principally due to the reclassification out of product
revenue under U.S. GAAP of revenues from discontinued operations of $175.2
million (2002: $362.0 million), offset by the release of deferred product
revenue under U.S. GAAP of $44.5 million net of related intangible assets of
$2.2 million related to Avinza, Actiq and nifedipine. This revenue was
recognised under Irish GAAP in 2002 on disposal of the product rights related
to these products while under U.S. GAAP Elan is recognising this revenue over
the periods it is committed to provide services to the purchasers of the
products. Elan provides these services at fair value. Elan recognised $37.6
million of product revenue under U.S. GAAP from disposal of these product
rights in 2002, net of related intangible assets of $6.1 million. Elan
recognised $154.7 million of product revenue under Irish GAAP from the disposal
of these product rights in 2002, net of related intangible assets of $38.9
million. The amounts of deferred revenue under U.S. GAAP for Avinza, Actiq and
nifedipine are $71.7 million, $Nil and $31.5 million, respectively, at 31
December 2003.

Contract revenue was higher under U.S. GAAP than under Irish GAAP for both 2003
and 2002 due principally to the impact of SAB 104. The total difference in
contract revenue between U.S. GAAP and Irish GAAP was $48.4 million for 2003
(2002: $221.0 million). This primarily relates to the deferral and amortisation
of up-front licence fees under U.S. GAAP, where such amounts were recognised
upon

--------------------------------------------------------------------------------
64

--------------------------------------------------------------------------------

receipt by Elan in prior periods under Irish GAAP. For 2003, Elan recorded
contract revenue related to the amortisation of up-front licence fees under
U.S. GAAP of $48.4 million (2002: $234.7 million), compared to licence fees
recorded under Irish GAAP of $Nil (2002: $7.1 million).

For additional information on the differences related to revenue recognition
between Irish GAAP and U.S. GAAP, please refer to Note 33g to the Consolidated
Financial Statements.

Other charges for 2003 were $271.9 million and principally comprised of
investment and guarantee related charges of $136.5 million, net gains on
divestment of businesses of $267.8 million and recovery plan and other
significant charges of $404.8 million. The net gain on the divestment of
businesses relates primarily to the gain of $264.4 million in relation to the
divestment of the primary care franchise to King. Other charges of $404.8
million includes $297.6 million in relation to the purchase of royalty rights,
$23.3 million for the impairment of tangible and intangible assets and $16.8
million for the EPIL II and EPIL III waiver fee.

Other charges of $1,987.0 million for 2002 were principally comprised of
investment and guarantee related charges of $1,443.0 million and recovery plan
related and other charges of $581.7 million. Other charges of $581.7 million
include $311.7 million for the impairment of tangible and intangible assets and
$121.0 million in relation to the repurchase of royalty rights.

Net loss after other charges in 2003 was $508.7 million compared to net loss of
$2,362.3 million in 2002. This decrease primarily reflects a decline in revenue
and the impact of other charges.

2002 COMPARED TO 2001 (U.S. GAAP)

Total revenue for 2002 decreased by 31% to $1,093.1 million from $1,576.3
million for 2001.

Total revenue under U.S. GAAP was lower than under Irish GAAP by $239.9 million
for 2002 and by $164.4 million for 2001. Product revenue under U.S. GAAP was
$743.6 million for 2002 (2001: $1,155.0 million), compared to $1,204.5 million
(2001: $1,407.0 million) under Irish GAAP. Contract revenue under U.S. GAAP was
$349.5 million (2001: $421.3 million), compared to $128.5 million (2001: $333.7
million) under Irish GAAP.

For 2002, the $460.9 million difference between product revenue under Irish
GAAP and U.S. GAAP arose principally due to the reclassification out of product
revenue under U.S. GAAP of revenues from discontinued operations of $362.0
million (2001: $286.2 million) and also the deferral under U.S. GAAP of $117.1
million of product revenue related to the disposals of certain rights related
to Avinza, Actiq and nifedipine. Under U.S. GAAP Elan deferred and amortised
this revenue as it committed to provide services to the purchasers. For
example, Elan manufactures Avinza and nifedipine. Elan recognised $37.6 million
of product revenue under U.S. GAAP from disposal of these product rights in
2002, net of related intangible assets of $6.1 million. Elan recognised $154.7
million of product revenue under Irish GAAP from the disposal of these product
rights in 2002, net of related intangible assets of $38.9 million. The amounts
of deferred revenue under U.S. GAAP for Avinza, Actiq and nifedipine were $96.7
million, $12.7 million and $40.5 million, respectively, at 31 December 2002.

Contract revenue was higher under U.S. GAAP than under Irish GAAP for both 2002
and 2001 due to the impact of SAB 104. The total difference in contract revenue
between U.S. GAAP and Irish GAAP was $221.0 million for 2002 (2001: $87.6
million). This primarily relates to the deferral and amortisation of up-front
licence fees under U.S. GAAP, where such amounts were recognised upon receipt
by Elan in prior periods under Irish GAAP. For 2002, Elan recorded contract
revenue related to the amortisation of up-front licence fees under U.S. GAAP of
$234.7 million (2001: $287.2 million), compared to licence fees recorded under
Irish GAAP of $7.1 million (2001: $173.6 million).

For additional information on the differences related to revenue recognition
between Irish GAAP and U.S. GAAP, please refer to Note 33g to the Consolidated
Financial Statements.

Other charges of $1,987.0 million for 2002 were principally comprised of
investment and guarantee related charges of $1,443.0 million and recovery plan
related and other charges of $581.7 million. Other charges of $581.7 million
include $311.7 million for the impairment of tangible and intangible assets and
$121.0 million in relation to the repurchase of royalty rights.

Other charges of $347.8 million for 2001 were principally comprised of
investment related charges of $24.5 million, asset write-downs of $210.4
million and rationalisation, integration and similar costs of $120.5 million.
Asset write-downs primarily related to Ceclor CD and Naprelan.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      65

FINANCIAL REVIEW
--------------------------------------------------------------------------------

Net loss after other charges in 2002 was $2,362.3 million compared to net
income of $268.9 million in 2001. This decrease primarily reflects a decline in
revenue and the impact of other charges.

CASH FLOW (U.S. GAAP)

In accordance with Irish GAAP, Elan complies with FRS No. 1, "Cash Flow
Statements" ("FRS 1"). Its objective and principles are similar to those set
out in SFAS No. 95, "Statement of Cash Flows" ("SFAS No. 95"). The principal
difference between the standards is in respect of classification. Under FRS 1,
the Group has presented its cash flows for (a) operating activities; (b)
returns on investments and servicing of finance; (c) taxation; (d) capital
expenditure and financial investment; (e) acquisitions and disposals; and (f)
financing activities. SFAS No. 95 requires only three categories of cash flow
activity: (a) operating; (b) investing; and (c) financing.

Cash flows arising from taxation and returns on investments and servicing of
finance under FRS 1 are included as operating activities under SFAS No. 95. In
addition, under FRS 1, cash and liquid resources include short term borrowings
repayable on demand. SFAS No. 95 requires movements in such borrowings to be
included in financing activities.

For the purposes of cash flows under U.S. GAAP the Group considers all highly
liquid deposits with an original maturity of three months or less to be cash
equivalents. Under Irish GAAP, cash represents cash held at bank available on
demand, offset by bank overdrafts. Liquid resources comprise bank fixed
deposits with maturities of greater than one day.

Cash balances held by EPIL (prior to March 2001) and EPIL II have been included
in cash and liquid resources under Irish GAAP as these entities have been
consolidated under Irish GAAP. As the entities have not been consolidated
subsidiaries under U.S. GAAP, their cash balances have not been included in
cash and cash equivalents under U.S. GAAP. In 2003, under U.S. GAAP, there were
marketable investments of $Nil (2002: $22.7 million) whose maturity was greater
than three months. These were treated as liquid resources under Irish GAAP as
they were readily convertible into cash and were traded in an active market.

2003

Cash and cash equivalents decreased by $206.4 million. Net cash outflow from
operating activities was $512.9 million. Included in cash flow from operating
activities was an outflow of $227.9 million from changes in assets and
liabilities. Cash outflows from working capital in 2003 primarily relate to a
decrease in accruals as a result of the completion of the recovery plan, and a
reduction in debt interest accruals mainly due to payment of accrued interest
on LYONs.

Cash inflow from investing activities was $469.7 million. Proceeds of $546.9
million were received for business disposals, mainly relating to the primary
care franchise. Proceeds from the sale of investments and marketable securities
were $338.3 million and proceeds from tangible asset disposals amounted to
$27.9 million. Proceeds of $46.1 million were received from the disposal of
subsidiaries, mainly relating to Elan Transdermal Technologies ("ETT").
Offsetting these inflows were amounts of $144.8 million for purchases of
intangible assets, purchases of investments and marketable securities of $13.9
million and additions to tangible assets of $33.7 million. Cash outflows also
included payments of $297.6 million made to acquire product royalty rights from
Pharma Operating.

Financing cash outflows amounted to $175.7 million, primarily reflecting a cash
outflow of $687.5 million on the repurchase of the LYONs (a further $115.9
million related to the LYONs repurchase is included as interest paid within
operating activities); offset by inflows from the proceeds from the sale of
share capital of $167.9 million and from the issuance of 6.5% Convertible Notes
of $443.9 million (net of financing costs of $16.1 million).

2002

Cash and cash equivalents decreased by $585.5 million in 2002. Net cash of
$148.3 million was generated from operating activities. Included in cash flow
from operating activities for 2002 was $195.0 million from proceeds of the
product disposal programme entered into as part of the recovery plan,
consisting of $100.0 million received from Ligand in relation to Avinza, $45.0
million received from Watson in relation to nifedipine, and $50.0 million
received from Anesta in relation to Actiq.

Cash outflows from investing activities were $63.1 million. This amount
included $315.5 million for purchases of intangible assets; purchases of
investments and marketable investment securities of $200.8 million and
purchases of tangible assets of $170.2 million. Also included was a payment of
$121.0 million to acquire the royalty rights held by Autoimmune. Cash inflows
from the disposal of tangible and intangible assets were $8.6 million and $9.4
million, respectively. Disposals of investments and marketable investment
securities resulted in a cash inflow of $283.3 million including $38.5 million
on the redemption of the Autoimmune investment and $9.3 million from the sale
of EPIL III assets in connection with the repayment of EPIL III debt. Cash of
$361.3 million was received in 2002 primarily

--------------------------------------------------------------------------------
66

--------------------------------------------------------------------------------

from the disposal of the Abelcet business. Cash received for the disposal of
the remaining holding in Athena Diagnostics (approximately 80%) was $81.8
million; approximately 20% of Athena Diagnostics was disposed in 2001 for $41.9
million.

Financing cash outflows amounted to $681.9 million, primarily reflecting an
outflow of $325.0 million on the repayment of the Revolving Credit Facility, a
cash outflow of $160.0 million in connection with the maturity of the EPIL III
Series A Guaranteed Notes, and repayment of the 3.5% Convertible Notes in the
amount of $62.6 million. Financing cash outflows also included a cash outflow
of $126.9 million on the repurchase of approximately 19% of the LYONs (a
further $22.9 million related to this LYONs repurchase is included as interest
paid within operating activities). Financing cash inflows of $148.0 million
reflect the proceeds received in June 2002 by Shelly Bay from borrowings under
a three month bank facility. The $148.0 million was repaid in September 2002.

EPIL II

Under U.S. GAAP, EPIL II has not been consolidated as a subsidiary of Elan.
Elan has provided a direct guarantee to the holders of the loan notes of EPIL
II for the repayment of the loan notes and the payment of any unpaid interest.
In the event that EPIL II does not meet its obligations to pay amounts due to
the noteholders, the noteholders may call upon the Elan guarantee.

For additional information on the guarantee provided by Elan to the noteholders
of EPIL II, please refer to Notes 15 and 33h to the Consolidated Financial
Statements.

INFLATION

Inflation had no material impact on Elan's operations during the year.

TREASURY POLICY

Elan uses derivative financial instruments primarily to reduce exposures to
market fluctuations in foreign exchange rates. Elan does not enter into
derivative financial instruments for trading or speculative purposes. The
treasury function operates within strict terms of reference which have been
approved by Elan's board of directors.

EXCHANGE RISK

Elan is a multinational business operating in many countries. The U.S. dollar
is the primary currency in which Elan conducts its business. The U.S. dollar is
used for planning and budgetary purposes and as the currency for financial
reporting. Elan has revenues, costs, assets and liabilities denominated in
currencies other than U.S. dollars. The Group manages its non-U.S. dollar
foreign exchange risk through derivative financial instruments.

The U.S. dollar is the base currency against which all identified transactional
foreign exchange exposures are managed and hedged. The principal risks to which
Elan is exposed are movements in the exchange rates of the U.S. dollar against
the Euro, Sterling, Swiss Franc and Japanese Yen. The main exposures are net
costs in Euro arising from a manufacturing and research presence in Ireland and
the sourcing of raw materials in European markets.

During 2003, average exchange rates were U.S.$1.1322 = EUR1. Elan sells U.S.
dollars to buy Euro for costs incurred in Euro. The recent strengthening of the
Euro against the U.S. dollar will result in a higher reported cost related to
Elan's Euro cost base in 2004 compared to 2003.

All derivative contracts entered into are in liquid markets with credit
approved counterparties. At 31 December 2003, Elan had not entered into any
forward foreign exchange contracts or foreign currency options.

For additional information regarding foreign exchange risk, please refer to
Note 21 to the Consolidated Financial Statements.

INTEREST RATE RISK

Elan's liquid funds are invested primarily in U.S. dollars except for the
working capital balances of subsidiaries operating outside of the United
States. Interest rate risk is mainly confined to the variability of returns on
investment funds as the majority of Elan's debt is fixed rate. The Group's
exposure to interest rate risk is actively monitored and managed with an
average duration of less than three months. By calculating an overall exposure
to interest rate risk rather than a series of individual instrument cash flow
exposures, the Company can more readily monitor and hedge these risks. Duration
analysis recognises the time value of money and in particular, prevailing
interest rates by discounting future cash flows.

For additional information regarding interest rate risk, please refer to Note
21 to the Consolidated Financial Statements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      67

FINANCIAL REVIEW
--------------------------------------------------------------------------------

CREDIT RISK

Elan's treasury function transacts business with counterparties that are
considered to be low investment risk. Credit limits are established
commensurate with the credit rating of the financial institution that business
is being transacted with. Elan does not believe that it has a significant
exposure to any one financial counterparty.

Elan does not currently transact significant business in countries that are
subject to major political and economic uncertainty. As a result, Elan is not
materially exposed to any sovereign risk or payment difficulties.

LIQUIDITY RISK

For additional information regarding liquidity risk and for sensitivity
analysis information, please refer to Note 21 to the Consolidated Financial
Statements.

EQUITY PRICE RISK (U.S. GAAP)

Elan is exposed to equity price risks primarily on its available for sale
securities which consist of equity investments in quoted companies. At 31
December 2003, available for sale securities had a fair value of $173.2 million
and had a cost of $86.1 million. These investments are primarily in emerging
pharmaceutical and biotechnology companies. A 10% adverse change in equity
prices would result in an approximate $17 million decrease in the fair value of
Elan's available for sale equity securities.

INTERNATIONAL FINANCIAL REPORTING STANDARDS

Under current European proposals, the Group will be required to adopt
International Financial Reporting Standards ("IFRSs") and International
Accounting Standards ("IASs") in the preparation of its Consolidated Financial
Statements from 2005 onwards. The international standard setter, the
International Accounting Standards Board ("IASB"), has undertaken an extensive
exercise to develop new standards and improve existing ones.

In order to manage the transition of financial reporting from Irish GAAP to
international accounting, the Company has completed initial assessments of the
impact on its results and net assets. Some of the principal policy and
disclosure changes required under IFRS are set out below.

BUSINESS COMBINATIONS, INTANGIBLE ASSETS AND GOODWILL

The more significant policy changes resulting from the transition to IFRS
include:

o    Replacement of goodwill amortisation with an annual impairment test; and

o    A broader definition of "intangible assets" to be recognised at
     acquisition.

FINANCIAL INSTRUMENTS

The adoption of IAS 32 and 39 (revised) will require all derivatives to be
recognised on the balance sheet at fair value. Subsequent changes in fair
values are either taken to equity, if the criteria for hedge accounting are
met, or to the income statement. Previously, derivatives qualifying as hedges
in accordance with Irish GAAP have been held off balance sheet and the fair
value disclosed within a note to the financial statements. Any derivatives
embedded within the terms of contractual commitments that are not considered
closely related to the underlying host contract will also be separately
identified and fair valued.

DEFERRED TAX

Deferred tax is to be recognised at acquisition as part of the fair value
exercise and will be provided on some balances previously excluded from
provision under Irish rules such as revaluations and fair value adjustments.

EMPLOYEE BENEFIT SCHEMES: POST-RETIREMENT AND SHARE OPTION REMUNERATION

IAS 19 requires companies to recognise the full deficit (or surplus) of defined
benefit pension schemes on the balance sheet, but permits a choice whereby
companies can choose to either defer actuarial gains or losses within a defined
range (the corridor approach) or, as expected in any revised IAS, can recognise
all actuarial gains or losses directly through equity.

Under IFRS, options granted by the Group to employees are to be fair valued at
grant date using an option pricing model and charged through the income
statement over the vesting period of the options.

--------------------------------------------------------------------------------
68

--------------------------------------------------------------------------------

PRESENTATION AND DISCLOSURE OF FINANCIAL INFORMATION

The transition to an international accounting framework will give rise to an
increase in certain disclosures to the financial statements. There will also be
some presentational changes. For example, the existing international accounting
framework has no direct equivalent of the Irish GAAP performance statement
"statement of total recognised gains and losses". Financial statements will
disclose a detailed reconciliation of reserve movements for the current year,
with comparatives.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      69

DIRECTORS' REPORT
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

INTRODUCTION

The directors submit their Annual Report, together with the audited financial
statements of Elan, for the year ended 31 December 2003.

REVIEW OF THE DEVELOPMENT OF THE BUSINESS

Elan is focused on the discovery, development, manufacturing, sale and
marketing of novel therapeutic products in neurology, autoimmune diseases and
severe pain. Elan's shares trade on the New York, London and Irish Stock
Exchanges.

Elan Corporation, plc is the parent company of a group of subsidiaries whose
principal activities are described in the Operating and Financial Reviews on
pages 4 to 69 of this report.

Information on legal proceedings pending against Elan is contained in Note 25
to the Consolidated Financial Statements.

POST BALANCE SHEET EVENTS

For additional information on post balance sheet events, please refer to Note
29 to the Consolidated Financial Statements.

RESEARCH AND DEVELOPMENT

During the year ended 31 December 2003, Elan's expenditure on research and
development, including exceptional items, amounted to $331.4 million compared
to $517.3 million, including exceptional items, for the year ended 31 December
2002.

FINANCIAL RESULTS AND DIVIDENDS

The results for the year are set out beginning on page 85 of this Annual
Report. The directors do not propose the payment of a dividend.

PRESENTATION OF FINANCIAL STATEMENTS

This Annual Report and Form 20-F is a requirement for foreign companies with
securities registered with the SEC. For the year ended 31 December 2003, the
Company has continued to prepare one Annual Report meeting the reporting
requirements of the Company pursuant to Irish company law, the listing rules of
the Irish Stock Exchange and the United Kingdom Listing Authority (the "Listing
Rules"), and the rules and regulations of the SEC in the United States.

HEALTH AND SAFETY

The well being of the Company's employees is safeguarded through the strict
adherence to health and safety standards. The Safety, Health and Welfare at
Work Act, 1989, imposes certain requirements on employers and the Company has
taken the necessary action to ensure compliance with the Act, including the
adoption of a safety statement.

DIRECTORS

Under the terms of the Company's articles of association, one-third of the
directors or, if their number is not a multiple of three, then the number
nearest to one-third shall retire from office at each annual general meeting.
The effect of this provision is that all of the Company's directors retire no
less than every third year and, occasionally, after two years. In accordance
with Elan's Articles of Association, Mr Boushel, Mr McLaughlin, Dr Selkoe, Mr
Thornburgh and Mr Groom hereby retire, and being eligible, offer themselves for
re-election.

--------------------------------------------------------------------------------
70

--------------------------------------------------------------------------------

DIRECTORS' INTERESTS

The beneficial interests of those persons who were directors and secretary of
Elan at the year end, including their spouses and children under eighteen years
of age, in the Ordinary Shares of the Company were as follows:

------------------------------------------------------------------------------------------------------------
                                                                          OPTIONS AND WARRANTS TO PURCHASE
                                    ORDINARY SHARES; PAR VALUE 5 EURO    ORDINARY SHARES; PAR VALUE 5 EURO
                                               CENTS EACH                            CENTS EACH
------------------------------------------------------------------------------------------------------------
                                                  AT                 AT                 AT                AT
                                    31 DECEMBER 2003   31 DECEMBER 2002   31 DECEMBER 2003  31 DECEMBER 2002
------------------------------------------------------------------------------------------------------------

 Garo H. Armen, PhD.                       270,000            170,000          1,025,000            587,000
------------------------------------------------------------------------------------------------------------
 Brendan E. Boushel                        838,698            838,698             25,000             47,000
------------------------------------------------------------------------------------------------------------
 Laurence G. Crowley                            --                 --             37,000             37,000
------------------------------------------------------------------------------------------------------------
 William F. Daniel                          50,000            15,000*            326,000            342,000
------------------------------------------------------------------------------------------------------------
 Alan R. Gillespie, C.B.E. PhD.            120,000                 --             37,000             37,000
------------------------------------------------------------------------------------------------------------
 Ann Maynard Gray                            3,500              3,500              5,000              5,000
------------------------------------------------------------------------------------------------------------
 John Groom                                510,000            510,000            316,720            343,720
------------------------------------------------------------------------------------------------------------
 G. Kelly Martin                           257,500            42,500*          2,000,000                 --
------------------------------------------------------------------------------------------------------------
 Kieran McGowan                              1,200              1,200             15,000             15,000
------------------------------------------------------------------------------------------------------------
 Kevin M. McIntyre, MD.                    179,356            179,356             25,000             42,000
------------------------------------------------------------------------------------------------------------
 Kyran McLaughlin                               --                 --             15,000             15,000
------------------------------------------------------------------------------------------------------------
 Dennis J. Selkoe, MD.                     163,175            163,175            108,648            108,648
------------------------------------------------------------------------------------------------------------
 Richard L. Thornburgh                         200                200             37,000             37,000
------------------------------------------------------------------------------------------------------------
 Daniel P. Tully                           177,548            137,548             15,000             15,000
------------------------------------------------------------------------------------------------------------

*    At date of appointment to the board on 4 February 2003

The following changes in directors' interests occurred between 31 December 2003
and 31 March 2004. On 10 March 2004, options to purchase ordinary shares were
granted to the following directors: Mr Martin 60,000 options; Dr Armen 50,000
options; Mr Boushel, Mr Crowley, Dr Gillespie, Ms Gray, Mr Groom, Mr McGowan,
Dr McIntyre, Mr McLaughlin, Dr Selkoe, Mr Thornburgh and Mr Tully 40,000
options each and Mr Daniel 30,000 options.

As more fully described in Note 20 to the Consolidated Financial Statements,
Elan previously issued 1,250,000 Series B Warrants (the "Series B Warrants") in
connection with the Neuralab Limited ("Neuralab") offering (the "Neuralab
Offering"). These expired on 14 January 2003. Mr Boushel, Mr Daniel, Dr
McIntyre and Mr Groom held a total of 21,500 Series B Warrants, exercisable for
an aggregate of 43,000 ADSs, which are included in the table above at 31
December 2002. All such Series B Warrants expired unexercised in January 2003.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      71

DIRECTORS' REPORT
--------------------------------------------------------------------------------

DIRECTORS' OPTIONS

-----------------------------------------------------------------------------------------------------------------
                                                                                               WEIGHTED AVERAGE
                                                                                                   SUBSCRIPTION
                                                                                                       PRICE OF
                                                                                                        OPTIONS
                                          AT                                             AT      OUTSTANDING AT
                              1 JANUARY 2003       GRANTED     EXPIRED     31 DECEMBER 2003    31 DECEMBER 2003
-----------------------------------------------------------------------------------------------------------------

 Garo H. Armen, PhD.                 587,000       450,000      12,000            1,025,000                3.68
-----------------------------------------------------------------------------------------------------------------
 Brendan E. Boushel                   37,000            --      12,000               25,000               32.07
-----------------------------------------------------------------------------------------------------------------
 Laurence G. Crowley                  37,000            --          --               37,000               26.31
-----------------------------------------------------------------------------------------------------------------
 William F. Daniel*                  341,000         6,000      21,000              326,000               17.49
-----------------------------------------------------------------------------------------------------------------
 Alan R. Gillespie, C.B.E.
 PhD.                                 37,000            --          --               37,000               26.31
-----------------------------------------------------------------------------------------------------------------
 Ann Maynard Gray                      5,000            --          --                5,000               54.85
-----------------------------------------------------------------------------------------------------------------
 John Groom                          316,720            --          --              316,720               17.87
-----------------------------------------------------------------------------------------------------------------
 G. Kelly Martin*                         --     2,000,000          --            2,000,000                4.56
-----------------------------------------------------------------------------------------------------------------
 Kieran McGowan                       15,000            --          --               15,000               35.49
-----------------------------------------------------------------------------------------------------------------
 Kevin M. McIntyre, MD.               37,000            --      12,000               25,000               32.07
-----------------------------------------------------------------------------------------------------------------
 Kyran McLaughlin                     15,000            --          --               15,000               35.49
-----------------------------------------------------------------------------------------------------------------
 Dennis J. Selkoe, MD.               108,648            --          --              108,648               16.91
-----------------------------------------------------------------------------------------------------------------
 Richard L. Thornburgh                37,000            --          --               37,000               26.31
-----------------------------------------------------------------------------------------------------------------
 Daniel P. Tully                      15,000            --          --               15,000               35.49
-----------------------------------------------------------------------------------------------------------------

*     Appointed to the board on 4 February 2003

No options were exercised during the year ended 31 December 2003. Options
outstanding at 31 December 2003 are exercisable at various dates between
January 2004 and November 2013. The closing market price at 31 December 2003,
on the New York Stock Exchange ("NYSE"), of the Company's ADSs was $6.89.
During the year ended 31 December 2003, the closing market price ranged from
$2.33 to $8.46 per ADS.

DIRECTORS' REMUNERATION
---------------------------------------------------------------------------------------------------------------------
                                                                                               YEAR ENDED 31 DECEMBER
---------------------------------------------------------------------------------------------------------------------
                                                              2003                   2003
                                                  2003      ANNUAL        2003     BENEFIT          2003          2002
                                           SALARY/FEES       BONUS     PENSION     IN KIND         TOTAL         TOTAL
EXECUTIVE DIRECTORS:                                 $           $                       $             $             $
---------------------------------------------------------------------------------------------------------------------

 G. Kelly Martin                               702,854     800,000       6,000      71,686     1,580,540            --
---------------------------------------------------------------------------------------------------------------------
 William Daniel                                266,666     150,000      29,767      17,758       464,191            --
---------------------------------------------------------------------------------------------------------------------
 Donal Geaney(1)                                    --          --          --          --            --     1,214,684
---------------------------------------------------------------------------------------------------------------------
 Thomas Lynch(1)                                    --          --          --          --            --       962,875
---------------------------------------------------------------------------------------------------------------------
 Total                                         969,520     950,000      35,767      89,444     2,044,731     2,177,559
---------------------------------------------------------------------------------------------------------------------
 Average number of executive directors                                                                 2             2
---------------------------------------------------------------------------------------------------------------------

(1)   Mr Geaney received a total bonus of $1.0 million in respect of 2001, of
      which $360,000 was paid in 2001 and disclosed in the 2001 Annual Report
      and Form 20-F and the balance of $640,000 was paid in 2002. Mr Lynch
      received a bonus of $500,000 in 2002 in respect of 2001.

--------------------------------------------------------------------------------
72

--------------------------------------------------------------------------------

On 9 July 2002, Mr Geaney and Mr Lynch resigned as chairman and vice-chairman
of the board, respectively, as well as from their respective positions as
officers of Elan. Under the terms of the agreements signed on 9 July 2002, Mr
Geaney and Mr Lynch will continue as employees of Elan as senior advisers to
the chairman until 31 July 2004 at their then current base salaries and shall
be entitled to continue to receive the pension and other benefits to which they
were then entitled. They are not entitled to any future bonuses. The
remuneration paid to them after 9 July 2002 is shown under payments to former
directors below.

----------------------------------------------------------------------------------------------
                                                                        YEAR ENDED 31 DECEMBER
----------------------------------------------------------------------------------------------
                                                2003                2003
                                       2003   ANNUAL      2003   BENEFIT        2003     2002
                                       FEES    BONUS   PENSION   IN KIND       TOTAL    TOTAL
NON-EXECUTIVE DIRECTORS:                  $        $         $         $           $        $
----------------------------------------------------------------------------------------------

 Garo H. Armen, PhD.                240,000       --        --        --     240,000    62,500
----------------------------------------------------------------------------------------------
 Brendan E. Boushel                  40,000       --        --        --      40,000    50,000
----------------------------------------------------------------------------------------------
 Laurence G. Crowley                 65,000       --        --        --      65,000    65,000
----------------------------------------------------------------------------------------------
 Alan R. Gillespie, C.B.E. PhD.      53,859       --        --        --      53,859    46,250
----------------------------------------------------------------------------------------------
 Ann Maynard Gray                    77,500       --        --        --      77,500    58,750
----------------------------------------------------------------------------------------------
 John Groom                         140,000       --   100,000        --     240,000   240,000
----------------------------------------------------------------------------------------------
 Kieran McGowan                      65,000       --        --        --      65,000    58,750
----------------------------------------------------------------------------------------------
 Kevin M. McIntyre, MD.              60,000       --        --        --      60,000    70,000
----------------------------------------------------------------------------------------------
 Kyran McLaughlin                    85,000       --        --        --      85,000    68,750
----------------------------------------------------------------------------------------------
 Dennis J. Selkoe, MD.               65,000       --        --        --      65,000   100,000
----------------------------------------------------------------------------------------------
 Richard L. Thornburgh               60,000       --        --        --      60,000    56,250
----------------------------------------------------------------------------------------------
 Daniel P. Tully                     77,500       --        --        --      77,500    58,750
----------------------------------------------------------------------------------------------
 Total                            1,028,859       --   100,000        --   1,128,859   935,000
----------------------------------------------------------------------------------------------
 Average number of non-executive directors                                        12        12
----------------------------------------------------------------------------------------------

On 12 February 2002, Elan entered into a consultancy agreement with Mr Groom.
On 1 April 2002, EPI entered into a consultancy agreement with Dr Selkoe. Dr
Selkoe is also a party to a consultancy agreement with Athena Neurosciences.
For additional information regarding these consultancy agreements, please refer
to "Service Contracts" in this Directors' Report.

Dr Selkoe received $25,000 and $50,000 from Elan in 2003 and 2002, respectively,
under consultancy agreements. Mr Groom received $200,000 in 2002 under a
consultancy agreement. Effective 1 July 2003, the consultancy agreement was
cancelled and the Company and Mr Groom entered into a pension agreement of
$200,000 per annum payable until 16 May 2008.

---------------------------------------------------------
                                       2003          2002
                                      TOTAL         TOTAL
PAYMENTS TO FORMER DIRECTORS:             $             $
---------------------------------------------------------

 James Balog                             --        20,000
---------------------------------------------------------
 Donal Geaney (1)                 1,122,082       554,684
---------------------------------------------------------
 Thomas Lynch (1)                   899,955       442,875
---------------------------------------------------------
 Donald Panoz                       160,000       160,000
---------------------------------------------------------
 Nancy Panoz                         25,000        25,000
---------------------------------------------------------
                                  2,207,037     1,202,559
---------------------------------------------------------

(1)   As explained above, Mr Geaney and Mr Lynch resigned as chairman and vice
      chairman on 9 July 2002. Their remuneration for 2002 is split between
      amounts paid to them as executive directors (see page 72) and as former
      directors above. The total amounts paid to Mr Geaney and Mr Lynch in
      respect of 2002 were $1,769,368 and $1,405,750 respectively.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      73

DIRECTORS' REPORT
--------------------------------------------------------------------------------

BOARD OF DIRECTORS AND SENIOR MANAGEMENT OF THE COMPANY

DIRECTORS

Garo H. Armen, PhD (51) was appointed a director of Elan in February 1994 and
was appointed chairman of Elan in July 2002. He has been chairman and chief
executive officer of Antigenics, Inc. ("Antigenics") since its initial public
offering in February 2000 and held the same positions in its predecessor,
Antigenics, LLC since its formation in 1994. Previously, Dr Armen was with Dean
Witter Reynolds as a senior vice president of research and with E.F. Hutton &
Company as first vice president, research.

Brendan E. Boushel (73) was appointed a director of Elan in January 1980. From
1966 until his retirement in 1994, Mr Boushel was a partner in the Irish law
firm of T.T.L. Overend McCarron & Gibbons. Mr Boushel also holds a number of
private company directorships.

Laurence G. Crowley (67) was appointed a director of Elan in March 1996. He is
governor (chairman) of the Bank of Ireland. He is presently chairman of PJ
Carroll & Co. and is a director of a number of private companies.

William F. Daniel (1) (52) was appointed a director of Elan in February 2003.
He has served as the Company's secretary since December 2001, having joined
Elan in March 1994 as group financial controller. In July 1996, he was
appointed group vice president, finance, group controller and principal
accounting officer. From 1990 to 1992, Mr Daniel was financial director of
Xtravision, plc.

Alan R. Gillespie, C.B.E. PhD (53) was appointed a director of Elan in March
1996. He is chairman of Ulster Bank Limited. From November 1999 until November
2002, he was chief executive officer of CDC Group, plc and was previously a
managing director of Goldman Sachs International.

Ann Maynard Gray (58) was appointed a director of Elan in February 2001. She
was formerly president of Diversified Publishing Group of Capital Cities/ABC,
Inc. Ms Gray is a director of Duke Energy Corporation and The Phoenix
Companies, Inc., and is a trustee of J.P. Morgan Funds.

John Groom (65) was appointed a director of Elan in July 1996 and served as
president and chief operating officer from then until his retirement in January
2001. Mr Groom was president, chief executive officer and director of Athena
Neurosciences prior to its acquisition by Elan in 1996. Mr Groom serves on the
boards of Neuronyx Inc., Ligand, CV Therapeutics and Amarin.

Kieran McGowan (60) was appointed a director of Elan in December 1998. From
1990 until his retirement in December 1998, he was chief executive of IDA
Ireland. He is chairman of the Governing Authority of University College Dublin
and is a director of CRH, plc, Irish Life and Permanent, plc, United Drug, plc,
Enterprise Ireland, An Post National Lottery Company Ltd., and a number of
private companies.

Kevin M. McIntyre, MD (68) was appointed a director of Elan in February 1984.
He is an associate clinical professor of medicine at Harvard Medical School and
has served as a consultant to the National Academy of Sciences.

Kyran McLaughlin (59) was appointed a director of Elan in January 1998. Since
1985, he has been head of equities and corporate finance at Davy Stockbrokers,
Ireland's largest stockbroker firm. He is a director of Ryanair Holdings, plc
and is a director of a number of private companies.

G. Kelly Martin(1) (45) was appointed a director of Elan in February 2003
following his appointment as president and chief executive officer. He was
formerly president of the International Private Client Group and a member of
the executive management and operating committee of Merrill Lynch & Co., Inc.
He spent over 20 years at Merrill Lynch & Co., Inc. in a broad array of
operating and executive responsibilities on a global basis.

Dennis J. Selkoe, MD (60) was appointed a director of Elan in July 1996,
following Elan's acquisition of Athena Neurosciences, where he served as a
director since July 1995. Dr Selkoe was a founder of, and consultant to, Athena
Neurosciences. Dr Selkoe, a neurologist, is a professor of neurology and
neuroscience at Harvard Medical School. He also serves as co-director of the
Center for Neurologic Disease at The Brigham and Women's Hospital.

The Honorable Richard L. Thornburgh (71) was appointed a director of Elan in
March 1996. He served as governor of Pennsylvania for two terms and as attorney
general of the United States from 1988 to 1991. He is presently of counsel to
the law firm of Kirkpatrick & Lockhart LLP in Washington, D.C. He was appointed
lead independent director of the Company in May 2002.

--------------------------------------------------------------------------------
74

--------------------------------------------------------------------------------

Daniel P. Tully (72) was appointed a director of Elan in February 1999. He is a
chairman emeritus of Merrill Lynch & Co., Inc., where he served as chairman of
the board from 1993 to 1997, and was its chief executive officer from 1992 to
1996. He served as vice chairman of the NYSE from 1994 to 1995, vice chairman
of the American Stock Exchange from 1984 to 1986 and chairman of the board of
governors of the National Association of Securities Dealers from 1996 to 1997.

Officers serve at the discretion of the board of directors. Directors of Elan
are compensated with fee payments and stock options (with additional payments
where directors are members of board committees) and are reimbursed for travel
expenses to and from board meetings.

(1) Member of executive management committee.

SENIOR MANAGEMENT

Paul Breen(1) (47) is executive vice president, global services and operations.
He joined Elan in July 2001. Prior to joining Elan, he was vice president and
joint managing director of Pfizer Pharmaceuticals Ireland. Prior thereto, he
was vice president and managing director of Warner-Lambert Company's Irish
operations.

Nigel Clerkin (30) was appointed senior vice president, finance and group
controller in January 2004, having previously held a number of financial and
strategic planning positions since joining Elan in January 1998. He is also the
Company's principal accounting officer. Mr Clerkin is a chartered accountant
and a graduate of Queen's University Belfast.

Shane Cooke(1) (41) joined Elan as executive vice president and chief financial
officer in July 2001. Prior to joining Elan, Mr Cooke was chief executive of
Pembroke Capital Limited, an aviation leasing company, and prior to that held a
number of senior positions in finance in the banking and aviation industries.
Mr Cooke is a chartered accountant and a graduate of University College Dublin.

Jean Duvall (1) (42) was appointed executive vice president and general counsel
in May 2003, having held a number of senior legal positions at Elan, most
recently senior vice president, legal affairs of EPI. Prior to joining Athena
Neurosciences in 1994, she held positions at Alza Corporation and at the law
firm of Morgan and Finnegan.

Lars Ekman,(1) MD, PhD (54) was appointed executive vice president and
president, global R&D and corporate strategy for Elan in June 2003. Previously,
Dr Ekman held the position of president, research and development since joining
the company in January 2001. Prior to joining Elan, he was evp, research and
development at Schwarz Pharma AG since 1997. From 1984 to 1997, Dr Ekman was
employed in a variety of senior scientific and clinical functions at Pharmacia
(now Pfizer). Dr Ekman is a board certified surgeon with a PhD in experimental
biology and has held several clinical and academic positions in both the United
States and Europe. He obtained his PhD and MD from the University of
Gothenburg, Sweden.

Arthur Falk, PhD (59) joined Elan as executive vice president, corporate
compliance, in May 2001. Dr Falk has 30 years experience in analytical
research, quality and compliance within the pharmaceutical industry. Prior to
joining Elan, he was the vice president, corporate quality, safety and
environmental affairs and managing compliance officer for the worldwide
operations of the Warner-Lambert Company.

Jack Laflin (56) joined Elan as executive vice president, human resources, in
January 2003. Mr Laflin was most recently vice president, human resources, at
Invensys, plc based in London. Prior thereto, he held senior positions in
Kulicke and Soffa Industries, Inc, ALG Group, Harris Corporation and with the
General Electric Company.

Ivan Lieberburg, MD, PhD (54) is executive vice president and chief medical
officer of Elan, where he has held a number of senior positions, most recently
senior vice president of research. Prior to joining Athena Neurosciences in
1987, Dr Lieberburg held faculty positions at the Albert Einstein College of
Medicine and Mt. Sinai School of Medicine in New York.

No director or officer has a family relationship with any other director or
officer.

(1) Member of executive management committee.

COMPENSATION OF DIRECTORS AND OFFICERS

For the year ended 31 December 2003, all executive officers and directors as a
group (19 persons) received total compensation of $7.2 million.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      75

DIRECTORS' REPORT
--------------------------------------------------------------------------------

Elan reimburses officers and directors for their actual business-related
expenses. For the year ended 31 December 2003, an aggregate of $0.3 million was
set aside or accrued by Elan to provide pension, retirement and other similar
benefits for directors and officers. Elan maintains certain health and medical
benefit plans for its employees in which Elan's officers participate along with
other employees generally.

For additional information on pension benefits for Elan employees, please refer
to Note 28 to the Consolidated Financial Statements, and to pages 174 to 176.

TRANSACTIONS WITH DIRECTORS

There were no transactions with directors during the year ended 31 December
2003 other than as outlined in Note 27 to the Consolidated Financial
Statements.

SIGNIFICANT SHAREHOLDINGS

As of 31 December 2003, Capital Research and Management Company ("Capital
Research") owned 45,382,000 Elan ADSs representing approximately 11.7% of the
issued share capital of the Company. Capital Research held approximately 11.6%
and 9% of the share capital of the Company at 31 December 2002 and 2001
respectively. Fidelity Management and Research Company ("Fidelity Management")
held approximately 5% of the issued share capital of the Company at 31 December
2001. At 31 March 2004, Fidelity Management had increased their shareholding to
31,486,620 ADSs representing approximately 8.1% of the issued share capital.
Save for these interests, the Company is not aware of any person who, directly
or indirectly, holds 3% or more of the issued share capital. Neither Capital
Research nor Fidelity Management have voting rights different from other
shareholders.

The following table sets forth certain information regarding the beneficial
ownership of Ordinary Shares at 31 March 2004 by all directors and officers of
Elan as a group (either directly or by virtue of ownership of Elan ADSs):

--------------------------------------------------------------------------------
                                                             NO. OF   PERCENT OF
NAME OF OWNER OR IDENTITY OF GROUP                           SHARES     CLASS(1)
--------------------------------------------------------------------------------

 All directors and officers as a group (18 persons)(2)  5.6 million         1.4%
--------------------------------------------------------------------------------

(1)   Based on 388.7 million Ordinary Shares outstanding on 31 March 2004 and
      3.0 million Ordinary Shares issuable upon the exercise of currently
      exercisable options held by directors and officers as a group as of 31
      March 2004.

(2)   Includes 3.0 million Ordinary Shares issuable upon exercise of currently
      exercisable options held by directors and officers of Elan as a group as
      of 31 March 2004.

No options were exercised by executive officers during the year ended 31
December 2003. Options outstanding at 31 December 2003 are exercisable at
various dates between January 2004 and November 2013.

There were no options exercised by executive officers to acquire Elan ADSs in
the period from 31 December 2003 to 31 March 2004.

Elan, to its knowledge, is not directly or indirectly owned or controlled by
another entity or by any government. Elan does not know of any arrangements,
the operation of which might result in a change of control of Elan.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The following statement, which should be read in conjunction with the Auditors'
Report set out on pages 83 and 84 of this Annual Report, is made with a view to
distinguishing for shareholders the respective responsibilities of the
directors and of the auditors in relation to the financial statements.

Irish company law requires the directors to ensure that financial statements
are prepared for each financial year which give a true and fair view of the
state of affairs of Elan Corporation, plc and of the Group and of the profit or
loss for that year.

With regard to the financial statements on pages 85 to 178 of this Annual
Report, the directors have determined that it is appropriate that they continue
to be prepared on a going concern basis and consider that in their preparation:

--------------------------------------------------------------------------------
76

--------------------------------------------------------------------------------

o    Suitable accounting policies have been selected and applied consistently;

o    Judgements and estimates that are reasonable and prudent have been made;
     and

o    Applicable accounting standards have been followed.

The directors have a responsibility for ensuring that proper books of account
are kept which disclose with reasonable accuracy at any time the financial
position of the Group and of Elan Corporation, plc and which enable them to
ensure that the financial statements comply with the Companies Acts (the
"Companies Acts"), 1963 to 2003, and all regulations to be construed as one
with those Acts. They also have general responsibility for taking such steps as
are reasonably open to them to safeguard the assets of the Group and to prevent
and detect fraud and other irregularities.

SERVICE CONTRACTS

Save as set out below, there are no service contracts in existence between any
of the directors and Elan.

o    On 1 July 2003, Elan entered into a pension agreement with Mr Groom, a
     director of Elan, whereby Elan shall pay a pension of $200,000 per annum,
     monthly in arrears, until 16 May 2008 in respect of his former senior
     executive roles in Elan and in Athena Neurosciences, Inc.

o    On 7 January 2003, Elan and EPI entered into an agreement with Mr Martin
     such that Mr Martin was appointed president and chief executive officer of
     Elan effective 3 February 2003. Mr Martin's annual salary under this
     agreement is $798,000. He is eligible for an annual bonus in a target
     amount equal to his salary depending on the achievement of established
     performance goals. Mr Martin was granted an initial option to purchase
     1,000,000 Ordinary Shares with an exercise price of $3.85 and vesting in
     three equal instalments on 31 December 2003, 31 December 2004 and 31
     December 2005. In accordance with the terms of his contract, in October
     2003, Mr Martin was granted an additional option to purchase 1,000,000
     Ordinary Shares with an exercise price of $5.28, equal to the fair market
     value of the shares on the date of grant, vesting on the same basis and
     dates as the initial option grant.

     Commencing in 2004, Mr Martin will be considered for additional option
     grants during the term of the agreement consistent with Elan's annual
     option grant practices.

     The agreement continues until 31 December 2005 and can be extended for a
     further year on each anniversary of that date thereafter unless 90 days
     notice is given by Elan or Mr Martin prior to the applicable anniversary
     date. In general, if Mr Martin's employment is involuntarily terminated
     (other than for cause or disability) or Mr Martin leaves for good reason,
     Elan will continue to pay his salary and target bonus for the following two
     years and his outstanding options will immediately accelerate and remain
     outstanding for the following two years. If, during the first two years of
     the agreement, Elan undergoes a change in control and Mr Martin is
     involuntarily terminated, then Mr Martin will receive the benefits outlined
     in the preceding sentence and a lump sum payment in an amount equal to $5.0
     million if the change of control occurs in the first year of the term, or
     $3.0 million if it occurs in the second year of the term.

     Mr Martin is eligible to participate in the pension, medical, disability
     and life insurance plans applicable to senior executives in accordance with
     the terms of those plans. He may also receive financial planning and tax
     support and advice from the provider of his choice at a reasonable and
     customary annual cost.

o    On 1 July 1986, Athena Neurosciences entered into a consultancy agreement
     with Dr Selkoe whereby Dr Selkoe agreed to provide certain consultancy
     services in the field of AD for a fee to be fixed annually, together with
     the reimbursement for all reasonable travel and other expenses incurred.
     The consultancy agreement renews automatically, unless notice of
     termination is provided 60 days prior to the anniversary date. No such
     notice has been provided.

o    On 1 April 2002, EPI entered into a consultancy agreement with Dr Selkoe
     whereby Dr Selkoe agreed to provide certain consultancy services, including
     services in the field of immunological approaches to the treatment of AD
     for a period of one year for a fee not to exceed $12,000.

ACCOUNTING RECORDS

The directors believe that they have complied with Section 202 of the Companies
Act, 1990 with regard to books of account by employing financial personnel with
appropriate expertise and by providing adequate resources to the financial
function. The books of account of Elan Corporation, plc are maintained at its
office in Monksland, Athlone, County Westmeath, Ireland.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      77

DIRECTORS' REPORT
--------------------------------------------------------------------------------

POLITICAL DONATIONS

There were no political contributions which require disclosure under the
Electoral Act, 1997.

SUBSIDIARY COMPANIES

For additional information regarding significant subsidiary and associated
undertakings, please refer to Note 32 to the Consolidated Financial Statements.

AUDITORS

In accordance with Section 160(2) of the Companies Act, 1963, the auditors,
KPMG, Chartered Accountants, will continue in office.

On behalf of the board, 23 April 2004

GARO ARMEN, chairman        KELLY MARTIN, president and chief executive officer

--------------------------------------------------------------------------------
78

CORPORATE GOVERNANCE
--------------------------------------------------------------------------------

POLICIES

Elan is committed to the adoption and maintenance of the highest standards of
corporate governance and compliance. The Company complies with the provisions
of The Combined Code which was adopted by the London Stock Exchange in June
1998 and by the Irish Stock Exchange in December 1998. One of the requirements
of The Combined Code is that listed companies make a statement in relation to
how they have complied with this code. A revised Combined Code on Corporate
Governance (the "Revised Code") was issued in July 2003 and compliance is
required for annual reports commencing in November 2003. The Company is
studying the Revised Code and believes it is in compliance with the Revised
Code.

In May 2002, following a review with external legal counsel, the board of
directors adopted a set of corporate governance guidelines ("the Guidelines")
and restructured the existing three board committees into four board
committees, the executive committee, audit committee, compensation committee
(now the leadership development and compensation committee), and nominating
committee and adopted a written charter for each committee (collectively the
"Committee Charters"). The Guidelines and the Committee Charters were revised
and updated in November 2003 to incorporate the requirements of the Sarbanes
Oxley Act, 2002, the revised listing rules of the NYSE and certain measures
agreed as part of the settlement of the derivative action (see Note 25 on pages
133 to 134). In addition, in November 2003 the Company adopted a code of
conduct (the "Code of Conduct") that applies to all employees of the Company,
including its principal executive officer, principal financial officer and
principal accounting officer. The Guidelines, the Committee Charters and the
Code of Conduct are available on the Company's website, www.elan.com, under
"Governance". Any amendments to or waivers from the Code of Conduct will also
be posted to the Company's website.

THE BOARD

The roles of chairman and chief executive officer are separated. Under the
Company's Corporate Governance Guidelines, it has committed that two-thirds of
the board will be independent by 30 June 2004. The board currently includes 10
independent, non-executive directors who constitute in excess of two-thirds of
the board. The Company decided to adopt a definition of independence based on
the rules of the NYSE, the exchange on which the majority of the Company's
shares are traded. In addition, the board has appointed the Honorable Richard
L. Thornburgh as lead independent director, in accordance with the provisions
of The Combined Code and best corporate governance practice in the United
States, the U.K. and Ireland.

The board regularly reviews its responsibilities and those of its committees
and management. The board meets regularly throughout the year, and all of the
directors have full and timely access to the information necessary to enable
them to discharge their duties. The board has reserved certain matters to its
exclusive jurisdiction, thereby maintaining control of the Company and its
future direction. All directors are appointed by the board, as nominated by its
nominating committee, and subsequently elected by the shareholders. Procedures
are in place where directors and committees, in furtherance of their duties,
may take independent professional advice, if necessary, at the Company's
expense. The board has delegated authority over certain areas of the Company's
activities to four standing committees, as more fully described below. The
board held 19 meetings during 2003.

EXECUTIVE COMMITTEE

The executive committee exercises the authority of the board during the
interval between board meetings, except to the extent that the board has
delegated authority to another committee or to other persons, or has reserved
authority to itself or as limited by Irish law. The members of the committee
are Dr Armen, chairman, Mr Crowley, Ms Gray, Mr Martin, Mr McLaughlin and Mr
Tully. The executive committee held 5 formal meetings during 2003.

AUDIT COMMITTEE

The audit committee, composed entirely of non-executive directors, helps the
board in its general oversight of the Company's accounting and financial
reporting practices, internal controls and audit functions, and is directly
responsible for the appointment, compensation and

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      79

CORPORATE GOVERNANCE
--------------------------------------------------------------------------------

oversight of the work of Elan's independent auditors. The audit committee
periodically reviews the effectiveness of the system of internal control. It
monitors the adequacy of internal accounting practices, procedures and
controls, and reviews all significant changes in accounting policies. The
committee meets regularly with the internal and external auditors and addresses
all issues raised and recommendations made by them. The members of the
committee are Mr McLaughlin, chairman, Dr Gillespie and Mr McGowan. The audit
committee held 10 formal meetings during 2003.

The Company's board of directors does not have an "audit committee financial
expert," within the meaning of such phrase under applicable regulations of the
SEC, serving on its audit committee. The board of directors believes that all
members of its audit committee are financially literate, experienced in
business matters, capable of analysing and evaluating the Company's financial
statements, understanding internal controls and procedures for financial
reporting purposes and understanding audit committee functions. The board of
directors expects to seek an appropriate individual to serve on the board of
directors and the audit committee who will meet the requirements necessary to
be an "audit committee financial expert."

Consistent with SEC policies regarding auditor independence, the audit
committee has responsibility for appointing, setting compensation and
overseeing the work of the independent auditor. In recognition of this
responsibility, the audit committee has established a policy to pre-approve all
audit and permissible non-audit services provided by the independent auditor.
Prior to engagement of the independent auditor for the next year's audit,
management will submit a list of services and related fees expected to be
rendered during that year within each of four categories of services to the
audit committee for approval: audit services; audit-related services; tax
services; and other fees.

Prior to engagement, the audit committee pre-approves independent auditor
services within each category. The fees are budgeted and the audit committee
requires the independent auditor and management to report actual fees versus
the budget periodically throughout the year by category of service. During the
year, circumstances may arise when it may become necessary to engage the
independent auditor for additional services not contemplated in the original
pre-approval categories. In those instances, the audit committee requires
specific pre-approval before engaging the independent auditor.

The audit committee may delegate pre-approval authority to one or more of its
members. The member to whom such authority is delegated must report, for
informational purposes only, any pre-approval decisions to the audit committee
at its next scheduled meeting.

LEADERSHIP DEVELOPMENT AND COMPENSATION COMMITTEE

The leadership development and compensation committee (the "LDCC"), composed
entirely of non-executive directors, reviews the compensation philosophy and
policies of the Company with respect to executive compensation, fringe benefits
and other compensation matters. The committee determines the compensation of
the chief executive officer and other executive directors and reviews the
compensation of the other members of the executive management. The committee
also administers the Company's share option plans. The members of the committee
are Dr McIntyre, chairman, Mr Crowley, Ms Gray and Mr Tully. The LDCC committee
held 9 formal meetings during 2003. For more information, see "Report of the
Leadership Development and Compensation Committee".

NOMINATING COMMITTEE

The nominating committee, composed entirely of non-executive directors, reviews
on an ongoing basis the membership of the board of directors and of the board
committees and the performance of the directors. It recommends new appointments
to fill any vacancy that is anticipated or arises on the board of directors. It
reviews and recommends changes in respect of the functions of the various
committees of the board. The members of the committee are Mr Thornburgh,
chairman, Ms Gray, Mr McGowan, Mr McLaughlin and Mr Tully. The nominating
committee held 1 formal meeting during 2003.

RELATIONS WITH SHAREHOLDERS

Elan communicates regularly with its shareholders throughout the year,
including following the release of quarterly and annual results, and after
major developments. Company general meetings and analyst briefings are webcast
and are available on the Company's website (www.elan.com). All shareholders are
given adequate notice of the Annual General Meeting.

--------------------------------------------------------------------------------
80

--------------------------------------------------------------------------------

INTERNAL CONTROL

The board of directors has overall responsibility for the Group's system of
internal control and for monitoring its effectiveness. Management is
responsible for the planning and implementation of the system of internal
control and ensuring that these controls apply throughout the Group. The system
of internal control is designed to provide reasonable, but not absolute,
assurance against material misstatement or loss.

The key procedures that have been established to provide effective internal
control include:

     o    A clear focus on business objectives is set by the board having
          considered the risk profile of the Group through;

     o    A formalised risk reporting system. Significant business risks are
          addressed at each board meeting;

     o    A clearly defined organisational structure under the day to day
          direction of its chief executive officer. Defined lines of
          responsibility and delegation of authority have been established
          within which the Group's activities can be planned, executed,
          controlled and monitored to achieve the strategic objectives which the
          board has adopted for Elan;

     o    A comprehensive system for reporting financial results to the board.
          This includes a budgeting system with an annual budget approved by the
          board. The board compares actual results with budgeted results
          regularly. Management accounts are prepared on a timely basis. They
          include a profit and loss account, balance sheet, cash flow and
          capital expenditure report, together with an analysis of performance
          of key operating divisions and subsidiaries;

     o    A system of management and financial reporting, treasury management
          and project appraisal. Management is responsible for reporting to the
          board on its progress in achieving objectives. The system of reporting
          covers trading activities, operational issues, financial performance,
          working capital, cash flow and asset management. This reporting
          happens in a timely and regular manner. In this context, progress is
          monitored against annual budgets and longer term objectives; and

     o    The establishment of corporate compliance and internal audit
          departments which review key systems and controls.

The directors reviewed the Group's system of internal control and also examined
the full range of risks affecting the Group and the appropriateness of the
internal control structures to manage and monitor these risks. This process
involved a confirmation that appropriate systems of internal control were in
place throughout the financial year and up to the date of signing of these
financial statements. It also involved an assessment of the ongoing process for
the identification, management and control of the individual risks and of the
role of the various Group Risk Management Functions and the extent to which
areas of significant challenges facing the Group are understood and are being
addressed. No material unaddressed issues emerged from this assessment. The
directors confirm that they have reviewed, in accordance with the Turnbull
Guidance, the effectiveness of the Group's systems of internal control for the
year ended 31 December 2003.

GOING CONCERN

The directors, having made inquiries, believe that Elan has adequate resources
to continue in operational existence for the foreseeable future and that it is
appropriate to continue to adopt the going concern basis in preparing the
financial statements.

DISCLOSURE CONTROLS AND PROCEDURES

The Company has put in place disclosure controls and procedures ("Disclosure
Controls") which are designed to ensure that information required to be
disclosed in the Company's reports filed under the Securities Exchange Act of
1934, as amended (the "1934 Act"), such as its Annual Report on Form 20-F, is
recorded, processed, summarised and reported within the time periods specified
in the SEC rules and forms. Disclosure Controls are also designed to ensure
that the information is accumulated and communicated to the Company's
management, including Mr Martin and Mr Cooke, as appropriate, to allow timely
decisions regarding required disclosure.

Based upon their evaluation of the Company's Disclosure Controls, Mr Martin and
Mr Cooke have concluded that the Company's Disclosure Controls are effective in
alerting management, including Mr Martin and Mr Cooke, in a timely manner, to
material information required to be disclosed in Elan's reports filed with the
Securities and Exchange Commission.

REPORT OF THE LEADERSHIP DEVELOPMENT AND COMPENSATION COMMITTEE

The terms of reference for the committee are to determine the compensation,
terms and conditions of employment of the chief executive officer and other
executive directors and to review the recommendations of the chief executive
officer with respect to the

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      81

CORPORATE GOVERNANCE
--------------------------------------------------------------------------------

remuneration and terms and conditions of employment of the Company's senior
management. The committee also exercises all the powers of the board of
directors to issue Ordinary Shares on the exercise of share options and to
generally administer the Company's share option plans.

The chief executive officer attends meetings of the committee except when his
own remuneration is being considered.

Each member of the committee is nominated to serve for a three year term
subject to a maximum of two terms of continuous service.

For additional information regarding directors' remuneration, shareholdings and
share options, please refer to Note 5 to the Consolidated Financial Statements
and "Directors' Interests", "Directors' Options" and "Directors' Remuneration"
in the Directors' Report.

REMUNERATION POLICY

The Company's policy on executive directors' remuneration is to set
remuneration levels which are appropriate for its senior executives having
regard to their substantial responsibilities, their individual performance and
the performance of the Company as a whole. It is the policy of the committee to
set remuneration levels after a review of remuneration packages of executives
in the pharmaceutical industry. During 2003, the committee took external advice
from independent benefit consultants on executive remuneration. In framing
remuneration policy, consideration has been given to Section B of the Code of
Best Practice of The Combined Code as issued by the London and Irish Stock
Exchanges.

The typical elements of the remuneration package for executive directors
include basic salary and benefits, annual cash incentive bonus, pensions and
participation in share option plans.

It is the policy of the committee to grant options to management to encourage
identification with shareholders' interests and to link performance to the long
term share price performance of the Company.

EXECUTIVE DIRECTORS' BASIC SALARY

The basic salaries of executive directors are reviewed annually having regard
to personal performance, company performance and market practice.

ANNUAL CASH INCENTIVE BONUS

An annual cash incentive bonus, which is not pensionable, is paid on the
recommendation of the committee to executive directors. Bonus determination is
not based on specific financial or operational targets, but on individual and
company performance.

SHARE OPTION PLANS

It is the policy of the committee, in common with other companies operating in
the pharmaceutical industry, to award share options to management and
employees. The options generally vest between one and five years. These plans
do not contain any performance conditions.

DIRECTORS' SERVICE CONTRACTS

See Directors' Report.

The compensation committee is pleased to submit this report to Elan's
shareholders on these matters.

COMPOSITION OF LEADERSHIP DEVELOPMENT AND COMPENSATION COMMITTEE

LEADERSHIP DEVELOPMENT AND COMPENSATION COMMITTEE
-------------------------------------------------------------------------------
Kevin M. McIntyre, Chairman                  Ann Maynard Gray
-------------------------------------------------------------------------------
Laurence G. Crowley                          Daniel P. Tully
-------------------------------------------------------------------------------

--------------------------------------------------------------------------------
82

INDEPENDENT AUDITORS' REPORT
--------------------------------------------------------------------------------

-------------------------------------------------------------------------------

TO THE MEMBERS OF ELAN CORPORATION, PLC

We have audited the financial statements on pages 85 to 178.

RESPECTIVE RESPONSIBILITIES OF DIRECTORS AND AUDITORS IN RELATION TO THE ANNUAL
REPORT AND FORM 20-F

The directors are responsible for having the Annual Report and Form 20-F
prepared. As described on pages 76 to 77, this includes responsibility for
preparing the financial statements in accordance with applicable Irish Law and
accounting standards; the directors have also presented additional information
under U.S. requirements. Our responsibilities, as independent auditors, are
established in Ireland by statute, the Auditing Practices Board, the Listing
Rules of the Irish Stock Exchange and by our profession's ethical guidance.

We report to you our opinion as to whether the financial statements give a true
and fair view and are properly prepared in accordance with the Companies Acts.
As also required by the Companies Acts, we state whether we have obtained all
the information and explanations we require for our audit, whether the
Company's balance sheet agrees with the books of account and report to you our
opinion as to whether:

o    the Company has kept proper books of account;

o    the directors' report is consistent with the financial statements; and

o    at the balance sheet date, a financial situation existed that may require
     the Company to hold an extraordinary general meeting on the grounds that
     the net assets of the Company, as shown in the financial statements, are
     less than half of its share capital.

We also report to you if, in our opinion, information specified by law or by
the Listing Rules regarding directors' remuneration and transactions with the
Group is not disclosed.

We review whether the statement on page 79 reflects the Company's compliance
with the seven provisions of The Combined Code specified for our review by the
Irish Stock Exchange, and we report if it does not. We are not required to
consider whether the board's statements on internal control cover all risks and
controls, or form an opinion on the effectiveness of the Group's corporate
governance procedures or its risk and control procedures.

We read the other information contained in the Annual Report and Form 20-F,
including the corporate governance statement, and consider whether it is
consistent with the audited financial statements. We consider the implications
for our report if we become aware of any apparent misstatements or material
inconsistencies with the financial statements.

BASIS OF AUDIT OPINION

We conducted our audit in accordance with Auditing Standards issued by the
Auditing Practices Board. An audit includes examination, on a test basis, of
evidence relevant to the amounts and disclosures in the financial statements.
It also includes an assessment of the significant estimates and judgements made
by the directors in the preparation of the financial statements, and of whether
the accounting policies are appropriate to the Group's circumstances,
consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and
explanations which we considered necessary in order to provide us with
sufficient evidence to give reasonable assurance that the financial statements
are free from material misstatement, whether caused by fraud or other
irregularity or error. In forming our opinion, we also evaluated the overall
adequacy of the presentation of information in the financial statements.

FUNDAMENTAL UNCERTAINTY

In forming our opinion, we considered the disclosures in note 25 to the
financial statements relating to the Company and certain of its former and
current officers and directors being named as defendants in a putative class
action in the U.S. District Court for the Southern

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      83

INDEPENDENT AUDITORS' REPORT
--------------------------------------------------------------------------------

District of New York, and the Company being the subject of an investigation by
the SEC's Division of Enforcement which commenced on or about 12 February 2002.
Elan is unable to predict or determine the outcome of the class action or the
SEC investigation or reasonably to estimate the amounts or range of loss, if
any, with respect to the resolution of the class action or the SEC
investigation. The possible outcome or resolution of the SEC investigation or
the class action could require Elan to make substantial payments. Our opinion
is not qualified in this respect.

OPINION

In our opinion, the financial statements give a true and fair view of the state
of affairs of the Group and the Company as at 31 December 2003 and of the loss
of the Group for the year then ended, and have been properly prepared in
accordance with the Companies Acts, 1963 to 2003, and all Regulations to be
construed as one with those Acts.

Accounting principles generally accepted in Ireland vary in certain significant
respects from accounting principles generally accepted in the United States.
Information relating to the nature and effect of such differences is presented
in Note 33 to the Consolidated Financial Statements.

We have obtained all the information and explanations we considered necessary
for the purposes of our audit. In our opinion, proper books of account have
been kept by the Company. The balance sheet of the Company is in agreement with
the books of account.

In our opinion, the information given in the Directors' Report on pages 70 to
78 is consistent with the financial statements.

The net assets of the Company, as stated in the balance sheet on page 90 are
more than half of the amount of its called-up share capital and, in our
opinion, on that basis there did not exist at 31 December 2003 a financial
situation which, under Section 40(1) of the Companies (Amendment) Act, 1983,
would require the convening of an extraordinary general meeting of the Company.

KPMG
Chartered Accountants
Registered Auditors
Dublin, Ireland

23 April 2004

The above opinion is provided in compliance with Irish requirements. An opinion
complying with auditing standards generally accepted in the United States will
be included in the Annual Report on Form 20-F filed with the U.S. Securities
and Exchange Commission.

--------------------------------------------------------------------------------
84

FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

-------------------------------------------------------------------------------

CONSOLIDATED PROFIT AND LOSS ACCOUNT

------------------------------------------------------------------------------------------------------------------------------
                                                                 YEAR ENDED 31 DECEMBER
------------------------------------------------------------------------------------------------------------------------------
                                              2003                                      2002
                                                $M          2003                          $M            2002
                                            BEFORE            $M          2003        BEFORE              $M            2002
                                       EXCEPTIONAL   EXCEPTIONAL            $M   EXCEPTIONAL     EXCEPTIONAL              $M
                               NOTES         ITEMS         ITEMS         TOTAL         ITEMS           ITEMS           TOTAL
------------------------------------------------------------------------------------------------------------------------------

 Revenue--continuing
  operations                       3         309.6            --         309.6         414.5           172.5           587.0
 Revenue--discontinued             6         452.5            --         452.5         746.0              --           746.0
------------------------------------------------------------------------------------------------------------------------------
 Total revenue                     2         762.1            --         762.1       1,160.5           172.5         1,333.0
 Cost of sales                     3         342.6           6.9         349.5         417.0            66.1           483.1
------------------------------------------------------------------------------------------------------------------------------
 Gross profit/(loss)                         419.5          (6.9)        412.6         743.5           106.4           849.9
 Selling, general and
  administrative
  expenses                         3         470.3         546.0       1,016.3         835.4         1,788.0         2,623.4
 Research and
  development
  expenses                         3         307.6          23.8         331.4         402.6           114.7           517.3
------------------------------------------------------------------------------------------------------------------------------
 Operating (loss)/profit--
  continuing operations                     (353.6)       (384.4)       (738.0)       (438.5)       (1,120.4)       (1,558.9)
 Operating loss--
  acquisitions                                  --            --            --            --              --              --
 Operating profit/(loss)--
  discontinued                     6          (4.8)       (192.3)       (197.1)        (56.0)         (675.9)         (731.9)
------------------------------------------------------------------------------------------------------------------------------
 Operating (loss)/profit           2        (358.4)       (576.7)       (935.1)       (494.5)       (1,796.3)       (2,290.8)
 Share of (losses)/profits
  of associates                             (  8.1)           --          (8.1)          6.0              --             6.0
 Loss on sale of securities/
  guarantee                        3            --            --            --            --          (217.0)         (217.0)
 Gain on disposal of
  businesses                       3            --         293.3         293.3           --             77.9            77.9
------------------------------------------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before
  interest and tax                          (366.5)       (283.4)       (649.9)       (488.5)       (1,935.4)       (2,423.9)
 Net interest and other
  expense                       3, 4        (153.8)        (33.7)       (187.5)       (156.7)       (1,014.0)       (1,170.7)
------------------------------------------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before tax            5        (520.3)       (317.1)       (837.4)       (645.2)       (2,949.4)       (3,594.6)
 Tax on (loss)/profit on
  ordinary activities              7          22.0            --          22.0         (19.8)             --           (19.8)
------------------------------------------------------------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities after tax                      (498.3)       (317.1)       (815.4)       (665.0)       (2,949.4)       (3,614.4)
 Minority interest                19            --            --            --          (0.7)             --            (0.7)
------------------------------------------------------------------------------------------------------------------------------
 Retained (loss)/profit for
  the year                                  (498.3)       (317.1)       (815.4)       (665.7)       (2,949.4)       (3,615.1)
------------------------------------------------------------------------------------------------------------------------------
 Basic (loss)/earnings per
  Ordinary Share                   8      $  (1.40)    $   (0.89)    $   (2.29)   $    (1.90)     $    (8.44)    $    (10.34)
 Diluted (loss)/earnings
  per Ordinary Share               8      $  (1.40)    $   (0.89)    $   (2.29)   $    (1.90)     $    (8.44)    $    (10.34)
 Weighted average
  number of Ordinary
  Shares outstanding
  (millions)                                 356.0         356.0         356.0         349.7           349.7           349.7
------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------
                                          YEAR ENDED 31 DECEMBER
--------------------------------------------------------------------------
                                       2001
                                         $M          2001
                                     BEFORE            $M          2001
                                EXCEPTIONAL   EXCEPTIONAL            $M
                                      ITEMS         ITEMS         TOTAL
--------------------------------------------------------------------------

 Revenue--continuing
  operations                         824.8         233.4        1,058.2
 Revenue--discontinued               688.1          (5.6)         682.5
--------------------------------------------------------------------------
 Total revenue                     1,512.9         227.8        1,740.7
 Cost of sales                       364.0          22.8          386.8
--------------------------------------------------------------------------
 Gross profit/(loss)               1,148.9         205.0        1,353.9
 Selling, general and
  administrative
  expenses                           697.5       1,084.2        1,781.7
 Research and
  development
  expenses                           323.3          78.6          401.9
--------------------------------------------------------------------------
 Operating (loss)/profit--
  continuing operations               58.9        (510.1)        (451.2)
 Operating loss--
  acquisitions                        (3.3)           --           (3.3)
 Operating profit/(loss)--
  discontinued                        72.5        (447.7)        (375.2)
--------------------------------------------------------------------------
 Operating (loss)/profit             128.1        (957.8)        (829.7)
 Share of (losses)/profits
  of associates                       10.3            --           10.3
 Loss on sale of securities/
  guarantee                             --            --             --
 Gain on disposal of
  businesses                            --            --             --
--------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before
  interest and tax                   138.4        (957.8)        (819.4)
 Net interest and other
  expense                            (76.3)         25.9          (50.4)
--------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities before tax               62.1        (931.9)        (869.8)
 Tax on (loss)/profit on
  ordinary activities                (17.4)           --          (17.4)
--------------------------------------------------------------------------
 (Loss)/profit on ordinary
  activities after tax                44.7        (931.9)        (887.2)
 Minority interest                      --            --             --
--------------------------------------------------------------------------
 Retained (loss)/profit for
  the year                            44.7        (931.9)        (887.2)
--------------------------------------------------------------------------
 Basic (loss)/earnings per
  Ordinary Share                 $    0.13    $    (2.77)    $    (2.64)
 Diluted (loss)/earnings
  per Ordinary Share             $    0.12    $    (2.77)    $    (2.64)
 Weighted average
  number of Ordinary
  Shares outstanding
  (millions)                         336.0         336.0          336.0
--------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

Garo Armen, chairman    G. Kelly Martin, president and chief executive officer

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      85

FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

CONSOLIDATED BALANCE SHEET

-------------------------------------------------------------------------------------------------------------------------------
                                                                                               AT 31 DECEMBER   AT 31 DECEMBER
                                                                                                         2003             2002
                                                                                     NOTES                 $M               $M
-------------------------------------------------------------------------------------------------------------------------------

 FIXED ASSETS
 Intangible assets                                                                      10            1,252.4          2,079.5
 Tangible assets                                                                        11              372.2            459.3
 Financial assets                                                                       12              407.9            734.6
-------------------------------------------------------------------------------------------------------------------------------
                                                                                                      2,032.5          3,273.4
-------------------------------------------------------------------------------------------------------------------------------
 CURRENT ASSETS
 Stocks                                                                                 13               78.4            149.8
 Debtors                                                                                14              145.9            186.6
 Financial assets                                                                       12               86.6             74.8
 Cash and liquid resources                                                           30(c)/(i)          828.0          1,086.5
-------------------------------------------------------------------------------------------------------------------------------
                                                                                                      1,138.9          1,497.7
 Convertible debt and guaranteed notes (amounts falling due within one year)            15             (471.4)          (796.3)
 Creditors (amounts falling due within one year)                                        16             (365.5)          (798.8)
-------------------------------------------------------------------------------------------------------------------------------
                                                                                                       (836.9)        (1,595.1)
-------------------------------------------------------------------------------------------------------------------------------
 Net current assets/(liabilities)                                                                       302.0            (97.4)
-------------------------------------------------------------------------------------------------------------------------------
 Total assets less current liabilities                                                                2,334.5          3,176.0
 Convertible debt and guaranteed notes (amounts falling due after one year)             15           (1,479.9)        (1,480.4)
 Creditors (amounts falling due after one year)                                         16              (29.2)          (236.2)
-------------------------------------------------------------------------------------------------------------------------------
 Net assets                                                                              2              825.4          1,459.4
-------------------------------------------------------------------------------------------------------------------------------
 CAPITAL AND RESERVES
 Called-up share capital                                                                17               22.0             19.9
 Share premium account                                                                                5,558.8          5,392.6
 Shares issuable                                                                                         17.7             18.0
 Capital conversion reserve fund                                                                          0.1              0.1
 Equity adjustment from foreign currency translation                                                    (12.2)           (25.0)
 Profit and loss account                                                                18           (4,761.0)        (3,945.6)
-------------------------------------------------------------------------------------------------------------------------------
 Shareholders' funds--equity                                                                            825.4          1,460.0
 Minority equity interests                                                              19                 --             (0.6)
-------------------------------------------------------------------------------------------------------------------------------
 Capital employed                                                                                       825.4          1,459.4
-------------------------------------------------------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

Garo Armen, chairman    G. Kelly Martin, president and chief executive officer

--------------------------------------------------------------------------------
86

--------------------------------------------------------------------------------

CONSOLIDATED STATEMENT OF CASH FLOWS

------------------------------------------------------------------------------------------------------------------------------
                                                                                                YEAR ENDED 31 DECEMBER
------------------------------------------------------------------------------------------------------------------------------
                                                                                              2003        2002          2001
                                                                                 NOTES          $M          $M            $M
------------------------------------------------------------------------------------------------------------------------------

 CASH FLOW FROM OPERATING ACTIVITIES                                             30(a)      (322.3)      259.6         524.6
------------------------------------------------------------------------------------------------------------------------------
 RETURNS ON INVESTMENTS AND SERVICING OF FINANCE
 Interest received                                                                            24.2        44.8          80.3
 Interest paid                                                                              (281.9)     (176.5)       (138.4)
------------------------------------------------------------------------------------------------------------------------------
 Cash outflow from returns on investments and servicing of finance                          (257.7)     (131.7)        (58.1)
------------------------------------------------------------------------------------------------------------------------------
 TAXATION                                                                                     (8.9)     ( 18.6)         (6.5)
------------------------------------------------------------------------------------------------------------------------------
 CAPITAL EXPENDITURE AND FINANCIAL INVESTMENT
 Additions to property, plant and equipment                                                  (33.7)     (170.2)       (120.8)
 Receipts from disposal of property, plant and equipment                                      27.9         8.6           2.0
 Payments to acquire intangible assets                                                      (144.8)     (315.5)       (286.7)
 Receipts from disposal of intangible assets                                                   0.5         9.4          11.2
 Payments to acquire Pharma Marketing/Autoimmune product royalty rights                     (297.6)     (121.0)           --
 Redemption of investment in Autoimmune                                                         --        38.5            --
 Sale of EPIL III investments in connection with the repayment of EPIL III
  debt                                                                                          --       148.0            --
 Payment under guarantee in connection with EPIL III sale of investments                        --      (141.6)           --
 Payments to acquire financial current assets                                                   --        (1.0)       (148.2)
 Sale and maturity of financial current assets                                                  --        83.9         143.3
 Payments to acquire financial fixed assets                                                  (13.9)     (191.2)       (624.3)
 Receipts from disposal of financial fixed assets                                            329.3        36.6          76.2
------------------------------------------------------------------------------------------------------------------------------
 Cash outflow from capital expenditure and financial investment                             (132.3)     (615.5)       (947.3)
------------------------------------------------------------------------------------------------------------------------------
 ACQUISITIONS AND DISPOSALS
 Cash paid on acquisitions                                                       30(d)          --          --          (9.5)
 Cash received on disposal of businesses                                         30(f)       546.9       361.3            --
 Cash received on disposal of subsidiaries                                       30(g)        46.1        81.8          41.9
------------------------------------------------------------------------------------------------------------------------------
 Cash inflow from acquisitions and disposals                                                 593.0       443.1          32.4
------------------------------------------------------------------------------------------------------------------------------
 Cash outflow before use of liquid resources and financing                                  (128.2)      (63.1)       (454.9)
------------------------------------------------------------------------------------------------------------------------------
 MANAGEMENT OF LIQUID RESOURCES                                                  30(b)        14.5       225.5         106.8
------------------------------------------------------------------------------------------------------------------------------
 FINANCING
 Proceeds from issue of share capital                                                        167.9         5.7         304.8
 Issue of loan notes                                                                         460.0          --       1,200.0
 Repurchase of LYONs                                                                        (687.5)     (126.9)           --
 Repayment of EPIL III debt                                                                     --      (160.0)           --
 Repayment of loans                                                                         ( 83.2)     (399.9)      ( 555.7)
 Bank borrowing                                                                                 --          --         342.8
------------------------------------------------------------------------------------------------------------------------------
 Cash (outflow)/inflow from financing                                                       (142.8)     (681.1)      1,291.9
------------------------------------------------------------------------------------------------------------------------------
 Net (decrease)/increase in cash                                                 30(c)      (256.5)     (518.7)        943.8
------------------------------------------------------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      87

FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)

-----------------------------------------------------------------------------------------------------
                                                                      YEAR ENDED 31 DECEMBER
-----------------------------------------------------------------------------------------------------
                                                                     2003         2002           2001
                                                       NOTES           $M           $M             $M
-----------------------------------------------------------------------------------------------------

 RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET DEBT
 (Decrease)/increase in cash for the period                      (256.5)      (518.7)          943.8
 Cash inflow from movement in liquid resources                    (14.5)      (225.5)         (106.8)
-----------------------------------------------------------------------------------------------------
                                                                 (271.0)      (744.2)          837.0
 Other borrowing                                                     --           --          (347.4)
 Repayment of loans                                                83.2        559.9          557.6
 Repurchase of LYONs                                              803.4        149.8             --
 Issue of loan notes                                             (460.0)          --       (1,200.0)
-----------------------------------------------------------------------------------------------------
 Change in net debt resulting from cash flows                     155.6        (34.5)        (152.8)
 Loans acquired with subsidiary undertaking                          --           --           (0.3)
 Non-cash movement--translation differences                        12.5         11.2           (1.4)
 Non-cash movement--notes                                         (18.0)         8.1          269.6
 Non-cash movement--other                                          (1.2)       (29.8)           1.1
-----------------------------------------------------------------------------------------------------
 Decrease/(increase) in net debt                      30(c)       148.9        (45.0)         116.2
-----------------------------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

--------------------------------------------------------------------------------
88

--------------------------------------------------------------------------------

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' FUNDS

-----------------------------------------------------------------------------------------------------------------------------------
                                                                                                     PROFIT
                                         NUMBER      SHARE        SHARE    SHARES      CAPITAL     AND LOSS TRANSLATION       TOTAL
                                      OF SHARES    CAPITAL      PREMIUM  ISSUABLE   CONVERSION      ACCOUNT  ADJUSTMENT      AMOUNT
                                              M         $M           $M        $M           $M           $M          $M          $M
-----------------------------------------------------------------------------------------------------------------------------------

 Balance at 31 December 2000              322.5       18.7      4,750.9      25.9          0.1        556.7       (36.8)    5,315.5
 Exercise of stock options and
  warrants                                 18.0        0.8        308.2        --           --           --          --       309.0
 Exchange of 4.75% Exchangeable
  Notes                                     9.1        0.4        324.2        --           --           --          --       324.6
 Stock issued as a result of
  acquisitions                              0.2         --          7.3      (7.3)          --           --          --          --
 Issue costs                                 --         --         (4.3)       --           --           --          --        (4.3)
 Equity adjustment from foreign
  currency translation                       --         --           --        --           --           --        (3.1)       (3.1)
 Retained loss                               --         --           --        --           --       (887.2)         --      (887.2)
-----------------------------------------------------------------------------------------------------------------------------------
 Balance at 31 December 2001              349.8       19.9      5,386.3      18.6          0.1       (330.5)      (39.9)    5,054.5
 Exercise of stock options and
  warrants                                  0.6         --          7.7        --           --           --          --         7.7
 Stock issued as a result of
  acquisitions                               --         --          0.6      (0.6)          --           --          --          --
 Issue costs                                 --         --         (2.0)       --           --           --          --        (2.0)
 Equity adjustment from foreign
  currency translation                       --         --           --        --           --           --        14.9        14.9
 Retained loss                               --         --           --        --           --     (3,615.1)         --    (3,615.1)
-----------------------------------------------------------------------------------------------------------------------------------
 Balance at 31 December 2002              350.4       19.9      5,392.6      18.0          0.1     (3,945.6)      (25.0)    1,460.0
 Exercise of stock options and
  warrants                                  0.8        0.1          2.5        --           --           --          --         2.6
 Stock issued as a result of
  acquisitions                               --         --          0.3      (0.3)          --           --          --          --
 Stock issued as a result of private
  offering                                 35.0        2.0        171.2        --           --           --          --       173.2
 Issue costs                                 --         --         (7.8)       --           --           --          --        (7.8)
 Equity adjustment from foreign
  currency translation                       --         --           --        --           --           --        12.8        12.8
 Retained loss                               --         --           --        --           --       (815.4)         --      (815.4)
-----------------------------------------------------------------------------------------------------------------------------------
 Balance at 31 December 2003              386.2       22.0      5,558.8      17.7          0.1     (4,761.0)      (12.2)      825.4
-----------------------------------------------------------------------------------------------------------------------------------

CONSOLIDATED STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

--------------------------------------------------------------------------------------------------
                                                                  YEAR ENDED 31 DECEMBER
--------------------------------------------------------------------------------------------------
                                                               2003            2002          2001
                                                                 $M              $M            $M
--------------------------------------------------------------------------------------------------

 Retained loss                                              (815.4)       (3,615.1)       (887.2)
 Equity adjustment from foreign currency translation          12.8            14.9          (3.1)
--------------------------------------------------------------------------------------------------
 Total recognised losses                                    (802.6)       (3,600.2)       (890.3)
--------------------------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      89

FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

COMPANY BALANCE SHEET

------------------------------------------------------------------------------------------
                                                          AT 31 DECEMBER   AT 31 DECEMBER
                                                                    2003             2002
                                                NOTES                 $M               $M
------------------------------------------------------------------------------------------

 FIXED ASSETS
 Intangible assets                                 31               76.1             88.8
 Tangible assets                                   31               14.4             17.7
 Financial assets                                  31            2,268.1          2,699.2
------------------------------------------------------------------------------------------
                                                                 2,358.6          2,805.7
------------------------------------------------------------------------------------------
 CURRENT ASSETS
 Debtors                                           31                9.9             19.4
 Cash and liquid resources                                          21.5            182.8
------------------------------------------------------------------------------------------
                                                                    31.4            202.2
 Creditors (amounts falling due within one year)   31             (888.5)        (1,536.4)
------------------------------------------------------------------------------------------
 Net current liabilities                                          (857.1)        (1,334.2)
------------------------------------------------------------------------------------------
 Total assets less current liabilities                           1,501.5          1,471.5
 Creditors (amounts falling due after one year)    31              (13.5)           (12.1)
------------------------------------------------------------------------------------------
 Net assets                                                      1,488.0          1,459.4
------------------------------------------------------------------------------------------
 CAPITAL AND RESERVES
 Called-up share capital                           17               22.0             19.9
 Share premium account                                           5,558.8          5,392.6
 Shares issuable                                                    17.7             18.0
 Capital conversion reserve fund                                     0.1              0.1
 Profit and loss account                           18           (4,110.6)        (3,971.2)
------------------------------------------------------------------------------------------
 Shareholders' funds--equity                                     1,488.0          1,459.4
------------------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

Garo Armen, chairman    G. Kelly Martin, president and chief executive officer

--------------------------------------------------------------------------------
90

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

1 SIGNIFICANT ACCOUNTING POLICIES

The financial statements are prepared in U.S. dollars under the historical cost
convention and in accordance with Irish GAAP and comply with the Financial
Reporting Standards ("FRS") of the Accounting Standards Board, as promulgated
by the Institute of Chartered Accountants in Ireland. Where there are
significant differences to U.S. GAAP, these have been described in Note 33 to
the Consolidated Financial Statements.

The following accounting policies have been applied consistently in dealing
with items which are considered material in relation to the Company's financial
statements.

A BASIS OF CONSOLIDATION AND PRESENTATION OF FINANCIAL INFORMATION

The Consolidated Financial Statements include the accounts of Elan and all of
its subsidiary undertakings and its share of profits or losses of associated
undertakings. Associated undertakings are accounted for under the equity method
of accounting. All significant intercompany profits, transactions and account
balances have been eliminated.

The Company has made significant losses during the last three financial years.
However, the directors, having made inquiries, believe that Elan has adequate
resources to continue in operational existence for the foreseeable future and
that it is appropriate to continue to adopt the going concern basis in
preparing the financial statements.

B DESCRIPTION OF BUSINESS

Elan, an Irish public limited company, is a neuroscience-based biotechnology
company headquartered in Dublin, Ireland that is focused on discovering,
developing, manufacturing and marketing advanced therapies in neurology,
autoimmune diseases and severe pain.

On 12 February 2004, Elan announced the formal completion of its recovery plan.
The recovery plan had been announced on 31 July 2002 to restructure Elan's
businesses, assets and balance sheet in order to enable it to meet its
financial commitments. As a cornerstone of the recovery plan, Elan turned its
focus to three core therapeutic areas: neurology, autoimmune diseases and
severe pain. During the course of the recovery plan, Elan was organised in two
business units, Core Elan and Elan Enterprises. With the completion of the
recovery plan, Elan announced the end of operations for its Elan Enterprises
business unit.

In February 2004, the Company's operations were reorganised into two business
units: Biopharmaceuticals and Global Services and Operations (GS&O).
Biopharmaceuticals engages in biopharmaceutical research and development
activities, and pharmaceutical commercial activities. Biopharmaceutical research
and development activities include the discovery and development of products in
the therapeutic areas of neurology, autoimmune diseases and severe pain. Elan's
pharmaceutical commercial activities include the marketing of neurology and pain
management products and hospital and specialty products. GS&O focuses on product
development and manufacturing to provide technology platforms that address the
drug delivery challenges of the pharmaceutical industry. In this amendment the
Company has recast all prior period financial information as presented in our
Form 20-F originally filed for 2003 to reflect this change in segmentation (see
Note 2 to the Company's Consolidated Financial Statement).

Since 1996, Elan has pursued collaborations with biotechnology, drug delivery
and pharmaceutical companies through a programme referred to as "the business
venture programme". Elan has not entered into any new business ventures under
the business venture programme since mid-2001. All business ventures have been
terminated, restructured or are now inactive. As a consequence, Elan does not
expect to provide any additional financing to the business ventures and
business venture parents. See Note 26 to the Consolidated Financial Statements
for a summary of the investments made and licence fees received from the
business venture arrangements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      91

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Elan has in the past entered into risk-sharing arrangements. Please refer to
Note 24 to the Consolidated Financial Statements for information on Elan's
risk-sharing arrangements. These arrangements have been terminated and Elan
will not earn any revenues from these risk-sharing arrangements or upfront
licence fees from business ventures in the future.

The composition of Elan's revenue for 2003, 2002 and 2001 is described below in
Note 1c to the Consolidated Financial Statements.

C REVENUE

Elan's revenues are derived from a number of different sources and are
classified within the categories of product revenue and contract revenue.
Revenue is shown net of value added tax and other sales taxes, trade discounts
and rebates.

Product revenue includes (i) the sale of products, (ii) royalties, (iii) the
sales of product rights and related inventory (referred to as product disposals
and product rationalisations), and (iv) product co-promotion, marketing and
similar activities.

The sale of products consists of the sale of pharmaceutical drugs and
diagnostic products primarily to wholesalers and physicians. Royalties arise
when Elan receives a percentage of revenue on a product marketed by a third
party. Revenue from the sale of product rights and related inventory consists
of the proceeds from the disposal of products, inventory and intellectual
property less the unamortised cost of the related intangible assets. Revenue
from product co-promotion, marketing and similar activities consists of the
reimbursement of commercialisation expenses from Elan's risk-sharing
arrangements. Elan had two risk-sharing arrangements which were with Pharma
Marketing and Autoimmune.

Product revenue from the sale of products is recognised when title passes, net
of applicable estimated discounts, sales returns, rebates and charge-backs.
Other product revenues are recognised based on the terms of the applicable
contract. Estimated sales returns, pursuant to rights of return granted to the
Company's customers, are reflected as a reduction of revenue in the same period
that the related sales are recorded. The sales returns provisions are based on
actual experience, although in certain situations, for example, a new product
launch or at patent expiry, further judgement may be required. These amounts
are included in other current liabilities (rebates) or deducted from trade
debtors (other discounts). Additionally, revenue is also recorded net of
provision, made at the time of sale for estimated cash discounts, rebates and
charge-backs. The Company enters into contracts with certain managed care
organisations to provide access to the Company's products. Based on a managed
care organisation's market share performance and utilisation of the Company's
products, the organisation receives rebates from the Company. In addition, the
Company is bound by certain laws and regulations to provide product at a
discounted rate to Medicaid recipients. Medicaid rebates are paid to each state
in the United States based on claims filed by pharmacies that provide the
Company's products to Medicaid recipients at the reduced rate. Charge-backs are
amounts paid to reimburse wholesalers for sales to third parties at reduced
prices based on contracts the Company negotiates. Cash discounts are provided
to customers that pay their invoice within a certain time period.

Contract revenue includes (i) licence fees, (ii) research revenue and (iii)
contract revenue from risk-sharing arrangements. Contract revenue arises from
contracts to perform research and development services on behalf of clients
and/or technology licensing and business ventures. Contract revenue is
recognised when earned and non-refundable, and when Elan has no future
obligation with respect to the revenue, in accordance with the terms prescribed
in the applicable contract.

Licence fees are up-front or milestone payments for intellectual property and
technology owned by Elan. Research revenue consists of payments or milestones
arising from research and development activities performed by Elan on behalf of
third parties. Contract revenue from risk-sharing arrangements consists of the
reimbursement of research and development costs by Pharma Marketing and
Autoimmune.

The composition of Elan's revenue for 2003, 2002 and 2001 was as follows:

                           2003           2002           2001
                             $M             $M             $M
--------------------------------------------------------------

 Product revenue          712.6        1,204.5        1,407.0
 Contract revenue          49.5          128.5          333.7
--------------------------------------------------------------
 Total revenue            762.1        1,333.0        1,740.7
--------------------------------------------------------------

--------------------------------------------------------------------------------
92

--------------------------------------------------------------------------------

Product revenue can be further analysed as follows:

                                    2003         2002         2001
                                      $M           $M           $M
------------------------------------------------------------------

 PRODUCT REVENUE
 Retained products(1)              266.2        221.5        246.1
 Divested products(1)              446.4        920.2      1,003.2
 Risk-sharing arrangements           --          62.8        157.7
------------------------------------------------------------------
                                   712.6      1,204.5      1,407.0
------------------------------------------------------------------

(1)   Product revenue from retained products and divested products reflects the
      fiscal 2004 sale of several pharmaceutical businesses and products. See
      Note 34 and Note 6 to Elan's Consolidated Financial Statements.

Divested products includes products divested since the beginning of 2001, and
products which are currently subject to divestment agreements. Retained
products includes products that were not divested and that are not subject to
divestment agreements. Included in divested product revenue for 2003, 2002 and
2001 were exceptional revenues of $Nil, $172.5 million and $231.4 million,
respectively, arising from product disposals and rationalisations. These
revenues represent the proceeds, net of the unamortised cost of the related
intangible assets, arising from the disposal of products during 2002 and 2001.

Contract revenue can be further analysed as follows:

                                      2003       2002         2001
                                        $M         $M           $M
------------------------------------------------------------------

 CONTRACT REVENUE
 Licence fees                           --        7.1        173.6
 Risk-sharing arrangements              --       37.2         58.7
 Research revenues/milestones         49.5       84.2        101.4
------------------------------------------------------------------
                                      49.5      128.5        333.7
------------------------------------------------------------------

Contract revenue from business venture arrangements, consisting of up-front
licence fees and research revenue, was as follows:

                              2003        2002         2001
                                $M          $M           $M
-----------------------------------------------------------

 Up-front licence fees          --          --        172.5
 Research revenue              3.7        13.4         15.0
-----------------------------------------------------------
 Total                         3.7        13.4        187.5
-----------------------------------------------------------

Elan made initial investments in the business venture arrangements of $Nil,
$Nil and $229.2 million for 2003, 2002 and 2001, respectively. Elan made
subsequent investments in the business venture parents of $7.1 million, $83.4
million and $92.2 million for 2003, 2002 and 2001, respectively. In addition,
Elan expensed $3.0 million, $23.9 million and $24.6 million of subsequent
funding to the business ventures in 2003, 2002 and 2001, respectively.

D EXCEPTIONAL ITEMS

Exceptional items are those items that in management's judgement are material
items which derive from events or transactions that fall within the ordinary
activities of the Group and which individually or, if of a similar type, in
aggregate, need to be disclosed by virtue of their size or incidence.

The principal items classified as exceptional items include exceptional
revenues recorded on the disposal of products and gains or losses recorded on
the disposal of businesses, tangible and intangible asset impairments, purchase
of royalty rights, severance and relocation costs, losses from litigation or
regulatory actions including shareholders litigation and SEC investigation, and
investment gains, losses and impairments (including those related to
investments in business ventures and business venture parents). These items
have been treated consistently from period to period. Management believes that
disclosure of exceptional items is meaningful because it provides additional
information in relation to these material items.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      93

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

E DISCONTINUED OPERATIONS

A discontinued operation is classified as an operation of the business which is
(i) sold or terminated and the sale or termination has been completed during
the year or within three months following the year end, (ii) the former
activities have ceased permanently, (iii) the operation had a material effect
on the nature and focus of the business and (iv) its financial results are
clearly distinguishable.

F TANGIBLE FIXED ASSETS AND IMPAIRMENT

Tangible fixed assets are stated at cost less accumulated depreciation.
Depreciation of tangible fixed assets is computed using the straight-line
method based on estimated useful lives at the following annual rates:

                                    %
-------------------------------------

 Buildings                   2.5--6.6
-------------------------------------
 Leasehold improvements    Lease term
-------------------------------------
 Plant and equipment            5--50
-------------------------------------

The average depreciation rate for buildings is 3% and for plant and equipment
is 12%.

Where events or circumstances are present which indicate that the carrying
amount of a tangible asset may not be recoverable, the Company estimates the
net realisable value (estimated sales proceeds less costs to sell) or the value
in use (present value of future cash flows) expected to result from use of the
asset and its eventual divestment. The recoverable amount is the higher of net
realisable value and value in use. Where the recoverable amount is less than
the carrying amount of the asset, the Company recognises an impairment loss
which is charged to the profit and loss account. Otherwise, no loss is
recognised.

G INTANGIBLE FIXED ASSETS AND IMPAIRMENT

Patents, licences, acquired IP and goodwill are stated at the lower of cost or
valuation. Patents and licences are amortised over their expected useful lives,
which range between 2 years and 20 years. The average amortisation period for
patents and licences is approximately 14 years. Goodwill arising on
acquisitions since 1998 is capitalised and amortised to the profit and loss
account over the period during which the benefits are expected to accrue, but
in no case greater than 20 years. The average amortisation period for goodwill
is 18 years. Prior to 1 January 1998, goodwill was written-off directly to
consolidated reserves in the year of acquisition. Acquired IP arising on
acquisitions is capitalised and amortised to the profit and loss account over
its estimated useful economic life. The useful economic life commences upon
generation of product revenue relating to the acquired IP.

Where events or circumstances are present which indicate that the carrying
amount of an intangible asset may not be recoverable, the Company estimates the
net realisable value (estimated sales proceeds less costs to sell) or the value
in use (present value of future cash flows) expected to result from use of the
asset and its eventual divestment. The recoverable amount is the higher of net
realisable value and value in use. Where the recoverable amount is less than
the carrying amount of the asset, the Company recognises an impairment loss
which is charged to the profit and loss account. Otherwise, no loss is
recognised.

H STOCKS

Stocks are valued at the lower of cost or market value. Cost in the case of raw
materials and supplies is calculated on a first-in, first-out basis and
comprises the purchase price, including import duties, transport and handling
costs and any other directly attributable costs, less trade discounts. Cost in
the case of work-in-progress and finished goods comprises direct labour,
material costs and attributable overheads.

I RESEARCH AND DEVELOPMENT

Research and development expenditure is charged to the profit and loss account
in the period in which it is incurred.

J TAXATION

Current tax, including Irish corporation tax and foreign taxes, is provided on
the Group's taxable profits, at amounts expected to be paid (or recovered)
using the tax rates and laws that have been enacted or substantially enacted by
the balance sheet date. Deferred taxation is recognised in full in respect of
timing differences that have originated but not reversed at the balance sheet
date.

--------------------------------------------------------------------------------
94

--------------------------------------------------------------------------------

K FOREIGN CURRENCIES AND TRANSLATION OF SUBSIDIARY AND ASSOCIATED UNDERTAKINGS

Transactions in foreign currencies are recorded at the rate ruling at the date
of the transaction. The resulting monetary assets and liabilities are
translated into U.S. dollars at exchange rates prevailing at the balance sheet
date. Profits and losses are dealt with in the profit and loss account and,
where material, they are separately disclosed.

The assets and liabilities of subsidiary undertakings are translated using
year-end rates and income is translated at average rates. The cumulative effect
of exchange differences arising on consolidation of the net investment in
overseas subsidiaries and associates are taken directly to reserves through the
Consolidated Statement of Total Recognised Gains and Losses.

L DERIVATIVE FINANCIAL INSTRUMENTS

The Company enters into transactions in the normal course of business using a
variety of financial instruments in order to hedge against exposures to
fluctuating exchange and interest rates.

Derivative financial instruments are utilised to mitigate interest rate and
currency exposures. Forward currency contracts and options and interest rate
derivatives are marked to market at each balance sheet date and the resulting
gains and losses are recognised in the profit and loss account. Gains and
losses on derivative financial instruments which qualify as hedges are
recognised in the profit and loss account when realised as an offset to the
related income or expense. The carrying value of derivative financial
instruments is generally reported within current assets or other current
liabilities.

M FINANCIAL ASSET INVESTMENTS AND IMPAIRMENT

Financial asset investments, other than associated undertakings, are stated at
cost less provision for impairment in value. The carrying values of financial
assets are assessed for impairment using established financial methodologies,
including quoted market prices for quoted equity securities. Unquoted equity
investments and non-traded securities of public entities are assessed using
methodologies including the Black-Scholes option-pricing model, the valuation
achieved in the most recent private placement by an investee, an assessment of
the impact of general private equity market conditions, and discounted
projected future cash flow models. The factors affecting carrying values
include both general financial market conditions for pharmaceutical and
biotechnology companies and factors specific to a particular company.

Financial current asset investments held for trading purposes are stated at
market value with interest and similar income taken to the profit and loss
account on a receivable basis. Other financial current asset investments are
accounted for on an amortised cost basis.

Investments in associated undertakings are accounted for under the equity
method where the Company holds voting equity in the investee and exercises
significant influence over the operating and financial policies of the
investee. Significant influence may exist even if the Company owns less than
20% of the investee's equity depending on the existence of factors such as
representation on the board of directors, participation in policy making
processes, material intercompany transactions, interchange of managerial
personnel or technological dependency. Certain circumstances, such as majority
ownership by another company, can offset the impact of such factors. The
determination to use cost or equity accounting requires a significant degree of
judgement on the facts and circumstances of a particular investment. Financial
asset investments which are accounted for under the equity method are stated at
cost, adjusted for the Company's share of the earnings or losses of the
investee after the date of investment, less any provision for impairment in
value.

N FINANCING COSTS

Debt finance costs are allocated to financial reporting periods over the term
of the related debt at a constant rate on the carrying amount. The carrying
amount of debt includes related financing costs.

O PENSIONS

The regular cost of providing benefits under defined benefit plans is charged
to the profit and loss account over the service lives of the members of the
schemes. The regular costs are determined in consultation with independent,
external, qualified actuaries. Variations from regular costs, where they arise,
are allocated to operating profit/(loss) over the expected remaining service
lives of the members.

The costs of providing defined contribution benefit plans are expensed as
incurred.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      95

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

P LEASING

Tangible fixed assets, acquired under a lease which transfers substantially all
of the risks and rewards of ownership to the Company, are capitalised as a
fixed asset. Amounts payable under such leases (finance leases), net of finance
charges, are shown as short or medium term borrowings as appropriate. Finance
charges on finance leases are charged to the profit and loss account over the
term of the lease to give a constant rate of charge in proportion to the
capital balances outstanding. Rentals on operating leases are charged to the
profit and loss account as incurred.

Q STOCK COMPENSATION

Stock option compensation expense is the difference between the market value of
shares at the date of the option grant and the amount of the consideration, if
any, that participants may be required to pay for the shares. The intrinsic
cost of awards to employees that take the form of shares or rights to shares
are recognised over the period of the employee's related performance. Where
there are no performance criteria, the cost is recognised when the employee
becomes unconditionally entitled to the shares.

R FINANCE CHARGES AND PRODUCT ACQUISITION ACCRUALS

Deferred and contingent payments on product acquisitions are recognised in
creditors on a time-discounted basis. The Company accrues such amounts where
payment is probable. Such amounts include contingent payments based on future
product revenues and future option payments that the Company may make to
acquire such products. A related finance charge is included annually in the
profit and loss account.

S RISKS AND UNCERTAINTIES

The Company is subject to certain risks and uncertainties arising from a number
of factors including competition, government regulation, litigation, liquidity
and financing, continued successful licensing and marketing, third party
reimbursement, pricing pressure, unpredictability of patent protection, the
value of its investments and other assets, unpredictability of product
approvals, tax reform and environmental liabilities. The Company makes a
provision for these risks and uncertainties when it has a present obligation as
a result of a past event in respect of which it is probable that a transfer of
economic benefits will be required to settle the obligation, and a reliable
estimate can be made of the amount, or the minimum amount, that will be
required to settle the obligation.

T USE OF ESTIMATES

The preparation of the Consolidated Financial Statements in conformity with
Irish GAAP requires management to make estimates and assumptions that affect
reported amounts and disclosures in these financial statements. Actual results
could differ from those estimates.

2 SEGMENT INFORMATION

During 2003, Elan's business was conducted through two business units, Core
Elan and Elan Enterprises. With the completion of the recovery plan on 12
February 2004, Elan announced the end of operations for its Elan Enterprises
business unit.

In February 2004, the Company's operations were reorganised into two business
units: Biopharmaceuticals and GS&O. In this reorganization, the Company's Core
Elan business, with the exception of its drug delivery businesses, now forms the
Biopharmaceuticals business unit. The remaining businesses in Elan Enterprises
comprising principally of drug delivery businesses and the drug delivery
business from Core Elan now form GS&O. All prior period financial information
has been recast to reflect the changes in segmentation. Biopharmaceuticals
engages in biopharmaceutical research and development activities, and
pharmaceutical commercial activities. Biopharmaceutical research and development
activities include the discovery and development of products in the therapeutic
areas of neurology, autoimmune diseases and severe pain. Elan's pharmaceutical
commercial activities include the marketing of neurology and pain management
products and hospital and specialty products. GS&O focuses on product
development and manufacturing to provide technology platforms that address the
drug delivery challenges of the pharmaceutical industry. In this amendment,
prior period financial information as presented in our Form 20-F as previously
filed for 2003, has been restated to reflect the new basis of segmentation.

--------------------------------------------------------------------------------
96

--------------------------------------------------------------------------------

A REVENUE BY GEOGRAPHICAL REGION WAS AS FOLLOWS:

                                                                               2003         2002         2001
                                                                                 $M           $M           $M
--------------------------------------------------------------------------------------------------------------

 GEOGRAPHICAL ORIGIN:
 Ireland                                                                      118.2        422.7        673.0
 Rest of Europe                                                                98.4         98.3         89.7
 United States                                                                543.6        804.5        928.4
 Other                                                                          1.9          7.5         49.6
--------------------------------------------------------------------------------------------------------------
 External revenue                                                             762.1      1,333.0      1,740.7
--------------------------------------------------------------------------------------------------------------
 DISTRIBUTION OF EXPORT REVENUE FROM IRELAND:
 United States                                                                 38.0        215.2        256.6
 Other                                                                         56.7        192.4        411.8
--------------------------------------------------------------------------------------------------------------
 Export revenue from Ireland                                                   94.7        407.6        668.4
--------------------------------------------------------------------------------------------------------------
 Export revenue from Ireland as a percentage of total external revenue           12%          31%          38%

B THE DISTRIBUTION OF OPERATING (LOSS)/PROFIT BY GEOGRAPHICAL AREA WAS AS
FOLLOWS:

                                        2003            2002          2001
                                          $M              $M            $M
---------------------------------------------------------------------------

 Ireland                              (678.9)       (1,860.8)       (636.2)
 Rest of Europe                        (36.1)          (37.5)        (29.7)
 United States                        (207.4)         (368.4)       (187.9)
 Other                                  (7.4)          (16.1)         31.4
---------------------------------------------------------------------------
                                      (929.8)       (2,282.8)       (822.4)
 Corporate costs                        (5.3)           (8.0)         (7.3)
---------------------------------------------------------------------------
 Total operating (loss)/profit        (935.1)       (2,290.8)       (829.7)
---------------------------------------------------------------------------

C THE DISTRIBUTION OF CONSOLIDATED NET ASSETS BY GEOGRAPHICAL AREA WAS AS
FOLLOWS:

                   AT 31 DECEMBER    AT 31 DECEMBER
                             2003              2002
                               $M                $M
---------------------------------------------------

 Ireland                  1,107.9           1,671.8
 Rest of Europe             (13.1)            102.0
 United States               39.4             242.3
 Bermuda                   (315.3)           (563.0)
 Other                        6.5               6.3
---------------------------------------------------
 Net assets                 825.4           1,459.4
---------------------------------------------------

D MAJOR CUSTOMERS

Cardinal Health, Amerisource Bergen and McKesson accounted for approximately
20%, 16% and 16%, respectively, of Elan's total revenue for 2003. Cardinal
Health, Amerisource Bergen and McKesson accounted for approximately 13%, 13%
and 12%, respectively, of Elan's total revenue for 2002. Cardinal Health and
Pharma Marketing accounted for approximately 14% and 11%, respectively, of
Elan's total revenue in 2001. No other customer accounted for more than 10% of
revenue in 2003, 2002 or 2001.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      97

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

E ANALYSIS BY CLASS OF BUSINESS

                                            BIOPHARMACEUTICALS                        GS&O
                                   ------------------------------------ --------------------------------
                                        2003         2002         2001       2003       2002       2001
                                          $M           $M           $M         $M         $M         $M
--------------------------------------------------------------------------------------------------------

 Total sales                           613.0      1,031.7      1,397.2      171.5      344.3      373.7
 Intersegment sales                     (0.4)        (7.2)        (6.0)     (22.0)     (35.8)     (24.2)
--------------------------------------------------------------------------------------------------------
 Sales to third parties                612.6      1,024.5      1,391.2      149.5      308.5      349.5
--------------------------------------------------------------------------------------------------------
 Operating loss                       (820.4)    (2,020.1)      (605.8)    (121.0)    (249.4)    (212.1)
 Intersegment loss/(profit)             (0.5)        (0.6)        (0.3)      12.1      (12.7)      (4.2)
--------------------------------------------------------------------------------------------------------
 External operating loss              (820.9)    (2,020.7)      (606.1)    (108.9)    (262.1)    (216.3)
--------------------------------------------------------------------------------------------------------
 External operating (loss)/profit
  before exceptional items            (281.2)      (361.5)        31.9      (71.9)    (125.0)     102.2
 Depreciation and amortisation         160.0        250.0        190.2       47.9       67.6       76.9
 Net assets                          1,096.6        851.8      2,807.2      316.9      772.7    1,257.1
 Capital expenditure (including
  acquisitions)                         24.5        150.5      1,174.3       24.3      131.8      154.3
--------------------------------------------------------------------------------------------------------

                                                  TOTAL
                                   ------------------------------------
                                        2003         2002         2001
                                          $M           $M           $M
-----------------------------------------------------------------------

 Total sales                           784.5      1,376.0      1,770.9
 Intersegment sales                    (22.4)       (43.0)       (30.2)
-----------------------------------------------------------------------
 Sales to third parties                762.1      1,333.0      1,740.7
-----------------------------------------------------------------------
 Operating loss                       (941.4)    (2,269.5)      (817.9)
 Intersegment loss/(profit)             11.6        (13.3)        (4.5)
-----------------------------------------------------------------------
 External operating loss              (929.8)    (2,282.8)      (822.4)
-----------------------------------------------------------------------
 External operating (loss)/profit
  before exceptional items            (353.1)      (486.5)       134.1
 Depreciation and amortisation         207.9        317.6        267.1
 Net assets                          1,413.5      1,624.5      4,064.3
 Capital expenditure (including
  acquisitions)                         48.8        282.3      1,328.6
-----------------------------------------------------------------------

(i)  Reconciliation of operating loss

                                 2003          2002        2001
                                   $M            $M          $M
----------------------------------------------------------------

 Segmental operating loss      (929.8)     (2,282.8)     (822.4)
 Corporate costs                 (5.3)         (8.0)       (7.3)
----------------------------------------------------------------
                               (935.1)     (2,290.8)     (829.7)
----------------------------------------------------------------

(ii)  Reconciliation of operating (loss)/profit before exceptional items

                                                                   2003        2002        2001
                                                                     $M          $M          $M
-----------------------------------------------------------------------------------------------

 Segmental operating (loss)/profit before exceptional items      (353.1)     (486.5)      134.1
 Corporate costs                                                   (5.3)       (8.0)       (6.0)
-----------------------------------------------------------------------------------------------
                                                                 (358.4)     (494.5)      128.1
-----------------------------------------------------------------------------------------------

(iii)  Reconciliation of net assets

                                       2003         2002         2001
                                         $M           $M           $M
---------------------------------------------------------------------

 Segmental net assets               1,413.5      1,624.5      4,064.3
 Corporate net assets                 354.4        671.3      1,238.6
 Interest bearing assets            1,032.6      1,479.4      2,846.7
 Interest bearing liabilities      (1,975.1)    (2,315.8)    (3,089.9)
---------------------------------------------------------------------
                                      825.4      1,459.4      5,059.7
---------------------------------------------------------------------

--------------------------------------------------------------------------------
98

--------------------------------------------------------------------------------

(iv) Reconciliation of depreciation and amortisation

                                                2003       2002       2001
                                                  $M         $M         $M
--------------------------------------------------------------------------

 Segmental depreciation and amortisation       207.9      317.6      267.1
 Corporate depreciation and amortisation         2.4        2.7        3.3
--------------------------------------------------------------------------
                                               210.3      320.3      270.4
--------------------------------------------------------------------------

(v) Reconciliation of capital expenditure

                                     2003       2002         2001
                                       $M         $M           $M
-----------------------------------------------------------------

 Segmental capital expenditure       48.8      282.3      1,328.6
 Corporate capital expenditure        0.3        1.9          1.8
-----------------------------------------------------------------
                                     49.1      284.2      1,330.4
-----------------------------------------------------------------

3 EXCEPTIONAL ITEMS

Exceptional items are those items that in management's judgement are material
items which derive from events or transactions that fall within the ordinary
activities of the Group and which individually or, if of a similar type, in
aggregate, need to be disclosed by virtue of their size or incidence.

The principal items classified as exceptional items include exceptional
revenues recorded on the disposal of products and gains or losses recorded on
the disposal of businesses, tangible and intangible asset impairments, purchase
of royalty rights, severance and relocation costs, losses from litigation or
regulatory actions including shareholders litigation and SEC investigation, and
investment gains, losses and impairments (including those related to
investments in business ventures and business venture parents). These items
have been treated consistently from period to period. Management believes that
disclosure of exceptional items is meaningful because it provides additional
information in relation to these material items.

The exceptional revenues and costs incurred in 2003, 2002 and 2001 are included
in the profit and loss account under the following statutory headings:

                                                      2003        2002        2001
                                                        $M          $M          $M
-----------------------------------------------------------------------------------

 Revenue                                                --      (172.5)     (227.8)
 Cost of sales                                         6.9        66.1        22.8
 Selling, general and administrative expenses        546.0     1,788.0     1,084.2
 Research and development expenses                    23.8       114.7        78.6
 Other ordinary activities                          (293.3)      139.1          --
 Net interest and other expense                       33.7     1,014.0       (25.9)
-----------------------------------------------------------------------------------
 Net exceptional charges                             317.1     2,949.4       931.9
-----------------------------------------------------------------------------------

2003

In 2003, Elan incurred net exceptional charges of $317.1 million.

The exceptional items for 2003 mainly relate to the implementation of Elan's
recovery plan and investment impairments. On 31 July 2002, Elan announced a
recovery plan to restructure its businesses, assets and balance sheet. Elan
decided to focus on three core therapeutic areas. These are neurology,
autoimmune diseases and severe pain. A key element of the recovery plan was the
divestment of businesses and products.

The exceptional charges and revenue in 2003 mainly relate to the:

o    Sale of businesses. The carrying value of these assets have been written
     down, where applicable, to their estimated recoverable amounts;

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                      99

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

o    Discontinuance of businesses;

o    Rationalisation and restructuring expenses incurred from a reduction in the
     scope of Elan's activities, a reduction in employee numbers and related
     write-downs in the carrying value of assets;

o    Simplification of Elan's business such as the termination of the Pharma
     Marketing risk-sharing arrangement; and

o    Termination, restructuring or cessation of activity in all of Elan's
     business ventures.

These exceptional costs have been included under the statutory format headings
to which they relate analysed as follows:

                                                            SELLING,     RESEARCH          OTHER
                                                COST     GENERAL AND          AND       ORDINARY          NET
                                            OF SALES  ADMINISTRATIVE  DEVELOPMENT     ACTIVITIES     INTEREST
                                                 (A)             (B)          (C)            (D)          (E)       TOTAL
                                                  $M              $M           $M             $M           $M          $M
-------------------------------------------------------------------------------------------------------------------------

 Acquired IP and goodwill impairment:
  Europe                                          --           108.2           --             --           --       108.2
  Dura                                            --            16.2           --             --           --        16.2
  Nanosystems                                     --            11.7           --             --           --        11.7
-------------------------------------------------------------------------------------------------------------------------
 Total acquired IP and goodwill impairment        --           136.1           --             --           --       136.1
-------------------------------------------------------------------------------------------------------------------------
 Product impairments:
  Myobloc                                         --            37.1           --             --           --        37.1
  All others                                      --             9.2          7.1             --           --        16.3
-------------------------------------------------------------------------------------------------------------------------
 Total product impairments                        --            46.3          7.1             --           --        53.4
-------------------------------------------------------------------------------------------------------------------------
 Purchase of Pharma Operating royalty
  rights                                          --           297.6           --             --           --       297.6
 Severance/relocation costs                      4.1            25.1          8.2             --           --        37.4
 Tangible fixed asset write-downs                3.4             9.3          1.7             --           --        14.4
 Gain on disposal of businesses                   --              --           --         (293.3)          --      (293.3)
 Waiver fee to EPIL II/III noteholders            --              --           --             --         16.8        16.8
 Investment impairments                           --              --           --             --        120.4       120.4
 Net gain on financial assets                     --              --           --             --       (106.3)     (106.3)
 Profit on repurchase of LYONs                    --              --           --             --         (1.6)       (1.6)
 Other                                          (0.6)           31.6          6.8             --          4.4        42.2
-------------------------------------------------------------------------------------------------------------------------
 Net exceptional charges                         6.9           546.0         23.8         (293.3)        33.7       317.1
-------------------------------------------------------------------------------------------------------------------------

(A) COST OF SALES

Exceptional cost of sales include $3.4 million on the impairment of certain
manufacturing fixed assets, severance/relocation costs of $4.1 million and
other exceptional cost of sales of $(0.6) million.

(B) SELLING, GENERAL AND ADMINISTRATIVE

Exceptional selling, general and administrative expenses were $546.0 million.
$182.4 million of the exceptional expenses relate to impairment charges arising
on write-downs of intangible assets. $297.6 million relates to the purchase of
royalty rights from Pharma Operating. For additional information on the
purchase of royalty rights from Pharma Operating, please refer to Note 24 to
the Consolidated Financial Statements. Other exceptional selling, general and
administrative expenses were $66.0 million. These include tangible fixed asset
write-downs of $9.3 million, severence/relocation costs of $25.1 million and
similar costs arising from the restructuring of the Group as part of the
recovery plan. They also include legal costs related to the SEC investigation,
shareholder litigation and litigation provisions.

In February 2004, Elan completed the sale of its European sales and marketing
business to Medeus. As a result, the related intangibles were written down to
their net realisable value at 31 December 2003. This resulted in an impairment
to goodwill of $108.2 million. The other goodwill impairment charge of $16.2
million related to Dura. Impairment charges to acquired IP arising from the
acquisition of Nanosystems was $11.7 million. Impairment charges to patents and
licences arising on write-downs of the product intangibles for

--------------------------------------------------------------------------------
100

--------------------------------------------------------------------------------

Myobloc amounted to $37.1 million. Other impairments to patents and licences
totalled $9.2 million. Each of these impairments arose due to changed
expectations for the related products.

(C) RESEARCH AND DEVELOPMENT

Exceptional research and development expenses were $23.8 million. These mainly
relate to product impairments of $7.1 million, severance/relocation costs of
$8.2 million and similar costs arising from the restructuring of the Group as a
part of the recovery plan.

(D) OTHER ORDINARY ACTIVITIES

Elan recognised a gain of $293.3 million on the sale of certain businesses as
part of the Group's recovery plan. In June 2003, Elan completed the sale of its
primary care franchise, comprising of Skelaxin and Sonata, to King. On
completion, Elan received a net cash payment of $510.9 million from King,
representing the total consideration, before agreed price adjustments and
expenses. The gain amounted to $284.8 million. In July 2003, Elan sold a
transdermal technology business to Nitto Americas for a cash consideration of
$45.0 million before expenses. The loss amounted to $30.3 million. In December
2003, Elan completed the sale of the Pain Portfolio business to aaiPharma. The
total consideration was $101.8 million, comprising a cash payment to Elan of
$50.4 million and the assumption, by aaiPharma, of $51.4 million of Elan's
product payment obligations to Roxane. Elan recorded a net gain of $40.2
million on the transaction. Other businesses divested by Elan in 2003 were its
operations in the Philippines and Taiwan, a Spanish primary care business, a
U.K. drug delivery business and an Italian manufacturing business. The total
net loss on these divestments amounted to $1.4 million.

(E) NET INTEREST

Exceptional net interest and other expense amounted to $33.7 million.

This includes a net gain of $1.6 million on the repurchase of $1,323.4 million
in principal amount at maturity of LYONs. These LYONs, having an accreted value
of $810.5 million at the date of purchase, were purchased at an aggregate cost
of $803.4 million, resulting in the net gain of $1.6 million after related
costs. For further information regarding the LYONs, please refer to Note 15 to
the Consolidated Financial Statements.

During 2003 the Company recognised a $120.4 million charge in relation to
investment impairments arising from Elan's investment portfolio, primarily
relating to investments in business ventures and business venture parents of
$4.0 million and $106.0 million, respectively.

During 2003 the Company recognised a net gain on financial assets of $106.3
million, primarily reflecting gains of $72.3 million on the disposal of Elan's
investment in Ligand.

On 10 November 2003, Elan announced that it had successfully completed a
private offering of $460.0 million in aggregate principal amount of 6.5%
Convertible Notes. In connection with this offering, a waiver fee of $16.8
million was paid to the holders of the EPIL II and EPIL III Notes.

2002

In 2002, Elan incurred net exceptional charges of $2,949.4 million.

The exceptional items for 2002 mainly relate to the implementation of Elan's
recovery plan, a significant decline during 2002 in the financial markets for
investments in emerging biotechnology, drug delivery and pharmaceutical
companies, and the introduction of generic competitors to some of Elan's
products. On 31 July 2002, Elan announced a recovery plan to restructure its
businesses, assets and balance sheet. Elan decided to focus on three core
therapeutic areas. These are neurology, autoimmune diseases and severe pain. A
key element of the recovery plan was the divestment of businesses and products.

The exceptional charges and revenue in 2002 mainly relate to the:

o  Sale of businesses and products. The carrying value of these assets have
been written down, where applicable, to their estimated recoverable amounts.
Exceptional revenue arises from the proceeds received on the disposal of
products;

o  Discontinuance of businesses or the decision not to exercise an option to
acquire a product, such as Elan's decision not to exercise its option to
acquire certain dermatology products from GSK;

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     101

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

o  Rationalisation and restructuring expenses incurred from a reduction in the
scope of Elan's activities, a reduction in employee numbers and related
write-downs in the carrying value of assets;

o  Simplification of Elan's business such as the termination of the Autoimmune
risk-sharing arrangement; and

o  Termination, restructuring or cessation of activity in Elan's business
ventures.

These exceptional revenues and costs have been included under the statutory
format headings to which they relate analysed as follows:

                                                                     SELLING,        RESEARCH        OTHER
                                                          COST    GENERAL AND             AND     ORDINARY         NET
                                            REVENUE   OF SALES ADMINISTRATIVE     DEVELOPMENT   ACTIVITIES    INTEREST
                                                (A)        (B)            (C)             (D)          (E)         (F)        TOTAL
                                                 $M         $M             $M              $M           $M          $M           $M
------------------------------------------------------------------------------------------------------------------------------------

 Product disposals and product
  rationalisations                           (172.5)       --              --              --            --         --       (172.5)
 Zanaflex inventory-generic competition          --      43.3              --              --            --         --         43.3
 Acquired IP and goodwill impairment:
  Dura                                           --        --           854.9              --            --         --        854.9
  Liposome                                       --        --           111.8              --            --         --        111.8
  Sano                                           --        --            89.8              --            --         --         89.8
  Quadrant                                       --        --            78.2              --            --         --         78.2
  Axogen                                         --        --            28.4              --            --         --         28.4
  Others                                         --        --            19.1            10.6            --         --         29.7
------------------------------------------------------------------------------------------------------------------------------------
 Total acquired IP and goodwill impairment       --        --         1,182.2            10.6            --         --      1,192.8
------------------------------------------------------------------------------------------------------------------------------------
 Product impairments:
  Pain Portfolio                                 --        --            86.3              --            --         --         86.3
  Myobloc                                        --        --            77.7              --            --         --         77.7
  Naprelan                                       --        --            35.7              --            --         --         35.7
  Myambutol                                      --        --            32.7              --            --         --         32.7
  Dermatology products                           --        --            29.8              --            --         --         29.8
  Frova                                          --        --            29.4              --            --         --         29.4
  Delsys                                         --        --              --            45.7            --         --         45.7
  All others                                     --       8.0            62.9            13.6            --         --         84.5
------------------------------------------------------------------------------------------------------------------------------------
 Total product impairments                       --       8.0           354.5            59.3            --         --        421.8
------------------------------------------------------------------------------------------------------------------------------------
 Purchase of Autoimmune royalty rights           --        --           121.0              --            --         --        121.0
 Severance/relocation costs                      --       8.4            23.2            19.7            --         --         51.3
 Litigation provisions                           --        --            19.0              --            --         --         19.0
 Tangible fixed asset write-downs                --       5.7            28.3            11.6            --         --         45.6
 Gain on disposal of businesses                  --        --              --              --         (77.9)        --        (77.9)
 Loss on sale of securities/guarantee            --        --              --              --         217.0         --        217.0
 Investment impairments                          --        --              --              --            --    1,045.9      1,045.9
 Net loss on financial assets                    --        --              --              --            --       10.0         10.0
 Profit on redemption of LYONs                   --        --              --              --            --      (37.7)       (37.7)
 Other                                           --       0.7            59.8            13.5            --       (4.2)        69.8
------------------------------------------------------------------------------------------------------------------------------------
 Net exceptional charges                     (172.5)     66.1         1,788.0           114.7         139.1    1,014.0      2,949.4
------------------------------------------------------------------------------------------------------------------------------------

(A) REVENUE

Exceptional product revenue of $172.5 million for 2002 includes $154.7 million
from product disposals arising from Elan's recovery plan, as well as $17.8
million relating to product rationalisations.

On 9 December 2002, Elan announced the amendment of the terms of its
development, licence and supply agreement with Ligand regarding Avinza. Elan
received a cash payment of $100.0 million from Ligand, in return for a
reduction in the ongoing royalty rate from the previous level of 30% of net
sales of Avinza in the United States and Canada to approximately 10%. In
addition, Elan agreed to forego its option to negotiate a co-promotion
agreement with Ligand for Avinza in the United States and Canada. Elan will
continue to manufacture the product in its Gainesville facility. Net of the
write-off of the related intangible assets, Elan recorded exceptional product
revenue of $75.6 million on the closing of this transaction.

--------------------------------------------------------------------------------
102

--------------------------------------------------------------------------------

On 3 October 2002, Elan announced that it sold its rights to Actiq in twelve
territories, principally in Europe, to Anesta. At the date of disposal, Actiq
was marketed by Elan in the United Kingdom, Ireland and Germany. Net of the
write-off of the related intangible assets, Elan recorded exceptional product
revenue of $40.3 million on the closing of this transaction.

On 23 August 2002, Elan announced a licensing agreement with Watson for
exclusive marketing rights to the 30 mg and 60 mg dosage strengths of Elan's
extended-release nifedipine tablets in the United States. Elan received $45.0
million in cash from Watson. Elan will continue to manufacture the products in
its Athlone facility. Net of the write-off of the related intangible assets,
Elan recorded exceptional product revenue of $38.8 million on the closing of
this transaction.

(B) COST OF SALES

Exceptional cost of sales were $66.1 million in 2002, including a charge of
$43.3 million related to the write-off of Zanaflex inventories due to the
impact of generic competition during 2002. Other exceptional cost of sales
includes $8.0 million on the write down of the intangible asset for Mysoline,
following generic competition for this product, severance/relocation costs of
$8.4 million, $5.7 million on the impairment of tangible fixed assets, and
other exceptional cost of sales of $0.7 million.

(C) SELLING, GENERAL AND ADMINISTRATIVE

Exceptional selling, general and administrative expenses were $1,788.0 million.
$1,536.7 million of the exceptional expenses relate to impairment charges
arising on write-downs of intangible assets. Other exceptional selling, general
and administrative expenses were $251.3 million. These include the purchase of
royalty rights from Autoimmune, fixed asset write-downs and similar costs
arising from the restructuring of the Group as part of the recovery plan. They
also include legal costs related to the SEC investigation, shareholder
litigation and litigation provisions.

Impairment charges to goodwill relating to the acquisitions of Dura, Liposome,
Quadrant and Sano were $854.9 million, $111.8 million, $78.2 million and $2.4
million, respectively. Impairment charges to acquired IP arising from the
acquisitions of Sano and Axogen were $87.4 million and $28.4 million,
respectively. Other impairments to goodwill totalled $19.1 million. Impairment
charges to patents and licences arising on write-downs of the product
intangibles for the Pain Portfolio, Myobloc, Naprelan, Myambutol, dermatology
products and Frova were $86.3 million, $77.7 million, $35.7 million, $32.7
million, $29.8 million and $29.4 million, respectively. Other impairments to
patents and licences totalled $62.9 million.

Dura

Elan acquired Dura in November 2000 for $1,590.7 million. Dura was a specialty
pharmaceutical company engaged in the marketing and sale of prescription
products for the treatment of infectious diseases and respiratory conditions.
The Dura acquisition added over 500 hospital and primary care sales
representatives to Elan's sales and marketing infrastructure and broadened
Elan's portfolio of marketed products. The purchase price was primarily
allocated to goodwill and patents and licences. In 2002, Elan wrote down
goodwill relating to the acquisition of Dura by $854.9 million. Elan acquired
Dura in order to significantly expand its sales and marketing infrastructure.
Elan's recovery plan aimed to create a research and development based
biopharmaceutical company focused on neurology, autoimmune diseases and severe
pain. Therefore, Elan decided to significantly reduce its sales and marketing
infrastructure. For example, during 2002, Elan decided to dispose of its
primary care franchise and related infrastructure. As a result of such
reductions in Elan's sales and marketing capability, the carrying value of the
Dura goodwill was impaired.

Liposome

Elan acquired Liposome in May 2000 for $731.8 million, which included a
milestone payment of $54.0 million paid on the receipt of marketing and pricing
approval for Myocet in certain countries of the EU. Liposome was a
biotechnology company engaged in the development, manufacturing and marketing
of therapeutic products to treat cancer and related diseases. The purchase
price was primarily allocated to goodwill and patents and licences. In 2002,
under its recovery plan, Elan disposed of its U.S., Canadian and any Japanese
rights to Abelcet, and certain related assets, and allocated $119.0 million of
goodwill to the sale of the Abelcet business based on the estimated relative
fair value of the Abelcet rights disposed. In 2002, Elan wrote down the
remaining goodwill arising from the acquisition of Liposome by $111.8 million,
as under its recovery plan Elan decided to close its oncology research and
development business. The residual value for goodwill of $86.8 million was
supported by European rights to Abelcet and Myocet.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     103

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Sano

Elan acquired Sano in February 1998 for $434.6 million. Sano was developing
transdermal drug delivery products. The purchase price was primarily allocated
to acquired IP. In 2002, Elan wrote down acquired IP and goodwill arising from
the acquisition of Sano by $87.4 million and $2.4 million, respectively, as
under its recovery plan Elan decided to dispose of its transdermal business.
This business was sold to Nitto Americas in July 2003.

Quadrant

Elan acquired Quadrant in December 2000 for $86.0 million. Quadrant was a drug
delivery company with proprietary formulation technology applicable to
pulmonary, oral and parenteral routes of administration. The purchase price was
primarily allocated to goodwill. In 2002, Elan wrote down goodwill arising from
the acquisition of Quadrant by $78.2 million to $Nil, as under its recovery
plan Elan decided to dispose of or close the Quadrant business. This business
was sold to a company managed by former employees of the business in July 2003.

Axogen

Elan acquired Axogen in December 1999 for $268.4 million. The purchase price
was primarily allocated to patents and licences and acquired IP. In 2002, Elan
wrote down acquired IP relating to Myobloc, arising from the acquisition of
Axogen, by $28.4 million. Elan also wrote down $77.7 million in respect of
other Myobloc intangible assets. The carrying value of Myobloc was written down
due to lower than expected revenue from this product for 2002 and changed
expectations for this product.

Other products

The intangible asset for the Pain Portfolio was written down due to supply
difficulties since its acquisition in 2001, leading to diminished selling
support from Elan as well as changed commercial expectations related to generic
competition. Naprelan and Myambutol have been written down due to the impact of
generic competition on these products in 2002 and reduced projected revenue and
profitability from these products. Frova was written down to reflect reduced
projected revenue and profitability from this product. In June 2002, Elan
elected not to exercise its purchase option to acquire certain dermatology
products from GSK. This resulted in rights to all products reverting to GSK at
the end of 2002. As a result of this decision, Elan wrote down the related
product intangible by $29.8 million to $Nil.

Autoimmune

In July 2002, Elan announced the termination of all agreements relating to the
risk-sharing arrangement with Autoimmune. The royalty obligations to Autoimmune
were terminated. The total consideration for the royalty rights was $121.0
million which, after taking account of the redemption of Elan's investment of
$38.5 million in Autoimmune, resulted in a net cash cost of $82.5 million. Elan
expensed $121.0 million as an exceptional selling, general and administration
expense arising from the acquisition of Autoimmune.

Litigation

Elan recorded a provision during 2002 of $19.0 million relating to litigation
with Schwarz, Allergan and shareholder derivative actions. For additional
information on these litigations, please refer to Note 25 to the Consolidated
Financial Statements.

(D) RESEARCH AND DEVELOPMENT

Exceptional research and development expenses were $114.7 million. These mainly
relate to product and goodwill impairments of $59.3 million and $10.6 million,
respectively, together with fixed asset write-downs of $11.6 million and
severance/relocation costs.

In September 2001, Elan acquired Delsys, for $50.0 million. Delsys was formed
in 1995 and was engaged in developing novel manufacturing technology. During
2002, Elan recorded an impairment charge for the intangible assets relating to
Delsys of $45.7 million, as under its recovery plan, Elan decided to close
Delsys.

(E) OTHER ORDINARY ACTIVITIES

Elan recognised a gain of $77.9 million on the disposal of Athena Diagnostics
and the Abelcet business. In November 2002, Elan completed the sale of its
U.S., Canadian and any Japanese rights to Abelcet, and certain related assets,
to Enzon. Elan received a net

--------------------------------------------------------------------------------
104

--------------------------------------------------------------------------------

cash payment of $360.0 million from Enzon, representing the total
consideration, after agreed price adjustments. The gain amounted to $12.7
million. In December 2002, Elan together with the other stockholders of Elan's
subsidiary, Athena Diagnostics, completed the sale of all of the outstanding
stock of Athena Diagnostics to Behrman. Elan realised net cash proceeds of
$81.8 million and a net gain of $65.2 million.

In its 2002 Annual Report and Form 20-F, Elan restated its U.S. GAAP financial
results as of and for the fiscal year ended 31 December 2001 to consolidate
EPIL III from its date of establishment on 15 March 2001. Under U.S. GAAP, EPIL
III had been historically accounted for by Elan as a qualifying special purpose
entity and was not, therefore, consolidated. In addition, in its 2002 Annual
Report and Form 20-F, Elan adjusted its previously announced unaudited U.S.
GAAP financial information as of and for the fiscal year ended 31 December 2002
to give effect to the consolidation of EPIL III and to consolidate Shelly Bay,
an entity established by Elan, from 29 June 2002 through 30 September 2002.
Shelly Bay acquired certain financial assets from EPIL III on 29 June 2002.
Under Irish GAAP, EPIL III had been accounted for as a consolidated subsidiary
since its date of establishment in accordance with the requirements of FRS 5.
Therefore, the 2001 restatement did not affect Elan's Irish GAAP financial
information, including the Irish GAAP financial information contained in this
Annual Report and Form 20-F. For additional information regarding the
restatement and the adjustments, please refer to Note 33 to the Consolidated
Financial Statements.

In March 2001, Elan transferred a portfolio of equity and debt securities to
EPIL III, a wholly owned subsidiary of Elan. EPIL III issued $160.0 million in
aggregate principal amount of Series A Guaranteed Notes, $190.0 million in
aggregate principal amount of Series B Guaranteed Notes and $200.0 million in
aggregate principal amount of Series C Guaranteed Notes. The Series A
Guaranteed Notes matured on 29 June 2002. To fund the repayment of the notes,
on 29 June 2002 EPIL III transferred certain financial assets, consisting of
certain of the securities included in the portfolio transferred to EPIL III, to
Shelly Bay and Shelly Bay made a $148.0 million cash payment to EPIL III. EPIL
III used the proceeds from the payment by Shelly Bay, together with existing
cash of $12.0 million, to repay the Series A Guaranteed Notes. The assets
transferred by EPIL III to Shelly Bay had a carrying value under Irish GAAP of
$223.4 million.

The documents that established EPIL III required that EPIL III dispose of
financial assets in order to repay the Series A Guaranteed Notes at maturity.
The documents also mandated the order in which the assets were to be sold prior
to the maturity date for the Series A Guaranteed Notes. However, due to a
number of factors, including the inability of Elan and EPIL III to locate the
list mandating the order of disposal of the financial assets, the disposal
process was commenced and completed over the one-week period ending on 29 June
2002. Although Elan, as servicing agent for EPIL III, contacted a number of
third parties regarding their potential interest in purchasing financial assets
from EPIL III, each of those parties indicated that they would not be able to
complete a due diligence analysis of the issuers of the financial assets to be
sold, or to receive all necessary internal approvals to complete the purchase,
on a timely basis.

Therefore, in an effort to enable EPIL III to dispose of the financial assets,
Elan determined that it would be necessary to provide non-recourse credit
support to third parties who would agree to purchase financial assets from EPIL
III. Credit support was offered to a number of potential purchasers of the
financial assets. However, ultimately, only Shelly Bay possessed the ability to
complete the transaction on a timely basis.

Elan established Shelly Bay specifically for the purpose of acquiring financial
assets from EPIL III. All of the capital stock of Shelly Bay was issued to its
sole shareholder. Elan did not own any capital stock of Shelly Bay and did not
have a representative on Shelly Bay's board of directors. In addition, the sole
shareholder of Shelly Bay had no previous contact with Elan. However, as
further described below, Elan possessed all of the financial risk of the Shelly
Bay transaction. Similar to all other potential purchasers contacted by Elan,
the sole shareholder of Shelly Bay was unwilling to invest capital to acquire
the financial assets until a due diligence analysis of the issuers of the
financial assets had been completed. Therefore, the sole shareholder of Shelly
Bay made no substantive capital investment in Shelly Bay and, although Shelly
Bay possessed all of the potential financial benefits of the transaction,
neither Shelly Bay nor its sole shareholder had any financial risk in the
transaction.

Elan believed that any failure by EPIL III to dispose of financial assets prior
to 29 June 2002 could potentially adversely impact the non-consolidated
accounting status of EPIL III under U.S. GAAP and could result in defaults
under Elan's debt instruments.

Under the terms of the transaction, Shelly Bay acquired certain financial
assets from EPIL III on 29 June 2002 and made a cash payment to EPIL III of
$148.0 million. Shelly Bay financed the entire purchase price of the financial
assets, together with the funds necessary to pay interest and other costs on
the loan to its maturity date, through borrowings under a $153.0 million
non-recourse bank loan facility maturing on 30 September 2002. Elan provided a
full and unconditional guarantee to the bank to support Shelly Bay's obligation
to repay the loan and provided $153.0 million in cash collateral to the bank to
secure Elan's obligations under its guarantee. Upon the closing of the
transaction, Elan paid to Shelly Bay approximately $1 million to reimburse
Shelly Bay for the expenses expected to be incurred by it in connection with
the transaction. In addition, Elan irrevocably waived all rights of recourse
against Shelly Bay in the event that it failed to repay the bank loan at
maturity.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     105

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

The cash payment made by Shelly Bay in connection with its acquisition of the
financial assets was based upon a valuation conducted by Elan. The valuation
utilised customary, widely-accepted valuation methodologies and required that
Elan make certain judgements and assumptions regarding the financial assets.
Elan did not receive any independent verification of the valuation at the time
of the transaction. In addition, EPIL III did not receive any bids for the
financial assets to be disposed of.

Upon the closing of the transaction, Shelly Bay's assets consisted solely of
the financial assets purchased from EPIL III. Under the terms of the
transaction, Shelly Bay was required to complete a due diligence analysis of
the issuers of the securities prior to 15 September 2002. Shelly Bay had the
right to either elect, on or prior to 15 September 2002, to retain the
financial assets on a long-term basis or to dispose of the financial assets
prior to 30 September 2002.

In the event that Shelly Bay elected to retain the financial assets, it was
required, within 15 days of the election, to obtain alternative financing in an
amount equal to the value, as of 29 June 2002, of the assets being retained, as
determined by an independent appraiser engaged by Shelly Bay. The net cash
proceeds received by Shelly Bay from any alternative financing were required to
be applied to repay amounts outstanding under Shelly Bay's bank loan.

In the event that Shelly Bay elected to dispose of the financial assets prior
to 30 September 2002, Shelly Bay was required to apply the net proceeds from
the dispositions to repay amounts outstanding under its bank loan. The
transaction agreements contained no limitation on the price at which any
financial asset could be sold by Shelly Bay or the party to whom any financial
asset could be sold. In addition, Elan agreed that it had no right to object to
the disposition of any financial asset, the party to whom it was disposed or
the price obtained for the disposition.

Given the non-recourse nature of the Shelly Bay bank loan, Elan possessed all
of the financial risk of the transaction under its guarantee of the bank loan,
and the cash collateral provided by Elan to secure the guarantee, in the event
of any shortfall in the aggregate proceeds received by Shelly Bay from the
refinancing or disposition of the financial assets. Although Shelly Bay
possessed all of the potential financial benefits of the transaction, neither
Shelly Bay nor its sole shareholder had any financial risk in the transaction.

As required by the terms of the transaction, Shelly Bay engaged an independent
appraiser to value the financial assets as of 29 June 2002. The appraisal,
which was prepared in early September 2002, valued the financial assets at $8.2
million.

Shelly Bay did not elect, under the terms of the transaction, to retain any of
the financial assets and obtain alternative financing in an amount equal to the
independent appraiser's valuation. Rather, by 30 September 2002, Shelly Bay had
disposed of all of the financial assets for aggregate net proceeds of $9.3
million. A number of the financial assets were disposed of, for net proceeds of
$1.8 million, to an affiliate of Shelly Bay. The remainder of the financial
assets were sold to third parties and in open market transactions. As described
above, the transaction agreements contained no limitation on the price at which
any financial asset could be sold by Shelly Bay or the party to whom any
financial asset could be sold, including to an affiliate of Shelly Bay. In
addition, Elan agreed that it had no right to object to the disposition of any
financial asset, the party to whom it was disposed or the price obtained for
the disposition.

As a result of the disposition of the financial assets by Shelly Bay for
aggregate net proceeds of $9.3 million, on 30 September 2002, Elan made a cash
payment of $141.6 million to satisfy its obligation under its guarantee. Under
the terms of the transaction agreements, Elan has no further obligation under
the guarantee and has no recourse to Shelly Bay or to its sole shareholder
arising from Elan's payment under the guarantee. The loss on the sale of the
securities was $217.0 million under Irish GAAP including the $141.6 million
under the guarantee.

(F) NET INTEREST

Exceptional net interest and other expenses were $1,014.0 million.

This includes a charge of $1,045.9 million relating to investments in Elan's
investment portfolio, including the investments held by EPIL II and EPIL III.
The financial markets for emerging biotechnology, drug delivery and
pharmaceutical companies declined significantly during 2002. The investment
impairment charge mainly reflects this significant decline in the financial
markets and also the impact of weak financial markets on the ability of
emerging biotechnology, drug delivery and pharmaceutical companies to raise
finance. The charge also includes impairments relating to investments in
business ventures and business venture parents. The investment impairments
comprise $215.4 million, $575.4 million and $255.1 million in relation to
quoted investments, unquoted investments and loans, and securitised
investments, respectively. In addition, during 2003 the Company recognised a
net loss on financial assets of $10.0 million.

--------------------------------------------------------------------------------
106

--------------------------------------------------------------------------------

Offsetting these charges was a net gain of $37.7 million on the repurchase of
$318.6 million in principal amount at maturity of LYONs. These LYONs, having an
accreted value of $190.1 million at the date of purchase, were purchased at an
aggregate cost of $149.8 million, resulting in the net gain of $37.7 million
after related costs. For further information regarding the LYONs, please refer
to Note 15 to the Consolidated Financial Statements.

2001

In 2001, Elan incurred net exceptional charges of $931.9 million. These
exceptional revenues and costs have been included under the statutory format
headings to which they relate analysed as follows:

-------------------------------------------------------------------------------------------------------------------------------
                                                                              SELLING,       RESEARCH
                                                                COST       GENERAL AND            AND         NET
                                                   REVENUE  OF SALES    ADMINISTRATIVE    DEVELOPMENT    INTEREST
                                                       (A)       (B)               (C)            (D)         (E)         TOTAL
                                                        $M        $M                $M             $M          $M            $M
-------------------------------------------------------------------------------------------------------------------------------

 Product rationalisations                          (231.4)      15.6                --             --          --       (215.8)
 Rationalisation of research and development
  activities                                         (2.0)        --                --           60.5          --         58.5
 Pharmaceutical division reorganisation costs          --        0.4              55.7             --          --         56.1
 Acquired IP and product impairment                    --         --           1,009.8             --          --      1,009.8
 Investment impairments                                --         --                --             --        24.1         24.1
 Net gain on financial assets                          --         --                --             --       (56.8)       (56.8)
 Asset write-downs and other                          5.6        6.8              18.7           18.1         6.8         56.0
-------------------------------------------------------------------------------------------------------------------------------
 Net exceptional charges                           (227.8)      22.8           1,084.2           78.6       (25.9)       931.9
-------------------------------------------------------------------------------------------------------------------------------

(A) REVENUE

Exceptional revenue in 2001 primarily relates to product rationalisation
revenue of $231.4 million.

(B) COST OF SALES

The exceptional cost of sales is primarily comprised of $15.6 million relating
to product rationalisation revenue.

(C) SELLING, GENERAL AND ADMINISTRATIVE

Exceptional selling, general and administrative expenses were $1,084.2 million.
$1,009.8 million of the exceptional charges relate to impairment charges
arising on write-downs of intangible assets. Impairment charges to acquired IP
arising from the acquisitions of Neurex and Sano were $500.0 million and $285.2
million, respectively. Impairment charges to patents and licences arising on
write-downs of the product intangibles for Naprelan, Ceclor CD and Myambutol
were $81.0 million, $94.2 million and $44.4 million, respectively. Other
impairments to patents and licences amounted to $5.0 million. Other exceptional
selling, general and administrative expenses were $74.4 million. These mainly
relate to severance, integration, relocation and similar costs and asset
write-downs arising from the integration of Elan's U.S. biopharmaceuticals
businesses.

Elan acquired Neurex in August 1998 for $810.0 million. Neurex was developing
Prialt. The purchase price was primarily allocated to acquired IP. In 2001,
Elan wrote down acquired IP arising from the acquisition of Neurex by $500.0
million. This write-down was due to delays in the product launch schedule and
reduced revenue projections for Prialt.

Elan acquired Sano in February 1998 for $434.6 million. Sano was developing
transdermal drug delivery products. The purchase price was primarily allocated
to acquired IP. In 2001, Elan wrote down acquired IP arising from the
acquisition of Sano by $285.2 million. The write-down was due to reduced
revenue projections from products under development and to Elan's decision to
focus its research and development efforts in other areas.

Ceclor CD and Myambutol were written down due to the impact of generic
competition on these products during 2001. Generic versions of each of these
products were approved and launched in 2001, which reduced projected revenues
and profitability from these

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     107

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

products. Revenue from Ceclor CD declined by $26.0 million in 2001, from $39.4
million in 2000 to $13.4 million in 2001. Naprelan was written down due to
lower than forecasted revenues in 2001 and reduced projected revenue and
profitability from this product. Revenue from Naprelan declined by $33.6
million in 2001, from $41.8 million in 2000 to $8.2 million in 2001.

(D) RESEARCH AND DEVELOPMENT

Exceptional research and development expenses were $78.6 million in 2001. These
mainly relate to severance, integration and similar costs and asset write-downs
arising from the re-organisation, closure or scaling back of various drug
delivery programmes and sites. Also included were costs of certain research
programmes that Elan does not intend to complete. These were the estimated
costs incurred pending closure or sale.

(E) NET INTEREST

Exceptional net interest and other expenses amounted to a net gain of $25.9
million in 2001. This mainly relates to net gains on financial assets of $56.8
million, offset by investment impairments of $24.1 million and costs of $6.8
million associated with the redemption in March 2001 of the 4.75% Exchangeable
Notes of Athena Neurosciences.

4 NET INTEREST AND OTHER EXPENSE

                                                                          2003            2002         2001
                                                                            $M              $M           $M
-----------------------------------------------------------------------------------------------------------

 INCOME FROM FINANCIAL ASSETS:
 Interest and other income                                                32.1            86.3        159.2
 Net gain on financial assets(1)                                         106.3              --         56.8
 Gain on repurchase of LYONs(1)                                            1.6            37.7           --
 Foreign exchange gains                                                    4.2             2.4          1.8
-----------------------------------------------------------------------------------------------------------
                                                                         144.2           126.4        217.8
-----------------------------------------------------------------------------------------------------------

 INTEREST PAYABLE AND SIMILAR CHARGES:
 Bank charges and interest on loans repayable within five years            1.4             6.1          5.7
 Interest capitalised                                                       --            (3.0)          --
 Foreign exchange losses                                                  11.7             6.4          0.3
 Original issue discount on LYONs                                         19.1            31.0         30.2
 Interest on 7.25% Senior Notes                                           47.1            47.1         40.3
 Interest on EPIL III Notes                                               29.9            37.2         35.4
 Interest on EPIL II Notes                                                43.0            43.0         43.0
 Interest on 6.5% Convertible Notes                                        4.1              --           --
 Interest on other guaranteed and exchangeable notes                        --             1.2          6.4
 Amortisation of financing costs                                          14.5            11.6         14.5
 Financing charges                                                        10.7            24.7         22.8
 Net loss on financial assets(1)                                            --            10.0           --
 Investment impairments(1)                                               120.4         1,045.9         24.1
 Share of funding of business ventures                                     3.0            23.9         24.6
 Waiver fee to EPIL II/III noteholders(1)                                 16.8              --           --
 Other financial charges                                                  10.0            12.0         20.9
-----------------------------------------------------------------------------------------------------------
                                                                         331.7         1,297.1        268.2
-----------------------------------------------------------------------------------------------------------
 Net interest and other expense                                         (187.5)       (1,170.7)       (50.4)
-----------------------------------------------------------------------------------------------------------

(1)   For additional information on exceptional items, please refer to Note 3
      to the Consolidated Financial Statements

--------------------------------------------------------------------------------
108

--------------------------------------------------------------------------------

5 (LOSS)/PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION

The (loss)/profit on ordinary activities before taxation has been arrived at
after charging/(crediting) the following items:

                                                           2003         2002         2001
                                                             $M           $M           $M
-----------------------------------------------------------------------------------------

 AUDITORS' REMUNERATION:
 Audit fees(1)                                              5.3          2.5          3.1
 Audit related fees(2)                                      1.2           --           --
-----------------------------------------------------------------------------------------
 AUDIT AND AUDIT RELATED FEES                               6.5          2.5          3.1
 Tax fees(3)                                                0.1          0.1          0.1
 All other fees(4)                                          --           --           0.2
-----------------------------------------------------------------------------------------
 TOTAL FEES                                                 6.6          2.6          3.4
-----------------------------------------------------------------------------------------
 DIRECTORS' EMOLUMENTS:
 Fees                                                       1.0          1.0          0.7
 Other emoluments and benefits in kind                      2.0          2.0          5.3
 Pension contributions                                      0.1          0.1          0.2
 Payments to retired directors                              2.2          1.2          0.2
-----------------------------------------------------------------------------------------
                                                            5.3          4.3          6.4
-----------------------------------------------------------------------------------------
 Amortisation of intangible assets                        159.3        264.5        215.2
 Depreciation of tangible assets                           51.0         55.8         55.2
 Loss/(profit) on disposal of fixed assets                  1.0         14.4         (0.1)
 Loss on sale of securities by EPIL III/guarantee            --        217.0           --
-----------------------------------------------------------------------------------------
 OPERATING LEASE RENTALS:
 Premises                                                  19.1         20.9         17.6
 Plant and equipment                                        2.1          8.0          9.3
 Grants amortised                                          (0.1)        (0.1)        (0.2)
-----------------------------------------------------------------------------------------

(1)   Audit services include audit work performed on the Consolidated Financial
      Statements, as well as work that generally only the independent auditor
      can reasonably be expected to provide, including comfort letters,
      statutory audits, and discussions surrounding the proper application of
      financial accounting and/or reporting standards.

(2)   Audit related services are for assurance and related services that are
      traditionally performed by the independent auditor, including due
      diligence related to mergers and acquisitions, employee benefit plan
      audits, and special procedures required to meet certain regulatory
      requirements.

(3)   Tax services include all services, except those services specifically
      related to the audit of the financial statements, performed by the
      independent auditor's tax personnel, including tax analysis; supporting
      other tax-related regulatory requirements; and tax compliance and
      reporting.

(4)   Other fees are those associated with services not captured in the other
      categories.

For additional information regarding directors' shareholdings, share options
and compensation, please refer to "Directors' Interests", "Directors' Options"
and "Directors' Remuneration" in the Directors' Report.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     109

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

6 DISCONTINUED OPERATIONS

In the first quarter of 2004, Elan concluded its recovery plan with the sale of
its European sales and marketing infrastructure. Subsequently, Elan sold
several pharmaceutical products and businesses, including Frova, Zonegran,
Myobloc, Zanaflex, Naprelan and other non-promoted pharmaceutical products.
Discontinued operations as of 31 December 2003 have been restated to reflect
the subsequent disposal of these products and businesses. Please refer to note
34. The results of these operations have been reported separately as
discontinued operations for 2003 and for comparative years. Other divestments
and closures include the sale of Elan's diagnostic businesses, the return of
the dermatology products to GSK, the Abelcet business, the sale of the primary
care franchise to King, the sale of the Pain Portfolio to aaiPharma and the
sale or closure of a number of drug delivery businesses including the sale of a
transdermal technology business, the closure of Elan's medipad business and
Elan's research facility in Princeton and the sale of a U.K. drug delivery
business. The results of discontinued operations are shown after exceptional
items. For additional information on exceptional items, please refer to Note 3
to the Consolidated Financial Statements. The gains/(losses) on disposal of
businesses are classified as exceptional items under other ordinary activities.

                                                                                       OPERATING
                                                                                   PROFIT/(LOSS)
                                                     SELLING,                              AFTER       GAIN/(LOSS)
2003                                  COST OF     GENERAL AND      RESEARCH AND      EXCEPTIONAL    ON DISPOSAL OF
                         REVENUE        SALES  ADMINISTRATION       DEVELOPMENT         ITEMS(1)     BUSINESSES(1)
                              $M           $M              $M                $M               $M                $M
------------------------------------------------------------------------------------------------------------------

 Europe                    112.4        (62.4)         (170.2)            (14.0)          (134.2)              2.4
 Diagnostics                 9.0         (4.9)           (3.1)            ( 0.5)             0.5                --
 Dermatology                 --            --            (2.7)               --             (2.7)               --
 Abelcet                     1.1         (1.6)            1.2                --              0.7                --
 Primary Care              108.4        (18.1)          (62.7)             (0.9)            26.7             284.8
 Pain Portfolio             68.0        (17.0)          (15.0)             (0.3)            35.7              40.2
 Drug Delivery              17.9        (17.5)          (10.5)            (35.7)           (45.8)            (34.1)
 Frova                      38.5        (36.5)          (14.0)               --            (12.0)               --
 Zonegran                   86.5        (43.0)          (24.1)            (13.9)             5.5                --
 Zanaflex                   (5.1)        (4.3)           (0.6)             (0.2)           (10.2)               --
 Naprelan                    0.5         (6.3)           (0.1)               --             (5.9)               --
 Myobloc                    14.9         (6.3)          (48.9)            (11.6)           (51.9)               --
 Other(2)                    0.4         (1.3)           (2.6)               --             (3.5)               --
------------------------------------------------------------------------------------------------------------------
 Total discontinued        452.5       (219.2)         (353.3)            (77.1)          (197.1)            293.3
------------------------------------------------------------------------------------------------------------------

                                                                                     OPERATING
                                                                                  PROFIT/(LOSS)
                                                     SELLING,                             AFTER       GAIN/(LOSS)
2002                                  COST OF     GENERAL AND     RESEARCH AND      EXCEPTIONAL    ON DISPOSAL OF
                         REVENUE        SALES  ADMINISTRATION      DEVELOPMENT         ITEMS(1)     BUSINESSES(1)
                              $M           $M              $M               $M               $M                $M
------------------------------------------------------------------------------------------------------------------

 Europe                    102.6        (64.8)          (80.8)           (16.0)           (59.0)              --
 Diagnostics                70.6        (29.4)          (37.2)            (3.4)             0.6             65.2
 Dermatology                47.6        (24.9)          (85.6)              --            (62.9)              --
 Abelcet                    64.6        (23.7)          (41.2)              --             (0.3)            12.7
 Primary Care              237.8        (39.6)         (136.7)            (0.5)            61.0               --
 Pain Portfolio             59.8        (19.4)         (103.1)            (0.2)           (62.9)              --
 Drug Delivery              27.4        (25.4)         (182.6)          (130.7)          (311.3)              --
 Frova                      16.2        (18.3)          (38.3)              --            (40.4)              --
 Zonegran                   49.2        (11.4)          (19.7)           (14.4)             3.7               --
 Zanaflex                   56.8        (70.8)          (20.9)            (2.2)           (37.1)              --
 Naprelan                 ( 8.3)        (15.2)          (35.8)              --            (59.3)              --
 Myobloc                    19.6         (6.5)         (126.2)           (14.4)          (127.5)              --
 Other(2)                    2.1         (1.4)          (37.2)              --            (36.5)              --
------------------------------------------------------------------------------------------------------------------
 Total discontinued        746.0       (350.8)         (945.3)           (181.8)         (731.9)             77.9
------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
110

--------------------------------------------------------------------------------

                                                                                      OPERATING
                                                                                  PROFIT/(LOSS)
                                                     SELLING,                             AFTER       GAIN/(LOSS)
2001                                  COST OF     GENERAL AND     RESEARCH AND      EXCEPTIONAL    ON DISPOSAL OF
                         REVENUE        SALES  ADMINISTRATION      DEVELOPMENT         ITEMS(1)     BUSINESSES(1)
                              $M           $M              $M               $M               $M                $M
------------------------------------------------------------------------------------------------------------------

 Europe                     90.9       (49.3)          (50.4)             (9.0)           (17.8)                --
 Diagnostics                51.7       (32.7)          (26.9)             (2.9)           (10.8)                --
 Dermatology                61.8       (28.5)          (41.3)               --             (8.0)                --
 Abelcet                    72.0       (14.3)          (55.3)               --              2.4                 --
 Primary Care              120.2       (20.9)          (45.9)              0.2             53.6                 --
 Pain Portfolio             15.4        (4.7)           (2.5)               --              8.2                 --
 Drug Delivery              37.8       (14.4)         (306.0)            (67.5)          (350.1)                --
 Frova                       --           --            (1.2)               --             (1.2)                --
 Zonegran                   37.8        (8.1)          (15.0)            (15.3)            (0.6)                --
 Zanaflex                  161.7       (20.0)          (27.4)             (1.7)           112.6                 --
 Naprelan                    8.4       (23.2)          (85.0)             (0.4)          (100.2)                --
 Myobloc                    11.6        (2.1)          (22.5)            (12.7)           (25.7)                --
 Other(2)                   13.2        (2.3)          (48.5)               --            (37.6)                --
------------------------------------------------------------------------------------------------------------------
  Total discontinued        682.5       (220.5)        (727.9)           (109.3)          (375.2)               --

(1)   For additional information on exceptional items, please refer to Note 3
      to the Consolidated Financial Statements.

(2)   Other products include primarily non-promoted pharmaceutical products
      such as Myambutol.

7 TAX ON (LOSS)/PROFIT ON ORDINARY ACTIVITIES

The components of the current tax (credit)/expense for the years ended 31
December were as follows:

                               2003        2002       2001
                                 $M          $M         $M
----------------------------------------------------------

 Irish corporation tax          9.7         2.3        1.5
 Foreign taxes                (31.7)       17.5       15.9
----------------------------------------------------------
                              (22.0)       19.8       17.4
----------------------------------------------------------

Current tax, including Irish corporation tax and foreign taxes, is provided on
the Group's taxable profits, at amounts expected to be paid (or recovered)
using the tax rates and laws that have been enacted or substantially enacted by
the balance sheet date. In each of the three years ended 31 December 2003, 31
December 2002 and 31 December 2001, substantially all of Elan's income in
Ireland was exempt from taxation by virtue of relief granted on income derived
from patents or due to tax losses incurred. The tax credit of $22.0 million for
2003 reflected tax at standard rates in the jurisdictions in which Elan
operates, income derived from Irish patents, which is exempt from tax, foreign
withholding tax and the availability of tax losses.

Reflecting the exempt nature of Irish income and the availability of tax losses
in Ireland and foreign operations, there was no deferred tax expense for the
above years.

Irish and overseas taxation have been provided at current rates on the profits
earned for the periods covered by the Consolidated Financial Statements.

A reconciliation of the expected tax expense (computed by applying the standard
Irish tax rate to (losses)/profits before tax) to the actual tax expense is as
follows:

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     111

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

                                                                                           2003         2002          2001
                                                                                             $M           $M            $M
---------------------------------------------------------------------------------------------------------------------------

 Taxes at the Irish standard rate of 12.5% in 2003, 16% in 2002 and 20% in 2001         (104.7)       (575.2)       (174.0)
 Irish income at reduced rates                                                            (6.9)        (18.4)        (33.7)
 Foreign income at rates other than the Irish standard rate                              (82.6)        (10.7)       (138.7)
 Losses creating no tax benefit                                                          170.3         620.8         363.2
 Share of investments accounted for under the equity method including elimination
  of revenue                                                                               1.5           2.8           2.6
 Other                                                                                     0.4           0.5          (2.0)
---------------------------------------------------------------------------------------------------------------------------
 Actual (credit)/provision for income taxes                                              (22.0)         19.8          17.4
---------------------------------------------------------------------------------------------------------------------------

The distribution of (loss)/profit on ordinary activities before taxes by
geographical area was as follows:

                                                             2003            2002          2001
                                                               $M              $M            $M
------------------------------------------------------------------------------------------------

 (LOSS)/PROFIT ON ORDINARY ACTIVITIES BEFORE TAXES:
 Ireland                                                   (734.7)       (1,961.9)       (691.6)
 Foreign                                                   (102.7)       (1,632.7)       (178.2)
------------------------------------------------------------------------------------------------
                                                           (837.4)       (3,594.6)       (869.8)
------------------------------------------------------------------------------------------------

Deferred taxation

                                                             AT 31 DECEMBER    AT 31 DECEMBER
                                                                       2003              2002
                                                                         $M                $M
----------------------------------------------------------------------------------------------

 DEFERRED TAXATION LIABILITIES:
 Fixed assets                                                        (45.8)             (14.9)
 Intangible assets on acquisition                                    (52.6)            (150.1)
 Deferred interest                                                    (2.9)                --
----------------------------------------------------------------------------------------------
                                                                    (101.3)            (165.0)
----------------------------------------------------------------------------------------------
 DEFERRED TAXATION ASSETS:
 Net operating losses                                                   --                2.1
 Reserves/provisions, deferred interest & capitalised items          101.3              162.9
----------------------------------------------------------------------------------------------
                                                                     101.3              165.0
----------------------------------------------------------------------------------------------
 Deferred tax asset/(liability)                                         --                 --
----------------------------------------------------------------------------------------------

Under Irish GAAP the Company applies FRS 19 "Deferred Tax."

Except as outlined below, deferred taxation is recognised in respect of all
timing differences that have originated but not reversed at the balance sheet
date. No taxes have been provided for the unremitted and untaxed earnings of
the Group companies overseas as these are, in the main, considered permanently
employed in the business of these companies. Cumulative unremitted earnings of
overseas subsidiaries and related undertakings totalled approximately $1,046.8
million at 31 December 2003. Deferred tax assets are recognised to the extent
that, on the basis of available evidence, it is regarded as more likely than
not that there will be suitable taxable profits from which the future reversal
of the underlying timing differences can be deducted. The calculation of the
deferred taxation asset or liability is based on the taxation rates that are
expected to apply in the periods in which the timing differences are expected
to reverse based on tax rates and laws that have been enacted or substantially
enacted at the balance sheet date.

--------------------------------------------------------------------------------
112

--------------------------------------------------------------------------------

Tax balances

                                                   AT 31 DECEMBER     AT 31 DECEMBER
                                                             2003               2002
                                                               $M                 $M
------------------------------------------------------------------------------------

 TAXATION AND SOCIAL SECURITY CREDITORS COMPRISE:
 Corporation tax                                             24.2               54.9
 Value added tax                                              1.6              (0.3)
 Payroll taxes                                                3.6                5.4
------------------------------------------------------------------------------------
                                                             29.4               60.0
------------------------------------------------------------------------------------

8 EARNINGS PER SHARE

Basic earnings per share is computed by dividing the net profit or loss for the
period available to ordinary shareholders by the sum of the weighted average
number of Ordinary Shares in issue and ranking for dividends during the period.
Diluted earnings per share is computed by dividing the net profit or loss for
the period by the weighted average number of Ordinary Shares in issue, adjusted
for the effect of all dilutive potential Ordinary Shares that were outstanding
during the period.

The following table sets forth the computation for basic and diluted earnings
per share ("EPS"):

Before exceptional items
                                                                        2003            2002         2001
---------------------------------------------------------------------------------------------------------

 NUMERATOR (AMOUNTS IN $M):
 Numerator for basic and diluted EPS--retained (loss)/profit          (498.3)         (665.7)        44.7
---------------------------------------------------------------------------------------------------------
 DENOMINATOR (AMOUNTS IN MILLIONS):
 Denominator for basic EPS--weighted average shares                    356.0           349.7        336.0
 Effect of dilutive securities--options and warrants                      --              --         23.3
---------------------------------------------------------------------------------------------------------
 Denominator for diluted EPS--weighted average shares                  356.0           349.7        359.3
---------------------------------------------------------------------------------------------------------
 Basic EPS                                                         $   (1.40)      $   (1.90)      $  0.13
 Diluted EPS                                                       $   (1.40)      $   (1.90)      $  0.12
---------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     113

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Exceptional items
                                                               2003              2002            2001
---------------------------------------------------------------------------------------------------------

 NUMERATOR (AMOUNTS IN $M):
 Numerator for basic and diluted EPS--retained loss           (317.1)         (2,949.4)         (931.9)
---------------------------------------------------------------------------------------------------------
 DENOMINATOR (AMOUNTS IN MILLIONS):
 Denominator for basic EPS--weighted average shares            356.0             349.7           336.0
 Effect of dilutive securities--options and warrants              --                --              --
---------------------------------------------------------------------------------------------------------
 Denominator for diluted EPS--weighted average shares          356.0             349.7           336.0
---------------------------------------------------------------------------------------------------------
 Basic EPS                                                  $  (0.89)      $     (8.44)      $   (2.77)
 Diluted EPS                                                $  (0.89)      $     (8.44)      $   (2.77)
---------------------------------------------------------------------------------------------------------

 Total

                                                                2003              2002            2001
---------------------------------------------------------------------------------------------------------
 NUMERATOR (AMOUNTS IN $M):
 Numerator for basic and diluted EPS--retained loss           (815.4)         (3,615.1)         (887.2)
-------------------------------------------------------     ---------       -----------       ---------
 DENOMINATOR (AMOUNTS IN MILLIONS):
 Denominator for basic EPS--weighted average shares            356.0             349.7           336.0
 Effect of dilutive securities--options and warrants              --                --              --
---------------------------------------------------------------------------------------------------------
 Denominator for diluted EPS--weighted average shares          356.0             349.7           336.0
---------------------------------------------------------------------------------------------------------
 Basic EPS                                                  $  (2.29)      $    (10.34)      $   (2.64)
 Diluted EPS                                                $  (2.29)      $    (10.34)      $   (2.64)
---------------------------------------------------------------------------------------------------------

9 STAFF NUMBERS AND COSTS

The average number of persons employed by the Company during 2003 was 2,688,
analysed over the following categories:

                                2003      2002      2001
--------------------------------------------------------

 Research and development        625     1,016     1,125
 Manufacturing                   755     1,079     1,012
 Sales                           761     1,592     1,651
 Administration                  547       690       740
--------------------------------------------------------
                               2,688     4,377     4,528
--------------------------------------------------------

At 31 December 2003, Elan had total worldwide employees of 2,159.

The aggregate payroll costs of employees were as follows:

                                 2003         2002         2001
                                   $M           $M           $M
---------------------------------------------------------------

 Wages and salaries            239.4        377.4        335.6
 Social security costs          29.0         43.8         34.4
 Pension costs                  13.5         12.1         12.7
---------------------------------------------------------------
                               281.9        433.3        382.7
---------------------------------------------------------------

--------------------------------------------------------------------------------
114

--------------------------------------------------------------------------------

10 FIXED ASSETS--INTANGIBLE ASSETS

                                                                   ACQUIRED
                                       PATENTS &               INTELLECTUAL
                                        LICENCES     GOODWILL      PROPERTY            TOTAL
                                              $M           $M            $M               $M
--------------------------------------------------------------------------------------------

 COST:
 At 1 January 2003                       1,655.6        606.8         427.8          2,690.2
 Additions                                  14.3           --            --             14.3
 Disposals                                (524.7)      (116.9)        (29.1)          (670.7)
 Impairments                               (53.4)      (124.4)        (11.7)          (189.5)
 Translation adjustment                      0.3          2.7            --              3.0
--------------------------------------------------------------------------------------------
 At 31 December 2003                     1,092.1        368.2         387.0          1,847.3
--------------------------------------------------------------------------------------------
 ACCUMULATED AMORTISATION:
 At 1 January 2003                         350.4        242.2          18.1            610.7
 Amortised in year                         123.9         29.5           5.9            159.3
 Disposals                                (123.9)       (47.1)         (4.5)          (175.5)
 Translation adjustment                      0.1          0.3            --              0.4
--------------------------------------------------------------------------------------------
 At 31 December 2003                       350.5        224.9          19.5            594.9
--------------------------------------------------------------------------------------------
 Net book value: 31 December 2003          741.6        143.3         367.5          1,252.4
--------------------------------------------------------------------------------------------
 Net book value: 31 December 2002        1,305.2        364.6         409.7          2,079.5
--------------------------------------------------------------------------------------------

At 31 December 2003, the main components of the carrying value of patents and
licences were $295.3 million for Maxipime/Azactam, $105.5 million for the AD
intellectual property and $89.2 million for Prialt.

At 31 December 2003, the main components of the carrying value of goodwill were
$86.0 million for Dura and $45.2 million for Nanosystems.

At 31 December 2003, the carrying values of acquired IP relating to the
acquisitions of Neurex, NanoSystems and Axogen were $286.9 million, $35.3
million and $45.3 million, respectively.

Disposals of intangible fixed assets during 2003 primarily relate to Skelaxin
and Sonata intangibles of $386.5 million sold as part of the sale of the
primary care franchise to King, and the intangible asset of $54.7 million for
the Pain Portfolio sold to aai Pharma.

Elan acquires companies engaged in research and development activities as it
expects that the intellectual property created through the acquired companies'
research and development processes may result in a future earnings stream.
Acquired IP represents that portion of the purchase price that Elan attributes
to the value of the research and development activity undertaken by the
acquired research and development company prior to acquisition. It is not a
payment for research and development but rather for the value created through
previous research and development.

Acquired IP is capitalised as an intangible asset and is amortised over its
useful economic life. The useful economic life is the period over which Elan
expects to derive economic benefits. Acquired IP rights of $286.9 million
(relating to Neurex) were not amortised in 2003, as the useful economic life of
those rights had not commenced. Elan expects to file an amendment to its NDA
for Prialt in the second quarter of 2004. Upon commencement of its useful
economic life, acquired IP will be amortised on a straight-line basis over the
period that economic benefits are expected to accrue, which is not expected to
exceed 20 years. In the case of each acquisition, the useful economic life of
acquired IP commences upon the generation of product revenue from that acquired
IP. Pharmaceutical products cannot be marketed until the successful completion
of research and development and the receipt of regulatory approval to market.
Under U.S. GAAP, the corresponding amounts were expensed immediately upon
acquisition as IPR&D costs.

In accordance with the requirements of FRS 11, "Impairment of Fixed Assets and
Goodwill" ("FRS 11"), Elan conducts an impairment review of acquired IP rights
at least annually, prior to the commencement of amortisation, to assess whether
its carrying value is supported.

For additional information on the impairments of intangible fixed assets,
please refer to Note 3 to the Consolidated Financial Statements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     115

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

11 FIXED ASSETS--TANGIBLE ASSETS

                                         LAND &       PLANT &
                                      BUILDINGS     EQUIPMENT         TOTAL
                                             $M            $M            $M
---------------------------------------------------------------------------

 COST:
 At 1 January 2003                        250.5         396.7         647.2
 Additions                                 10.1          24.7          34.8
 Disposals                                (35.1)        (72.9)       (108.0)
 Impairments                               (9.2)         (5.2)        (14.4)
 Transfers                                 37.6         (37.6)           --
 Translation adjustment                     0.7           2.6           3.3
---------------------------------------------------------------------------
 At 31 December 2003                      254.6         308.3         562.9
---------------------------------------------------------------------------
 ACCUMULATED DEPRECIATION:
 At 1 January 2003                         33.6         154.3         187.9
 Charged in year                            8.3          42.7          51.0
 Disposals                                (13.5)        (36.9)        (50.4)
 Transfers                                 10.5         (10.5)           --
 Translation adjustment                     0.3           1.9           2.2
---------------------------------------------------------------------------
 At 31 December 2003                       39.2         151.5         190.7
---------------------------------------------------------------------------
 Net book value: 31 December 2003         215.4         156.8         372.2
---------------------------------------------------------------------------
 Net book value: 31 December 2002         216.9         242.4         459.3
---------------------------------------------------------------------------

Tangible fixed assets disposals during 2003 include fixed assets sold with a
transdermal technologies business, sale of the corporate aircraft and disposal
of fixed assets relating to the primary care franchise of $18.9 million, $17.3
million and $16.6 million, respectively.

Included in the carrying value of tangible fixed assets is $220.8 million
(2002: $222.7 million) relating to Elan's manufacturing facility in Athlone,
Ireland.

The net book value of tangible assets held under finance leasing arrangements
at 31 December 2003 amounted to $53.2 million (2002: $54.2 million) and related
depreciation for the period amounted to $11.4 million (2002: $13.9 million).

Fixed asset additions include interest capitalised of $Nil (2002: $3.0
million). Interest is capitalised on assets being constructed for their
intended use at an average rate of 6.5% per annum.

For additional information on the impairments of tangible fixed assets, please
refer to Note 3 to the Consolidated Financial Statements.

12 FIXED ASSETS--FINANCIAL ASSETS

                                          AT 31 DECEMBER    AT 31 DECEMBER
                                                    2003              2002
                                                      $M                $M
---------------------------------------------------------------------------

 Investments in and loans to associates             23.9              63.2
 Quoted investments                                 35.8              96.4
 Unquoted investments and loans                    197.9             368.8
 Securitised investments                           150.3             206.2
 Other marketable securities                        86.6              74.8
---------------------------------------------------------------------------
 Total                                             494.5             809.4
 Less current financial assets                    (86.6)            (74.8)
---------------------------------------------------------------------------
 Fixed assets--financial assets                    407.9             734.6
---------------------------------------------------------------------------

--------------------------------------------------------------------------------
116

--------------------------------------------------------------------------------

A MOVEMENTS ON NON-CURRENT FINANCIAL ASSETS FOR THE YEAR WERE AS FOLLOWS:

                                INVESTMENTS IN                          UNQUOTED
                                  AND LOANS TO           QUOTED      INVESTMENTS    SECURITISED
                                    ASSOCIATES      INVESTMENTS        AND LOANS    INVESTMENTS          TOTAL
                                            $M               $M               $M             $M             $M
---------------------------------------------------------------------------------------------------------------

 At 1 January 2003                        63.2             96.4            368.8          206.2          734.6
 Additions                                  --             21.4             22.3             --           43.7
 Disposals/repayments                    (31.3)           (79.3)          (131.7)          (7.8)        (250.1)
 Share of losses of associates            (8.8)              --               --             --           (8.8)
 Impairment                                 --            ( 2.7)           (68.2)         (49.5)        (120.4)
 Interest income                           0.8               --              6.7            1.4            8.9
---------------------------------------------------------------------------------------------------------------
 At 31 December 2003                      23.9             35.8            197.9          150.3          407.9
---------------------------------------------------------------------------------------------------------------

Quoted investments at 31 December 2003 carried at a cost of $35.8 million
(2002: $96.4 million) had a market value at that date of $70.1 million (2002:
$100.0 million).

B ASSOCIATES

Net revenues from associates amounted to $0.3 million (2002: $4.8 million;
2001: $16.9 million) from Amarin (see Note 27 "Related Parties") and $0.5
million (2002: $0.9 million; 2001: $2.6 million) from other associates during
2003. These other associates are subsidiaries of unrelated companies. The
revenues from associates that are subsidiaries of unrelated companies arose
under licence agreements whereby Elan has licensed rights to drug delivery
technologies, products and development-stage pharmaceutical compounds to these
associates in return for licence fees, future milestone payments and royalties
on sales. In certain cases, Elan may provide contract research and development
services billable on a cost-plus basis in line with normal commercial terms and
Elan may provide additional funding to associates. At 31 December 2003, trading
balances owed to the Company from associates amounted to $Nil (2002: $18.1
million) of which $Nil (2002: $13.7 million) relates to Amarin and balances
owed by the Company amounted to $Nil (2002: $1.0 million).

Elan's total investment in Amarin at 31 December 2003 amounted to $23.9
million, consisting of loans, including interest, of $20.9 million and a net
equity investment of $3.0 million.

For additional information on Amarin, including in relation to the 2003 and
2004 amendments, please refer to Note 27 to the Consolidated Financial
Statements.

C SIGNIFICANT ADDITIONS

Total additions to quoted and unquoted investments made in 2003 were $43.7
million, primarily relating to the conversion of convertible investments in
business venture parents to preferred/common stock investments for $32.5
million.

D SIGNIFICANT DISPOSALS

Total disposals of quoted and unquoted investments in 2003 amounted to $211.0
million, primarily relating to the disposal of Elan's investments in Xcel and
Ligand which had carrying values of $89.5 million and $65.7 million,
respectively.

E INVESTMENT IMPAIRMENTS

During 2003 the Company recognised a $120.4 million charge in relation to
investment impairments arising from Elan's investment portfolio, primarily
relating to investments in business ventures and business venture parents of
$4.0 million and $106.0 million, respectively.

F SECURITISED INVESTMENTS

The securitised investments at 31 December 2003 with a carrying value of $150.3
million, had a fair value at that date of $237.0 million. These investments are
held as security against the EPIL II Notes and the EPIL III Notes in an
aggregate principal amount of $840.0 million, issued in securitisation
transactions. For additional information regarding these notes, please refer to
Note 15 to the Consolidated Financial Statements.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     117

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

13 STOCKS

                  AT 31 DECEMBER     AT 31 DECEMBER
                            2003               2002
                              $M                 $M
---------------------------------------------------

 Raw materials              17.1               40.9
 Work-in-process            21.3               28.0
 Finished goods             40.0               80.9
---------------------------------------------------
                            78.4              149.8
---------------------------------------------------

The decrease in stocks during 2003 primarily reflects the divestment of
businesses and products under the recovery plan. The replacement cost of stock
does not differ materially from its carrying value.

14 DEBTORS

                                            AT 31 DECEMBER    AT 31 DECEMBER
                                                      2003              2002
                                                        $M                $M
----------------------------------------------------------------------------

 Trade debtors                                        88.6             148.4
 Less amounts provided for doubtful debts            (11.6)            (23.1)
----------------------------------------------------------------------------
                                                      77.0             125.3
 Other debtors                                        50.9              39.2
 Prepayments                                          18.0              22.1
----------------------------------------------------------------------------
                                                     145.9             186.6
----------------------------------------------------------------------------

Included in debtors is an amount of $11.8 million (2002: $10.8 million) due
after one year.

                                        2003        2002
PROVISION FOR DOUBTFUL DEBTS:             $M          $M
---------------------------------------------------------

 Balance at 1 January                   23.1        15.0
---------------------------------------------------------
 Profit and loss account charge          6.9        20.8
 Amounts utilised                      (18.4)      (12.7)
---------------------------------------------------------
 Balance at 31 December                 11.6        23.1
---------------------------------------------------------

The decrease in trade debtors during 2003 primarily reflects the impact of the
divestment of businesses and products under the recovery plan.

--------------------------------------------------------------------------------
118

--------------------------------------------------------------------------------

15 CONVERTIBLE DEBT AND GUARANTEED NOTES

                                                   AT 31 DECEMBER     AT 31 DECEMBER
                                       REPAYMENT             2003               2002
                                           DATES               $M                 $M
------------------------------------------------------------------------------------

 DUE WITHIN ONE YEAR
 EPIL II Notes                              2004            450.0                 --
 3.25% LYONs                                2003               --              682.0
 Interest accrued                                            21.4              114.3
------------------------------------------------------------------------------------
 Debt due within one year                                   471.4              796.3
------------------------------------------------------------------------------------
 DUE AFTER ONE YEAR
 EPIL III Notes                             2005            389.5              387.5
 EPIL II Notes                              2004              --               449.0
 7.25% Senior Notes                         2008            645.1              643.9
 6.5% Convertible Notes                     2008            444.4                --
 3.25% LYONs                                2008              0.9                --
------------------------------------------------------------------------------------
 Debt due after more than one year                        1,479.9            1,480.4
------------------------------------------------------------------------------------

EPIL II Notes

In June 2000, the Company transferred a portfolio of equity and debt securities
to a special purpose entity, EPIL II, a wholly owned subsidiary of the Company.
On 28 June 2000, EPIL II issued $450.0 million in aggregate principal amount of
the EPIL II Notes, in a private placement to a group of financial institutions.
The EPIL II Notes mature on 28 June 2004. EPIL II paid cash of $340.0 million
to the Company for the portfolio of investments transferred to it. Other than a
payment of $0.8 million (2002: $0.8 million; 2001: $0.8 million) for
administration services, there were no cash flows between EPIL II and the
Company in 2003, 2002 or 2001. The investments and cash in EPIL II are held as
security against the EPIL II Notes. These assets are not available for
distribution outside EPIL II. The investments and cash had a fair value of
$105.8 million, and a carrying value of $77.1 million, at 31 December 2003. The
EPIL II Notes are guaranteed on a subordinated basis by Elan and, consequently,
in accordance with the provisions of FRS 5, the EPIL II Notes and the
investments are both included separately in the Company's consolidated balance
sheet. The EPIL II Notes bear interest at the rate of 9.56% per annum, payable
in cash. Issue costs associated with the financing amounted to $5.9 million.

Interest charged in 2003 amounted to $43.0 million (2002: $43.0 million; 2001:
$43.0 million). The liability outstanding at 31 December 2003, net of financing
costs, was $450.0 million (2002: $449.0 million) with interest accrued of $0.4
million (2002: $0.4 million).

3.25% LYONs

In December 1998 EFC issued, in a private placement and at a substantial
discount, LYONs due 2018 in the principal amount of $1,643.5 million at
maturity. The issue price of the LYONs was $524.78 per $1,000 principal amount
at maturity and the gross proceeds to the Company amounted to $862.5 million.
The expenses associated with the transaction amounted to $23.1 million. The
LYONs are exchangeable at any time at the option of the holder into 13.75 Elan
ADSs per each $1,000 principal amount at maturity. The securities are
redeemable for cash at any time, at the option of the Company, on or after 14
December 2003. Holders of the LYONs may require Elan to purchase all or any
portion of their LYONs on 14 December 2003, 14 December 2008 and 14 December
2013 at a purchase price equal to the issue price plus all accrued original
issue discount up to the purchase date. Elan may, at its option, elect to pay
the purchase price for the LYONs in cash, by the delivery of ADSs, at then
existing market prices, or any combination of cash and ADSs. Elan's right to
pay the purchase price for the LYONs by delivering ADSs is subject to certain
conditions, including the registration of the ADSs to be delivered under the
Securities Act of 1933 and the listing of those ADSs on the NYSE.

In December 2002, Elan repurchased $318.6 million in principal amount at
maturity of LYONs (representing approximately 19% of the originally issued
LYONs) in separate privately negotiated purchases. These LYONs, having an
accreted value of $190.1 million at the dates of acquisition, were purchased at
an aggregate cost of $149.8 million, resulting in a net gain of $37.7 million
after related costs at the dates of acquisition. This was a discount of
approximately 24% to the accreted value of such LYONs at 14 December 2003 of
$196.5 million.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     119

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Through 3 June 2003, Elan repurchased an additional $523.7 million in principal
amount at maturity of the LYONs (representing approximately 32% of the
originally issued LYONs) in separate privately negotiated purchases. The
aggregate cost was $310.3 million. This was a discount of approximately 4% to
the accreted value of such LYONs at 14 December 2003 of $322.9 million.

On 14 November 2003, Elan announced that holders of the remaining outstanding
LYONs had the right to surrender their LYONs for purchase during the period
that began then and ended on 15 December 2003. Pursuant to the indenture under
which the LYONs were issued in December 1998, each holder of LYONs had the
right to require Elan to purchase, until 5:00 p.m., New York time, on 15
December 2003, such holder's LYONs at a price equal to $616.57 per $1,000
principal amount at maturity of the LYONs.

Under the terms of the LYONs, Elan had the option to pay for the LYONs in cash,
in ADSs, representing Ordinary Shares, of Elan, or in any combination of cash
and ADSs. Elan elected to pay for the LYONs in cash. The aggregate principal
amount due at maturity for all outstanding LYONs was approximately $801.3
million.

On 16 December 2003, Elan announced that LYONs with an aggregate principal
amount at maturity of approximately $799.7 million were validly surrendered for
repurchase and not withdrawn, and Elan had repurchased all such LYONs.
Approximately $1.6 million in aggregate principal amount at maturity of LYONs
remain outstanding following the completion of the repurchase. The aggregate
purchase price for all LYONs validly surrendered for repurchase and not
withdrawn was approximately $493.1 million. The accreted value of the remaining
LYONs was $0.9 million at 31 December 2003.

The original issue discount charged to income in the year to 31 December 2003
amounted to $19.1 million (2002: $31.0 million, 2001: $30.2 million). At 31
December 2003, the liability represented a price of $616.57 per $1,000
principal amount at maturity.

The liability outstanding at 31 December 2003, net of financing costs of $Nil
(2002: $13.3 million), was $0.9 million (2002: $682.0 million) with interest
accrued of $Nil (2002: $97.0 million). Inclusive of financing costs, the
accreted value of the LYONs at 31 December 2003 was $0.9 million (2002: $792.3
million).

EPIL III NOTES

In March 2001, the Company transferred a portfolio of equity and debt
securities to a special purpose entity, EPIL III, a wholly owned subsidiary of
the Company. EPIL III issued $200.0 million in aggregate principal amount of
the Series C Guaranteed Notes in a private placement to a group of financial
institutions. In addition, EPIL III issued $160.0 million in aggregate
principal amount of the Series A Guaranteed Notes and $190.0 million of the
Series B Guaranteed Notes, in exchange for all outstanding 8.43% Guaranteed
Notes issued in June 1999 by EPIL. The Series A Guaranteed Notes were, and the
Series B Guaranteed Notes and Series C Guaranteed Notes are, fully and
unconditionally guaranteed on a subordinated basis by Elan. The Series A
Guaranteed Notes bore interest at the rate of 8.43% per annum. The Series B
Guaranteed Notes bore interest at the rate of 8.43% per annum through June 2002
and 7.72% per annum thereafter. The Series C Guaranteed Notes bear interest at
the rate of 7.62% per annum.

In 2001, EPIL III paid cash of $106.0 million to the Company and also exchanged
the EPIL III Series A and Series B Guaranteed Notes for all outstanding 8.43%
Guaranteed Notes as consideration for the portfolio of investments transferred
to it. Other than these payments and a payment of $0.8 million (2002: $0.8
million, 2001: $0.6 million) for administration services, there were no other
cash flows between EPIL III and the Company in 2003, 2002 or 2001. The
remaining investments and cash in EPIL III are held as security against the
EPIL III Series B Guaranteed Notes and the Series C Guaranteed Notes. These
assets are not available for distribution outside EPIL III. The investments and
cash had a fair value of $152.3 million, and a carrying value of $94.3 million,
at 31 December 2003. The Series B Guaranteed Notes and the Series C Guaranteed
Notes are guaranteed on a subordinated basis by Elan and, consequently, in
accordance with the provisions of FRS 5, the Series B Guaranteed Notes and the
Series C Guaranteed Notes, investments and cash are included separately in the
Company's consolidated balance sheet. Issue costs associated with the financing
of the EPIL III Notes amounted to $6.1 million.

In June 2002, EPIL III disposed of securitised investments in order to repay
the $160.0 million in the aggregate principal amount of its Series A Guaranteed
Notes which matured on 29 June 2002.

For additional information relating to the disposal of financial assets by EPIL
III, please refer to Note 3 and Note 33 to the Consolidated Financial
Statements.

Interest charged on the EPIL III notes in 2003 amounted to $29.9 million (2002:
$37.2 million, 2001: $35.4 million). The liability outstanding at 31 December
2003, net of financing costs, was $389.5 million (2002: $387.5 million) with
interest accrued of $0.2 million (2002: $0.2 million).

--------------------------------------------------------------------------------
120

--------------------------------------------------------------------------------

7.25% SENIOR NOTES

In February 2001, Athena Finance, an indirect wholly owned subsidiary of Elan,
issued $650.0 million in aggregate principal amount of 7.25% Senior Notes due
2008 at a discount of $2.5 million. The 7.25% Senior Notes are senior,
unsecured obligations of Athena Finance and are fully and unconditionally
guaranteed on a senior unsecured basis by Elan. Issue costs associated with the
financing amounted to $8.3 million.

Interest is paid in cash semi-annually. Interest charged in the year ending 31
December 2003 amounted to $47.1 million (2002: $47.1 million, 2001: $40.3
million). The liability outstanding at 31 December 2003, net of financing
costs, was $645.1 million (2002: $643.9 million) with interest accrued of $16.7
million (2002: $16.7 million, 2001: $16.7 million).

On 14 January 2002, Elan entered into an interest rate swap to convert its
fixed rate interest obligations for $100.0 million of the 7.25% Senior Notes to
variable rate interest obligations. The swap had a fair value gain of $8.5
million at 31 December 2003 (2002: $8.1 million).

6.5% CONVERTIBLE NOTES

In November 2003, Elan announced that it had completed the offering and sale of
$460.0 million in aggregate principal amount of 6.5% Convertible Notes issued
by ECC, an indirect wholly-owned subsidiary of Elan, and guaranteed by Elan.
The 6.5% Convertible Notes mature on 10 November 2008.

Holders of the 6.5% Convertible Notes have the right to convert the notes into
fully-paid ADSs at a conversion price of $7.42 at any time up to 10 November
2008 or seven trading days preceding the date of redemption if the notes are
called for redemption.

Elan may, at any time after 1 December 2006, redeem all or part of the 6.5%
Convertible Notes then outstanding at par, with interest accrued to the
redemption date provided that, within a period of 30 consecutive trading days
ending five trading days prior to the date on which the relevant notice of
redemption is published, the official closing price per share of the ADSs on
the NYSE for 20 trading days shall have been at least 150% of the conversion
price deemed to be in effect on each of such trading days.

Interest is paid in cash semi-annually. Interest charged in the year ending 31
December 2003 amounted to $4.1 million (2002: $Nil, 2001: $Nil). The liability
outstanding at 31 December 2003, net of financing costs, was $444.4 million
(2002: $Nil) with interest accrued of $4.1 million (2002: $Nil).

COVENANTS

The agreements governing certain of Elan's outstanding indebtedness contain
various restrictive covenants that restrict the Group's ability to, among other
things, incur additional indebtedness (including intercompany indebtedness),
create liens and other encumbrances, enter into transactions with related
parties, sell or otherwise dispose of assets and merge or consolidate with
another entity. In addition, some of these agreements require Elan to maintain
certain financial ratios. Elan does not currently, and does not expect in the
foreseeable future, to have the ability to incur any additional indebtedness
under certain of these covenants, unless it receives a waiver from the holders
of a majority of the applicable indebtedness.

As a result of Elan's failure to timely complete and file with the SEC Elan's
Annual Report on Form 20-F for its fiscal year ended 31 December 2002, on 30
June 2003, Elan defaulted under certain covenants contained in the agreements
governing the EPIL II Notes and the Series B and Series C Guaranteed Notes
issued by EPIL III. The covenants required that Elan provide to each of the
holders of such notes Elan's audited consolidated financial statements,
together with an officer's certificate relating thereto, on or prior to 29 June
2003. On 15 July 2003, Elan also defaulted under a covenant contained in the
indenture governing the 7.25% Senior Notes that required Elan to file its 2002
Annual Report on Form 20-F with the SEC on or prior to 15 July 2003.

Commencing on 29 July 2003, Elan received a series of separate agreements from
a majority of the holders of the EPIL II Notes and the holders of the Series B
and Series C Guaranteed Notes waiving compliance by Elan with the applicable
covenants described above. The series of waivers was effective through 5
September 2003. With the completion and filing with the SEC of Elan's 2002
Annual Report on Form 20-F, the defaults described above were cured in all
respects. In the absence of the waivers, the defaults under the EPIL II Notes
and the Series B and Series C Guaranteed Notes would have become events of
default on 30 July 2003. In the absence of the completion and

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     121

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

filing with the SEC of Elan's 2002 Annual Report on Form 20-F, the default
under the indenture governing the 7.25% Senior Notes would have become an event
of default on 16 September 2003.

16 CREDITORS

                                        AT 31 DECEMBER     AT 31 DECEMBER
                                                  2003               2002
                                                    $M                 $M
-------------------------------------------------------------------------

 AMOUNTS FALLING DUE WITHIN ONE YEAR:
 Trade creditors                                  32.7               59.0
 Accrued liabilities                             258.4              371.7
 Product acquisitions and alliances               19.4              277.6
 Other creditors                                  25.6               30.5
 Taxation and social security (Note 7)            29.4               60.0
-------------------------------------------------------------------------
                                                 365.5              798.8
-------------------------------------------------------------------------
 AMOUNTS FALLING DUE AFTER ONE YEAR:
 Product acquisitions and alliances               11.2              204.6
 Other creditors                                  18.0               31.6
-------------------------------------------------------------------------
                                                  29.2              236.2
-------------------------------------------------------------------------

PRODUCT ACQUISITIONS AND ALLIANCES

At 31 December 2003, Elan included in creditors $30.6 million relating to
future payments and/or future potential payments on products. Of the $30.6
million, $19.4 million was owing at 31 December 2003 and $11.2 million was
potentially payable, contingent on future events. Elan is a party to certain
product acquisition or alliance agreements that contain staged or option
payments which may be uncertain in amount, which may be paid at Elan's
discretion, such as upon the exercise of an option to acquire the product, or
which must be paid upon the occurrence of future events, such as the attainment
of pre-determined product revenue targets or other milestones. Elan has accrued
$19.4 million within creditors (within one year), including $15.6 million for
Maxipime/Azactam and $11.2 million within creditors (after one year) for Frova.

At 31 December 2002, Elan included in creditors $482.2 million relating to
future payments and/or future potential payments on products. The reduction of
$451.6 million from December 2002 to December 2003 primarily reflects product
payments made during the year of $212.4 million and product payment obligations
assumed by King and aaiPharma of $218.8 million and $51.4 million,
respectively.

--------------------------------------------------------------------------------
122

--------------------------------------------------------------------------------

The balance outstanding at 31 December was as follows:

                             2003         2002
                               $M           $M
----------------------------------------------

 WITHIN ONE YEAR:
 Maxipime/Azactam            15.6        130.7
 Sonata                       --         114.7
 Pain Portfolio               --          28.3
 Other                        3.8          3.9
----------------------------------------------
                             19.4        277.6
----------------------------------------------
 AFTER ONE YEAR:
 Sonata                       --         146.0
 Pain Portfolio               --          49.1
 Frova                       11.2          6.1
 Other                        --           3.4
----------------------------------------------
                             11.2        204.6
----------------------------------------------

17 SHARE CAPITAL

AUTHORISED SHARE CAPITAL                                               NO. OF ORDINARY SHARES
---------------------------------------------------------------------------------------------

 AT 31 DECEMBER 2003 AND 2002:
 Ordinary Shares (par value 5 Euro cents)                                         600,000,000
 Executive Shares (par value 1.25 Euro)(the "Executive Shares")                         1,000
 "B" Executive Shares (par value 5 Euro cents)(the "B" Executive Shares")              25,000
---------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------
                                            AT 31 DECEMBER 2003       AT 31 DECEMBER 2002
-----------------------------------------------------------------------------------------
ISSUED AND FULLY PAID SHARE CAPITAL           NUMBER      $000S          NUMBER     $000S
-----------------------------------------------------------------------------------------

 Ordinary Shares                         386,182,274     22,015     350,408,863    19,939
 Executive Shares                              1,000          2           1,000         2
 "B" Executive Shares                         21,375          2          21,375         2

On 5 November 2003, Elan announced that it had successfully completed a private
offering of 35 million Ordinary Shares at a price of $4.95 per share.

The Executive Shares do not confer on the holders thereof the right to receive
notice of, attend or vote at any meetings of the Company, or the right to be
paid a dividend out of the profits of the Company, except for such dividends as
the directors may from time to time determine.

The "B" Executive Shares confer on the holders thereof the same voting rights
as are enjoyed by the holders of Ordinary Shares. The "B" Executive Shares do
not confer on the holders thereof the right to be paid a dividend out of the
profits of the Company except for such dividends as the directors may from time
to time determine.

Shares issuable at 31 December 2003 of $1.3 million relate to shares of Athena
Neurosciences, Sano, Neurex, Liposome and Dura common stock remaining to be
converted into Ordinary Shares pursuant to the acquisition of these companies
and warrants over 1,500,000 Ordinary Shares valued at $16.4 million issued to
Eastman Kodak Company on the acquisition of NanoSystems by Elan.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     123

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

18 PROFIT AND LOSS ACCOUNT

                                          AT 31 DECEMBER     AT 31 DECEMBER
                                                    2003               2002
                                                      $M                 $M
----------------------------------------------------------------------------

 Holding company                                (4,110.6)          (3,971.2)
 Subsidiary and associated undertakings            (76.1)             599.9
 Goodwill written-off                             (574.3)            (574.3)
----------------------------------------------------------------------------
                                                (4,761.0)          (3,945.6)
----------------------------------------------------------------------------

Elan has availed of the Companies (Amendment) Act 1986 exemption from the
requirement to present its separate non-consolidated profit and loss account.
Of the consolidated net loss after tax, a loss of $139.4 million (2002:
$5,723.3 million) is dealt with in the profit and loss account of the Company.

19 MINORITY INTEREST

The minority interest at 31 December 2002 related to the minority interest in
Elan Pharma Taiwan and Elan Pharmaceutical Corporation, Philippines. These
subsidiaries were sold during 2003.

20 SHARE OPTIONS AND WARRANTS

Share options have been granted to directors, employees, consultants and
certain other parties. Options are granted at the price equal to the market
value at the date of grant and will expire on a date not later than ten years
after their grant. Options generally vest between one and five years from the
date of grant. There were 48,737,057 options outstanding under these
arrangements at 31 December 2003.

Under the terms of the 1986 and 1989 Elan employee stock option plans, options
to purchase 44,400 Ordinary Shares were outstanding at 31 December 2003. No
options were available for grant under these plans at 31 December 2003. Under
the terms of the 1996 Elan stock option plans, options to purchase 9,290,558
Ordinary Shares were outstanding at 31 December 2003. Options to purchase a
further 4,342,004 shares were available for grant at 31 December 2003. Under
the terms of the 1998 Elan employee stock option plan, options over 4,841,957
Ordinary Shares were outstanding at 31 December 2003. No options were available
for grant under this plan at 31 December 2003. Under the terms of the 1999 Elan
employee stock option plan, options over 33,758,641 Ordinary Shares were
outstanding at 31 December 2003. Options to purchase a further 2,802,142 shares
were available for grant at 31 December 2003.

As a result of the acquisition of Athena Neurosciences on 1 July 1996, options
and warrants granted by Athena Neurosciences prior to the acquisition date
vested and were converted into options and warrants to acquire 6,346,424
Ordinary Shares. As a result of the acquisition of Sano on 27 February 1998,
options granted by Sano were converted into a total of 2,216,850 options to
acquire Ordinary Shares. As a result of the acquisition of Neurex on 14 August
1998, options and warrants granted by Neurex were converted into a total of
3,011,702 options to acquire Ordinary Shares. As a result of the acquisition of
Liposome on 12 May 2000, options and warrants granted by Liposome were
converted into a total of 1,875,260 options to acquire Ordinary Shares. As a
result of the acquisition of Dura on 9 November 2000, options and warrants
granted by Dura vested and were converted into options and warrants to acquire
5,513,457 Ordinary Shares. At 31 December 2003, 563,332 of the options arising
from the acquisitions of Athena Neurosciences, Sano, Neurex, Liposome and Dura
were outstanding.

From January 1998, Elan was a party to a development and licence agreement (the
"Neuralab Development Contract") and a services agreement with Neuralab, to
identify therapeutic compounds for use in the treatment of AD. In January 1998,
a private placement of 1,250,000 units was completed. In connection with the
Neuralab offering, Elan issued 1,250,000 warrants. The warrants were
exercisable at $65.01 for two Ordinary Shares until 14 January 2003.

Arising from the acquisition by Elan of all the assets and liabilities of
NanoSystems, Elan granted 750,000 warrants to purchase 1,500,000 Ordinary
Shares. The warrants are exercisable at $45.00 per share from 1 February 1999
to 1 October 2006.

--------------------------------------------------------------------------------
124

--------------------------------------------------------------------------------

The share options and warrants outstanding and exercisable are summarised as
follows:

                                                          OPTIONS                         WARRANTS
--------------------------------------------------------------------------------------------------
                                            SHARES      WAEP* ($)            SHARES      WAEP* ($)
--------------------------------------------------------------------------------------------------

 Outstanding at 31 December 2000        43,651,900         29.77         16,349,266         26.95
 Exercised                              (7,886,459)        28.83        (10,227,644)        19.20
 Granted                                 8,686,283         53.20                 --           --
 Expired                                (3,537,813)        39.74                 --           --
--------------------------------------------------------------------------------------------------
 Outstanding at 31 December 2001        40,913,911         34.06          6,121,622         39.89
 Exercised                                (544,124)        17.59             (7,432)        28.01
 Granted                                21,905,272          5.46                 --           --
 Expired                                (9,253,816)        34.89         (1,045,246)        46.05
--------------------------------------------------------------------------------------------------
 Outstanding at 31 December 2002        53,021,243         22.28          5,068,944         38.64
 Exercised                                (764,944)         2.39                 --           --
 Granted                                 5,956,098          4.47                 --           --
 Expired                                (8,912,008)        24.54         (2,494,498)        32.51
--------------------------------------------------------------------------------------------------
 Outstanding at 31 December 2003        49,300,389         20.03          2,574,446         39.20
 Exercisable at 31 December 2003        32,060,013         24.11          2,574,446         39.20
--------------------------------------------------------------------------------------------------

*     Weighted average exercise price

At 31 December 2003, the range of exercise prices and weighted average
remaining contractual life of outstanding and exercisable options were as
follows:

                                                WEIGHTED AVERAGE
NUMBER                                     REMAINING CONTRACTUAL              NUMBER
OUTSTANDING    WAEP ($)         RANGE ($)           LIFE (YEARS)         EXERCISABLE    WAEP ($)
------------------------------------------------------------------------------------------------

 19,625,820       2.78    $ 1.93--$10.00                    6.9            7,717,935       2.15
 11,151,496      17.08    $10.01--$25.00                    3.9            8,974,149      17.82
 11,380,436      32.35    $25.01--$40.00                    3.2           10,289,788      32.31
  7,142,637      52.39    $40.01--$58.60                    4.6            5,078,141      51.98
------------------------------------------------------------------------------------------------
 49,300,389      20.03    $ 1.93--$58.60                    5.0           32,060,013      24.11
------------------------------------------------------------------------------------------------

21 FINANCIAL INSTRUMENTS

The Company uses derivative financial instruments to reduce exposure to market
risk resulting from fluctuations in foreign exchange rates and interest rates.
The Company does not enter into derivative financial instruments for trading or
speculative purposes.

Derivative instruments are contractual agreements whose value reflects price
movements in an underlying asset or liability. The Company uses derivatives,
where appropriate, to generate the desired effective profile of currency and
interest rate risk.

The main risks arising from the use of financial instruments are market rate
risk and liquidity risk. Market rate risk is defined as the exposure of Elan to
adverse movements in interest and foreign exchange risks. The Company only
enters into contracts with parties that have at least an "A" or equivalent
credit rating. The counterparties to these contracts are major financial
institutions. Management believes that the risk of any net loss is remote and
would not be material to the Company.

Short term debtors and creditors have been excluded from all numerical
disclosures below, excluding the currency rate risk analysis. As explained in
Note 1 to the Consolidated Financial Statements, the financial statements are
prepared in U.S. dollars and, therefore, the Company is exposed to foreign
exchange risks related to costs incurred and revenues earned in currencies
other than U.S. dollars.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     125

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

A INTEREST RATE RISK

The interest rate risk profile of Elan's financial liabilities was as follows:

                                             AT 31 DECEMBER 2003                             AT 31 DECEMBER 2002
-----------------------------------------------------------------------------------------------------------------
                        FIXED  FLOATING  NO INTEREST       TOTAL       FIXED  FLOATING  NO INTEREST        TOTAL
PRINCIPAL CURRENCY         $M        $M           $M          $M          $M        $M           $M           $M
-----------------------------------------------------------------------------------------------------------------

 U.S. Dollars            21.8       1.9         11.9        35.6        34.4       4.7        204.7        243.8
-----------------------------------------------------------------------------------------------------------------

The following fixed-rate liabilities are not included in the above table:

EPIL II Notes due 2004--the liability outstanding on these notes at 31 December
2003 was $450.4 million (2002: $449.4 million) including interest accrued.

EPIL III Notes due 2005--the liability outstanding on these notes at 31
December 2003 was $389.7 million (2002: $387.7 million) including interest
accrued.

3.25% Zero Coupon Subordinated Exchangeable Notes due 2018 (LYONs)--the
liability outstanding on these notes at 31 December 2003 was $0.9 million
(2002: $779.0 million) including interest accrued.

7.25% Senior Notes due 2008--the liability outstanding on these notes at 31
December 2003 was $661.8 million (2002: $660.6 million) including interest
accrued.

6.5% Convertible Notes due 2008--the liability outstanding at 31 December 2003
was $448.5 million (2002: $Nil) including interest accrued.

For additional information regarding the above debt, please refer to Note 15 to
the Consolidated Financial Statements.

All fixed-rate liabilities have a weighted average interest rate of 7.7% (2002:
6.4%), maturing between 2004 and 2008. The weighted average life of the fixed
rate debt is 2.9 years (2002: 2.5 years).

The weighted average period until maturity for financial liabilities on which
no interest is paid is Nil (2002: 2.5 years).

Variable interest rates on liabilities were generally based on the appropriate
LIBOR.

The interest rate risk profile of Elan's financial assets was as follows:

                                                        AT 31 DECEMBER 2003                                   AT 31 DECEMBER 2002
---------------------------------------------------------------------------------------------------------------------------------
                                FIXED    FLOATING  NO INTEREST        TOTAL        FIXED      FLOATING  NO INTEREST         TOTAL
                                   $M          $M           $M           $M           $M            $M           $M            $M
---------------------------------------------------------------------------------------------------------------------------------

 Investments(1)                 204.6          --        266.0        470.6        392.9            --        353.3         746.2
 Cash and liquid resources         --       828.0           --        828.0           --       1,086.5           --       1,086.5
---------------------------------------------------------------------------------------------------------------------------------

(1)   Excludes investments in and loans to associates.

Fixed interest rates on investments have a weighted average interest rate of
8.4% (2002: 7.6%), maturing between 2004 and 2006. The weighted average life of
the fixed interest rate investments is 0.1 years (2002: 0.2 years).

Cash and liquid resources include restricted cash, held by EPIL II and EPIL
III, in an amount of $21.1 million.

Variable interest rates on cash and liquid resources are generally based on the
appropriate Euro Interbank Offered Rate, London Interbank Bid Rate or bank
rates dependent on principal amounts on deposit.

--------------------------------------------------------------------------------
126

--------------------------------------------------------------------------------

B CURRENCY RATE RISK

The Group has exposure to various reporting currencies due to the international
nature of its operation.

The table below shows Elan's currency exposure. Such exposure comprises the
monetary assets and monetary liabilities of Elan that are not denominated in
the operating currency of the operating unit involved. At 31 December 2003 and
2002, respectively, these exposures were as follows:

NET FOREIGN CURRENCY                                     FUNCTIONAL CURRENCY OF GROUP OPERATION
--------------------------------------------------------------------------------------------------------------
MONETARY (LIABILITIES)/ASSETS                     AT 31 DECEMBER 2003                      AT 31 DECEMBER 2002
--------------------------------------------------------------------------------------------------------------
IN U.S. $M                    SWISS FRANCS   U.S. DOLLAR        TOTAL   SWISS FRANCS   U.S. DOLLAR       TOTAL
--------------------------------------------------------------------------------------------------------------

 Sterling                            (0.1)           1.0          0.9          (0.1)            --        (0.1)
 Euro                                (0.2)         (20.5)       (20.7)         (1.0)            --        (1.0)
 Swiss Franc                           --          ( 0.2)        (0.2)           --           (1.7)       (1.7)
 Israeli Shekel                        --            0.1          0.1            --            0.2         0.2
 Taiwan Dollar                         --             --           --            --           (0.3)       (0.3)
 Canadian Dollar                       --            0.4          0.4            --            1.2         1.2
--------------------------------------------------------------------------------------------------------------
 Total                               (0.3)         (19.2)       (19.5)         (1.1)          (0.6)       (1.7)
--------------------------------------------------------------------------------------------------------------

The amounts shown in the table above take into account the effect of forward
contracts and other derivatives entered into to manage these currency
exposures.

C FAIR VALUES

Fair value is the amount at which a financial instrument could be exchanged in
an arm's-length transaction between informed and willing parties, other than in
a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair value of
each material class of financial instrument:

Financial assets--the fair values of financial assets have been estimated for
quoted equity securities utilising quoted market prices, for debt securities by
methods including utilising current market interest rates for loans with
similar risk and duration profile and for material unquoted equity investments
generally by the most recent private financing prices, discounted projected
future cash flows and option valuation models. The fair values of marketable
securities, including interest rate futures, have been estimated based on
quotes obtained from brokers for these and similar instruments.

Cash and liquid resources--carrying amount approximates fair value due to the
short term nature of these instruments.

3.25% Zero Coupon Subordinated Exchangeable Notes (LYONs), 6.5% Convertible
Notes and 7.25% Senior Notes--the fair values have been assessed based on the
quoted market price.

EPIL II Notes and EPIL III Notes--the fair values have been assumed to be the
carrying values.

The carrying value of financial instruments below have been stated before
financing costs and include accrued interest.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     127

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

The fair value of financial instruments was as follows:

                                                                      AT 31 DECEMBER 2003           AT 31 DECEMBER 2002
-----------------------------------------------------------------------------------------------------------------------
                                                                    CARRYING         FAIR       CARRYING           FAIR
                                                                       VALUE        VALUE          VALUE          VALUE
FINANCIAL INSTRUMENTS                                                    $M           $M             $M             $M
-----------------------------------------------------------------------------------------------------------------------

 Financial assets(1)                                                  470.6        665.1          746.2          795.0
 Cash and liquid resources                                            828.0        828.0        1,086.5        1,086.5
 6.5% Convertible Notes(2)                                           (464.2)      (594.1)            --             --
 EPIL II Notes(2)                                                    (450.4)      (450.4)        (450.4)        (450.4)
 EPIL III Notes(2)                                                   (390.2)      (390.2)        (390.2)        (390.2)
 3.25% Zero Coupon Subordinated Exchangeable Notes (LYONs)(2)          (0.9)        (0.9)        (792.3)        (636.0)
 7.25% Senior Notes(2)                                               (666.7)      (600.4)        (666.7)        (371.0)
-----------------------------------------------------------------------------------------------------------------------

(1)   Excludes investments in and loans to associates.

(2)   Before financing costs.

D LIQUIDITY RISK

The objective of liquidity management is to ensure the availability of
sufficient funds to meet Elan's requirements and to repay maturing debt.

The maturity profile of Elan's financial liabilities was as follows:

                                                      AT 31 DECEMBER     AT 31 DECEMBER
                                                                2003               2002
                                                                  $M                 $M
---------------------------------------------------------------------------------------

 In one year or less, or on demand                               7.0                7.6
 In more than one year but not more than two years              17.7              111.7
 In more than two years but not more than five years             8.9              113.5
 In more than five years                                         2.0               11.0
---------------------------------------------------------------------------------------
                                                                35.6              243.8
---------------------------------------------------------------------------------------

The above table excludes the maturity of the EPIL II Notes, the EPIL III Notes,
the 7.25% Senior Notes, the 6.5% Convertible Notes and the 3.25% Zero Coupon
Subordinated Exchangeable Notes (LYONs) which mature in 2004, 2005, 2008, 2008
and 2018, respectively.

For additional information on liquidity, please refer to the Financial Review.

E DERIVATIVE INSTRUMENTS

Under Elan's accounting policy, foreign currency options and forward exchange
contracts are valued at fair value. Consequently, changes in fair value
attributable to movements in exchange rates are recognised in the profit and
loss account.

At 31 December 2003, Elan had not entered into forward foreign exchange
contracts or foreign currency options.

At 31 December 2002, Elan had entered into a number of forward foreign exchange
contracts and foreign currency options at various rates of exchange in the
normal course of business. The nominal value of forward foreign exchange
contracts to sell Japanese Yen for U.S. dollars at that date was $7.9 million
and these contracts had a fair value loss of $0.4 million. These contracts all
expired on various dates up to and including September 2003.

The nominal value of forward foreign exchange contracts to sell U.S. dollars
for Euro at 31 December 2003 was $Nil  (2002: $39.8 million) and these
contracts had a fair value of $Nil (2002: $5.0 million gain). These contracts
all expired on various dates up to and including October 2003.

--------------------------------------------------------------------------------
128

--------------------------------------------------------------------------------

The nominal value of forward foreign exchange contracts to sell U.S. dollars
for Sterling at 31 December 2003 was $Nil (2002: $4.6 million) and these
contracts had a fair value of $Nil (2002: $0.2 million gain). These contracts
all expired by June 2003.

The nominal value of currency options to sell U.S. dollars for Euro at 31
December 2003 amounted to $Nil (2002: $24.0 million) and these options had a
fair value of $Nil (2002: $3.0 million gain). These options expired on various
dates up to and including December 2003.

In February 2001, Elan raised $650.0 million of 7.25% Senior Notes due 2008. On
14 January 2002, Elan entered into an interest rate swap to convert its fixed
rate interest obligations for $100.0 million of the 7.25% Senior Notes to
variable rate interest obligations. The swap had a fair value gain of $8.5
million at 31 December 2003 (2002: $8.1 million gain).

F SENSITIVITY ANALYSIS

A sensitivity analysis of the market value of Elan's financial instruments to
hypothetical changes in applicable market rates at 31 December 2003 indicated
that their effect would not be material. The range scenario included was based
on Elan's expectation of what would be reasonable on a 12 month time frame and
involved a 10% movement in foreign exchange rates and a 1% movement in interest
rates. The effect of such an adverse movement in rates would be a decrease in
income of approximately $8 million.

Elan is exposed to equity price risks primarily on equity investments in quoted
companies. At 31 December 2003, quoted securities had a fair value of $204.2
million and had a cost of $102.2 million. These investments are primarily in
emerging pharmaceutical and biotechnology companies. A 10% adverse change in
equity prices would result in an approximate $20 million decrease in the fair
value of these quoted securities.

22 ACQUISITIONS AND DISPOSALS OF SUBSIDIARY UNDERTAKINGS

Details of the disposal of subsidiary undertakings are given below:

           NET CASH   NET ASSETS        NET
           PROCEEDS     DISPOSED       LOSS
2003             $M           $M         $M
-------------------------------------------

 ETT           44.7         75.0      (30.3)
 Other          1.4          3.8       (2.4)
-------------------------------------------

On 3 July 2003, Elan sold ETT to Nitto Americas. Other subsidiary undertakings
sold includes Elan Drug Delivery Ltd, sold on 10 July 2003; Elan Pharma Taiwan
sold on 24 March 2003 and Elan Pharmaceutical Corporation, Philippines sold in
January 2003.

                        NET CASH   NET ASSETS       NET
                        PROCEEDS     DISPOSED      GAIN
2002                          $M           $M        $M
-------------------------------------------------------

 Athena Diagnostics         81.8         16.6      65.2
-------------------------------------------------------

On 19 December 2001, Elan sold approximately 20% of Athena Diagnostics for cash
in a private placement, resulting in $41.9 million of gross proceeds to Elan,
before accrued costs. On 31 December 2002, Elan together with the other
stockholders of Elan's subsidiary, Athena Diagnostics, completed the sale of
all of the outstanding stock of Athena Diagnostics to Behrman. Elan realised
net cash proceeds of $81.8 million and a net gain of $65.2 million after
adjusting for net assets sold.

Details of the acquisition of a subsidiary undertaking are given below:

2001

DELSYS

In September 2001, Elan acquired Delsys. The total consideration amounted to
$50.0 million. This included cash paid together with the cost of Elan's
existing investment in the Company. Net liabilities assumed amounted to $1.2
million. Delsys was formed in 1995 and was

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     129

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

engaged in developing novel manufacturing technology. The purchase of Delsys
was accounted for as an acquisition. At the date of acquisition, the fair value
adjustment related to technologies of Delsys, which are separable from the
business, was $51.2 million. During 2002, Elan recorded an impairment charge of
$45.7 million as under its recovery plan Elan decided to close Delsys.

23 COMMITMENTS AND CONTINGENCIES

The Company and its subsidiaries occupy certain facilities under lease
arrangements and lease certain equipment. Future minimum rental commitments for
operating leases with non-cancellable terms in excess of one year are as
follows:

                     MINIMUM RENTAL PAYMENTS
-------------------------------------------------
                 PREMISES      OTHER       TOTAL
                       $M         $M          $M
-------------------------------------------------

 2004                19.1        0.7        19.8
 2005                17.6        0.7        18.3
 2006                18.0        0.2        18.2
 2007                12.7        --         12.7
 2008                14.5        --         14.5
 Later years         74.1        --         74.1
-------------------------------------------------
                    156.0        1.6       157.6
-------------------------------------------------

As of 31 December 2003, the Company had commitments under finance leases as
follows:

                                                             2003        2002
                                                               $M          $M
-----------------------------------------------------------------------------

 Within one year                                             14.9        14.6
 In more than one year, but not more than five years         39.8        40.3
 After five years                                            62.1        62.1
-----------------------------------------------------------------------------
 Total gross payments                                       116.8       117.0
 Less: finance charges included above                       (31.4)      (30.0)
-----------------------------------------------------------------------------
                                                             85.4        87.0
-----------------------------------------------------------------------------

As of 31 December 2003, the following capital commitments for the purchase of
property, plant and equipment had been authorised by the directors:

                     AT 31 DECEMBER     AT 31 DECEMBER
                               2003               2002
                                 $M                 $M
------------------------------------------------------

 Contracted for                 8.8               30.4
 Not-contracted for             4.2                6.5
------------------------------------------------------
                               13.0               36.9
------------------------------------------------------

In prior years, Elan disposed of plant and equipment and subsequently leased
the plant and equipment back and also entered into an arrangement with a third
party bank, the substance of which allows the Company to require a net
settlement of its obligations under the leases. The related assets and
liabilities of these previous sale and leaseback transactions have been offset
in the financial statements in the amount of $63.8 million at 31 December 2003
(2002: $56.2 million).

At 31 December 2003, Elan had commitments to invest $3.8 million (2002: $3.2
million) in healthcare managed funds.

At 31 December 2003, the Company had deferred purchase arrangements for certain
products, which amounted to $4.5 million (2002: $4.5 million). These payments
were dependent on various approvals and milestones being met. These deferred
purchase arrangements were transferred to Medeus upon disposal of the European
sales and marketing business in 2004.

--------------------------------------------------------------------------------
130

--------------------------------------------------------------------------------

Elan, in disposing of assets or businesses, often provides customary
representations, warranties and indemnities (if any) to cover various risks.
Elan does not have the ability to estimate the potential liability from such
indemnities because they relate to unknown conditions. However, Elan has no
reason to believe that these uncertainties would have a material adverse effect
on the Group's financial condition or results of operations.

24 RISK-SHARING ARRANGEMENTS

PHARMA MARKETING

In June 2000, Elan disposed of royalty rights on certain products and
development projects to Pharma Marketing. Pharma Marketing completed a private
placement of its common shares to a group of institutional investors, resulting
in gross proceeds of $275.0 million. Elan holds no investment in Pharma
Marketing and has no representative on its board of directors. Concurrent with
the private placement, Pharma Marketing entered into a Program Agreement with
Elan. The Program Agreement, which substantially regulated the relationship
between Elan and Pharma Marketing, represents a risk-sharing arrangement
between Elan and Pharma Marketing. Under the terms of the Program Agreement,
Pharma Marketing acquired certain royalty rights to each of the following
products for the designated indications (including any other product which
contains the active ingredient included in such product for any other
designation): (i) Frova, for the treatment of migraine; (ii) Myobloc, for the
treatment of cervical dystonia; (iii) Prialt, for the treatment of acute pain
and severe chronic pain; (iv) Zanaflex, for the treatment of spasticity and
painful spasm; and (v) Zonegran, for the treatment of epilepsy. Pharma
Marketing agreed to make payments to Elan in amounts equal to expenditures made
by Elan in connection with the commercialisation and development of these
products, subject to certain limitations. These payments were made on a
quarterly basis based on the actual costs incurred by Elan. Elan did not
receive a margin on these payments.

Elan received no revenue from Pharma Marketing during 2003. Elan's revenue from
Pharma Marketing was $31.3 million for 2002, consisting of $24.0 million for
commercialisation expenditures, which has been recorded as product revenue, and
$7.3 million for development expenditures, which has been recorded as contract
revenue. Pursuant to the Program Agreement, Pharma Marketing utilised all of
its available funding by mid-2002. Elan will not receive any future revenue
from Pharma Marketing. Elan's revenue from Pharma Marketing was $189.8 million
for 2001, consisting of $141.8 million for commercialisation expenditures, and
$48.0 million for development expenditures. In 2003, the royalty rate on net
sales of all designated products was 27.71% on the first $122.9 million of net
sales and 52.5% for net sales above $122.9 million. In 2002, the royalty rate
on net sales of all designated products was 15.79% on the first $122.9 million
of net sales and 3.51% for net sales above $122.9 million. In 2001, the royalty
rate on net sales of Zanaflex was 8.44% on the first $38.0 million of net sales
and 1.88% for net sales of Zanaflex above $38.0 million. No royalties were
payable on the other products in 2001. Elan paid aggregate royalties of $43.3
million for 2003 (2002: $24.1 million; 2001: $5.6 million). This was recorded
as a cost of sale.

In December 2001, the Program Agreement was amended such that Elan re-acquired
the royalty rights to Myobloc and disposed of royalty rights on Sonata to
Pharma Marketing. The amendment was transacted at estimated fair value. The
board of directors and shareholders of Pharma Marketing approved this
amendment. The estimated difference in relative fair value between the royalty
rights on Sonata and the royalty rights on Myobloc was $60.0 million. This
amount was paid to Pharma Marketing by Elan in cash and was capitalised by Elan
as an intangible asset.

Under the original agreements, Elan could have, at its option at any time prior
to 30 June 2003, acquired the royalty rights by initiating an auction process.
This date was extended to 3 January 2005 under the settlement with Pharma
Marketing and Pharma Operating described below. In addition, the holders of
Pharma Marketing common shares were entitled to initiate the auction process
earlier upon the occurrence of certain events. Pursuant to the auction process,
the parties were to negotiate in good faith to agree on a purchase price,
subject to Elan's right to re-acquire the royalty rights at a maximum purchase
price. The maximum purchase price was approximately $413 million at 31 December
2002 and increased by approximately 25% annually (less royalty payments). The
purchase price was reduced under the settlement with Pharma Marketing and
Pharma Operating described below.

On 17 January 2003, Elan announced that Pharma Operating had filed a lawsuit in
the Supreme Court of the State of New York against Elan and certain of its
subsidiaries in connection with the risk-sharing arrangement between the
parties. The lawsuit sought, among other things, a court determination that
Pharma Operating's approval would be required in the event of a sale by Elan of
its interest in Sonata to a third party. On 30 January 2003, Elan, Pharma
Operating and its parent, Pharma Marketing agreed to settle the lawsuit and,
under the terms of the settlement agreement, Pharma Operating dismissed the
litigation between the parties without prejudice. Pursuant to the settlement
agreement, effective upon the sale of Sonata to King on 12 June 2003, (i) Elan
paid Pharma Operating $196.4 million in cash (representing $225.0 million less
royalty payments on all related products paid or due to Pharma Operating from 1
January 2003

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     131

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

through 12 June 2003) to acquire Pharma Operating's royalty rights with respect
to Sonata and Prialt and (ii) Elan's maximum purchase price for the remaining
products in the arrangement, Zonegran, Frova and Zanaflex, was reduced to
$110.0 million, which increased at a rate of 15% per annum from 12 June 2003
(less royalty payments made for periods after 12 June 2003). The parties also
agreed to extend Elan's purchase option termination date to 3 January 2005 from
the original termination date of 30 June 2003.

In connection with the settlement agreement, Elan agreed that it would cause
certain subsidiaries in the United States, Ireland, the United Kingdom,
Germany, France, Spain and Italy to pledge their accounts receivable from
commercial sales of pharmaceutical products and services to Pharma Operating as
collateral to secure Elan's obligations in relation to royalty payments under
the Pharma Marketing arrangement and the settlement agreement. Elan also agreed
that, following the closing of a sale of Sonata, it would grant Pharma
Operating additional collateral to the extent that the aggregate value of the
collateral package, which was to be tested on a quarterly basis, was less than
the maximum purchase price for the royalty rights on Zonegran, Frova and
Zanaflex. On 6 March 2003, EPI and Pharma Operating entered into a security
agreement pursuant to which EPI granted Pharma Operating a first priority
security interest in its accounts receivable from commercial sales of
pharmaceutical products in the United States. On that same date, Elan and
Pharma Operating agreed to the terms of the additional collateral mechanism. On
20 May 2003, EPL and Pharma Operating entered into a security agreement
pursuant to which EPL granted Pharma Operating a security interest in its
accounts receivable from commercial sales of pharmaceutical products and
services in the United Kingdom. A similar agreement was entered into in
relation to Ireland by Elan Pharma Limited (Ireland) on 10 June 2003.

In November 2003, Elan exercised its option to purchase the remaining royalty
rights in respect of Zonegran, Frova and Zanaflex from Pharma Operating for
$101.2 million. As a result, all of Elan's agreements with Pharma Marketing
were terminated. During 2003, Elan expensed $297.6 million as an exceptional
selling, general and administrative expense arising from the acquisition of
royalty rights from Pharma Operating.

AUTOIMMUNE

In December 2001, Autoimmune, in an initial tranche, completed a private
placement of its common shares to a group of institutional investors, resulting
in gross proceeds to Autoimmune of $95.0 million. In the same initial tranche,
Elan purchased non-voting preferred shares of Autoimmune's subsidiary for an
aggregate purchase price of $37.5 million. Elan had no representative on the
board of directors of Autoimmune. The existing group of institutional investors
and Elan also committed to a second investment tranche in the same amounts to
be completed in April 2003, subject to certain conditions. Autoimmune entered
into a Program Agreement with Elan. The Program Agreement, which substantially
regulated the relationship between Elan and Autoimmune, represented a
risk-sharing arrangement among the companies. Under the terms of the Program
Agreement, Autoimmune acquired royalty rights to each of the following products
and development projects for the designated indications: (i) Antegren, for the
treatment of relapsing forms of MS, moderate-to-severe inflammatory bowel
disease, including Crohn's disease and ulcerative colitis, and
moderate-to-severe rheumatoid arthritis; (ii) Maxipime, for the treatment of
infection; (iii) Azactam, for the treatment of infection; and (iv) Abelcet, for
the treatment of severe fungal infection. Autoimmune also acquired royalty
rights on certain development projects, as well as any other product
subsequently developed or acquired by Elan that had an indication substantially
the same as Maxipime, Azactam, or Abelcet and that would be in direct
competition with Maxipime, Azactam or Abelcet. Autoimmune agreed to make
payments to Elan in amounts equal to expenditures made by Elan in connection
with the commercialisation and development of these products, subject to
certain limitations. These payments were to be made on a quarterly basis based
on actual costs incurred by Elan. Elan did not receive a margin on these
payments. Elan's revenue from Autoimmune was $68.7 million for 2002 (2001:
$26.6 million), consisting of $38.8 million (2001: $15.9 million) for
commercialisation expenditures, which has been recorded as product revenue, and
$29.9 million (2001: $10.7 million) for development expenditures, which has
been recorded as contract revenue. Elan has received no revenue from Autoimmune
since June 2002. Elan will not receive any future revenue from Autoimmune. No
royalties were payable to Autoimmune by Elan in 2003, 2002 or 2001.

Under the original agreement, Elan could, at its option at any time prior to
April 2005, acquire the royalty rights by initiating an auction process. In
addition, the holders of the Autoimmune common shares could initiate the
auction process earlier upon the occurrence of certain events. If the auction
process had not been initiated prior to October 2004, it would have
automatically commenced. Pursuant to the auction process, Elan and Autoimmune
would have negotiated in good faith to agree on a purchase price, subject to
Elan's right to re-acquire the royalty rights at a maximum purchase price. This
maximum purchase price increased at various rates, approximately 25% annually,
subject to certain conditions.

In July 2002, Elan announced the termination of all agreements relating to the
risk-sharing arrangement with Autoimmune. The royalty obligations to Autoimmune
were terminated. The total consideration for the royalty rights was $121.0
million which, after taking

--------------------------------------------------------------------------------
132

--------------------------------------------------------------------------------

account of the redemption of Elan's investment of $38.5 million in Autoimmune,
resulted in a net cash cost of $82.5 million. Elan expensed $121.0 million as
an exceptional selling, general and administrative expense arising from the
acquisition of royalty rights from Autoimmune.

25 LITIGATION

Elan is involved in various legal and administrative proceedings, relating to
securities matters/SEC investigation, patent matters, antitrust matters and
other matters. The most significant of these matters are described below.

Elan recorded a provision during 2003 of $11.1 million relating to the
litigation with Allergan and BioPort Corporation ("BioPort") described below.
With the exception of the litigations with Allergan and BioPort, Elan does not
believe that it is feasible to predict or determine the outcomes of the pending
actions, investigations and proceedings and any possible effect on the Group's
business or to reasonably estimate the amounts of minimum losses or potential
range of losses, if any, with respect to the pending actions, investigations
and proceedings. The costs and other effects of pending or future litigation,
governmental investigations, legal and administrative cases and proceedings,
settlements, judgements and claims, and changes in those matters (including the
matters described below) and developments or assertions by or against the Group
relating to intellectual property, could have a material adverse effect on the
Group's business, financial condition, results of operations and liquidity.

SECURITIES MATTERS/SEC INVESTIGATION

Commencing in January 1999, several class actions were filed in the U.S.
District Court for the Southern District of California against Dura, one of
Elan's subsidiaries, and various then current or former officers of Dura. The
actions, which allege violations of the U.S. federal securities laws, were
consolidated and purport to seek damages on behalf of a class of shareholders
who purchased Dura common stock during a defined period. In July 2000, the
court issued an order granting the defendants' motion to dismiss the complaint
without prejudice on the basis that it failed to state an actionable claim. In
November 2001, the court granted Dura's motion to dismiss with prejudice and
judgement was entered in Dura's favour. In December 2001, plaintiffs filed an
appeal of the judgement with the Ninth Circuit Court of Appeals. Oral argument
was held on 4 February 2003. On 5 August 2003, the Ninth Circuit issued its
opinion, reversing the lower court's prior dismissal. A timely petition for
rehearing en banc was filed, but was denied by the Ninth Circuit on 29
September 2003. Thereafter, Elan petitioned the U.S. Supreme Court for a writ
of certiorari. On 5 March 2004, the U.S. Supreme Court reviewed Elan's petition
and asked the U.S. Solicitor General's office to submit a brief on whether the
case should be accepted for review. If the matter is accepted for review, it
will be heard in the term commencing in October 2004. If the writ is denied,
then the Elan parties will return to District Court and begin the pleading
process in the underlying action.

The Company and certain of its former and current officers and directors are
named as defendants in a putative class action in the U.S. District Court for
the Southern District of New York, which consolidated several class actions
filed in early 2002 (the "Class Action"). The amended and consolidated
complaint filed 24 January 2003 in the action (the "Complaint") alleges claims
under the U.S. federal securities laws, specifically, Sections 11, 12(a)(2) and
15 of the Securities Act of 1933, as amended (the "1933 Act"), and Sections
10(b), 14(a) and 20(a) of the 1934 Act, and Rule 10b-5 promulgated thereunder.
The Complaint alleges claims on behalf of classes of persons and entities who
purchased securities of the Company during periods of time commencing on 7
February 2000 and ending on 1 July 2002. The Complaint also alleges claims on
behalf of two sub-classes that consist of persons and entities who held stock
in Dura and Liposome and exchanged such stock for ADSs in Elan pursuant to
those companies' mergers with the Company in 2000. In addition to the Company,
defendants named in the Complaint include Donal J. Geaney, Thomas G. Lynch,
Shane M. Cooke, William F. Daniel, KPMG LLP and KPMG, Chartered Accountants.
The Complaint alleges that the Company's financial statements were not in
accordance with generally accepted accounting principles, and that the
defendants disseminated materially false and misleading information concerning
the Company's business and financial results, with respect to the Company's
investments in certain business ventures and business venture parents and the
licence fees and research revenues received from the business ventures; the
accounting for proceeds from the Company's sale of certain product lines and
disclosure concerning those sales; the accounting for certain risk-sharing
arrangements that the Company entered into and disclosure concerning those
arrangements; the accounting for certain qualified special purpose entities and
disclosure concerning those entities; the disclosure of compensation of certain
officers of the Company; and certain alleged related party transactions. The
Complaint seeks compensatory damages and other relief that the court may deem
just and proper. Elan and the individual defendants moved to dismiss the
Complaint on 25 March 2003. The motions to dismiss have been fully briefed,
however, the court has not issued its decision.

The Company was a nominal defendant in two derivative actions filed against
certain of its former and current directors and certain of its former and
current officers on or about 14 March 2002 and 20 March 2002 in the Superior
Court of the State of California, County of

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     133

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

San Diego. The two actions were consolidated, and the plaintiffs filed a
consolidated complaint. The complaint contained allegations similar to those
set forth in the foregoing actions, but alleged, among other things, that the
defendant officers and directors breached their duties to the Company by
causing the Company to undertake the actions alleged in the complaint. Among
other relief, the action sought damages against the defendant officers and
directors on behalf of the Company. The individual defendants filed motions to
dismiss on the grounds of lack of personal jurisdiction, and all of the
defendants filed a motion to dismiss on the grounds of forum non conveniens, or
inconvenient forum. In October 2003, the Company settled this matter and the
lawsuit was dismissed. Pursuant to the terms of the parties' settlement, the
Company agreed to adopt certain corporate governance provisions and to pay
plaintiffs' attorneys fees in the amount of $527,495.

The Company is the subject of an investigation by the SEC's Division of
Enforcement commenced on or about 12 February 2002, which the Company believes
relates primarily to the issues described in the immediately preceding two
paragraphs. Elan is unable to predict or determine the outcome of the Class
Action or the SEC investigation or to reasonably estimate the amounts or range
of loss, if any, with respect to the resolution of the Class Action or the SEC
investigation. Elan is also unable to predict or determine the impact, if any,
that the 2001 U.S. GAAP restatement may have on the outcome of the Class
Action. In addition, the timing and final resolution of the Class Action and
SEC investigation is uncertain. The Company continues to believe that it has
prepared its financial statements in accordance with applicable GAAP (subject
to the restatement relating to EPIL III under U.S. GAAP, described on pages 150
to 154). The findings and outcome of the SEC investigation may adversely affect
the course of the Class Action. The possible outcome or resolution of the SEC
investigation or the Class Action could require Elan to make substantial
payments. See Note 34 for developments subsequent to the initial filing of the
Company's Form 20-F for 2003.

PATENT MATTERS

In October 1998, Elan filed a patent infringement action in the U.S. District
Court for the Southern District of Florida against Andrx alleging that, by its
submission of an ANDA for a generic version of Naprelan, which submission
included a paragraph IV certification, Andrx infringed Elan's U.S. Patent No.
5,637,320 (the "320 patent"). In March 2002, the court issued a decision
finding the 320 patent invalid and dismissed the action. The court did not
consider the issue of infringement. In March 2003, the court denied Elan's
motion for reconsideration and confirmed its previous finding of invalidity.
Elan filed a notice of appeal with the U.S. Court of Appeals for the Federal
Circuit ("CAFC") and all parties fully briefed the issues on appeal. On 3 March
2004, the CAFC heard oral argument on the appeal and took the matter under
submission. The parties are currently awaiting the CAFC's decision.

In November 2002, Allergan filed a complaint against Elan in the U.S. District
Court for the District of Delaware. The complaint alleges that Elan wilfully
infringed U.S. Patent No. 6,290,961 by virtue of its manufacture, sale and
offer for sale of its Myobloc product. Allergan is seeking injunctive relief
and unspecified damages. In February 2003 Elan filed an answer and
counterclaim, denying allegations of infringement, asserting that the patent is
invalid and unenforceable and alleging antitrust violations against Allergan.
In February 2003, Allergan filed its reply to Elan's counterclaim. The parties
subsequently settled this matter in February 2004 and have dismissed the
litigation. The settlement agreement, which is made effective as of 1 January
2003, grants Elan an exclusive licence to U.S. Patent No. 6,290,961 and any
related patents.

Eon submitted to the FDA an ANDA for a generic equivalent of Elan's 400 mg
Skelaxin product. The application included a paragraph IV certification
pertaining to U.S. patent No. 6,407,128 (the "128 patent"). Eon provided notice
to Elan of its paragraph IV certification in November 2002, and Elan filed a
patent infringement suit against Eon in the U.S. District Court for the Eastern
District of New York on 2 January 2003. Eon filed its answer and counterclaim
on 23 January 2003 and then filed an amended answer and counterclaim on 19
February 2003. Elan filed its reply to the counterclaim on 7 March 2003.
Discovery is in its early stages and no trial date has been set. Corepharma LLC
("Corepharma") also has submitted to the FDA an ANDA for a generic equivalent
of Elan's 400 mg Skelaxin product, including a paragraph IV certification
pertaining to the 128 patent. Corepharma provided notice to Elan of its
paragraph IV certification in January 2003, and Elan filed a patent
infringement suit against Corepharma in the U.S. District Court for the
District of New Jersey on 7 March 2003. In May 2003, Elan and Corepharma agreed
to transfer the Corepharma litigation to the U.S. District Court for the
Eastern District of New York for consolidation with the Eon litigation. Elan
and King are cooperating in the prosecution of these actions, and are working
together to substitute King as a plaintiff to the two actions.

ANTITRUST MATTERS

In March 2001, Andrx filed a complaint against Elan in the U.S. District Court
for the Southern District of Florida alleging that Elan engaged in
anti-competitive activities in an effort to prevent or delay the entry of a
generic alternative to Naprelan. Elan filed a motion to dismiss the complaint
and for judgement on the pleadings. In April 2003, the court granted Elan's
motion and dismissed Andrx's

--------------------------------------------------------------------------------
134

--------------------------------------------------------------------------------

complaint with prejudice and without leave to amend. In June 2003, the court
reaffirmed its April decision, denying Andrx's motion for reconsideration and
for leave to amend its complaint. On 14 July 2003, Andrx filed a notice of
appeal. All parties have filed their briefs in connection with the appeal.
Either the court will decide the matter without oral argument, or it will
notify the parties of a hearing date sometime in the future. In September 2003,
the 11th Circuit conducted a mediation of this dispute in accordance with its
local rules, but the matter was not resolved. Accordingly, all parties are
currently awaiting action from the 11th Circuit on Andrx's appeal.

Three putative class actions have been filed in the U.S. District Court for the
Eastern District of Pennsylvania against Elan and Skye Pharma, Inc. by indirect
purchasers of Naprelan. In September 2002, the cases were consolidated and in
October 2002, a consolidated amended class action complaint was filed. The
consolidated complaint alleges that Elan violated the antitrust laws by
engaging in sham patent litigation and entering into an unlawful settlement
agreement in an effort to prevent or delay the entry of a generic alternative
to Naprelan. The damages claimed are unspecified. Elan has not yet answered or
otherwise responded to the amended complaint. Other than preliminary document
production, the litigation has been stayed and the case placed on the court's
suspense docket pending the outcome of further proceedings in the pending Andrx
patent infringement litigation described above. On 4 August 2003 plaintiffs
filed a motion to remove the litigation from the court's suspension docket.
However, the court subsequently denied plaintiffs' motion.

In June 2002, Elan entered into a settlement with the FTC resolving the FTC's
investigation of a licensing arrangement between Elan and Biovail relating to
nifedipine, the generic version of the hypertension drug Adalat CC. The
settlement is reflected in a consent order which, by its terms, does not
constitute an admission by Elan that any law has been violated, and does not
provide for monetary fines or penalties. Elan continues to satisfy all of the
terms of the consent order.

In June 2001, Elan received a letter from the FTC stating that the FTC was
conducting a non-public investigation to determine "whether Brightstone Pharma,
Inc., Elan Corporation or others may have engaged in an effort to restrain
trade by entering into an agreement which may restrict the ability of
Brightstone or others to market a bioequivalent or generic version of
Naprelan". In October 2001, counsel for Elan met informally with FTC Staff to
discuss the matter. No further communication from the FTC was received until
December 2002, when Elan was served with a subpoena duces tecum from the FTC
for the production of documents related to Naprelan. Elan has voluntarily
provided documents and witness testimony in response to the subpoena and
continues to cooperate with the FTC relating to this investigation.

Elan is aware that ten actions have been filed in the U.S. District Courts on
various dates between July 2002 and July 2003 (seven in the District of
Columbia and three in the Southern District of New York) claiming that Elan
(and others) have violated federal and state antitrust laws based on the
licensing arrangement with Biovail relating to nifedipine described in the
immediately preceding paragraph. The complaints seek various forms of remedy,
including declaratory judgement, damages (including treble and/or punitive
damages where allowed), disgorgement and injunctive relief. The actions have
been brought by putative classes of direct purchasers, individual direct
purchasers, and putative classes of indirect purchasers. On 29 May 2003, the
Multidistrict Panel granted Elan's and Biovail's motion to coordinate and
consolidate for pre-trial proceedings all pending cases in the District of
Columbia. Since consolidation of the matters, the court has held several case
management conferences to coordinate the early stages of the case. The
plaintiffs in the action filed amended complaints on or about 15 October 2003
in accordance with a scheduling order issued by the Court. Elan and codefendant
Biovail responded by filing an omnibus motion to dismiss in response to the
amended complaints. Co-defendant Teva filed a joinder in support of Elan's and
Biovail's motion. To date, the court has not scheduled a hearing on the motion
to dismiss. Meanwhile, the parties in the litigation have begun preliminary
discovery.

On 13 March 2003, Elan received notification from the FTC that the FTC's Bureau
of Competition was conducting an investigation to determine whether Elan, King
or any other person was engaging in unfair methods of competition in violation
of Section 5 of the Federal Trade Commission Act, including, among other
things, by preventing or slowing generic competition to Skelaxin. The FTC's
stated focus of the investigation was Elan's listing in the Orange Book of at
least one patent for Skelaxin, and other actions with regard to the FDA
regulatory process. On 8 May 2003, Elan received notification from the FTC that
it had discontinued that portion of its investigation concerning whether Elan
wrongfully listed its patent for Skelaxin in the Orange Book.

OTHER MATTERS

On 27 June 2002, BioPort filed suit against Elan in the Superior Court of the
State of California alleging breach of certain collaboration and supply
agreements relating to the development, manufacture and supply of botulinum
toxin. In addition to claims for breach of contract, BioPort asserted claims
for intentional interference with contractual relations (as to Elan), unfair
business practices, and unjust enrichment. The complaint sought a five percent
royalty on net sales of Myobloc, payments allegedly owned under the
collaboration agreement, a declaration that BioPort has an ownership interest
in Myobloc, and other relief including punitive damages. On 17 March 2003, the
court sustained Elan's demurrer to BioPort's claim for unfair business
practices. On 1 April 2003, Elan filed an answer to

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     135

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

BioPort's complaint, including a general denial of the complaint and
affirmative defences. Elan also filed a cross-complaint against BioPort,
seeking declaratory relief and damages for breach of contract. On 19 May 2003,
BioPort filed a demurrer to Elan's cross-complaint. On 20 May 2003, Elan filed
a motion to strike BioPort's demurrer. On 30 May 2003, BioPort and Elan both
filed motions for summary adjudication. On 5 June 2003, the parties
participated in a court ordered mediation, and have since engaged in settlement
discussions. To date, however, the parties have not been able to settle this
matter and are proceeding with the underlying litigation. The court
subsequently lifted the litigation stay and scheduled a trial date of 4 October
2004. Meanwhile, the parties have recommenced their discovery pre-trial
preparation efforts.

On 11 December 2003, two of Elan's subsidiaries, EPI and Neuralab, commenced
AAA arbitration proceedings against Pfizer and Pharmacia and Upjohn Company
("Pharmacia") in connection with certain alleged breaches relating to an
Exclusive Mutual Beta Secretase Inhibitors Research, Development and Marketing
Collaboration Agreement, dated 28 July 2000, originally between Pharmacia and
Neuralab. As a result of these breaches, the Company believes it holds an
exclusive worldwide licence of, among other things, all of Pfizer's and
Pharmacia's interest in regulatory approvals, patents, and know-how relating to
the subject matter of the parties' collaboration. In response to the
commencement of Elan's arbitration proceeding, on 23 December 2003, Pfizer and
Pharmacia asked the New York State Supreme Court to stay Elan's arbitration
proceedings. On 23 December 2003, the court issued a temporary restraining
order staying the AAA arbitration proceedings and scheduling a subsequent
hearing in January 2004. The court subsequently held a final hearing on
Pfizer's and Pharmacia's application and entered an order staying the AAA
arbitration proceedings. On 29 January 2004, Elan filed a notice of appeal of
the court's order staying arbitration. On 30 January 2004, Pfizer and Pharmacia
sent Elan a notice of breach contending, among other things, that Pfizer and
Pharmacia hold an exclusive worldwide licence of all of Elan's and Neuralab's
interest in regulatory approvals, patents, and know-how relating to the subject
matter of the parties' collaboration. Elan's appeal has been briefed by all
parties. Oral argument on the appeal is currently scheduled to be heard on 14
April 2004. If Elan's appeal is granted, this matter may return to AAA
arbitration. If not, the parties are likely to commence court proceedings to
resolve their disputes regarding the issues raised in Elan's arbitration
materials. While Elan believes that it holds the exclusive worldwide licence to
the intellectual property developed in connection with the Pfizer
collaboration, Pfizer disputes this. There can be no assurance that the
arbitral tribunal or court will ultimately accept Elan's position.

26 BUSINESS VENTURES

Since 1996, Elan has pursued collaborations with biotechnology, drug delivery
and pharmaceutical companies in order to leverage Elan's drug delivery
technologies and its proprietary neurological and oncology research, and to
access complementary or synergistic research and development programmes in
Elan's areas of expertise. Elan has historically referred to this programme in
a number of ways, including as a joint venture programme, a business venture
programme, and a strategic licensing programme. For the purposes of these
Consolidated Financial Statements, this programme will be referred to as the
"business venture programme". Elan has not entered into any new business
ventures under the business venture programme since mid-2001.

In 2002, as part of the recovery plan, Elan completed a review of its business
venture portfolio to conserve cash and reflect the reduced scope of Elan's
activities. As a result, Elan decided to restructure or terminate substantially
all of its business ventures with the aim of substantially reducing or
eliminating future cash outlays by Elan. The restructuring process and any
terms agreed have been the result of negotiations between Elan and the
respective business venture parents. As such, the agreed terms arising from the
restructuring process vary between different business venture relationships.
Typically, as part of the termination of a business venture, the technologies
contributed by the business venture parent and Elan are returned, the
technology developed in the business venture is transferred to the business
venture parent and/or Elan, and Elan transfers its interest in the business
venture to the business venture parent in exchange for a continuing interest in
the product or technology previously in the business venture, such as a
royalty. There were approximately 55 business ventures in place prior to the
announcement of the recovery plan on 31 July 2002. All business ventures have
been terminated, restructured or are now inactive. As a consequence, Elan does
not expect to provide any additional financing to the business ventures and
business venture parents.

As all business ventures have been terminated, restructured or are now
inactive, the description of the business venture programme below is described
in the past tense.

The business venture programme generally involved licensing drug delivery
technologies and know-how, or pharmaceutical research and development assets,
to a newly formed subsidiary ("the business venture") of an emerging
biotechnology; drug delivery or pharmaceutical company ("the business venture
parent") and the establishment of a joint development collaboration.

Contemporaneously with the licensing and collaborative transaction, Elan
typically made an investment in the business venture. Investments in business
ventures were in various forms. Prior to mid 1999, those investments were
generally in the form of voting

--------------------------------------------------------------------------------
136

--------------------------------------------------------------------------------

common stock. Subsequently, these investments were in the form of non-voting
preferred stock convertible into common stock after a period of two years. Elan
typically held an initial fully diluted equity interest of 19.9% in the
business venture. Elan also typically made a contemporaneous investment in the
business venture parent in the form of common equity and
convertible/exchangeable preferred stock and/or convertible/exchangeable debt.
The convertible/exchangeable securities in the business venture parent were
generally convertible, at Elan's option, into common equity of the business
venture parent or exchangeable for up to 30.1% of the common equity in the
business venture, potentially bringing Elan's fully diluted equity interest in
the business venture up to 50%. In many transactions, if Elan chose to exchange
the convertible/exchangeable securities in the business venture parent into
common equity of the business venture, then it would be required to pay the
business venture parent an amount equal to 30.1% of the cumulative operating
funding of the business venture to the date of exchange such that Elan and the
business venture parent would have shared equally (on a cumulative basis) in
such funding. Elan sold certain of its investments in the business ventures and
the business venture parents to EPIL II in June 2000 and to EPIL III in March
2001. EPIL II and EPIL III are securitisation entities and the investments are
held by EPIL II and EPIL III as security for outstanding indebtedness issued by
the entities. For additional information regarding these special purpose
entities, please refer to Notes 15 and 33 to the Consolidated Financial
Statements.

The business venture generally conducted research and development activities
using its technologies and proprietary know-how in an agreed research field.
Elan's partner, the business venture parent, principally managed the business
venture. The technologies and proprietary know-how of the business venture were
in-licensed by the business venture from Elan and the business venture parent.
On formation, a number of contracts were entered into to govern the
in-licensing of intellectual property assets to the business venture from Elan
and the business venture parent.

Development of products and technologies for pharmaceutical applications
involves risk. The nature of pharmaceutical development, with stringent
regulatory constraints and guidelines designed to protect the health and safety
of patients and those working with the products, means that development
activities are costly and time consuming. Elan's portfolio of business ventures
allowed it to diversify the risks associated with product development.
Individual development programmes within the business ventures had varying
degrees of success and failure. Elan and the business venture parent would
typically work together using commercially reasonable efforts and their
combined technical, regulatory and clinical expertise to increase the
likelihood of success of the business ventures. This could lead to changes in
the direction of a development programme, adding or substituting technologies
or products and redirection of clinical programmes as deemed necessary.

The business venture, the business venture parent and Elan continually reviewed
the progress of the research and development activities in the business
venture. As part of this review, the parties could decide that it was not
commercially or technically practical to continue to support the business
venture.

Elan received and recorded initial revenue from the business ventures set out
in the table on page 139 of $Nil, $Nil and $172.5 million for 2003, 2002 and
2001, respectively. Elan's initial investments in the business ventures and the
business venture parents were $Nil, $Nil and $229.2 million for 2003, 2002 and
2001, respectively.

The business ventures typically had the following operational structure. The
board of directors of a business venture was generally comprised of a majority
of directors from the business venture parent and one director nominated by
Elan. For a quorum, the presence of the Elan nominated director was required.
The business plan required the approval of the board of directors of the
business venture, including the Elan nominated director. This approval was
subject to the directors' fiduciary duty to the business venture. The contracts
of establishment provided for subsequent reviews, either annually or more
frequently, of the business plan and required the continuing approval by the
Elan nominated director. The business ventures also typically had a management
committee and/or research and development committee. These committees generally
provided for equal representation by Elan and the business venture parent. The
committees had responsibility for day to day activities of the business venture
and for the implementation of the business plan. At their inception, the
business ventures typically had no funds after payment of the initial fee to
Elan. The operating funding of the business venture was provided by the
business venture parent and Elan, subject to the approval of both parties.
Funding was generally utilised to pay for research and development activities.
Typically, such subsequent financial support was provided in proportion to the
respective fully diluted ownership of the business venture by the business
venture parent and Elan (typically 80.1% and 19.9%, respectively). Elan
expensed the subsequent funding it provided directly to the business venture.
This was expensed within the interest and other expense line. Elan expensed
$3.0 million, $23.9 million and $24.6 million of subsequent business venture
funding in 2003, 2002 and 2001, respectively. If both Elan and the business
venture parent agreed to provide subsequent financial support to the business
venture through their ongoing approval of a business plan, then, if requested
by the business venture parent, Elan was required to make additional
investments in the business venture parent, typically in the form of
convertible debt, in an amount equal to the business venture parent's
proportion of such subsequent financial support, the proceeds of which the
business venture parent was required to use to fund its

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     137

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

proportion of the subsequent support of the business venture. This amount was
recorded by Elan as a financial asset. Elan provided additional financing of
$7.1 million, $83.4 million and $92.2 million to business venture parents in
2003, 2002 and 2001, respectively. All business ventures have been terminated,
restructured or are now inactive. As a consequence, Elan does not expect to
provide any additional financing to the business ventures and business venture
parents.

The business ventures incurred research and development expenditures of
approximately $17 million, $125 million and $125 million in 2003, 2002 and
2001, respectively. While the business ventures and the business venture
parents were generally responsible for ongoing research and development
activities, they could request that Elan conduct research and development on
their behalf. If Elan undertook such work, the work was typically charged to
the business venture at pre-determined rates, which were set to recover Elan's
costs plus a mark-up. Elan received research revenue from the business ventures
of $3.7 million, $13.4 million and $15.0 million in 2003, 2002 and 2001,
respectively. Elan does not expect to receive any future research revenues from
the business ventures.

Investments in the business ventures and the business venture parents were made
at fair value. The fair value of investments was typically initially determined
by Elan using established financial methodologies, including quoted market
prices for quoted equity securities. Unquoted equity investments and non-traded
securities of public entities were assessed using methodologies including the
Black-Scholes option-pricing model, the valuation achieved in the most recent
private placement by an investee, an assessment of the impact of general
private equity market conditions, and discounted projected future cash flow
models.

Subsequent to Elan's investment in a business venture and business venture
parent, the fair values of the investments have been typically determined
periodically, but not less frequently than yearly, by an independent financial
institution using methodologies similar to those described above.

The table on page 139 sets forth certain information regarding the 12 business
ventures that were formed in 2001. No new business ventures were formed in 2003
or 2002. Of all of the business ventures formed since the commencement of the
business venture programme in 1996, approximately 55 were still in place prior
to the announcement of the recovery plan on 31 July 2002. All business ventures
have been terminated, restructured or are now inactive. As a consequence, Elan
does not expect to provide any additional financing to the business ventures
and business venture parents.

Elan recognised exceptional charges in its profit and loss account for 2003 to
reflect impairments to the Group's investment portfolio, including investments
held by EPIL II and EPIL III. This includes impairment charges relating to
investments in business ventures and business venture parent companies of $4.0
million (2002: $114.4 million; 2001: $13.4 million) and $106.0 million (2002:
$880.0 million; 2001: $Nil), respectively. For additional information on
exceptional charges, please refer to Note 3 to the Consolidated Financial
Statements.

--------------------------------------------------------------------------------
138

--------------------------------------------------------------------------------

BUSINESS VENTURES--2001
------------------------------------------------------------------------------------------------------------------------
                                    AGGREGATE INITIAL
                                    AMOUNT INVESTED
                                    (IN BOTH BUSINESS                                                    INITIAL FEE
                                    VENTURE AND BUSINESS                                                 RECEIVED
BUSINESS VENTURE PARENT             VENTURE PARENT)        FIELD OF RESEARCH AND DEVELOPMENT             BY ELAN
------------------------------------------------------------------------------------------------------------------------

 Allergy Therapeutics Ltd.          $20.7 million          Development of anti-histamine                 $15.0 million
                                                           formulations
------------------------------------------------------------------------------------------------------------------------
 Applied Genetics                   $19.0 million          Topical treatments of skin disease            $15.0 million
 Incorporated Dermatics                                    including skin cancer
                                                           (Dimericine (Trade Mark)--liposomal T4N5)
------------------------------------------------------------------------------------------------------------------------
 Beyond Genomics, Inc.              $15.0 million          Research into Alzheimer's disease and/or      $10.0 million
                                                           mild cognitive impairment
------------------------------------------------------------------------------------------------------------------------
 CeNeS Limited                      $21.0 million          Treatment of pain                             $15.0 million
                                                           (morphine-6-glucuronide)
------------------------------------------------------------------------------------------------------------------------
 ChemGenex                          $20.0 million          Treatment of cancer                           $15.0 million
 Therapeutics, Inc.
------------------------------------------------------------------------------------------------------------------------
 Cogent Neuroscience, Inc.          $17.5 million          Treatment of CNS diseases                     $12.5 million
------------------------------------------------------------------------------------------------------------------------
 Curis, Inc.                        $19.0 million          Treatment of neurological disorders           $15.0 million
------------------------------------------------------------------------------------------------------------------------
 eNOS Pharmaceuticals, Inc.         $17.0 million          Treatment of neurological and                 $15.0 million
                                                           cardiovascular diseases in
                                                           non-hypercholesterolemic humans
                                                           (EN-110)
------------------------------------------------------------------------------------------------------------------------
 GlycoGenesys, Inc.                 $20.0 million          Treatment of cancer (GCS-100, formerly        $15.0 million
                                                           known as GBC-590)
------------------------------------------------------------------------------------------------------------------------
 Inex Pharmaceuticals Corporation   $20.0 million          Treatment of cancer (VSLI (Trade Mark) )      $15.0 million
------------------------------------------------------------------------------------------------------------------------
 Lipocine Inc.                      $20.0 million          Oral hormone replacement therapy              $15.0 million
                                                           combination product
------------------------------------------------------------------------------------------------------------------------
 Nobex Corporation                  $20.0 million          Treatment of post-menopausal                  $15.0 million
                                                           osteoporosis or Paget's disease
                                                           (Oratonin (Trade Mark) )
------------------------------------------------------------------------------------------------------------------------
 Total                              $229.2 million                                                       $172.5 million
------------------------------------------------------------------------------------------------------------------------

27 RELATED PARTIES

ANTIGENICS

At 31 December 2003, the Company had invested a total of $14.9 million (2002:
$14.9 million) in Antigenics, a biotechnology company whose chairman, Dr Garo
Armen, is also the chairman of Elan. Elan's investments in Antigenics,
consisting of common stock holdings, were made in 1998 ($2.5 million), 1999
($10.4 million) and 2002 ($2.0 million). At 31 December 2003, Elan's
shareholding represented approximately 2.8% of Antigenics' outstanding share
capital. At 31 December 2003, this investment had a carrying value of $11.0
million and a fair value of $12.5 million. In February and March 2004, Elan
disposed of its total shareholding of 1,098,937 common stock in Antigenics for
$11.4 million.

Following the appointment of Dr Armen as chairman on 9 July 2002, the Company
signed a memorandum of understanding between itself and Antigenics in respect
of costs incurred by either company in respect of work done for the other. The
agreement provided that

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     139

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

no profit margin should be charged on such costs. In 2003, the amount of such
charges from Antigenics was $162,242 and the amount of such charges to
Antigenics was $170,734 (2002: $44,888 charges from Antigenics to the Company).

In addition, on 28 February 2003, a settlement was signed between Antigenics,
Neuralab and EPI regarding a dispute that arose in respect of a supply
agreement entered into on 23 November 1999 between Antigenics, then known as
Aquila Biopharmaceuticals, Inc., Neuralab and EPI. Under the terms of the
settlement, Elan paid Antigenics $333,594 and received an agreed amount of an
adjuvant.

DR SELKOE

Dr Selkoe, a director of Elan, received $25,000 and $50,000 from Elan in 2003
and 2002, respectively, under consultancy agreements with the Group.

MR GROOM

Mr Groom, a director of Elan, received $100,000 and $200,000 in 2003 and 2002,
respectively, under a consultancy agreement with the Group. Effective 1 July
2003, the consultancy agreement was cancelled and the Company and Mr. Groom
entered into a pension agreement of $200,000 per annum payable until 16 May
2008. Mr. Groom received $100,000 under this pension agreement in 2003.

AMARIN

Amarin is a specialty pharmaceutical company focused on neurology and pain
management. Mr Thomas Lynch, an employee of Elan and formerly its executive
vice chairman, and Mr John Groom, a director of Elan, serve on Amarin's board
of directors. Mr Lynch is non-executive chairman of Amarin.

In May 2001, Elan and Amarin entered into a distribution and option agreement,
whereby Amarin agreed to market and distribute Permax in the United States, and
was granted an option to acquire rights to the product from Elan. Permax is
used for the treatment of Parkinson's disease and falls within Amarin's focus
on neurology. In September 2001, this agreement was amended, whereby Amarin was
appointed the sole distributor of Permax in the United States until August
2002. Elan recorded consideration of $45.0 million under the terms of the
amended distribution and option agreement and retained a royalty right of 3.5%
on net sales of Permax by Amarin from 1 January 2002 through the date on which
Amarin exercised or terminated its option to acquire Permax. In 2001, Elan also
recorded a net amount of $6.2 million from Amarin for distribution fees and
royalties on sales of Permax. After reducing the carrying value of the Permax
intangible and equity accounting, Elan recorded net revenue from Amarin of
$16.9 million in 2001 which includes the distribution revenue. Amarin's option
to purchase Permax was exercisable between September 2001 and May 2002 for an
exercise price of $37.5 million, payable $7.5 million on exercise of the option
and $2.5 million in quarterly instalments thereafter, and a royalty of between
7% and 10% on future net sales of Permax by Amarin. On 11 March 2002, Amarin
exercised its option to acquire Permax and paid Elan the first instalment of
the exercise price of $7.5 million. Elan did not recognise the unpaid option
exercise price, but rather intended to record such consideration as it was
received due to uncertainties surrounding its ultimate collectibility.

In connection with the amended distribution and option agreement, Elan provided
a loan of $45.0 million to Amarin. The loan bore interest at a rate equal to
LIBOR plus a margin of 2%. Amarin repaid $2.5 million of this loan in July
2002. In January 2003, $19.9 million of this loan, including interest of $2.4
million, was repaid by Amarin and the maturity of the remaining amount of the
loan was amended to $10.0 million payable in September 2004 and $15.0 million
payable in September 2005.

During 2001, Elan granted Amarin a purchase option to acquire Zelapar. Zelapar
is a fast melt formulation of selegiline for the treatment of Parkinson's
disease.

In August 2003, Elan and Amarin agreed to amend certain terms of their
agreements whereby Amarin had until 31 December 2003 to pay $30.0 million to
Elan. If Amarin did so, all loans referred to above and outstanding deferred
payments due in connection with the purchase of Permax would be discharged in
full, and Amarin would be deemed to have exercised its option to acquire
Zelapar. Elan would additionally receive a royalty of 12.5% of net sales of
Zelapar by Amarin, and may have received a future revenue-contingent milestone
payment of $10.0 million in ordinary shares of Amarin if annual sales of
Zelapar exceeded $20.0 million. All quarterly payments due in connection with
the purchase of Permax and all loan interest payments due were subject to a
moratorium that expired on 31 December 2003.

In December 2003, Elan agreed further amendments of those terms, by increasing
the amount Amarin could pay to discharge its indebtedness and acquire Zelapar,
from $30.0 million to $31.5 million, and extending the time for doing so to 31
March 2004.

--------------------------------------------------------------------------------
140

--------------------------------------------------------------------------------

Consequently, the time for exercise of the Zelapar option and the moratorium on
payments due in connection with the purchase of Permax and all loan interest
payments due were also extended to 31 March 2004.

Additionally, Elan agreed to a loan facility to Amarin of up to $6.0 million to
finance Amarin's cash requirements through 31 March 2004 and repayable on 31
March 2004. Amarin drew down $4.0 million of this facility through February
2004. Amarin agreed to pay Elan a monthly fee for this facility. In February
2004, Amarin paid $0.3 million to Elan, representing the amount of this fee for
January 2004.

Amarin repaid $11.1 million to Elan in December 2003. In February 2004, Elan
and Amarin agreed to further amend their contractual arrangements subject to
the sale by Amarin of certain of its U.S. assets, including its rights to
Zelapar and Permax, to Valeant. On 25 February 2004, Amarin's sale of assets to
Valeant closed and the amendments became effective. The amendments required, in
full settlement of all previous liabilities owed by Amarin to Elan and as a
deemed exercise of Amarin's option to acquire Zelapar, the payment by Amarin of
$17.2 million to Elan and the issuance of a $5.0 million five-year 8% loan note
and warrants to purchase 500,000 ordinary shares in Amarin to Elan. Under the
amendments, Elan is also entitled to receive a $1.0 million milestone payment
from Amarin upon the successful completion of certain Zelapar safety studies.
Elan is also entitled to receive from Valeant a revenue contingent milestone on
Zelapar of $10.0 million if annual sales of Zelapar exceed $20.0 million, and
royalties on future net sales by Valeant of 12.5% for Zelapar and 10% for
Permax. As a consequence of these amendments Amarin paid $17.2 million to Elan
in February 2004.

At 31 December 2003, Elan held approximately 26% of the outstanding ordinary
shares of Amarin. As described above, in February 2004 Elan received warrants
to purchase 500,000 ordinary shares in Amarin. As a result, Elan's share
ownership in Amarin is now approximately 28% on a fully diluted basis.

Under Irish GAAP Elan accounted for Amarin using the equity method, based on
Elan's fully diluted equity investment in Amarin in 2003 and 2002. Amarin is a
related party to Elan. Elan recorded net revenue from Amarin of $0.3 million in
2003 (2002: $4.8 million; 2001: $16.9 million). Elan's total investment in
Amarin at 31 December 2003 amounted to $23.9 million, consisting of loans,
including interest, of $20.9 million and a net equity investment of $3.0
million. In addition, Elan had trading balances due from Amarin of $Nil at 31
December 2003 (2002: $13.7 million). As described above, Amarin paid a net
$13.5 million to Elan during January/February 2004, and now owes Elan $5.0
million under a five-year loan note and a potential $1.0 million milestone
payment on Zelapar. Aside from the $5.0 million five-year loan note and the
potential $1.0 million milestone payment on Zelapar, Amarin has no remaining
debt obligations to Elan.

28 PENSION PLANS

The Company has continued to account for pensions in accordance with SSAP No.
24, "Accounting for Pensions" ("SSAP 24"), and the disclosures given in (a) are
those required by that standard. FRS 17 "Retirement Benefits" ("FRS 17") will
not be mandatory for the Company until the year ended 31 December 2005. Prior
to this, phased transitional disclosures are required by FRS 17 and, to the
extent they are not given in (a), are set out below in (b).

(A) SSAP 24 DISCLOSURES

                                                     2003       2002       2001
PENSION COSTS                                          $M         $M         $M
--------------------------------------------------------------------------------

 Pension cost of defined benefit schemes              4.3        3.3        2.8
 Pension cost of defined contribution schemes         9.2        8.8        9.9
--------------------------------------------------------------------------------
                                                     13.5       12.1       12.7
--------------------------------------------------------------------------------

(i) Defined benefit schemes

The Company funds the pension entitlements of certain employees through defined
benefit plans. Two plans are operated for Irish employees. In general, on
retirement, a member is entitled to a pension calculated at 1/60th of final
pensionable salary for each year of pensionable service, subject to a maximum
of 40 years. These plans are funded externally and the related pension costs
and liabilities are assessed in accordance with the advice of a professionally
qualified actuary. The investments of the plans at 31 December 2003 consisted
of units held in independently administered funds. The most recent actuarial
valuations of the plans were carried out in April 2002 using the projected unit
credit method and the valuation reports are not available for public
inspection.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     141

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

The principal actuarial assumption used was that the rate of real investment
returns will exceed the rate of salary inflation by 2%.

The actuarial report showed that at 1 April 2002, the market value of the
assets of the schemes was $19.4 million and the actuarial value of the assets
represented 106% of the benefits accrued to members for the two plans.

These schemes are fully funded on a discontinuance basis.

(ii) Defined contribution schemes

In addition, Elan operates a number of defined contribution pension plans,
primarily for employees outside of Ireland. The costs of these plans are
charged to the profit and loss account in the period in which incurred.

(iii) Balance sheet amounts

At the year ended 31 December 2003, there was a pension contribution due
included in accruals of $2.3 million (2002: $0.5 million) and a pension
prepayment of $0.3 million (2002: $0.2 million).

(B) FRS 17 RETIREMENT BENEFITS

The valuations of the defined benefit schemes used for the purpose of FRS 17
disclosures have been based on the most recent actuarial valuations as
identified above. These have been updated by the actuary to take account of the
requirements of FRS 17 in order to assess the liabilities at each balance sheet
date. Scheme assets are stated at their market value at each balance sheet
date. The contribution rate, inclusive of the members contributions, for the
Employee Benefit Plan is 17.4% of pensionable salaries. The contribution rate,
inclusive of the members contributions, for the Pension and Life Assurance Plan
is 31.0% of pensionable salaries.

The financial assumptions used to calculate the retirement benefit liability
under FRS 17 were as follows:

                                       31 DECEMBER 2003    31 DECEMBER 2002
VALUATION METHOD                         PROJECTED UNIT      PROJECTED UNIT
---------------------------------------------------------------------------

 Discount rate                                  5.2%                5.5%
 Inflation rate                                 2.5%                3.0%
 Increase to pensions in payment                5.0%(1)             5.0%(1)
 Future salary increases                        4.0%                3.5%
---------------------------------------------------------------------------

(1)   5% per annum limited to CPI increases assumed to be 2.5% for 2003 (2002:
      3%).

--------------------------------------------------------------------------------
142

--------------------------------------------------------------------------------

The market values of the assets in the pension schemes and the expected rates of
return were:

                                                    LONG TERM                       LONG TERM
                                                      RATE OF                         RATE OF
                                                       RETURN        VALUE AT          RETURN       VALUE AT
                                                  EXPECTED AT     31 DECEMBER     EXPECTED AT    31 DECEMBER
                                                  31 DECEMBER            2003     31 DECEMBER           2002
                                                         2003              $M            2002             $M
------------------------------------------------------------------------------------------------------------

 Equities                                                7.5%            25.7            6.5%           14.1
 Bonds                                                   4.5%             5.8            5.0%            4.3
 Property                                                6.5%             2.4            6.5%            1.6
 Cash                                                    2.5%             0.6            2.5%            1.0
------------------------------------------------------------------------------------------------------------
 Total market value of pension plans assets                              34.5                           21.0
 Present value of funded pension liabilities                            (37.6)                         (27.4)
------------------------------------------------------------------------------------------------------------
 Net deficit in funded pension plans                                     (3.1)                          (6.4)
 Related deferred tax asset                                               0.4                            1.3
------------------------------------------------------------------------------------------------------------
 Net pension deficit                                                     (2.7)                          (5.1)
------------------------------------------------------------------------------------------------------------
 ANALYSED AS:
 Pension & Life Assurance Plan
 Net pension assets                                                       8.5                            3.8
 Net pension liabilities                                                 (9.4)                          (7.7)
 Related deferred tax asset                                               0.1                            0.8
 Employee Benefit Plan
 Net pension assets                                                      26.0                           17.2
 Net pension liabilities                                                (28.2)                         (19.7)
 Related deferred tax asset                                               0.3                            0.5
------------------------------------------------------------------------------------------------------------
                                                                         (2.7)                          (5.1)
------------------------------------------------------------------------------------------------------------

Movement in deficit during the year.

                                               31 DECEMBER   31 DECEMBER
                                                      2003          2002
                                                        $M            $M
-------------------------------------------------------------------------

 Deficit at 1 January                                (5.1)          (0.6)
 Service cost                                        (2.1)          (1.8)
 Company contributions paid                           3.9            2.2
 Other finance income (expected net return             --            0.1
 Actuarial gain/(loss)                                2.3           (5.5)
 Foreign exchange rate charges                       (0.6)          (0.7)
 Related deferred tax asset                          (1.1)           1.2
-------------------------------------------------------------------------
 Deficit at 31 December                              (2.7)          (5.1)
-------------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     143

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Had FRS 17 been reflected in the primary financial statements, the following
are the amounts that would have been included in the Consolidated Profit and
Loss Account and the Consolidated Statement of Total Recognised Gains and
Losses:

                                                                            YEAR ENDED     YEAR ENDED
                                                                           31 DECEMBER    31 DECEMBER
                                                                                  2003           2002
                                                                                    $M             $M
-----------------------------------------------------------------------------------------------------

 INCLUDED IN PAYROLL COSTS:
 Current service costs                                                             2.1            1.8
-----------------------------------------------------------------------------------------------------
 Net operating profit charge                                                       2.1            1.8
-----------------------------------------------------------------------------------------------------
 INCLUDED IN FINANCE COSTS/(INCOME):
 Interest cost                                                                     1.6            1.2
 Expected return on assets                                                       (1.6)          (1.3)
-----------------------------------------------------------------------------------------------------
 Net finance income                                                                --           (0.1)
-----------------------------------------------------------------------------------------------------
 INCLUDED IN STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES:
 Difference between expected and actual return on assets                         (1.7)            6.4
 Experience gains and losses on plan's liabilities                               (3.1)          (2.6)
 Effect of changes in actuarial assumptions                                        2.5            1.7
-----------------------------------------------------------------------------------------------------
 Net (gain)/loss in Consolidated Statement of Total Recognised Gains and
  Losses                                                                         (2.3)            5.5
-----------------------------------------------------------------------------------------------------

History of actuarial gains and losses

                                                            YEAR ENDED     YEAR ENDED
                                                           31 DECEMBER    31 DECEMBER
                                                                  2003           2002
                                                                    $M             $M
-------------------------------------------------------------------------------------

 Difference between expected and actual return on assets          (1.7)           6.4
 Expressed as a percentage of plan's assets                       (4.9%)         30.4%
-------------------------------------------------------------------------------------
 Experience gains and losses on scheme liabilities                (3.1)          (2.6)
 Expressed as a percentage of plan's liabilities                   8.2%           9.4%
-------------------------------------------------------------------------------------
 Total actuarial (gains)/losses                                   (2.3)           5.5
 Expressed as a percentage of plan's liabilities                  (6.1%)         20.1%
-------------------------------------------------------------------------------------

                                                                       31 DECEMBER    31 DECEMBER
                                                                              2003           2002
                                                                                $M             $M
-------------------------------------------------------------------------------------------------

 NET ASSETS
 Group's net assets per Consolidated Balance Sheet                           825.4        1,459.4
-------------------------------------------------------------------------------------------------
 PENSION & LIFE ASSURANCE PLAN
 Net pension assets                                                            8.5            3.8
 Net pension liabilities                                                      (9.4)          (7.7)
 Related deferred tax asset                                                    0.1            0.8
-------------------------------------------------------------------------------------------------
                                                                              (0.8)          (3.1)
 EMPLOYEE BENEFIT PLAN
 Net pension assets                                                           26.0           17.2
 Net pension liabilities                                                     (28.2)         (19.7)
 Related deferred tax asset                                                    0.3            0.5
-------------------------------------------------------------------------------------------------
                                                                              (1.9)          (2.0)
-------------------------------------------------------------------------------------------------
 Net assets including pension assets and liabilities                         822.7        1,454.3
-------------------------------------------------------------------------------------------------
 RESERVES
 Profit and loss reserve excluding pension assets and liabilities         (4,761.0)      (3,945.6)
 Pension reserve                                                              (2.7)          (5.1)
-------------------------------------------------------------------------------------------------
 Profit and loss reserve                                                  (4,763.7)      (3,950.7)
-------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
144

--------------------------------------------------------------------------------

29 POST BALANCE SHEET EVENTS

Sale of European business

On 12 February 2004, Elan announced the completion of the sale of its European
sales and marketing business to Medeus, a new U.K. pharmaceutical company
backed by Apax Partners Funds. Elan realised total consideration of
approximately $120 million from this transaction (subject to adjustment for
certain movements in indebtedness and working capital in the period to
completion), which was previously announced on 23 December 2003. Approximately
180 employees of Elan's European sales and marketing business have tranferred
their employment to Medeus. Separately, Elan completed the sale of certain
rights to two products in the U.K. and Ireland for approximately $10 million
during the first quarter of 2004.

Zonegran & Frova

On 30 March 2004, Elan announced an agreement with Eisai for the purchase of
Elan's interests in Zonegran in North America and Europe. On closing, Eisai
will pay Elan consideration of $130.0 million for these interests, including
inventory, with an estimated value of approximately $26 million and the
associated sales team of approximately 115 employees. In addition, Elan may
earn future deferred purchase payments of up to $110.0 million, primarily
contingent on when generic zonisamide is introduced in the U.S., and including
up to $25.0 million contingent on receiving marketing approval for Zonegran in
Europe. Elan will also receive additional deferred purchase payments on net
sales of Zonegran in North America and Europe if certain additional conditions
are met. Elan will be required to pay $17.0 million to Dainippon on closing for
the assignment of the Zonegran North American and European licence agreements
to Eisai. Elan will continue to manufacture Zonegran in all three dosage
strengths of 25 mg, 50 mg, and 100 mg capsules in Athlone, Ireland. The
transaction is subject to regulatory approvals, third party consents and other
customary conditions, and is expected to close before the end of the second
quarter of 2004.

Also on 30 March 2004, Elan announced an agreement with Vernalis for the
termination of the development and licence agreements between Elan and Vernalis
regarding Frova. Vernalis agreed to purchase Elan's commercialisation rights in
North America for Frova. Vernalis will pay Elan a total of approximately $55
million for rights to Frova in North America, comprising $5.0 million on
closing; $20.0 million and $25.0 million on 31 December 2004 and 31 December
2005, respectively; and, no later than 31 December 2004, Elan will receive a
payment for its Frova inventory, estimated at approximately $5 million.
Vernalis intends to seek additional equity funding over the next twelve months
to assist with the payments to Elan. Elan's co-promotion agreement with UCB
will be terminated at closing, and Elan will pay UCB approximately $10 million
as a result of the termination. The completion of the transaction is subject to
the approval of Vernalis' shareholders, U.S. anti-trust clearance if required,
third party consents and other customary conditions. The transaction is
expected to close before the end of the second quarter of 2004.

Subsequent Events

For a description of the restatement of these Financla Statements and other
events occuring subsequent to the initial issuance of these financial statements
or presented on our originally filed for 2003 please refer to note 34.

30 CONSOLIDATED CASH FLOW STATEMENT

A RECONCILIATION OF OPERATING LOSS TO OPERATING CASH FLOWS

                                                                               2003            2002          2001
                                                                                 $M              $M            $M
------------------------------------------------------------------------------------------------------------------

 Operating loss                                                              (935.1)       (2,290.8)       (829.7)
 Depreciation and amortisation                                                210.3           320.3         270.4
 Impairment of intangibles                                                    189.5         1,614.6       1,009.8
 Disposal of intangibles                                                        1.8            65.0         127.9
 Disposal and write-down of tangible fixed assets                              15.6            46.1          17.8
 Purchase of product royalty rights from Pharma Marketing/Autoimmune          297.6           121.0           --
 Other                                                                          0.4            99.5          58.0
 Decrease in debtors                                                           29.9           209.9          23.2
 Decrease/(increase) in stocks                                                  9.9           (13.0)        (37.6)
 (Decrease)/increase in creditors                                            (142.2)           87.0        (115.2)
------------------------------------------------------------------------------------------------------------------
 Net cash (outflow)/inflow from operating activities                         (322.3)          259.6         524.6
------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     145

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

B MANAGEMENT OF LIQUID RESOURCES

The management of liquid resources comprises the movement in short term
deposits, commercial paper and repurchase agreements, excluding those repayable
on demand.

C ANALYSIS OF NET DEBT

                                              AT 1 JANUARY          CASH        OTHER  EXCHANGE RATE    AT 31 DECEMBER
                                                      2003          FLOW    MOVEMENTS      MOVEMENTS              2003
                                                        $M            $M           $M             $M                $M
----------------------------------------------------------------------------------------------------------------------

 Cash                                              1,071.9        (256.5)          --           12.5             827.9
 Liquid resources                                     14.6         (14.5)          --             --               0.1
----------------------------------------------------------------------------------------------------------------------
 Cash and liquid resources                         1,086.5        (271.0)          --           12.5             828.0
----------------------------------------------------------------------------------------------------------------------
 3.25% Zero Coupon Subordinated Exchangeable
  Notes (LYONs)                                     (779.0)        803.4(1)     (25.3)            --              (0.9)
 Guaranteed and Exchangeable Notes                (1,497.7)       (460.0)         7.3             --          (1,950.4)
 Other debt                                         (105.6)         83.2         (1.2)            --             (23.6)
----------------------------------------------------------------------------------------------------------------------
 Debt                                             (2,382.3)        426.6        (19.2)            --          (1,974.9)
----------------------------------------------------------------------------------------------------------------------
 Net debt                                         (1,295.8)        155.6        (19.2)          12.5          (1,146.9)
----------------------------------------------------------------------------------------------------------------------

(1)   Includes interest paid of $115.9 million.

D NET OUTFLOW OF CASH AND CASH EQUIVALENTS IN RESPECT OF THE PURCHASES OF
  SUBSIDIARY UNDERTAKINGS

                                   2003     2002         2001
                                     $M       $M           $M
-------------------------------------------------------------

 Cash consideration paid             --       --         10.0
 Cash of acquired subsidiaries       --       --        (0.5)
-------------------------------------------------------------
 Net cash outflow                    --       --          9.5
-------------------------------------------------------------

E EFFECT OF ACQUIRED COMPANIES ON CASH FLOW

There were no company acquisitions during 2003 or 2002. Cash flows in 2001
included cash outflows from operating activities of $5.1 million which relate
to companies acquired during that year.

F CASH RECEIVED ON DISPOSAL OF BUSINESSES

Cash of $546.9 million received in 2003 principally comprises net receipts of
$484.7 million from the sale of the primary care franchise to King, $50.1
million on disposal of the Pain Portfolio and proceeds from other business
disposals of $12.1 million. Cash of $361.3 million was received in 2002
primarily from the disposal of the Abelcet business. Proceeds of $46.1 million
were received from the disposal of subsidiaries, mainly relating to ETT.

--------------------------------------------------------------------------------
146

--------------------------------------------------------------------------------

G NET INFLOW OF CASH AND CASH EQUIVALENTS IN RESPECT OF THE DISPOSAL OF
SUBSIDIARY UNDERTAKINGS

                                      2003        2002         2001
                                     TOTAL       TOTAL        TOTAL
                                        $M          $M           $M
-------------------------------------------------------------------

 Cash consideration received          47.1        87.6         41.9
 Cash of disposed subsidiaries        (1.0)       (5.8)          --
--------------------------------------------------------------------
 Net cash inflow                       46.1        81.8        41.9
--------------------------------------------------------------------

H EFFECT OF DISPOSED COMPANIES ON CASH FLOW

Cash flows in 2003 included cash outflows from operating activities of $4.2
million and repayments of loans of $5.2 million, which relate to companies
disposed of during 2003.

I RESTRICTED CASH

Cash and liquid resources include restricted cash held by EPIL II and EPIL III
in an amount of $21.1 million.

31 COMPANY BALANCE SHEET

Fixed assets--intangible assets

                                      PATENTS &
                                       LICENCES
                                             $M
-----------------------------------------------

 COST:
 At 1 January 2003                        185.0
 Additions                                  0.8
 Impairment                                (4.3)
-----------------------------------------------
 At 31 December 2003                      181.5
-----------------------------------------------
 ACCUMULATED AMORTISATION:
 At 1 January 2003                         96.2
 Amortised in year                          9.2
-----------------------------------------------
 At 31 December 2003                      105.4
-----------------------------------------------
 Net book value: 31 December 2003          76.1
 Net book value: 31 December 2002          88.8
-----------------------------------------------

FIXED ASSETS--TANGIBLE ASSETS

                            LAND &
                         BUILDINGS      EQUIPMENT       TOTAL
                                $M             $M          $M
-------------------------------------------------------------

 NET BOOK VALUE
 At 1 January 2003            11.0           6.7         17.7
 Movements                    (0.8)         (2.5)        (3.3)
-------------------------------------------------------------
 At 31 December 2003          10.2           4.2         14.4
-------------------------------------------------------------

The net book value of tangible assets held under finance lease arrangements at
31 December 2003 amounted to $3.5 million (2002: $5.1 million) and related
depreciation for the year amounted to $1.6 million (2002: $3.1 million).

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     147

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Fixed assets--financial assets

                                            AT 31 DECEMBER  AT 31 DECEMBER
                                                      2003            2002
                                                        $M              $M
--------------------------------------------------------------------------

 Investments in subsidiary undertakings              246.0              --
 Loans to subsidiary undertakings                  2,022.1         2,699.2
--------------------------------------------------------------------------
                                                   2,268.1         2,699.2
--------------------------------------------------------------------------

                         INVESTMENTS IN       LOANS TO
                           SUBSIDIARIES   SUBSIDIARIES        TOTAL
                                     $M             $M           $M
--------------------------------------------------------------------

 Cost
 At 1 January 2003                   --        2,699.2      2,699.2
 Movements                        246.0         (677.1)      (431.1)
--------------------------------------------------------------------
 At 31 December 2003              246.0        2,022.1      2,268.1
--------------------------------------------------------------------

DEBTORS

                                        AT 31 DECEMBER  AT 31 DECEMBER
                                                  2003            2002
                                                    $M              $M
----------------------------------------------------------------------

 Trade debtors                                     9.1            11.8
 Amounts owed by group undertakings                0.5             1.3
 Other debtors                                     0.3             6.3
----------------------------------------------------------------------
                                                   9.9            19.4
----------------------------------------------------------------------

CREDITORS (AMOUNTS FALLING DUE WITHIN ONE YEAR)

                               AT 31 DECEMBER  AT 31 DECEMBER
                                         2003            2002
                                           $M              $M
-------------------------------------------------------------

 Trade creditors                          1.3             1.5
 Other creditors                          0.2             0.3
 Due to group undertakings              880.9         1,518.3
 Accrued expenses                         5.0            15.4
 Lease obligation                         1.1             0.9
-------------------------------------------------------------
                                        888.5         1,536.4
-------------------------------------------------------------

For additional information regarding guarantees, please refer to Note 15 to the
Consolidated Financial Statements.

--------------------------------------------------------------------------------
148

--------------------------------------------------------------------------------

Creditors (amounts falling due after one year)

                                                    AT 31 DECEMBER  AT 31 DECEMBER
                                                              2003            2002
                                                                $M              $M
----------------------------------------------------------------------------------

 FINANCE LEASE OBLIGATIONS (NET OF FINANCE CHARGES):
 Payable within two to five years                              4.5             4.0
 Payable after five years                                      9.0             8.1
----------------------------------------------------------------------------------
                                                              13.5            12.1
----------------------------------------------------------------------------------

32 SUBSIDIARY AND ASSOCIATED UNDERTAKINGS

At 31 December 2003, Elan had the following principal subsidiary and associated
undertakings:

                                                                                                     REGISTERED OFFICE &
                                                                                   GROUP          COUNTRY OF INCORPORATION &
COMPANY                                              NATURE OF BUSINESS           SHARE %                 OPERATION
-------------------------------------------   --------------------------------   ---------   -----------------------------------

 Elan International Services Ltd              Financial services company           100       Clarendon House, 2 Church St
                                                                                             Hamilton, Bermuda

 Elan Management Ltd.                         Provision of management              100       Lincoln House, Lincoln Place
                                              services                                       Dublin 2, Ireland

 Elan Pharmaceuticals, Inc.                   Research and development and         100       800 Gateway Blvd
                                              sale of pharmaceutical                         South San Francisco, CA,
                                              products                                       United States

 Athena Neurosciences, Inc.                   Holding company                      100       800 Gateway Blvd
                                                                                             South San Francisco, CA,
                                                                                             United States

 Elan Pharma International Ltd                Research and development,            100       WIL House, Shannon Business Park
                                              sale and distribution of                       Co. Clare, Ireland
                                              pharmaceutical products and
                                              financial services

 Elan Pharma Ltd                              Manufacture of pharmaceutical        100       Monksland, Athlone
                                              products                                       Co. Westmeath, Ireland

 Elan Finance Corporation Ltd                 Financial services company           100       Clarendon House, 2 Church St
                                                                                             Hamilton, Bermuda

 Elan Pharmaceutical Investments II, Ltd      Investment holding company           100       Clarendon House, 2 Church St
                                                                                             Hamilton, Bermuda

 Elan Pharmaceutical Investments III, Ltd     Investment holding company           100       Clarendon House, 2 Church St
                                                                                             Hamilton, Bermuda

 Elan Holdings Ltd                            Holding company                      100       Monksland, Athlone
                                                                                             Co. Westmeath, Ireland

 Elan Holdings Inc.                           Manufacture, marketing and           100       1300 Gould Drive
                                              distribution of pharmaceutical                 Gainesville, GA, United States
                                              and medical device products

 Elan Drug Delivery, Inc.                     Research and development             100       3000 Horizon Drive
                                                                                             King of Prussia, PA, United States

 Monksland Holdings BV                        Financial services company           100       Amsteldijte 166
                                                                                             6th Floor
                                                                                             1079 LH Amsterdam
                                                                                             The Netherlands

 Elan Capital Corporation Ltd                 Financial services company           100       Clarendon House, 2 Church St
                                                                                             Hamilton, Bermuda

 Amarin Corporation plc(1)                    Specialty pharmaceutical              26       7 Curzon Street,
                                              company                                        London W1J 5HG,
                                                                                             United Kingdom

(1)   Associate

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     149

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Information regarding all other subsidiaries will be filed with the Company's
next annual return as provided for by Section 16[3](a) of the Companies
(Amendment) Act, 1986.

33 U.S. GAAP INFORMATION

RESTATEMENT

INCOME TAXES

In this 2003 Annual Report and Form 20-F/A, Elan has restated its U.S. GAAP
financial results as of and for the year ended 31 December 2003 following a
reassessment of the amount of net operating loss carryforwards expected to be
realised on a probable basis. This correction has the impact of reducing the
previously reported tax charge and net loss reported under U.S. GAAP by $26.7
million resulting in a tax credit of $22.8 million and a net loss of $508.7
million respectively. In addition, additional paid-in capital loss from
continuing operations has been reduced by $26.7 million and retained earnings
has been increased by $26.7 million. Basic and diluted loss per ordinary share
for the year ended 31 December 2003 was restated to $(1.43) from $(1.50).

EPIL III

In its 2002 Annual Report and Form 20-F, Elan restated its U.S. GAAP financial
results as of and for the fiscal year ended 31 December 2001 to consolidate
EPIL III from its date of establishment on 15 March 2001. Under U.S. GAAP, EPIL
III had been historically accounted for by Elan as a qualifying special purpose
entity and was not, therefore, consolidated.

In addition, in its 2002 Annual Report and Form 20-F, Elan adjusted its
previously announced unaudited U.S. GAAP financial information as of and for
the fiscal year ended 31 December 2002 to give effect to the consolidation of
EPIL III and to consolidate Shelly Bay, an entity established by Elan, from 29
June 2002 through 30 September 2002. Shelly Bay acquired certain financial
assets from EPIL III on 29 June 2002. The 2001 restatement and the adjustments
to the 2002 U.S. GAAP financial information are described below.

Under Irish GAAP, EPIL III had been accounted for as a consolidated subsidiary
since its date of establishment in accordance with the requirements of FRS 5.
Therefore, the 2001 restatement did not affect Elan's Irish GAAP financial
information, including the Irish GAAP financial information contained in this
Annual Report and Form 20-F.

Background

In March 2001, Elan transferred a portfolio of equity and debt securities to
EPIL III, a wholly owned subsidiary of Elan. EPIL III issued $160.0 million in
aggregate principal amount of Series A Guaranteed Notes, $190.0 million in
aggregate principal amount of Series B Guaranteed Notes and $200.0 million in
aggregate principal amount of Series C Guaranteed Notes. The Series A
Guaranteed Notes matured on 29 June 2002. To fund the repayment of the notes,
on 29 June 2002 EPIL III transferred certain financial assets, consisting of
certain of the securities included in the portfolio transferred to EPIL III, to
Shelly Bay and Shelly Bay made a $148.0 million cash payment to EPIL III. EPIL
III used the proceeds from the payment by Shelly Bay, together with existing
cash of $12.0 million, to repay the Series A Guaranteed Notes.

The documents that established EPIL III required that EPIL III dispose of
financial assets in order to repay the Series A Guaranteed Notes at maturity.
The documents also mandated the order in which the assets were to be sold prior
to the maturity date for the Series A Guaranteed Notes. However, due to a
number of factors, including the inability of Elan and EPIL III to locate the
list mandating the order of disposal of the financial assets, the disposal
process was commenced and completed over the one-week period ending on 29 June
2002. Although Elan, as servicing agent for EPIL III, contacted a number of
third parties regarding their potential interest in purchasing financial assets
from EPIL III, each of those parties indicated that they would not be able to
complete a due diligence analysis of the issuers of the financial assets to be
sold, or to receive all necessary internal approvals to complete the purchase,
on a timely basis.

Therefore, in an effort to enable EPIL III to dispose of the financial assets,
Elan determined that it would be necessary to provide non-recourse credit
support to third parties who would agree to purchase financial assets from EPIL
III. Credit support was offered to a number of potential purchasers of the
financial assets. However, ultimately, only Shelly Bay possessed the ability to
complete the transaction on a timely basis.

Elan established Shelly Bay specifically for the purpose of acquiring financial
assets from EPIL III. All of the capital stock of Shelly Bay was issued to its
sole shareholder. Elan did not own any capital stock of Shelly Bay and did not
have a representative on Shelly Bay's board of directors. In addition, the sole
shareholder of Shelly Bay had no previous contact with Elan. However, as
further described below, Elan possessed all of the financial risk of the Shelly
Bay transaction. Similar to all other potential purchasers contacted by Elan,
the sole shareholder of Shelly Bay was unwilling to invest capital to acquire
the financial assets until a due diligence analysis of the issuers of the

--------------------------------------------------------------------------------
150

--------------------------------------------------------------------------------

financial assets had been completed. Therefore, the sole shareholder of Shelly
Bay made no substantive capital investment in Shelly Bay and, although Shelly
Bay possessed all of the potential financial benefits of the transaction,
neither Shelly Bay nor its sole shareholder had any financial risk in the
transaction.

Elan believed that any failure by EPIL III to dispose of financial assets prior
to 29 June 2002 could potentially adversely impact the non-consolidated
accounting status of EPIL III under U.S. GAAP and could result in defaults
under Elan's debt instruments.

Transaction structure

Under the terms of the transaction, Shelly Bay acquired certain financial
assets from EPIL III on 29 June 2002 and made a cash payment to EPIL III of
$148.0 million. Shelly Bay financed the entire purchase price of the financial
assets, together with the funds necessary to pay interest and other costs on
the loan to its maturity date, through borrowings under a $153.0 million
non-recourse bank loan facility maturing on 30 September 2002. Elan provided a
full and unconditional guarantee to the bank to support Shelly Bay's obligation
to repay the loan and provided $153.0 million in cash collateral to the bank to
secure Elan's obligations under its guarantee. Upon the closing of the
transaction, Elan paid to Shelly Bay approximately $1 million to reimburse
Shelly Bay for the expenses expected to be incurred by it in connection with
the transaction. In addition, Elan irrevocably waived all rights of recourse
against Shelly Bay in the event that it failed to repay the bank loan at
maturity.

The cash payment made by Shelly Bay in connection with its acquisition of the
financial assets was based upon a valuation conducted by Elan. The valuation
utilised customary, widely-accepted valuation methodologies and required that
Elan make certain judgements and assumptions regarding the financial assets.
Elan did not receive any independent verification of the valuation at the time
of the transaction. In addition, EPIL III did not receive any bids for the
financial assets to be disposed of.

Upon the closing of the transaction, Shelly Bay's assets consisted solely of
the financial assets purchased from EPIL III. Under the terms of the
transaction, Shelly Bay was required to complete a due diligence analysis of
the issuers of the securities prior to 15 September 2002. Shelly Bay had the
right to either elect, on or prior to 15 September 2002, to retain the
financial assets on a long-term basis or to dispose of the financial assets
prior to 30 September 2002.

In the event that Shelly Bay elected to retain the financial assets, it was
required, within 15 days of the election, to obtain alternative financing in an
amount equal to the value, as of 29 June 2002, of the assets being retained, as
determined by an independent appraiser engaged by Shelly Bay. The net cash
proceeds received by Shelly Bay from any alternative financing were required to
be applied to repay amounts outstanding under Shelly Bay's bank loan.

In the event that Shelly Bay elected to dispose of the financial assets prior
to 30 September 2002, Shelly Bay was required to apply the net proceeds from
the dispositions to repay amounts outstanding under its bank loan. The
transaction agreements contained no limitation on the price at which any
financial asset could be sold by Shelly Bay or the party to whom any financial
asset could be sold. In addition, Elan agreed that it had no right to object to
the disposition of any financial asset, the party to whom it was disposed of or
the price obtained for the disposition.

Given the non-recourse nature of the Shelly Bay bank loan, Elan possessed all
of the financial risk of the transaction under its guarantee of the bank loan,
and the cash collateral provided by Elan to secure the guarantee, in the event
of any shortfall in the aggregate proceeds received by Shelly Bay from the
refinancing or disposition of the financial assets. Although Shelly Bay
possessed all of the potential financial benefits of the transaction, neither
Shelly Bay nor its sole shareholder had any financial risk in the transaction.

As required by the terms of the transaction, Shelly Bay engaged an independent
appraiser to value the financial assets as of 29 June 2002. The appraisal,
which was prepared in early September 2002, valued the financial assets at $8.2
million.

Shelly Bay did not elect, under the terms of the transaction, to retain any of
the financial assets and obtain alternative financing in an amount equal to the
independent appraiser's valuation. Rather, by 30 September 2002, Shelly Bay had
disposed of all of the financial assets for aggregate net proceeds of $9.3
million. A number of the financial assets were disposed of, for net proceeds of
$1.8 million, to an affiliate of Shelly Bay. The remainder of the financial
assets were sold to third parties and in open market transactions. As described
above, the transaction agreements contained no limitation on the price at which
any financial asset could be sold by Shelly Bay or the party to whom any
financial asset could be sold, including to an affiliate of Shelly Bay. In
addition, Elan agreed that it had no right to object to the disposition of any
financial asset, the party to whom it was disposed of or the price obtained for
the disposition.

As a result of the disposition of the financial assets by Shelly Bay for
aggregate net proceeds of $9.3 million, on 30 September 2002, Elan made a cash
payment of $141.6 million to satisfy its obligation under its guarantee. Under
the terms of the transaction agreements, Elan has no further obligation under
the guarantee and has no recourse to Shelly Bay or to its sole shareholder
arising from Elan's payment under the guarantee.

Restatement of previously reported U.S. GAAP financial results

In its 2002 Annual Report and Form 20-F, Elan restated its U.S. GAAP financial
results to consolidate EPIL III from its date of establishment on 15 March
2001. The manner in which the Shelly Bay transaction was completed, including
Elan's facilitation of the transaction, which

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     151

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

resulted in an intercompany transfer of financial assets by EPIL III to Shelly
Bay at a price above fair value, demonstrated that Elan possessed the ability
to control EPIL III. This ability to control EPIL III was inconsistent with
SFAS No. 125 and EITF Topic D-66 "Effects of a Special-Purpose Entity's Powers
to Sell, Exchange, Repledge, or Distribute Financial Assets under SFAS
Statement No. 125".

Adjustment of previously announced unaudited U.S. GAAP financial information
for 2002

In its 2002 Annual Report and Form 20-F, Elan also adjusted its previously
announced unaudited U.S. GAAP financial information for 2002 to give effect to
the consolidation of EPIL III and to consolidate Shelly Bay from 29 June 2002
through 30 September 2002 under EITF D-14 "Transactions Involving Special
Purpose Entities" ("D-14"). Elan established Shelly Bay. The sole shareholder
of Shelly Bay did not make a substantive capital investment in Shelly Bay and
neither Shelly Bay nor its sole shareholder possessed any financial risk in the
transaction. Elan possessed the financial risk associated with the Shelly Bay
transaction until 30 September 2002. Under D-14, these factors required that
Elan consolidate Shelly Bay from 29 June 2002 through 30 September 2002.

The following tables present the effects of consolidating EPIL III on Elan's
previously reported U.S. GAAP net (loss)/income, shareholders' equity, total
assets, total liabilities and cash flows for 2001 and the effects of
consolidating EPIL III and Shelly Bay on Elan's previously announced unaudited
U.S. GAAP financial information for 2002:

NET (LOSS)/INCOME:

                                                                                               2002(1)           2001(2)
                                                                                           (UNAUDITED)        (RESTATED)
                                                                                                   $M               $M
------------------------------------------------------------------------------------------------------------------------

 Prior to restatement                                                                       (2,432.5)            342.8
                                                                                          ------------------------------
 Changes in:
 Net interest and other expense                                                                (25.5)(3)         (62.0)(4)
 Impairment of investments                                                                    (151.9)(5)         (11.9)(5)
 Charge arising from EPIL III guarantee                                                        247.6 (6)            --
                                                                                          ------------------------------
 Difference in net (loss)/income                                                                70.2             (73.9)
 As restated                                                                                (2,362.3)            268.9
------------------------------------------------------------------------------------------------------------------------
 Basic (loss)/earnings per Ordinary Share under U.S. GAAP, prior to restatement               $(6.96)            $1.02
 Basic (loss)/earnings per Ordinary Share under U.S. GAAP, as restated                        $(6.75)            $0.80
 Diluted (loss)/earnings per Ordinary Share under U.S. GAAP, prior to restatement             $(6.96)            $0.95
 Diluted (loss)/earnings per Ordinary Share under U.S. GAAP, as restated                      $(6.75)            $0.75
------------------------------------------------------------------------------------------------------------------------

SHAREHOLDERS' EQUITY:

                                         AT 31 DECEMBER       AT 31 DECEMBER
                                                2002(1)              2001(2)
                                            (UNAUDITED)           (RESTATED)
                                                    $M                   $M
---------------------------------------------------------------------------

 Prior to restatement                            828.7              3,283.9
                                         ----------------------------------
 Changes in:
 Retained earnings and other reserves             (1.8)(7)            (85.0)(8)

 As restated                                     826.9              3,198.9
---------------------------------------------------------------------------

152

--------------------------------------------------------------------------------

TOTAL ASSETS:

                                                     AT 31 DECEMBER    AT 31 DECEMBER
                                                            2002(1)           2001(2)
                                                        (UNAUDITED)        (RESTATED)
                                                                 $M                $M
-------------------------------------------------------------------------------------

 Prior to restatement                                       3,874.7           6,363.7
                                                     --------------------------------
 Changes in:
 Cash and cash equivalents                                      8.9              26.9
 Marketable investment securities                              79.2             144.9
 Accounts receivable and prepayments                            5.2              (0.3)
 Intangible assets                                              2.5(9)            4.5(9)
 Investments and marketable investment securities              45.0             288.6
                                                     ---------------------------------
 Increase in total assets                                     140.8             464.6
 As restated                                                4,015.5           6,828.3
-------------------------------------------------------------------------------------

TOTAL LIABILITIES:

                                    AT 31 DECEMBER     AT 31 DECEMBER
                                           2002(1)            2001(2)
                                       (UNAUDITED)         (RESTATED)
                                                $M                 $M
---------------------------------------------------------------------

 Prior to restatement                      3,046.0            3,079.8
                                    ---------------------------------
 Changes in:
 Long term and convertible debt              390.2              549.6
 Other liabilities                          (247.6)(6)             --
                                    ---------------------------------
 Increase in total liabilities               142.6              549.6
 As restated                               3,188.6            3,629.4
---------------------------------------------------------------------

CASH FLOWS FROM OPERATING ACTIVITIES:

                                   2002(1)              2001(2)
                               (UNAUDITED)           (RESTATED)
                                        $M                   $M
--------------------------------------------------------------------

 Prior to restatement                197.2                542.6
                                ------------------------------------
 Restatement adjustments            (48.9)(10)           (18.9)(11)
                                -----------------------------------
 As restated                         148.3                523.7
-------------------------------------------------------------------

CASH FLOWS FROM INVESTING ACTIVITIES:

                                    2002(1)               2001(2)
                                (UNAUDITED)            (RESTATED)
                                         $M                   $M
--------------------------------------------------------------------

 Prior to restatement               (244.2)               (849.7)
                                ------------------------------------
 Restatement adjustments             181.1 (12)           (504.2)(13)
                                ------------------------------------
 As restated                        ( 63.1)             (1,353.9)
--------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     153

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

CASH FLOWS FROM FINANCING ACTIVITIES:

                                    2002(1)                2001(2)
                                (UNAUDITED)             (RESTATED)
                                         $M                    $M
---------------------------------------------------------------------

 Prior to restatement               (531.7)               1,077.8
                                ------------------------------------
 Restatement adjustments            (150.2)(14)            550.0(15)
                                ------------------------------------
 As restated                        (681.9)               1,627.8
--------------------------------------------------------------------

(1)   Reflects the impact of consolidating EPIL III for 2002, and of
      consolidating Shelly Bay from 29 June 2002 through 30 September 2002, on
      Elan's U.S. GAAP unaudited financial results for fiscal year ended 31
      December 2002.

(2)   Reflects the impact of consolidating EPIL III from 15 March 2001, the
      date of its establishment, on Elan's U.S. GAAP financial results for
      2001, which were contained in Elan's Annual Report and Form 20-F for
      2001.

(3)   Primarily reflects interest expense on the EPIL III notes of $37.2
      million, less interest income on the financial assets held by EPIL III of
      $9.4 million.

(4)   Primarily reflects the reversal of a previously recorded gain arising on
      the sale of investments by Elan to EPIL III of $40.5 million and interest
      expense on the EPIL III notes of $35.4 million, less interest income on
      the financial assets held by EPIL III of $15.8 million.

(5)   Reflects impairment charges on financial assets held by EPIL III.

(6)   Represents the reversal of a previously recorded provision for the
      guarantee issued by Elan to the noteholders of EPIL III.

(7)   Represents the cumulative impact of the difference in net loss on
      retained earnings of $(3.7) million, together with a mark to market
      adjustment on common stock held by EPIL III of $1.9 million.

(8)   Represents the impact of the difference in net income on retained
      earnings of $(73.9) million, together with a mark to market adjustment on
      common stock held by EPIL III of $(11.1) million.

(9)   Reflects transaction costs related to the issuance of the EPIL III notes.

(10)  Primarily reflects interest paid on the EPIL III notes of $46.6 million.

(11)  Primarily reflects interest paid on the EPIL III notes of $25.9 million
      and an inflow of $6.0 million from the reclassification of the
      transaction costs to cash flows from investing activities.

(12)  Reflects the reclassification of the payment under the guarantee related
      to Shelly Bay of $141.6 million, the maturity of cash placed in
      short-term money market instruments of $30.2 million and the proceeds of
      the sale of investments by Shelly Bay of $9.3 million.

(13)  Primarily reflects the reversal of previously recorded investing cash
      inflows of $454.3 million from the sale of investments by Elan to EPIL
      III and the placing of cash of $43.9 million in short-term money market
      instruments.

(14)  Primarily reflects the repayment of EPIL III's Series A Guaranteed Notes
      in June 2002 of $160.0 million.

(15)  Reflects a financing cash inflow of $550.0 million from the issuance of
      the EPIL III Notes.

DIFFERENCES BETWEEN IRISH AND U.S. ACCOUNTING PRINCIPLES

The financial statements of Elan have been prepared in accordance with Irish
GAAP, which differ in certain significant respects from U.S. GAAP. The
presentation of information also differs. For example, exceptional items are
separately disclosed within their statutory classifications under Irish GAAP,
while U.S. GAAP does not use or define the term "exceptional items" and
therefore does not provide for the characterisation of items as exceptional.
U.S. GAAP income statement data, comprehensive income statement data, balance
sheet data and cash flow data have been provided on pages 169 to 171. These
reflect the 2001 restatement described above for EPIL III and the restated 2003
tax charge also described above. The material differences as they apply to
Elan's financial statements are as follows:

A DISCONTINUED OPERATIONS

Under Irish GAAP, a discontinued operation is classified as an operation of the
business which is (i) sold or terminated and the sale or termination has been
completed during the year or within three months following the year end, (ii)
the former activities have ceased permanently, (iii) the operation had a
material effect on the nature and focus of the business and (iv) its financial
results are clearly distinguishable. For information on products and businesses
which have been treated as discontinued operations under Irish GAAP, please
refer to Note 6 to the Consolidated Financial Statements. Under U.S. GAAP, a
discontinued operation is a component of an entity whose operations and
cashflows have been or will be eliminated from the ongoing operations of the
entity and the entity will not have any significant continuing involvement in
the operations of the component after its disposal. For information on the
products and businesses which have been treated as discontinued operations
under U.S. GAAP, please refer to page 172. As the criteria for the
determination of discontinued operations are different under Irish GAAP and
U.S. GAAP, the products and businesses treated as discontinued operations
differ under each. All of the operations that have been treated as discontinued
operations under U.S. GAAP have also been treated as discontinued operations
under Irish GAAP. However, the primary care franchise, the European sales and
marketing business, Zonegran, Zanaflex, Naprelan and certain drug delivery
operations have been treated as discontinued operations under Irish GAAP, but
as continuing operations under U.S. GAAP, because Elan believes that it has
significant continuing involvement in

--------------------------------------------------------------------------------
154

--------------------------------------------------------------------------------

the operation of these businesses, for example through ongoing supply
arrangements or formulation activities. As further discussed in note 29, Frova
and Zonegran were sold subsequent to 31 December 2003. The financial statements
have been amended to reflect these additional differences in discontinued
operations. Please refer to note 34 for further information thereof. The
presentation of discontinued operations differs between Irish GAAP and U.S.
GAAP. Under Irish GAAP, the results of discontinued operations remain within
the profit and loss account captions to which they relate, but additional
disclosures are given both on the face of the profit and loss account and
within Note 6 to the Consolidated Financial Statements. Under U.S. GAAP, the
results of discontinued operations are shown as a separate component of income
before extraordinary items and the cumulative effect of accounting changes (if
applicable). There are no reconciling differences to net (loss)/income or
shareholders' equity between Irish GAAP and U.S. GAAP related to discontinued
operations.

B BUSINESS COMBINATIONS

1. Dura: On 9 November 2000, Elan completed a merger with Dura. At the time of
this merger, Irish and U.S. GAAP had different criteria for establishing the
method of accounting required for business combinations.

o    Under U.S. GAAP, the merger with Dura required the application of the
     pooling of interests method of accounting. The assets and liabilities of
     Dura and Elan were combined and carried forward to the merged enterprise at
     their pre-combination recorded amounts. Therefore, under U.S. GAAP, the
     assets and liabilities of Dura were recorded at their historical carrying
     amounts and no goodwill arose from the merger of Dura and Elan. The income
     statements of Dura and Elan for 2000 and prior years were combined and
     reported as income statements of the merged enterprise. The costs of the
     transaction were expensed.

o    Under Irish GAAP, the acquisition of Dura by Elan was accounted for using
     acquisition accounting. The cost of the investment in Dura was calculated
     based on the fair value of the shares issued, together with the related
     transaction costs. The assets and liabilities of Dura were recorded based
     on their fair values at the date of acquisition. The difference between the
     cost of the investment and the fair value of the assets and liabilities of
     Dura was recorded as goodwill. Until 1 October 2002, this goodwill was
     being amortised over twenty years. This estimated useful life was reduced
     to 10 years effective 1 October 2002. With effect from July 2003, the
     cashflow method of amortisation has been applied as it better reflects the
     expected use of the asset. Pre-acquisition results for both companies were
     not combined. The profit and loss accounts have been consolidated for the
     post-acquisition period only.

The differences in accounting for the Dura transaction between Irish and U.S.
GAAP resulted in the following reconciling items:

o    A goodwill amortisation expense arose under Irish GAAP. The goodwill
     amortisation expense for 2003, 2002 and 2001 was $20.5 million, $68.9
     million and $55.2 million, respectively. Accumulated goodwill amortisation
     at 31 December 2003 amounted to $154.2 million (included within
     amortisation of intangible assets of $249.7 million). No goodwill
     amortisation expense arose under U.S. GAAP, as no additional goodwill was
     recognised in connection with the acqusition under U.S. GAAP;

o    In accordance with FRS 11, Elan performed an impairment review at 31
     December 2003 of the goodwill arising from the acquisition of Dura under
     Irish GAAP. As a result of this review, Elan recorded an impairment charge
     of $16.2 million for 2003 (2002: $854.9 million), reducing the carrying
     value of the Dura goodwill to $86.0 million (net of accumulated goodwill
     amortisation of $154.2 million) at 31 December 2003. Under U.S. GAAP, no
     goodwill arose from the merger of Dura and Elan;

o    The exclusion of pre-acquisition profits and losses under Irish GAAP
     compared to the combination of historic income statements under U.S. GAAP
     resulted in a reconciling item of $0.4 million between Irish and U.S. GAAP
     net income/(loss) for 2001, being losses on managed funds recorded by Dura
     in 2001 which related to pre-acquisition balances;

o    Goodwill and the fair value adjustment to licences and patents arising
     under Irish GAAP, on the acquisition of Dura, resulted in a reconciling
     difference to shareholders' equity of $293.5 million at 31 December 2003
     (2002: $309.7 million). In addition, the accumulated Irish GAAP goodwill
     amortisation expense at 31 December 2003 of $154.2 million (2002: $133.7
     million) (included within amortisation of intangible assets of $249.7
     million) does not arise under U.S. GAAP.

2. Other business combinations: Under Irish and U.S. GAAP, all of Elan's
acquisitions, except for Dura, were accounted for using acquisition (purchase)
accounting.

Under acquisition accounting, Irish and U.S. GAAP require the fair value of the
purchase consideration to be allocated to the net assets acquired based on
their fair values on the date of acquisition. The difference between the fair
value of the purchase consideration and the fair value of the net assets
acquired is recorded as goodwill. Under U.S. GAAP, the fair value of equity
securities issued to effect a purchase business combination is determined based
on the market price of the equity securities over a reasonable period of time
before and after the proposed transaction is announced. Under Irish GAAP, the
fair value of shares issued is determined based on the market price of these
shares at the acquisition date. There were no material differences between the
fair value of shares issued by Elan to effect purchase business combinations
under Irish and U.S. GAAP for the periods presented.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     155

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Under U.S. GAAP, the fair values of acquired IPR&D assets were expensed
immediately in the income statement. The amounts were capitalised and treated
as either goodwill or acquired IP under Irish GAAP. IPR&D expenses were $Nil
for 2003, 2002 and 2001. The difference in shareholders' equity between Irish
and U.S. GAAP, arising from the expensing of IPR&D, under U.S. GAAP, was
$2,121.1 million at 31 December 2003 (2002: $2,121.1 million). Under Irish
GAAP, Elan has subsequently recognised impairment charges to such goodwill and
acquired IP. To the extent that these amounts were previously expensed as
IPR&D, under U.S. GAAP, such impairment charges have resulted in reconciling
differences between Irish and U.S. GAAP net income/(loss). These impairment
charges were $112.8 million, $249.6 million and $785.2 million for 2003, 2002
and 2001, respectively. This resulted in a difference in shareholders' equity
between Irish and U.S. GAAP of $1,149.4 million at 31 December 2003 (2002:
$1,036.6 million). For additional information regarding intangible assets,
please refer to Notes 3 and 10 to the Consolidated Financial Statements.

Under Irish GAAP, prior to 31 December 1998, goodwill arising on acquisitions
was immediately written-off to shareholders' equity. Since 1998, in accordance
with FRS 10, "Goodwill and Intangible Assets", goodwill is no longer
written-off immediately to shareholders' equity but is capitalised and
amortised over its useful life. The difference in shareholders' equity between
Irish and U.S. GAAP, arising from goodwill previously written-off immediately
against reserves, was $574.3 million at 31 December 2003 (2002: $574.3
million).

Under U.S. GAAP, Elan adopted SFAS No. 142, "Goodwill and Other Intangible
Assets" ("SFAS No. 142"), effective 1 January 2002. Prior to this date,
intangible assets, including goodwill, were amortised over their estimated
useful lives. SFAS No. 142 requires that goodwill and other intangible assets
with indefinite lives no longer be amortised but instead be tested for
impairment at least annually. The difference in net loss between Irish and U.S.
GAAP, arising from the amortisation of intangible assets (mainly goodwill and
acquired IP) in 2003 was $40.7 million, of which $20.5 million related to Dura.

The following table discloses U.S. GAAP reported net (loss)/income, basic
(loss)/earnings per share and diluted (loss)/earnings per share for 2003 and
2002, and what these amounts would have been for 2001 if goodwill was not
amortised for 2001:

                                              2003
                                         (RESTATED)             2002        2001
-----------------------------------------------------------------------------------
                                             ($M EXCEPT FOR PER SHARE AMOUNTS)
-----------------------------------------------------------------------------------

 Net (loss)/income                          (508.7)         (2,362.3)      268.9
 Add back: Goodwill amortisation                --                --        30.0
-----------------------------------------------------------------------------------
 Adjusted net (loss)/income                 (508.7)         (2,362.3)      298.9
-----------------------------------------------------------------------------------
 Basic (loss)/earnings per share         $   (1.43)      $     (6.75)     $ 0.80
-----------------------------------------------------------------------------------
 Impact of goodwill amortisation                --                --      $ 0.09
-----------------------------------------------------------------------------------
 Adjusted (loss)/earnings per share      $   (1.43)      $     (6.75)     $ 0.89
-----------------------------------------------------------------------------------
 Diluted (loss)/earnings per share       $   (1.43)      $     (6.75)     $ 0.75
-----------------------------------------------------------------------------------
 Impact of goodwill amortisation                --                --      $ 0.08
-----------------------------------------------------------------------------------
 Adjusted (loss)/earnings per share      $   (1.43)      $     (6.75)     $ 0.83
-----------------------------------------------------------------------------------

There are differences between Irish and U.S. GAAP in the manner by which the
carrying value of goodwill is allocated for purposes of calculating the profit
or loss upon a disposal of a business. Under Irish GAAP, the carrying value of
goodwill is based on relative fair values on the date of acquisition. Under
U.S. GAAP, SFAS No. 142 requires that the allocation be determined based on the
relative fair value of the business being disposed of to the fair value of that
component of the reporting unit being retained. This is based on relative fair
values on the date of disposal.

During 2003, Elan sold a number of businesses. In June 2003, Elan sold its
primary care franchise which had been acquired through the acquisition of
Carnrick and the Sonata product intangible. The primary care franchise formed
part of the Core Elan reporting unit. Under Irish GAAP, goodwill and acquired
IP of $45.2 million was expensed in connection with the sale. Under U.S. GAAP,
goodwill of $34.4 million was expensed, resulting in a reconciling difference
of $10.8 million between Irish and U.S. GAAP net gain for 2003.

In July 2003, Elan sold its subsidiary ETT, a separate reporting unit. Under
Irish GAAP, goodwill and acquired IP of $28.5 million was expensed in
connection with the sale. Under U.S. GAAP, goodwill of $3.5 million was
expensed resulting in a reconciling difference of $25.0 million between Irish
and U.S. GAAP net loss for 2003.

--------------------------------------------------------------------------------
156

--------------------------------------------------------------------------------

In December 2003, Elan divested the Pain Portfolio which had been acquired from
Roxane in September 2001. The Pain Portfolio business formed part of the Core
Elan reporting unit. Under U.S. GAAP, SFAS No. 142 required a goodwill charge
of $3.5 million, based on the relative fair value of the business being
disposed of compared to the fair value of those being retained. Under Irish
GAAP no goodwill arose on the acquisition of the Pain Portfolio resulting in a
reconciling difference of $3.5 million.

During 2002, Elan divested Abelcet which had been acquired through the
acquisition of Liposome. Abelcet formed part of the Core Elan reporting unit.
Under Irish GAAP, goodwill of $119.0 million was expensed in connection with
the sale of the Abelcet business, while under U.S. GAAP, goodwill of $19.0
million was expensed in connection with the sale. This resulted in a
reconciling difference of $100.0 million between Irish and U.S. GAAP net loss
for 2002.

C IMPAIRMENT OF INTANGIBLE ASSETS

Under Irish GAAP, FRS 11 requires that intangible assets be reviewed for
impairment if there is an indication that a reduction in value may have
occurred. As described in Notes 3 and 10 to the Consolidated Financial
Statements, Elan recorded impairment charges to intangible assets of $173.3
million in 2003. These amounts are in addition to the charge of $16.2 million
also recorded in 2003, for the impairment to the carrying value of the goodwill
arising from the acquisition of Dura. Under U.S. GAAP, $60.5 million of the
$173.3 million was expensed in 2003. Hence there was a reconciling difference
of $112.8 million between Irish and U.S. GAAP net loss. Under U.S. GAAP, $11.7
million was expensed as IPR&D prior to 2003.

The total impairment charges to goodwill and acquired IP were $337.9 million
under Irish GAAP for 2002. Under U.S. GAAP, $88.3 million of this amount was
also expensed in 2002. Under U.S. GAAP, the remaining $249.6 million of the
$337.9 million was expensed as IPR&D prior to 2002. Hence this amount was a
reconciling difference between Irish and U.S. GAAP net income/(loss) for 2002.

The total impairment charges to acquired IP were $785.2 million under Irish
GAAP for 2001. Under U.S. GAAP, all of this amount was expensed as IPR&D prior
to 2001. Hence this amount was a reconciling difference between Irish and U.S.
GAAP net income/(loss) for 2001.

D IMPAIRMENT OF OTHER INTANGIBLE ASSETS

Under U.S. GAAP, in accordance with SFAS No. 144 "Accounting for the Impairment
or Disposal of Long-Lived Assets" ("SFAS No. 144") and pre-2002 (under SFAS No.
121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to Be Disposed Of"), intangibles are assessed for impairment based on
undiscounted cash flows. If the estimated future non-discounted cash flows
indicate that an impairment had arisen, the amount of the impairment was then
measured using projected future discounted cash flows. Under Irish GAAP, the
carrying value of an intangible asset is compared to its discounted cash flows
for purposes of assessing whether an impairment has arisen.

In 2001, Elan recorded an impairment charge of $44.4 million on Myambutol under
Irish GAAP, as the estimated future discounted cash flows were less than the
carrying value for this intangible. Under U.S. GAAP, no impairment charge arose
in 2001 as the estimated future undiscounted cash flows were greater than the
carrying value for this intangible.

In 2002, Elan recorded an impairment charge of $44.4 million on Myambutol under
U.S. GAAP, as the projected future cash flows had decreased such that the
estimated future undiscounted cash flows were less than the carrying value for
this intangible asset. As discussed above, Elan had recorded an equivalent
impairment charge in 2001 under Irish GAAP.

E ACCOUNTING FOR DERIVATIVES

Under Irish GAAP, Elan marks free-standing derivative instruments to market at
each balance sheet date and the resulting gains and losses are recognised in
the profit and loss account. The carrying values of derivative financial
instruments are generally reported within current assets or other current
liabilities.

Under U.S. GAAP, SFAS No. 133 "Accounting for Derivative Instruments and
Hedging Activities" ("SFAS No. 133") became effective in 2001. SFAS No. 133
requires that derivatives be recognised as either assets or liabilities and
measured at fair value. Changes in the fair value of derivatives are recorded
each period in current earnings or other comprehensive income, depending on
whether the derivative is designated as part of a hedge transaction and, if it
is, the type of hedge transaction.

The definition of a derivative instrument is significantly broader under U.S.
GAAP than under Irish GAAP. This gives rise to a reconciling difference, as
certain financial assets and liabilities are accounted for as derivative
instruments under U.S. GAAP and are not accounted

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     157

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

for as derivative instruments under Irish GAAP. The adoption of SFAS No. 133 in
2001 had a cumulative after tax income impact under U.S. GAAP of $7.8 million
relating to embedded derivatives and free-standing warrants. The fair value of
these derivative instruments at 31 December 2003 was $44.1 million (2002: $34.9
million).

The difference in net loss between Irish and U.S. GAAP arising from the
accounting for derivatives amounted to $26.9 million, $(4.4) million and $3.8
million for 2003, 2002 and 2001, respectively, resulting in a reconciling
difference to shareholders' equity of $34.1 million (2002: $7.2 million).

In 2003, Elan exercised its option to convert certain financial instruments
into common shares of the same companies and a gain of $13.4 million was
recognised in the profit and loss account representing the excess in value of
the equity financial instrument received over the carrying value of the
convertible instruments. The instruments do not qualify as SFAS No. 133
derivative instruments and hence no gain falls to be recognised in the income
statement under U.S. GAAP.

In 2002 and 2001, Elan exercised its option to convert debt in Ligand into
common shares of Ligand. Under Irish GAAP, gains of $10.1 million and $17.7
million were recognised for 2002 and 2001 in the profit and loss account
representing the excess in the value of the equity financial instrument
received over the carrying value of the convertible debt. Since 1 January 2001,
under U.S. GAAP, Elan has accounted for the convertible debt in Ligand in
accordance with the requirements of SFAS No. 133, as the conversion option
constituted an embedded derivative. As such, changes in fair value of $3.2
million and $20.7 million were recorded as income during 2002 and 2001,
respectively. The cumulative catch up adjustment for the implementation of SFAS
No. 133, recorded at 1 January 2001, included a cumulative gain of $3.9 million
with respect to Ligand convertible debt.

F ACQUIRED PRODUCT RIGHTS AND FINANCE CHARGES

Under Irish GAAP, contingent and potential acquisition payments which are
likely to be made in the future are recognised as creditors. Such contingent
payments on product acquisitions and alliances are capitalised and recorded as
creditors on a time discounted basis. A corresponding finance charge is
recorded annually in the profit and loss account. Under U.S. GAAP, such
payments are not recognised in the financial statements until the related
contingencies are resolved. This resulted in a difference between Irish GAAP
and U.S. GAAP net loss of $7.4 million, $19.2 million and $34.6 million for
2003, 2002 and 2001, respectively, consisting of finance and amortisation
charges. The difference in shareholders' equity between Irish and U.S. GAAP was
$61.2 million at 31 December 2003 (2002: $53.8 million).

Under Irish GAAP, Elan had recognised contingent and potential acquisition
payments relating to the Sonata product intangible which were likely to be
made. In June 2003, Elan disposed of the Sonata product intangible as part of
the sale of the primary care franchise to King. King assumed Elan's future
liabilities under this agreement. Elan therefore de-recognised the net
capitalised product intangible and accrued contingent and potential acquisition
payments of $31.2 million in 2003 which were no longer due.

G REVENUE RECOGNITION

Contract revenue, including research revenues and licence fees, arises from
contracts related to research and development activities on behalf of clients
and/or technology licensing and business ventures. Under Irish GAAP,
non-refundable up-front licence fee revenue is recognised when earned and when
the licensor has no future legal obligation pursuant to the licence fee.
Refundable licence fees are treated as deferred revenue until such time as they
are no longer refundable.

Elan sometimes enters into contractual arrangements which include multiple
elements such as the sale of a product and related research and development or
manufacturing arrangements. In accordance with the provisions included in
Application Note G of FRS 5, Elan accounts for each individual component of the
transaction separately, where each component represents a separable good or
service and Elan is capable of determining a reliable fair value for each such
component.

Under U.S. GAAP, the accounting treatment adopted by Elan for non-refundable
up-front licence fees was similar to Irish GAAP prior to 2000. In December
1999, the SEC issued SAB 101, which was adopted by the Company in 2000. In
December 2003, the SEC issued SAB 104 which updates the guidance in SAB 101.
SAB 104 provides guidance on revenue recognition and related disclosures in
financial statements. In contrast to Irish GAAP, SAB 104 generally requires
deferral and amortisation of up-front licence fees where there is a continuing
involvement with the licensed asset through the provision of research and
development services, manufacturing services or other similar activities. SAB
104 also applies to up-front fees other than licence fees. Elan adopted SAB 101
in 2000.

Following the adoption of SAB 101, as updated by SAB 104, under U.S. GAAP, Elan
defers and amortises up-front licence fees to the income statement over the
"performance period". The performance period is the period over which Elan
expects to provide services to

--------------------------------------------------------------------------------
158

--------------------------------------------------------------------------------

the licencee. It is determined by the provisions of, and by the facts and
circumstances of, the relevant contract. Generally, milestone payments have
been treated similarly under both Irish GAAP and U.S. GAAP. They have been
recognised when earned and non-refundable, and when Elan has no future legal
obligation pursuant to the milestone payment. However, the actual accounting
for milestones depends on the facts and circumstances of each contract. Elan
applies the substantive milestone method in accounting for milestone payments
under U.S. GAAP. This method requires that substantive effort must have been
applied to achieve the milestone prior to revenue recognition. If substantive
effort has been applied, the milestone is recognised as revenue, subject to it
being earned, non-refundable and not subject to future legal obligation. This
requires an examination of the facts and circumstances of each contract.
Substantive effort may be demonstrated by various factors, including the risks
associated with achieving the milestone, the period of time over which effort
was expended to achieve the milestone, the economic basis for the milestone
payment and licensing arrangement and the costs and staffing to achieve the
milestone. It is expected that the substantive milestone method will be
appropriate for most contracts. If Elan determines the substantive milestone
method is not appropriate, Elan will apply the performance method to the
relevant contract under U.S. GAAP. This method recognises as revenue the
percentage of cumulative non-refundable cash payments earned under the
contract, based on the percentage of costs incurred to date compared to the
total costs expected under the contract. This is subject to the milestone being
earned, non-refundable and not subject to future legal obligation.

Elan implemented SAB 101 in the fourth quarter of 2000. For the year ended 31
December 2000, Elan recorded a non-cash charge of $344.0 million under U.S.
GAAP for the cumulative effect of this accounting change relating to revenue
recognised in periods up to 31 December 1999. The difference in shareholders'
equity between Irish and U.S. GAAP, arising from the application of SAB 104
under U.S. GAAP, was $153.4 million at 31 December 2003 (2002: $254.3 million).

Deferred revenue at 31 December 2003 consists principally of amounts arising
from the disposal of product rights to Avinza and nifedipine in 2002. These
arrangements are described in more detail below.

The performance period was typically between two and three years for
non-refundable up-front licence fees received by Elan from business ventures
pursuant to Elan's business venture programme. The performance period was
determined by the facts and circumstances and could have been shorter or longer
in duration than the typical two to three year period. Under U.S. GAAP, Elan
recognised $35.2 million, $203.8 million and $255.0 million in licence fee
revenue from business ventures in 2003, 2002 and 2001, respectively. There are
no remaining unamortised licence fees from the business ventures at 31 December
2003.

Total contract revenue recognised under Irish GAAP was $49.5 million, $128.5
million and $333.7 million in 2003, 2002 and 2001, respectively. Under U.S.
GAAP, Elan recognised $97.9 million, $349.5 million and $421.3 million of
contract revenue in 2003, 2002 and 2001, respectively, comprising amortised
licence fee revenue of $48.4 million, $233.5 million and $287.2 million,
respectively. Of these amounts, $10.1 million, $45.2 million and $88.6 million
of the revenue in 2003, 2002 and 2001, respectively, were included as part of
the SAB 104 cumulative adjustment.

Under Irish GAAP, revenue from the sale of product rights and related inventory
is recognised when earned and non-refundable. The same accounting is generally
applicable under U.S. GAAP. However, in certain circumstances, such as when
Elan manufactures the product, subsequent to the sale deferral and amortisation
of such revenue may be appropriate. Elan deferred and amortised the revenue
received on the disposal of certain products, principally Avinza, Actiq and
nifedipine during 2002. Elan manufactures Avinza and nifedipine. The amounts of
deferred revenue under U.S. GAAP for Avinza, Actiq and nifedipine are $71.7
million, $Nil and $31.5 million, respectively, at 31 December 2003. Elan
recognised $44.5 million of product revenue under U.S. GAAP and $7.6 million of
amortisation from these products in 2003 (2002: $37.6 million). The deferred
revenue on Actiq was fully amortised in the first quarter of 2003. Elan
continues to manufacture Avinza and nifedipine and is amortising these deferred
revenue balances over 4 and 5 years, respectively. Under Irish GAAP, Elan
recognised $154.7 million of product revenue from these product disposals in
2002 as the manufacturing services provided under each contract represented a
separable component for which Elan was able to establish a reliable fair value.

Total revenue under U.S. GAAP was lower than Irish GAAP by $76.5 million,
$239.9 million and $164.4 million for 2003, 2002 and 2001, respectively.

This difference in revenue mainly arose due to:

o    $(175.2) million, $(362.0) million and $(286.2) million for 2003, 2002 and
     2001, respectively, relating to the reclassification of revenue within
     discontinued operations under U.S. GAAP as one line item below net income
     before tax;

o    $100.9 million, $61.8 million and $98.6 million for 2003, 2002 and 2001,
     respectively, relates to the application of SAB 104 under U.S. GAAP. SAB
     104 does not apply under Irish GAAP;

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     159

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

o    $Nil, $1.6 million and $19.7 million for 2003, 2002 and 2001, respectively,
     relates to the differences in the application of the equity method of
     accounting between Irish and U.S. GAAP; and

o    $(2.2) million, $58.7 million and $Nil for 2003, 2002 and 2001,
     respectively, relates to differences in the carrying value of divested
     intangibles assets. The revenue recorded on the divestment of products is
     based on the consideration received less the carrying value of the
     intangible asset.

The following table shows these reconciling differences in revenue between Irish
and U.S. GAAP.

                                                            2003           2002           2001
                                                              $M             $M             $M
------------------------------------------------------------------------------------------------

 Irish GAAP revenue                                        762.1        1,333.0        1,740.7
 Difference                                                (76.5)        (239.9)        (164.4)
                                                         ---------------------------------------
 U.S. GAAP revenue                                         685.6        1,093.1        1,576.3
 Difference analysed as:
 Product revenue                                          (124.9)        (460.9)        (252.0)
 Contract revenue                                           48.4          221.0           87.6
                                                         ---------------------------------------
 Total Difference                                          (76.5)        (239.9)        (164.4)
                                                         ---------------------------------------
 MAIN COMPOSITION OF DIFFERENCE
 Impact of discontinued operations under U.S. GAAP        (175.2)        (362.0)        (286.2)
 Impact of SAB 104 on revenue                              100.9           61.8           98.6
 Impact of equity accounting on revenue                       --            1.6           19.7
 Impact of intangibles on revenue                           (2.2)          58.7             --
------------------------------------------------------------------------------------------------

H NON-CONSOLIDATED SUBSIDIARIES (EPIL / EPIL II)

Under Irish GAAP, EPIL and EPIL II have been consolidated as subsidiaries of
Elan. Elan owns 100% of the equity in the companies. The individual investments
held by EPIL and EPIL II have remained on Elan's balance sheet and the related
loan notes of each of the companies have been included as a liability. Elan
expensed the related interest charge in the profit and loss account.

Under U.S. GAAP, EPIL II has not been consolidated as a subsidiary of Elan.
EPIL has been consolidated as a subsidiary of Elan under U.S. GAAP from March
2001 when control of EPIL reverted to Elan. Prior to this date, it was not
consolidated. EPIL (prior to March 2001) and EPIL II qualify as special purpose
entities within the meaning of SFAS No. 125, as grandfathered under SFAS No.
140, as Elan has effected a true legal sale of the investments and has not
retained control over such assets. Accordingly, the transfer of investments to
EPIL (prior to March 2001) and EPIL II was treated as a sale of the assets at
fair value under U.S. GAAP and the related loan notes have not been included as
a liability. Elan has not expensed the related interest charge in the income
statement.

EPIL's qualifying special purpose entity status was established in June 1999.
EPIL issued $350.0 million of loan notes with a maturity date of June 2002.
EPIL II's qualifying special purpose entity status was established in June
2000. EPIL II issued $450.0 million of loan notes with a maturity date of June
2004. In March 2001, pursuant to an exchange offer and consent solicitation,
EPIL III offered to exchange its Series A Guaranteed Notes and Series B
Guaranteed Notes for all the loan notes previously issued by EPIL in June 1999.
The consent solicitation requested consents from the holders of EPIL's loan
notes to amend the agreements under which these notes were issued. These
amendments removed restrictions on EPIL, including those relating to entering
into transactions with affiliates, merging, changing its business, amending its
charter documents, selling assets or making investments. The acceptance of the
exchange offer and consent solicitation by all of EPIL's note holders caused
control of EPIL to revert to Elan. Effectively upon closing of the exchange
offer and consent solicitation, EPIL's qualifying status terminated and EPIL
was consolidated by Elan under U.S. GAAP.

Elan holds a retained interest in EPIL II through its ownership of the retained
beneficial interest (100% of the common stock). The retained beneficial
interest entitles Elan to any residual proceeds in EPIL II after repayment of
the EPIL II Notes. Pursuant to the Stock Pledge Agreement, Elan has pledged the
common stock in EPIL II to the noteholders of EPIL II. The holders of the loan
notes have control of key voting rights, such as the right to approve the
appointment of directors of EPIL II and the right to approve amendments to the
Memorandum of Association and By-Laws of EPIL II. The board of directors of
EPIL II is independent of Elan and is comprised of a majority of independent
directors and one director appointed by Elan. EPIL II may dispose of financial
assets upon maturity of its loan notes. Upon the maturity of the loan notes due
2004, if there are more than sufficient financial assets to repay the loan
notes, the

--------------------------------------------------------------------------------
160

--------------------------------------------------------------------------------

organisational documents of EPIL II do not contain provisions concerning the
selection of financial assets, or the amount of financial assets, to be
disposed of. In this situation, any decision as to which assets to dispose of
would be made by the board of directors of EPIL II. When the loan notes of EPIL
II are repaid, the Stock Pledge Agreement terminates and Elan is entitled to
the residual proceeds, if any, through ownership of the common stock in EPIL
II. Elan does not have a call option or similar unilateral legal right over the
transferred investments. Elan has provided a direct guarantee to the holders of
the loan notes of EPIL II for the repayment of the loan notes and the payment
of any unpaid interest. In the event that EPIL II does not meet its obligations
to pay amounts due to the noteholders, the noteholders may call upon the Elan
guarantee.

Elan's accounting policy is to allocate the previous carrying amount of the
financial assets transferred, between the financial assets transferred and the
retained interest based on their relative fair values on the date of transfer.
The fair value of a retained interest, both for initial and subsequent
measurement, is calculated as the fair value of the qualifying special purpose
entity's assets less the fair value of its liabilities. For disclosure
purposes, the fair value of the assets of EPIL II is estimated using
established financial methodologies, including quoted market prices, where
available, and takes into account the time value of money. The fair value of
investments in private entities and non-traded securities of public entities is
typically measured by valuation methodologies such as option-pricing models and
valuations achieved in recent private placements by the investee. The key
assumptions used in measuring the fair value of Elan's retained interest in
EPIL II are common stock prices for equity-based assets and the discount rate
used for debt-based assets. The fair value of the liabilities of EPIL II is
measured as the total amount outstanding under its loan notes, including
accrued but unpaid interest (if any), and takes into account the time value of
money. The fair value of the guarantee was measured as de minimis on the
transfer date. The guarantee has subsequently been accounted for, under U.S.
GAAP, as a loss contingency in accordance with the requirements of SFAS No. 5,
"Accounting for Contingencies". This requires that Elan record a charge under
the guarantee if it is probable that a payment will be made under the guarantee
to the EPIL II noteholders.

Elan's retained interest in EPIL II had a fair value of $Nil on the transfer
date. Elan is carrying the common stock of EPIL II at cost, as it does not
qualify as a debt security or a debt-like security as defined in SFAS No. 115
"Accounting for Certain Investments in Debt and Equity Securities" ("SFAS No.
115").

On 31 December 2003, the estimated fair value of Elan's retained interest in
EPIL II was $Nil. Elan has guaranteed the debt of EPIL II, to the extent that
the investments held by it are insufficient to repay the debt when it falls due
in 2004. At 31 December 2003, Elan had recorded a provision of $344.5 million
under U.S. GAAP in respect of this guarantee. After providing for the estimated
investment shortfalls, the carrying values and cash position of EPIL II at 31
December 2003 were as follows:

                                            $M
-----------------------------------------------

 Investments in public companies          76.3
 Investments in private companies          9.0
 Cash                                     20.5
 Accrued interest and expenses            (0.3)
                                        ------
 Total assets                            105.5
 Provision for guarantees                344.5
                                        ------
 Total guaranteed indebtedness           450.0
-----------------------------------------------

An adverse change of 10% (20%) in the common stock prices used to estimate the
fair value of equity-based assets held by EPIL II would result in a decline of
$5.9 million ($11.6 million) in the estimated fair value of the investment
portfolio of EPIL II. An adverse change of 10% (20%) in the annual discount
rate used to estimate the fair value of debt-based assets held by EPIL II would
result in a decline of $0.7 million ($1.4 million) in the estimated fair value
of the investment portfolio of EPIL II.

The sensitivities outlined above regarding the fair value of Elan's retained
interest in EPIL II are hypothetical and should be used with caution. As the
figures indicate, changes in fair value based on a 10% variation in an
assumption generally cannot be extrapolated because the relationship of the
change in assumption to the change in fair value may not be linear. Also, in
the sensitivities outlined above, the effect of a variation in a particular
assumption on the fair value of the retained interest is calculated without
changing any other assumption. In reality, changes in one factor may result in
changes in another, which may magnify or counteract the sensitivities. For
example, increases in market interest rates may result in declines in market
common stock prices.

Elan provides services such as bookkeeping and administration, monitoring,
administering compliance with applicable laws and regulations and custodian
service to EPIL II. Such services are for the benefit of EPIL II. All
compensation paid to Elan represents an

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     161

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

arms-length price for those services. In 2003, Elan received a fee of $Nil
(2002: $Nil, 2001: $0.2 million) and $0.8 million (2002: $0.8 million, 2001:
$0.8 million) for providing these services to EPIL and EPIL II, respectively.

The differences between U.S. and Irish GAAP due to EPIL and EPIL II are as
follows:

                        NET (LOSS)/INCOME                   SHAREHOLDERS' EQUITY
---------------------------------------------------------------------------------------
                                                       AT 31 DECEMBER    AT 31 DECEMBER
                    2003         2002         2001               2003              2002
                      $M           $M           $M                 $M                $M
---------------------------------------------------------------------------------------

 IMPACT OF:
 EPIL                 --        (78.9)        49.8              (19.1)            (19.1)
 EPIL II            21.4        (75.9)        41.1               26.6               5.2
---------------------------------------------------------------------------------------
                    21.4       (154.8)        90.9                7.5             (13.9)
---------------------------------------------------------------------------------------

These net reconciling differences between Irish and U.S. GAAP arose mainly due
to profits on disposals, interest charges and impairment charges.

There was no gain or loss to Elan arising from the disposal of investments to
EPIL in 1999. Under U.S. GAAP, there was a gain of $39.2 million to Elan
arising from the disposal of investments to EPIL II in June 2000. No gain or
loss was recognised upon the termination of EPIL's qualifying special purpose
entity status in March 2001. Under Irish GAAP, as these entities are
consolidated subsidiaries, such gains are not included in Elan's profit and
loss account.

Under Irish GAAP, the interest charges recorded for the EPIL and EPIL II loan
notes were $43.0 million, $43.0 million and $49.1 million for 2003, 2002 and
2001, respectively. Under U.S. GAAP, such charges are not recorded in Elan's
income statement.

The remaining reconciling differences arise due to operating expenses/(income)
recorded under Irish GAAP but not under U.S. GAAP of $1.1 million, $(5.3)
million and $(9.4) million in 2003, 2002 and 2001, respectively, and the impact
of different cost bases for the investments held by EPIL/EPIL II under Irish
GAAP compared to U.S. GAAP, resulting in reconciling differences of $(22.7)
million, $(192.5) million and $51.2 million in 2003, 2002 and 2001,
respectively.

I ASSOCIATE ACCOUNTING

The difference between Irish and U.S. GAAP net (loss)/income arising from
differences in the application of the equity method of accounting, was $Nil,
$(3.8) million and $13.0 million for 2003, 2002 and 2001, respectively.

Most of the difference arises on the accounting for Elan's investment in
Amarin. Under U.S. GAAP, Elan's investment in Amarin was accounted for using
the equity method in 2002 based on the percentage of voting equity shares held
by the Group. Under Irish GAAP, the investment was accounted for using the
equity method in 2002 based on the percentage of stock held on a fully diluted
basis, including non-voting convertible preference shares. This resulted in a
reconciling item to the net (loss)/income of $(3.8) million between U.S. and
Irish GAAP in 2002 (2001: $11.0 million). During 2003 Elan only held equity
investments in Amarin, therefore, Elan's investment in Amarin was accounted for
similarly under both U.S. GAAP and Irish GAAP.

Under U.S. GAAP, certain investments of Elan were accounted for under the
equity method of accounting and treated as associates. Under Irish GAAP, these
investments were accounted for under the cost method. These investments were
written-off under Irish GAAP in 2001 resulting in a reconciling item to the net
(loss)/income of $Nil (2002: $Nil, 2001: $2.0 million) due to the different
cost basis of the investments.

J STOCK OPTION COMPENSATION

Elan grants options to employees under its stock option plans. These options
are granted at fixed exercise prices equal to the market value on the date of
grant. Under Irish GAAP, no compensation cost has been accrued for options
awarded to employees as the exercise price has been set equal to the market
value on the date of grant.

--------------------------------------------------------------------------------
162

--------------------------------------------------------------------------------

Under U.S. GAAP, Elan applies Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issues to Employees" ("APB 25"). In accordance with APB
25, no compensation cost was initially recognised for stock options granted, as
they have been granted to employees at market value and at a fixed exercise
price. In accordance with Financial Accounting Standards Board ("FASB")
Financial Interpretation No. 44 (FIN No. 44), "Accounting for Certain
Transactions Involving Stock Compensation", a compensation expense has been
recognised under U.S. GAAP where the original terms of a stock option award
were modified. Such modifications result in the fair value of the options being
recognised as a compensation expense over any remaining service period. Elan
recognised a compensation expense of $1.1 million, $0.1 million and $0.2
million in 2003, 2002 and 2001, respectively, arising from modifications. The
modifications included option acceleration upon severance of employees and a
change of status from employees to non-employees. Under Irish GAAP, no
compensation expense arose as a result of such modifications.

Under Irish GAAP, no compensation expense arises as a result of grants to
non-employees. Under U.S. GAAP, options granted to non-employees have been
valued at fair value and the related compensation expense is being amortised
over the service period. Elan recognised a compensation expense of $Nil, $Nil
and $0.3 million in 2003, 2002 and 2001, respectively, arising from options
granted to non-employees.

K PENSIONS

The main differences between Irish and U.S. GAAP in accounting for pension costs
are:

o    Under Irish GAAP, plan assets are valued on the basis of a discounted
     present value of expected future income. U.S. GAAP requires that plan
     assets are valued by reference to their market value.

o    Under Irish GAAP, pension costs in connection with defined benefit plans
     are assessed in accordance with the advice of independent actuaries using
     assumptions and methods which produce the actuaries' best estimates of the
     cost of providing the relevant pension benefits. U.S. GAAP requires the use
     of the projected unit credit method and the matching of the projected
     benefit obligation against the fair value of the plan's assets, as adjusted
     to reflect any unrecognised obligations or assets.

o    Under Irish GAAP, the measurement of plan assets and obligations may be
     based on the most recent actuarial valuation. Under U.S. GAAP, calculations
     must be made as of the date of the financial statements or a date not more
     than three months prior to that date.

o    Under Irish GAAP, pension credits are not recognised in the financial
     statements unless a refund of, or reduction in, contributions is likely.
     Under U.S. GAAP, a negative pension cost may arise where a significant
     unrecognised net asset or gain exists at the time of implementation. This
     is required to be amortised on a straight-line basis over the average
     remaining service period of employees.

The reconciling difference for net (loss)/income between Irish and U.S. GAAP
was $3.2 million, $2.2 million and $1.2 million for 2003, 2002 and 2001,
respectively. The reconciling difference to shareholders' equity includes
prepaid pension assets of $11.1 million. In 2002 a $9.8 million shortfall
between the unfunded accumulated benefit obligation and the unrecognised prior
service cost and prepaid benefit cost existed which was part of the
shareholders' equity reconciling difference. No such shortfall occurred as at
31 December, 2003 and the $9.8 million shortfall was reversed.

Under Irish GAAP, Elan has accounted for pensions in accordance with SSAP 24. A
new accounting standard, FRS 17, was issued in 2001 dealing with retirement
benefits. This is not mandatory until 2005. Prior to this, phased transitional
disclosures are required, which are detailed in Note 28 to the Consolidated
Financial Statements. The standard introduces changes to the accounting for
defined benefit schemes, the basic requirements of which are: pension scheme
assets are measured using fair values; pension scheme liabilities are measured
using a projected unit method and discounted at the current rate of return on a
high quality corporate bond; and full actuarial valuations should be obtained
at intervals not exceeding three years. There is also a requirement that these
valuations be updated at each balance sheet date.

L FINANCIAL FIXED ASSETS

Under Irish GAAP, non-current financial fixed assets are recorded at cost less
provision for permanent impairment in value. Under U.S. GAAP, in accordance
with SFAS No. 115 certain financial fixed assets were classified as available
for sale and reported at fair value and the unrealised gains and losses were
excluded from earnings and reported as a separate component of comprehensive
income (net of tax). The difference in shareholders' equity between Irish and
U.S. GAAP, arising from differences in the accounting treatment for financial
fixed assets, was $97.0 million at 31 December 2003 (2002: $21.0 million).

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     163

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

M CONSOLIDATED CASH FLOW DATA

In accordance with Irish GAAP, Elan complies with FRS No. 1, "Cash Flow
Statements" ("FRS 1"). Its objective and principles are similar to those set
out in SFAS No. 95, "Statement of Cash Flows" ("SFAS No. 95"). The principal
difference between the standards is in respect of classification. Under FRS 1,
the Group has presented its cash flows for (a) operating activities; (b)
returns on investments and servicing of finance; (c) taxation; (d) capital
expenditure and financial investment; (e) acquisitions and disposals; and (f)
financing activities. SFAS No. 95 requires only three categories of cash flow
activity, (a) operating; (b) investing; and (c) financing.

Cash flows arising from taxation and returns on investments and servicing of
finance under FRS 1 are included as operating activities under SFAS No. 95. In
addition, under FRS 1, cash and liquid resources include short term borrowings
repayable on demand. SFAS No. 95 requires movements in such borrowings to be
included in financing activities.

For the purposes of cash flows under U.S. GAAP, the Group considers all highly
liquid deposits with an original maturity of three months or less to be cash
equivalents. Under Irish GAAP, cash represents cash held at bank available on
demand, offset by bank overdrafts. Liquid resources comprise bank fixed
deposits with maturities of greater than one day.

The reconciling difference between Irish GAAP cash and liquid resources and
U.S. GAAP cash and cash equivalents is included on page 172. Cash balances held
by EPIL (prior to March 2001) and EPIL II have been included in cash and liquid
resources under Irish GAAP as these entities have been consolidated under Irish
GAAP. As the entities have not been consolidated subsidiaries under U.S. GAAP,
their cash balances have not been included in cash and cash equivalents under
U.S. GAAP. In 2003, under U.S. GAAP, there were marketable investments of $Nil
(2002: $22.7 million) whose maturity was greater than three months. These were
treated as liquid resources under Irish GAAP as they were readily convertible
into cash and were traded in an active market.

N GUARANTEES

In November 2002, the FASB issued FASB Interpretation No. 45 "Guarantor's
Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others" ("FIN 45"). This interpretation addresses
the disclosure to be made by a guarantor in its financial statements about its
obligation under guarantees. FIN 45 also requires the guarantor to recognise a
liability for the non-contingent component of the guarantee, that is the
obligation to stand ready to perform in the event that specified triggering
events or conditions occur. The initial measurement of this liability is the
fair value of the guarantee at inception. The disclosure requirements in this
interpretation are effective for financial statements of interim and annual
periods ending after 15 December 2002. The recognition and measurement
provisions are applicable on a prospective basis to guarantees issued or
modified after 31 December 2002, irrespective of the guarantor's fiscal
year-end. The Group has adopted the disclosure requirements of FIN 45 and has
applied the recognition and measurement provisions for all guarantees entered
into or modified after 31 December 2002. In accordance with FIN 45, the
following table provides the undiscounted amount of maximum potential future
payments for each major group of guarantee:

--------------------------------------------------------------------------------
164

--------------------------------------------------------------------------------

                                                                           AT 31 DECEMBER      AT 31 DECEMBER
                                                                                     2003                2002
                                                                                       $M                  $M
-------------------------------------------------------------------------------------------------------------

 PARENT COMPANY GUARANTEES RELATING TO PRODUCT ACQUISITIONS AND ALLIANCES
  Sonata                                                                               --               294.9
  Pain Portfolio                                                                       --                90.0
 PARENT COMPANY GUARANTEES RELATING TO DEBT FACILITIES
  LYONs                                                                                1.6            1,324.9
  EPIL II Notes                                                                      450.0              450.0
  EPIL III Notes                                                                     390.0              390.0
  7.25% Senior Notes                                                                 650.0              650.0
  6.5% Convertible Notes                                                             460.0                --
                                                                                   -------            -------
                                                                                   1,951.6            3,199.8
-------------------------------------------------------------------------------------------------------------

Under its strategic alliance with Wyeth, Elan assumed responsibility for the
U.S. marketing of Sonata and had the option to acquire the U.S. product rights
to Sonata. Elan Corporation, plc had guaranteed all of its subsidiary's
commitments under the agreements with Wyeth. At 31 December 2002, the estimated
potential payment due in connection with Sonata was $294.9 million, of which
$63.7 million was recorded as a liability under U.S. GAAP. The remaining
balance of $231.2 million represented the undiscounted amount of potential
future payments in respect of Elan's parent company guarantee under the Wyeth
agreements. As part of the disposal of Elan's primary care franchise, the
product payments related to Sonata were assumed by King.

In September 2001, Elan acquired the Pain Portfolio from Roxane. Elan
Corporation, plc has guaranteed all of its subsidiary's commitments under the
agreements with Roxane. At 31 December 2002, the potential payment due in
connection with the Pain Portfolio was $90.0 million, of which $77.4 million
was recorded as a liability under U.S. GAAP. The remaining balance of $12.6
million represents the undiscounted amount of potential future payments in
respect of Elan's parent company guarantee under the Roxane agreements. As part
of the disposal of Elan's Pain Portfolio, the related product payments were
assumed by aaiPharma.

For additional information regarding Elan's future payments and potential
future payments relating to product acquisitions and alliances, please refer to
Note 16 to the Consolidated Financial Statements.

Elan Corporation, plc has provided subordinated guarantees to the holders of
the LYONs for the repayment of the loan notes. In the event that Elan Finance
does not meet its obligations to pay amounts due to the noteholders, the
noteholders may call upon the Elan Corporation, plc guarantees.

Elan Corporation, plc has provided guarantees to the holders of the EPIL II
Notes and the EPIL III Notes for the repayment of the loan notes and the
payment of any unpaid interest. In the event that EPIL II or EPIL III do not
meet their obligations to pay amounts due to the noteholders, the noteholders
may call upon the Elan Corporation, plc guarantees.

Elan Corporation, plc has provided guarantees to the holders of the 7.25%
Senior Notes for the repayment of the loan notes and the payment of any unpaid
interest. In the event that Athena Finance does not meet its obligations to pay
amounts due to the noteholders, the noteholders may call upon the Elan
Corporation, plc guarantees.

Elan Corporation, plc has provided guarantees to the holders of the 6.5%
Convertible Notes for the repayment of the loan notes and the payment of any
unpaid interest. In the event that ECC does not meet its obligations to pay
amounts due to the noteholders, the noteholders may call upon the Elan
Corporation, plc guarantees.

For additional information regarding Elan's outstanding debt, please refer to
Note 15 to the Consolidated Financial Statements.

O NEW ACCOUNTING STANDARDS (U.S. GAAP)

Adopted

In June 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement
Obligations" ("SFAS No. 143"). SFAS No. 143 addresses financial accounting and
reporting for obligations associated with the retirement of long-lived tangible
assets and the associated asset

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     165

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

retirement costs. The Statement requires that the fair value of liabilities for
asset retirement obligations be recorded in the period in which they are
incurred if a reasonable estimate of fair value can be made. The associated
asset retirement costs are capitalised as part of the carrying amount of the
long-lived asset. This statement is effective for financial statements issued
for fiscal years beginning after 15 June 2002. Elan adopted SFAS No. 143
effective 1 January 2003. The adoption of SFAS No. 143 has not had a material
impact on the Company's Consolidated Financial Statements.

In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements No.
4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections"
("SFAS No. 145"). SFAS No. 145 provides for the rescission of several
previously issued accounting standards, new accounting guidance for the
accounting for certain lease modifications and various technical corrections
that are not substantive in nature to existing pronouncements. SFAS No. 145 was
adopted beginning 1 January 2003, except for the provisions relating to the
amendment of SFAS No. 13, which were adopted for transactions occurring
subsequent to 15 May 2002. SFAS No. 145 has not had a material impact on the
Company's Consolidated Financial Statements.

In June 2002, the FASB issued SFAS No. 146 "Accounting for the Costs Associated
with Exit or Disposal Activities" ("SFAS No. 146"), which nullifies EITF Issue
94-3, Liability Recognition for Certain Employee Termination Benefits and Other
Costs to Exit an Activity (Including Certain Costs Incurred in a
Restructuring). SFAS No. 146 requires that a liability for costs associated
with exit or disposal activities first be recognised when the liability is
irrevocably incurred rather than at the date of management's commitment to an
exit or disposal plan. In addition, SFAS No. 146 stipulates that the liability
be measured at fair value and adjusted for changes in estimated cash flows.
Elan adopted SFAS No. 146 effective 1 January 2003. The adoption of SFAS No.
146 has not had a material impact on the Company's Consolidated Financial
Statements.

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock Based
Compensation--Transition and Disclosure--an Amendment of SFAS Statement No.
123" ("SFAS No. 148"). SFAS No. 148 provides alternative methods of transition
for a voluntary change to the fair value based method of accounting for
stock-based employee compensation. In addition, this statement amends the
disclosure requirements of SFAS No. 123 to require prominent disclosures in
both annual and interim financial statements about the method of accounting for
stock-based employee compensation and the effect of the method used on reported
results. The transition provisions of SFAS No. 148 are effective for fiscal
years ending after 15 December 2002. The enhanced disclosure requirements are
effective for periods beginning after 15 December 2002 and are included on page
177 to the Consolidated Financial Statements. The Company has elected to
continue to apply APB 25 in the determination of compensation expense under
U.S. GAAP.

In December 2003, the FASB issued Interpretation No. 46, revised--Consolidation
of Variable Interest Entities, an Interpretation of ARB No. 51 ("FIN 46R"). FIN
46R addresses the consolidation of variable interest entities ("VIEs"), which
include entities that have one or more of the following characteristics: (1)
The equity investment at risk is not sufficient to permit the entity to finance
its activities without additional subordinated financial support; (2) The
equity investors lack essential characteristics of a controlling financial
interest (as defined by FIN 46R); and (3) The equity investors have voting
rights that are not proportionate to their economic interests, and the
activities of the entity involve or are conducted on behalf of an investor with
a disproportionally small voting interest. In addition, FIN 46R provides for
certain scope exceptions to its application. Adoption of this Interpretation is
required in financial statements that have interests in VIEs or potential VIEs,
commonly referred to as special-purpose entities, for periods ending after 15
December 2003. Application for all other types of entities is required in
financial statements for periods ending after 15 March 2004. The adoption of
FIN 46R has not had a material impact on the Company's Consolidated Financial
Statements.

In April 2003, the FASB issued SFAS Statement No. 149, "Amendment of Statement
133 on Derivative Instruments and Hedging Activities" ("SFAS No. 149"), which
amends SFAS Statement No. 133, to address (1) decisions reached by the
Derivatives Implementation Group, (2) developments in other FASB projects that
address financial instruments, and (3) implementation issues related to the
definition of a derivative. SFAS No. 149 has multiple effective date provisions
depending on the nature of the amendment to SFAS No. 133. SFAS No. 149 did not
have a material impact on the Company's Consolidated Financial Statements.

In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial
Instruments with Characteristics of both Liabilities and Equity". SFAS No. 150
establishes standards for how an issuer classifies and measures certain
financial instruments with characteristics of both liabilities and equity. It
requires that an issuer classify a financial instrument that is within its
scope as a liability (or an asset in some circumstances). Many of those
instruments were previously classified as equity. SFAS No. 150 is effective for
financial instruments entered into or modified after 31 May 2003, and otherwise
is effective at the beginning of the first interim period beginning after 15
June 2003, except for certain mandatorily redeemable financial instruments. It
is to be implemented by reporting the cumulative effect of a change in an
accounting principle for financial instruments created before the issuance date
of SFAS No. 150 and still existing at the beginning of the interim period of
adoption. Restatement is not permitted. SFAS No. 150 did not have a material
impact on the Company's Consolidated Financial Statements.

--------------------------------------------------------------------------------
166

--------------------------------------------------------------------------------

In December 2003, the FASB issued SFAS Statement No. 132 (revised), "Employers'
Disclosures about Pensions and Other Postretirement Benefits" ("SFAS No. 132
(revised)"). SFAS No. 132 (revised) will revise employers' disclosures about
pension plans and other postretirement benefit plans. It does not change the
measurement or recognition of those plans. SFAS No. 132 (revised) will retain
and revise the disclosure requirements contained in the original SFAS No. 132.
It also requires additional disclosures about the assets, obligations, cash
flows, and net periodic benefit cost of defined benefit pension plans and other
postretirement benefit plans. The Statement generally is effective for fiscal
years ending after December 15, 2003. SFAS No. 132 did not have a material
impact on the Company's Consolidated Financial Statements.

P FINANCIAL STATEMENT FORMAT

The following is a summary of the material adjustments to net income and
shareholders' equity which would be required had the financial statements been
prepared in accordance with U.S. GAAP:

(I) NET (LOSS)/INCOME

                                                                                          2003                          2001
                                                                                    (RESTATED)            2002     (RESTATED)
                                                                                            $M              $M            $M
-----------------------------------------------------------------------------------------------------------------------------

 Net loss as stated under Irish GAAP                                                    (815.4)       (3,615.1)       (887.2)
 ADJUSTMENTS TO CONFORM TO U.S. GAAP:
 Pooling of interests accounting/acquisition accounting for Dura        (b)(1)
  Goodwill amortisation                                                                   20.5            68.9          55.2
  Goodwill impairment                                                                     16.2           854.9            --
  Pre-acquisition results of Dura                                                           --              --          (0.4)
 Purchase accounting                                                    (b)(2)
  Impairment of intangible assets                                         (c)            112.8           249.6         785.2
  Amortisation of intangible assets                                                       20.2            45.0          22.3
  Pain Portfolio (goodwill)                                             (b)(2)            (3.5)             --            --
  Abelcet business (goodwill)                                           (b)(2)              --           100.0            --
  Primary care franchise acquired IP                                    (b)(2)            10.8              --            --
  ETT acquired IP                                                       (b)(2)            25.0              --            --
 Impairment of Myambutol                                                  (d)               --           (44.4)         44.4
 Accounting for derivatives                                               (e)             26.9            (4.4)          3.8
 Gain on conversion                                                       (e)            (13.4)             --            --
 Amortisation of acquired product rights and finance charges              (f)              7.4            19.2          34.6
 Reversal of Sonata acquired product rights and finance charges on
  disposal                                                                (f)            (31.2)             --            --
 Revenue recognition--impact of SAB 104                                   (g)            100.9            61.8          98.6
 Revenue recognition--write-off of related intangibles                    (g)             (2.2)           58.7            --
 Amortisation of nifedipine/Avinza intangible                             (g)             (7.6)             --            --
 Non-consolidated subsidiaries                                            (h)             21.4          (154.8)         90.9
 Associate accounting                                                     (i)               --            (3.8)         13.0
 Stock option compensation expenses                                       (j)             (1.1)           (0.1)         (0.5)
 Pensions and other                                                       (k)              3.6             2.2           1.2
-----------------------------------------------------------------------------------------------------------------------------
 Net (loss)/income from continuing operations                                           (477.2)       (2,173.7)        281.4
 Net income/(loss) from discontinued operations                                          (31.5)         (188.6)        (20.3)
-----------------------------------------------------------------------------------------------------------------------------
 Net (loss)/income before cumulative effect of accounting change
  as stated under U.S. GAAP                                                             (508.7)       (2,362.3)        261.1
 Cumulative effect of accounting change (net of tax)                      (e)               --              --           7.8
-----------------------------------------------------------------------------------------------------------------------------
 Net (loss)/income as stated under U.S. GAAP                                            (508.7)       (2,362.3)        268.9
-----------------------------------------------------------------------------------------------------------------------------
 Basic (loss)/earnings per Ordinary Share from continuing
  operations                                                                         $   (1.34)    $     (6.21)    $    0.84
 Basic (loss)/earnings per Ordinary Share from discontinued
  operations                                                                         $   (0.09)    $     (0.54)    $   (0.06)
-----------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     167

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

                                                                                  2003                        2001
                                                                            (RESTATED)        2002      (RESTATED)
                                                                                    $M          $M              $M
------------------------------------------------------------------------------------------------------------------

 Basic (loss)/earnings per Ordinary Share under U.S. GAAP before
  cumulative effect of accounting change                                      $ (1.43)     $(6.75)         $  0.78
 Cumulative effect of accounting change                                            --          --          $  0.02
------------------------------------------------------------------------------------------------------------------
 Basic (loss)/earnings per Ordinary Share under U.S. GAAP                     $ (1.43)     $(6.75)         $  0.80
------------------------------------------------------------------------------------------------------------------
 Diluted (loss)/earnings per Ordinary Share from continuing
  operations                                                                  $ (1.34)     $(6.21)         $  0.79
 Diluted (loss)/earnings per Ordinary Share from discontinued
  operations                                                                  $ (0.09)     $(0.54)         $ (0.06)
 Diluted (loss)/earnings per Ordinary Share under U.S. GAAP before
  cumulative effect of accounting change                                      $ (1.43)     $(6.75)         $  0.73
 Cumulative effect of accounting change                                            --          --          $  0.02
------------------------------------------------------------------------------------------------------------------
 Diluted (loss)/earnings per Ordinary Share under U.S. GAAP                   $ (1.43)     $(6.75)        $   0.75
------------------------------------------------------------------------------------------------------------------

(II) SHAREHOLDERS' EQUITY

                                                                                               AT 31 DECEMBER   AT 31 DECEMBER
                                                                                                         2003             2002
                                                                                                           $M               $M
------------------------------------------------------------------------------------------------------------------------------

 Shareholders' equity as stated under Irish GAAP                                                        825.4          1,460.0
 ADJUSTMENTS TO CONFORM TO U.S. GAAP:
 Pooling of interests accounting/acquisition accounting for Dura                   (b)(1)
  Elimination of goodwill and licence and patents arising on acquisition of Dura                       (293.5)          (309.7)
 Purchase accounting                                                               (b)(1)(2)
  Amortisation of intangible assets                                                                     249.7            209.0
  Goodwill written-off                                                                                  574.3            574.3
 Acquired IPR&D                                                                                     (2,121.1)         (2,121.1)
 Impairment of intangible assets                                                   (b)(2)/(c)         1,149.4          1,036.6
 Pain Portfolio (goodwill)                                                         (b)(2)                (3.5)              --
 Primary care franchise acquired IP                                                (b)(2)                10.8               --
 ETT acquired IP                                                                   (b)(2)                25.0               --
 Abelcet business (goodwill)                                                       (b)(2)               100.0            100.0
 Accounting for derivatives                                                          (e)                 34.1              7.2
 Amortisation of acquired products and finance charges                               (f)                 61.2             53.8
 Reversal of Sonata acquired product rights and finance charges on disposal          (f)                (31.2)              --
 Revenue recognition including cumulative effect of accounting change                (g)               (153.4)          (254.3)
 Revenue recognition--write-off of related intangibles                               (g)                 56.5             58.7
 Amortisation of nifedipine/Avinza intangible                                        (g)                 (7.6)              --
 Non-consolidated subsidiaries                                                       (h)                  7.5            (13.9)
 Associate accounting                                                                (i)                  7.2              7.2
 Pensions and other                                                                  (k)                 11.3             (1.9)
 Financial fixed assets                                                              (l)                 97.0             21.0
------------------------------------------------------------------------------------------------------------------------------
 Shareholders' equity as stated under U.S. GAAP                                                         599.1            826.9
------------------------------------------------------------------------------------------------------------------------------

U.S. GAAP CONDENSED FINANCIAL DATA

Due to the differences between Irish and U.S. GAAP, and in particular the
accounting of the merger of Dura and Elan as a pooling of interests under U.S.
GAAP, the following condensed financial data is presented on pages 169 to 171.

Additionally, under Irish GAAP, exceptional items are those items that in
management's judgement are material items which derive from events or
transactions that fall within the ordinary activities of the Group and which
individually or, if of a similar type, in aggregate, need

--------------------------------------------------------------------------------
168

--------------------------------------------------------------------------------

to be disclosed by virtue of their size or incidence. Under U.S. GAAP, there is
no concept similar to exceptional items, and such items would be included in
income from continuing operations or discontinued operations. Accordingly,
items classified as "exceptional" in the Company's consolidated profit and loss
account under Irish GAAP have been reflected in their appropriate line items
under U.S. GAAP under either continuing or discontinued operations in the U.S.
GAAP condensed financial data that follows. Cash flows relating to product
rationalisations are included in operating cash flows.

U.S. GAAP INCOME STATEMENT DATA

                                                                                                2003                     2001
                                                                                          (RESTATED)         2002  (RESTATED)
                                                                                                  $M           $M          $M
-----------------------------------------------------------------------------------------------------------------------------

 Revenue                                                                                       685.6      1,093.1     1,576.3
-----------------------------------------------------------------------------------------------------------------------------
 Costs and expenses:
 Cost of sales                                                                                 248.9        262.3       258.7
 Selling, general and administrative expenses                                                  386.9        545.5       451.7
 Research and development expenses                                                             277.6        353.9       277.6
 Gain on sale of businesses                                                                   (267.8)          --          --
 Gain on repurchase of LYONs                                                                    (1.6)       (37.7)         --
 Other charges, primarily relating to the write-down of tangible and intangible assets,
  acquisition of in-process research and development, merger costs, rationalisation
  and similar costs                                                                            404.8        581.7       323.3
-----------------------------------------------------------------------------------------------------------------------------
 Total operating expenses                                                                    1,048.8      1,705.7     1,311.3
-----------------------------------------------------------------------------------------------------------------------------
 Operating (loss)/income                                                                      (363.2)      (612.6)      265.0
 Net interest expense                                                                          (95.0)       (68.3)       (9.3)
 Business venture funding                                                                       (3.0)       (23.9)      (24.6)
 Investment gains                                                                              132.9         24.9       106.2
 Impairment of investments                                                                     (87.5)    (1,006.0)      (24.5)
 Loss on sale of investments by EPIL III/Shelly Bay transaction                                   --       (141.6)         --
 Charge arising from guarantee to EPIL II noteholders                                          (49.0)      (295.4)         --
 Investment losses and other                                                                   (35.2)       (42.8)      (14.7)
-----------------------------------------------------------------------------------------------------------------------------
 (Loss)/income from continuing operations before provision for income taxes                   (500.0)    (2,165,7)      298.1
 Provision for income taxes                                                                     22.8         (8.0)      (16.7)
-----------------------------------------------------------------------------------------------------------------------------
 Net (loss)/income from continuing operations                                                 (477.2)    (2,173.7)      281.4
 Net income/(loss) from discontinued operations (net of tax)                                   (31.5)      (188.6)      (20.3)
-----------------------------------------------------------------------------------------------------------------------------
 Net (loss)/income before cumulative effect of accounting change                              (508.7)    (2,362.3)      261.1
 Cumulative effect of accounting change (net of tax)                                              --           --         7.8
-----------------------------------------------------------------------------------------------------------------------------
 Net (loss)/income after cumulative effect of accounting change                               (508.7)    (2,362.3)      268.9
-----------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     169

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

U.S. GAAP COMPREHENSIVE INCOME STATEMENT DATA

                                                                                          2003                          2001
                                                                                    (RESTATED)            2002    (RESTATED)
                                                                                            $M              $M            $M
----------------------------------------------------------------------------------------------------------------------------

 Net (loss)/income                                                                     (508.7)        (2,362.3)        268.9
----------------------------------------------------------------------------------------------------------------------------
 OTHER COMPREHENSIVE INCOME/(LOSS):
 Foreign currency translation adjustment (net of $Nil tax)                                12.4             14.9         (3.3)
 Unrealised gains on securities (net of $Nil tax)                                         90.9              9.4         43.1
 Reclassification adjustment for gains included in net income (net of $Nil tax)           (1.3)           (30.1)       (16.4)
 Minimum pension liability adjustment (net of $Nil tax)                                    9.8             (9.8)          --
----------------------------------------------------------------------------------------------------------------------------
 Other comprehensive income/(loss) (net of $Nil tax)                                     111.8            (15.6)         23.4
----------------------------------------------------------------------------------------------------------------------------
 Comprehensive (loss)/income                                                            (396.9)        (2,377.9)        292.3
----------------------------------------------------------------------------------------------------------------------------

U.S. GAAP BALANCE SHEET DATA

                                                     AT 31 DECEMBER
                                                               2003    AT 31 DECEMBER
                                                         (RESTATED)              2002
                                                                 $M                $M
-------------------------------------------------------------------------------------

 CURRENT ASSETS
 Cash and cash equivalents                                    807.5           1,013.9
 Marketable investment securities                             349.4             450.6
 Accounts receivable and prepayments                          158.5             166.9
 Inventories                                                   69.5             132.5
 Held for sale assets                                         135.2             148.4
-------------------------------------------------------------------------------------
 Total current assets                                       1,520.1           1,912.3
 Property, plant and equipment                                369.1             451.2
 Intangible assets                                            928.9           1,338.8
 Investments and marketable investment securities             192.9             313.2
-------------------------------------------------------------------------------------
 Total assets                                               3,011.0           4,015.5
-------------------------------------------------------------------------------------
 LIABILITIES AND SHAREHOLDERS' EQUITY
 Current liabilities                                          707.9           1,485.4
 Other liabilities                                             20.4             373.6
 Held for sale liabilities                                     27.9              25.6
 Deferred revenue                                             154.8             258.2
 Long term and convertible debt                             1,500.9           1,046.3
 Minority interest                                               --              (0.5)
-------------------------------------------------------------------------------------
                                                            2,411.9           3,188.6
-------------------------------------------------------------------------------------
 SHAREHOLDERS' EQUITY
 Share capital                                                 22.0              19.9
 Additional paid-in capital                                 4,707.4           4,540.4
 Retained earnings and other reserves                      (4,130.3)         (3,733.4)
-------------------------------------------------------------------------------------
 Shareholders' equity                                         599.1             826.9
-------------------------------------------------------------------------------------
 Total liabilities and shareholders' equity                 3,011.0           4,015.5
-------------------------------------------------------------------------------------

In accordance with SFAS No. 144, Elan has recorded as held for sale the assets
and liabilities related to its former European sales and marketing business,
and Elan Pharma S.A., a manufacturing and research and development business
based in Switzerland. Both of these divestments closed during the first quarter
2004. Held for sale assets included property, plant and equipment of $3.1
million (2002: $8.1 million).

--------------------------------------------------------------------------------
170

--------------------------------------------------------------------------------

U.S. GAAP CASH FLOW DATA

------------------------------------------------------------------------------------------------------------------------------
                                                                                                  YEAR ENDED 31 DECEMBER
------------------------------------------------------------------------------------------------------------------------------
                                                                                              2003                       2001
                                                                                        (RESTATED)         2002    (RESTATED)
                                                                                                $M           $M           $M
------------------------------------------------------------------------------------------------------------------------------

 CASH FLOWS FROM OPERATING ACTIVITIES:
 Net (loss)/income                                                                          (508.7)   (2,362.3)        268.9
 Adjustments to reconcile net (loss)/income to net cash provided by operating activities:
 SFAS No. 133 accounting for derivatives                                                     (18.7)       10.7         (34.6)
 Amortisation of deferred revenue                                                            (99.0)      (62.8)        (98.6)
 Depreciation and amortisation                                                               187.7       206.3         179.1
 Interest expense on loan notes                                                               21.2       115.3          82.3
 Gain on sale of marketable investment securities                                            (68.7)       (1.8)        (48.5)
 Impairment of investments                                                                    87.5     1,006.0          24.5
 Provision against EPIL II guarantee                                                          49.0       295.4            --
 Disposals/write-down of other assets                                                         72.2       660.2         321.8
 Purchase of product royalty rights from Pharma Marketing/Autoimmune                         297.6       121.0            --
 Gain on sale of businesses                                                                 (294.6)     (176.4)           --
 Gain on repurchase of LYONs                                                                  (1.6)      (37.7)           --
 Loss on sale of investments by EPIL III/Shelly Bay transaction                                 --       141.6            --
 Waiver fee to EPIL II/III noteholders                                                        16.8          --            --
 Other                                                                                       (25.7)       84.9          (6.8)
 Net changes in assets and liabilities:
 Decrease in receivables                                                                      27.2       210.1          23.1
 Decrease/(Increase) in inventories                                                            9.9       (13.0)        (37.6)
 Decrease in accounts payable and accruals                                                  (265.0)      (49.2)       (149.9)
------------------------------------------------------------------------------------------------------------------------------
 Net cash (used in)/provided by operating activities                                        (512.9)      148.3         523.7
------------------------------------------------------------------------------------------------------------------------------
 CASH FLOWS FROM INVESTING ACTIVITIES:
 Proceeds from disposal of property, plant and equipment                                      27.9         8.6           2.0
 Purchase of property, plant and equipment                                                   (33.7)     (170.2)       (120.8)
 Purchase of investments                                                                     (11.8)     (117.1)       (640.7)
 Proceeds from disposal of investments                                                        70.6        12.9          21.9
 Purchase of marketable investment securities                                                 (2.1)      (83.7)       (568.1)
 Sale and maturity of marketable investment securities                                       267.7       222.6         194.9
 Purchase of intangible assets                                                              (144.8)     (315.5)       (286.7)
 Proceeds from disposal of intangible assets                                                   0.5         9.4          11.2
 Proceeds of business disposals                                                              546.9       361.3            --
 Purchase of product royalty rights from Pharma Marketing/Autoimmune                        (297.6)     (121.0)           --
 Redemption of investment in Autoimmune                                                         --        38.5            --
 Sale of EPIL III assets in connection with the repayment of EPIL III debt                      --         9.3            --
 Disposal of subsidiaries                                                                     46.1        81.8          41.9
 Acquisition of subsidiaries primarily represented by:
 Goodwill and other intangible assets arising on acquisitions                                   --          --          (9.5)
------------------------------------------------------------------------------------------------------------------------------
 Net cash provided by/(used in) investing activities                                         469.7       (63.1)     (1,353.9)
------------------------------------------------------------------------------------------------------------------------------
 CASH FLOWS FROM FINANCING ACTIVITIES:
 Proceeds from sale of share capital                                                         167.9         5.7         304.8
 Repayment of EPIL III debt                                                                     --      (160.0)           --
 Repayment of loans                                                                         (770.7)     (527.6)       (205.5)
 Issue of loan notes                                                                         443.9          --       1,185.7
 Bank loans                                                                                     --          --         342.8
 Waiver fee to EPIL II/III noteholders                                                       (16.8)         --            --
 Shelly Bay bank loan                                                                           --       148.0            --
 Repayment of Shelly Bay bank loan                                                              --      (148.0)           --
------------------------------------------------------------------------------------------------------------------------------
 Net cash (used in)/provided by financing activities                                        (175.7)     (681.9)      1,627.8
------------------------------------------------------------------------------------------------------------------------------
 Effect of exchange rate changes on cash                                                      12.5        11.2          (0.7)
------------------------------------------------------------------------------------------------------------------------------
 Net (decrease)/increase in cash and cash equivalents                                       (206.4)     (585.5)        796.9
------------------------------------------------------------------------------------------------------------------------------
 Cash and cash equivalents at beginning of year                                            1,013.9     1,599.4         802.5
------------------------------------------------------------------------------------------------------------------------------
 Cash and cash equivalents at end of year                                                    807.5     1,013.9       1,599.4
------------------------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     171

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

DISCONTINUED OPERATIONS

In accordance with SFAS No. 144, the results and gains or losses arising from
discontinued operations are aggregated for U.S. GAAP presentation and included
within one line in the income statement "Net income/(loss) from discontinued
operations." A discontinued operation is a component of an entity whose
operations and cashflows have been or will be eliminated from the ongoing
operations of the entity and the entity will not have any significant
continuing involvement in the operations of the component after its disposal.

Elan has recorded the results and gains or losses on the divestment of its
discontinued operations including ETT, Athena Diagnostics, Elan Diagnostics, a
manufacturing business in Italy, the Pain Portfolio, Actiq, the dermatology
portfolio of products, Abelcet U.S./Canada and Frova within discontinued
operations in the income statement. Please refer to note 29 for further
explanation of the Frova disposition and the related amendments to note 34.

During the course of the recovery plan, Elan sold a number of other assets and
businesses (principally the primary care franchise and the European sales and
marketing business) which in accordance with SFAS No. 144 are not included in
discontinued operations. Elan believes that it has a significant continuing
involvement in the operations of these businesses, for example through ongoing
supply arrangements or formulation activities.

An analysis of the effect on the results of discontinued operations is set out
below together with prior period comparatives.

                                                                2003         2002         2001
                                                                  $M           $M           $M
----------------------------------------------------------------------------------------------

 Revenue                                                       175.2        362.0        286.2
----------------------------------------------------------------------------------------------
 Costs and expenses:
 Cost of sales                                                  93.6        154.7        120.8
 Selling, general and administrative expenses                   50.5        168.6        151.8
 Research and development expenses                              23.5         43.3         43.6
 Gain on disposal of businesses                               (22.9)      (177.9)          --
 Recovery plan and other significant charges                    58.7        344.2         27.1
----------------------------------------------------------------------------------------------
 Total operating expenses                                      203.4        532.9        343.3
----------------------------------------------------------------------------------------------
 Operating income/(loss)                                      (28.2)      (170.9)       (57.1)
 Net interest and other (loss)/income                         ( 2.5)      (  5.9)         37.5
----------------------------------------------------------------------------------------------
 Income/(loss) from discontinued operations before tax        (30.7)      (176.8)       (19.6)
 Provision for income taxes                                   ( 0.8)      ( 11.8)       ( 0.7)
----------------------------------------------------------------------------------------------
 Income/(loss) from discontinued operations                   (31.5)      (188.6)       (20.3)
----------------------------------------------------------------------------------------------

CASH BALANCES

RECONCILIATION BETWEEN IRISH GAAP AND U.S. GAAP

--------------------------------------------------------------------------------
                                               AT 31 DECEMBER     AT 31 DECEMBER
                                                         2003               2002
                                                           $M                 $M
--------------------------------------------------------------------------------

 Cash and liquid resources (Irish GAAP)                 828.0            1,086.5
 Non-consolidated subsidiaries cash balances           (20.5)           (  49.9)
 Marketable investments                                   --            (  22.7)
--------------------------------------------------------------------------------
 Cash and cash equivalents (U.S. GAAP)                  807.5            1,013.9
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
172

--------------------------------------------------------------------------------

MARKETABLE INVESTMENT SECURITIES (U.S. GAAP)

For the purposes of U.S. GAAP, the following information on marketable
investment securities is presented in accordance with the requirements of SFAS
No. 115.

----------------------------------------------------------
                          AT 31 DECEMBER    AT 31 DECEMBER
                                    2003              2002
                                      $M                $M
----------------------------------------------------------

 TRADING SECURITIES
 Equity                             86.6              74.8
 Debt                                --               23.5
----------------------------------------------------------
                                    86.6              98.3
----------------------------------------------------------

TRADING SECURITIES

The unrealised gains included in earnings for 2003, 2002 and 2001 were $11.8
million, $0.8 million and $7.7 million, respectively. The unrealised losses
included in earnings for 2003, 2002 and 2001 were $Nil, $12.5 million and $2.7
million, respectively.

AVAILABLE FOR SALE SECURITIES
--------------------------------------------------------------------------------------------

 Equity                                                                   173.2        165.2
 Debt                                                                      89.6        187.1
--------------------------------------------------------------------------------------------
                                                                          262.8        352.3
--------------------------------------------------------------------------------------------
 Total marketable investment securities (current and non-current)         349.4        450.6
--------------------------------------------------------------------------------------------

The cash inflows arising from the sale and maturity of marketable investment
securities were $267.7 million, $222.6 million and $194.9 million in 2003, 2002
and 2001, respectively. The cash outflows arising from the purchase of
marketable investment securities were $2.1 million, $83.7 million and $568.1
million in 2003, 2002 and 2001, respectively.

AVAILABLE FOR SALE

Available for sale securities at 31 December 2003 and 2002 are analysed as
follows:

--------------------------------------------------------------------------------
                                         UNREALISED     UNREALISED         FAIR
                                COST          GAINS         LOSSES        VALUE
                                  $M             $M             $M           $M
--------------------------------------------------------------------------------

 AT 31 DECEMBER 2003
 Equity securities              86.1           87.2          (0.1)        173.2
 Debt securities                75.4           14.2             --         89.6
 AT 31 DECEMBER 2002
 Equity securities             159.8            5.4             --        165.2
 Debt securities               180.9            6.4          (0.2)        187.1
--------------------------------------------------------------------------------

Available for sale securities consist of equity and debt securities. The net
unrealised holding gains on available for sale equity securities at 31 December
2003, 31 December 2002 and 31 December 2001 were $87.1 million, $5.4 million
and $12.1 million, respectively. The net unrealised holding gains on available
for sale debt securities at 31 December 2003, 31 December 2002 and 31 December
2001 were $14.2 million, $6.2 million and $29.6 million, respectively. The cash
inflows arising from sales of available for sale securities during 2003, 2002
and 2001 were $244.1 million, $18.3 million and $51.6 million, respectively.
The cash outflows arising from purchases of available for sale securities
during 2003, 2002 and 2001 were $2.1 million, $73.6 million and $260.5 million,
respectively.

Based on fair value, the maturity of debt securities classified as available
for sale at 31 December 2003 was $Nil within one year, $89.6 million within one
to five years and $Nil between five and ten years. Based on fair value, the
maturity of debt securities classified as available for sale at 31 December
2002 was $1.7 million within one year, $93.7 million within one to five years
and $91.7 million between five and ten years. Based on cost, the maturity of
debt securities classified as available for sale at 31 December 2003 was $Nil
within one year, $75.4 million within one to five years and $Nil between five
and ten years. Based on cost, the maturity of debt securities classified as
available for sale at 31 December 2002 was $1.7 million within one year, $87.5
million within one to five years and $91.7 million between five and ten years.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     173

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

The gross realised gains on available for sale securities for 2003, 2002 and
2001 were $74.1 million, $11.8 million and $53.1 million, respectively. The
gross realised losses on available for sale securities in 2003, 2002 and 2001
were $0.3 million, $32.6 million and $2.2 million, respectively. Realised gains
and losses are determined on a cost basis.

Elan has accounted for available for sale debt securities at fair value in 2003
and 2002. The fair value of these debt securities was estimated at $89.6
million and $187.1 million as of 31 December 2003 and 31 December 2002,
respectively. The cost of these debt securities was $75.4 million and $180.9
million as of 31 December 2003 and 31 December 2002, respectively. These debt
securities have been disclosed in this note in accordance with the disclosure
requirements of SFAS No. 115.

Elan has accounted for certain free-standing warrants and embedded derivatives
in accordance with SFAS No. 133 in 2003 and 2002. This resulted in a cumulative
catch up adjustment of $7.8 million at 1 January 2001. The income effect of
derivative fair value movements for 2003 was $26.9 million (2002: $(4.4)
million; 2001: $3.8 million). Included in the 2003 impairment charge relating
to investments held by Elan of $87.5 million (2002: $1,006.0 million; 2001:
$24.5 million) was $Nil (2002: $31.6 million; 2001: $Nil) in relation to the
impairment of SFAS No. 133 derivative instruments. These derivatives had a fair
value of $44.1 million and $34.9 million at 31 December 2003 and 31 December
2002, respectively.

The unrealised losses on available for sale securities at 31 December 2003 are
analysed as follows:

                                  LESS THAN 12 MONTHS       12 MONTHS OR LONGER             TOTAL
----------------------------------------------------------------------------------------------------------
                                           UNREALISED                UNREALISED                UNREALISED
                             FAIR VALUE        LOSSES   FAIR VALUE       LOSSES   FAIR VALUE       LOSSES
DESCRIPTION OF SECURITIES            $M            $M           $M           $M           $M           $M
----------------------------------------------------------------------------------------------------------

 Equity Securities                  0.4         (0.1)          0.8           --          1.2         (0.1)
 Debt Securities                     --            --           --           --           --           --
 Total                              0.4         (0.1)          0.8           --          1.2         (0.1)
----------------------------------------------------------------------------------------------------------

The unrealised losses on available for sale equity securities at 31 December
2003 was $0.1 million (2002: $Nil). This loss related to two equity security
investments of which $0.1 million was incurred within twelve months and $Nil
was incurred in greater than twelve months.

The unrealised losses on available for sale debt securities at 31 December 2003
was $Nil (2002: $0.2 million).

HELD TO MATURITY

The fair value of held to maturity securities at 31 December 2003 was $Nil
(2002: $Nil).

The amortised cost of fixed income securities which matured during 2003 was
$Nil. As part of its recovery plan, Elan liquidated the remainder of its held
to maturity securities during 2002. In 2002, the amortised cost of the
liquidated securities was $39.9 million and a gain of $0.7 million was realised
on liquidation of these securities. The cash inflows arising from maturities of
held to maturity securities during 2003, 2002 and 2001 were $Nil, $18.3 million
and $87.0 million, respectively. The cash inflows arising from disposals of
held to maturity securities during 2003, 2002 and 2001 were $Nil, $39.5 million
and $Nil respectively. The cash outflows arising from purchases of held to
maturity securities during 2003, 2002 and 2001 were $Nil, $Nil and $73.5
million, respectively.

PENSION AND POST-RETIREMENT BENEFITS (U.S. GAAP)

For the purposes of U.S. GAAP, the pension costs of the major Irish retirement
plans have been presented in the following tables in accordance with the
requirements of SFAS No. 132 "Employees' Disclosures about Pensions and Other
Postretirement Benefits". The Company funds the pension entitlements of certain
employees through defined benefit plans. Two plans are operated for Irish
employees. In general, on retirement, a member is entitled to a pension
calculated at 1/60th of final pensionable salary for each year of pensionable
service, subject to a maximum of 40 years. These plans are managed externally
and the related pension costs and liabilities are assessed in accordance with
the advice of a professionally qualified actuary. The investments of the plans
at 31 December 2003 consisted of units held in independently administered
funds. The measurement date used for the plans is 31 December.

--------------------------------------------------------------------------------
174

--------------------------------------------------------------------------------

                                          AT 31 DECEMBER     AT 31 DECEMBER
                                                    2003               2002
                                                      $M                 $M
---------------------------------------------------------------------------

 CHANGE IN BENEFIT OBLIGATION:
 Benefit obligation at beginning of year            27.4               19.7
 Service cost                                        2.1                1.8
 Interest cost                                       1.6                1.2
 Plan participants' contributions                    1.4                1.6
 Actuarial loss                                     (0.6)              (0.8)
 Benefits paid                                      (0.3)              (0.1)
 Foreign currency exchange rate changes              6.0                4.0
---------------------------------------------------------------------------
 Benefit obligation at end of year                  37.6               27.4
---------------------------------------------------------------------------

-----------------------------------------------------------------------------------
                                                 AT 31 DECEMBER     AT 31 DECEMBER
                                                           2003               2002
                                                             $M                 $M
-----------------------------------------------------------------------------------

 CHANGE IN PLAN ASSETS:
 Fair value of plan assets at beginning of year            21.0               19.0
 Actual return on plan assets                               3.3               (5.0)
 Employer contribution                                      3.9                2.2
 Plan participants' contributions                           1.4                1.6
 Benefits paid                                             (0.3)              (0.1)
 Foreign currency exchange rate changes                     5.2                3.3
-----------------------------------------------------------------------------------
 Fair value of plan assets at end of year                  34.5               21.0
-----------------------------------------------------------------------------------
 Funded status                                             (3.1)              (6.4)
 Unrecognised net actuarial gain                           13.1               12.9
 Unamortised prior service cost                             1.1                1.0
 Additional liability recognised                            --                 0.4
 Minimum pension liability adjustment                       --                (9.8)
-----------------------------------------------------------------------------------
 Prepaid benefit cost/(pension liability)                  11.1               (1.9)
-----------------------------------------------------------------------------------

The net periodic pension cost was comprised of the following:

                                           2003       2002       2001
                                             $M         $M         $M
----------------------------------------------------------------------

 Service cost                               2.1        1.8        1.2
 Interest cost                              1.6        1.2        0.9
 Expected return on plan assets            (2.1)      (1.9)      (1.6)
 Amortisation of net loss                   0.6        0.3         --
 Amortisation of prior service cost         0.1        0.1        0.1
----------------------------------------------------------------------
 Net periodic pension cost                  2.3        1.5        0.6
----------------------------------------------------------------------

WEIGHTED AVERAGE ASSUMPTIONS USED TO DETERMINE NET PERIODIC PENSION COST

                                AT 31 DECEMBER    AT 31 DECEMBER
                                          2003              2002
----------------------------------------------------------------

 Discount rate                             5.2%             5.5%
 Expected return on plan assets            9.0%             9.0%
 Rate of compensation increase             4.0%             3.5%
----------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     175

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

The expected long-term rate of return on assets of 9.0% was calculated based on
the assumptions of the following returns for each asset class:

Equities            7.5%
Property            6.5%
Government Bonds    4.5%
Cash                2.5%

The fixed interest yield at 31 December 2003 was 4.5% hence the assumed return
on bonds is 4.5%. The return for the other asset classes are set by reference
to the fixed interest yield plus a risk premium. For equities the risk premium
is 3% and for property the premium is 2%.

WEIGHTED AVERAGE ASSUMPTIONS USED TO DETERMINE BENEFIT OBLIGATION

                                     AT 31 DECEMBER    AT 31 DECEMBER
                                               2003              2002
---------------------------------------------------------------------

 Discount rate                                 5.2%              5.5%
 Rate of compensation increase                 4.0%              3.5%
---------------------------------------------------------------------

The weighted average asset allocations at 31 December 2003 and 31 December 2002
by asset category are as follows:

                 AT 31 DECEMBER    AT 31 DECEMBER
ASSET CATEGORY             2003              2002
-------------------------------------------------

 Equity                   74.5%             67.0%
 Bonds                    16.8%             20.6%
 Property                  6.9%              7.8%
 Cash / other              1.8%              4.6%
-------------------------------------------------
                         100.0%            100.0%
-------------------------------------------------

At 31 December 2003 the Elan pension scheme assets were invested in two pension
managed unit trusts. The key objective of the Elan pension trusts is to achieve
long term capital growth. The unit trusts seek to achieve this objective by
investing primarily in a range of Eurozone and international equities, bonds,
property and cash.

The investment mix is biased towards equities, with a diversified domestic and
international portfolio of shares listed and traded on recognised Exchanges.

The long-term asset allocation ranges of the trusts are as follows:

Equities       55% -- 85%
Bonds          8% -- 40%
Property       0% -- 10%
Cash           0% -- 15%

The accumulated benefit obligation for all defined benefit pension plans was
$31.3 million at 31 December 2003 (2002: $24.1 million).

Elan recognised a $9.8 million charge to Other Comprehensive Income in 2002 in
respect of the shortfall between the unfunded accumulated benefit obligation
less the unrecognised prior service cost and the prepaid benefit cost. This was
reversed in 2003 as the shortfall no longer existed at 31 December, 2003.

Elan expects to contribute $3.0 million to its pension plan in 2004.

In addition, Elan operates a number of defined contribution pension plans,
primarily for employees outside of Ireland. The costs of these plans are
charged to the income statement in the period they are incurred. The pension
cost for these plans was $9.2 million, $8.8 million and $9.9 million for 2003,
2002 and 2001, respectively.

--------------------------------------------------------------------------------
176

--------------------------------------------------------------------------------

COMPENSATION COST (U.S. GAAP)

Elan grants options to employees under the Group's stock option plans. These
options are granted at fixed exercise prices equal to the market value on the
date of grant.

The Company applies APB 25 in accounting for its stock option plans and,
accordingly under U.S. GAAP, no compensation expense is recognised when stock
options are initially granted to employees, as the exercise price is equal to
the market price on the date of grant. If the Company determined compensation
cost based on the fair value at the grant date for its stock options under SFAS
No. 123, the effect on net income under U.S. GAAP would be as shown below.

                                                                                         2003                            2001
                                                                                   (RESTATED)             2002     (RESTATED)
                                                                                           $M               $M            $M
-----------------------------------------------------------------------------------------------------------------------------

 Net (loss)/income under U.S. GAAP as reported                                        (508.7)         (2,362.3)        268.9
 Add: Stock-based compensation expense included in reported net income                   1.1               0.1           0.5
 Deduct: Total stock-based employee compensation expense determined under fair
  value based method for all awards                                                    (75.2)           (127.5)       (157.0)
-----------------------------------------------------------------------------------------------------------------------------
 Pro-forma net (loss)/income                                                          (582.8)         (2,489.7)        112.4
 Basic (loss)/earnings per Ordinary Share
 As reported                                                                       $   (1.43)      $     (6.75)     $   0.80
 Pro-forma                                                                         $   (1.64)      $     (7.12)     $   0.33
 Diluted (loss)/earnings per Ordinary Share
 As reported                                                                       $   (1.43)      $     (6.75)     $   0.75
 Pro-forma                                                                         $   (1.64)      $     (7.12)     $   0.31
-----------------------------------------------------------------------------------------------------------------------------

The weighted average fair value of the individual options granted during the
years ended 31 December 2003, 2002 and 2001 is estimated as $3.50, $4.11 and
$21.47, respectively, on the date of grant. The fair value of options granted
was estimated using the Black-Scholes option-pricing model with the following
weighted average assumptions:

                                 2003         2002         2001
------------------------------------------------------------------

 Risk-free interest rate         1.02%        1.62%        3.47%
 Volatility                     99.32%       91.00%       46.99%
 Dividend yield                   Nil          Nil          Nil
 Expected life (years)            6.7          5.9          4.1
------------------------------------------------------------------

DEFERRED TAXATION (U.S. GAAP)

The deferred taxation provision under U.S. GAAP is calculated in accordance
with the requirements of SFAS No. 109 "Accounting for Income Taxes" ("SFAS No.
109").

The full potential amounts of deferred taxation and amounts accounted for in
the Group balance sheet comprised the following deferred tax assets and
liabilities:

                                 AT 31 DECEMBER
                                            2003   AT 31 DECEMBER
                                      (RESTATED)             2002
                                              $M               $M
------------------------------------------------------------------

 DEFERRED TAXATION LIABILITIES:
 Fixed assets                             (45.8)           ( 14.9)
 Intangible asset on acquisition          (52.6)           (150.1)
 Deferred interest                         (2.9)               --
------------------------------------------------------------------
                                         (101.3)           (165.0)
------------------------------------------------------------------
 DEFERRED TAXATION ASSETS
 Net operating losses                     232.3             264.7
 Tax credits                               83.9              70.8
 Deferred interest                         92.2              41.0
 Capitalised items                        128.6             112.5
 Reserves/provisions                       70.3              98.4
 Other                                      2.6               9.2
------------------------------------------------------------------
                                          609.9             596.6
------------------------------------------------------------------
 Valuation allowance                      508.6             431.6
 Deferred tax asset/(liability)              --                --
------------------------------------------------------------------

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     177

NOTES RELATING TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

Under U.S. GAAP, Elan applies SFAS No. 109 which requires the asset and
liability method of accounting for income taxes. Under this method, deferred
tax assets and liabilities are recognised for the future tax consequences
attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases and operating
loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or
settled. The effect on deferred tax assets and liabilities of a change in tax
rates is recognised in income in the period that includes the enactment date. A
valuation allowance has been established in respect of those deferred tax
assets where it is more likely than not that some portion will not be realised
in the future. The valuation allowance recorded against the deferred tax assets
as of 31 December 2003 was $508.6 million. The net change in the valuation
allowance for 2003 was an increase of $77.0 million (2002: increase of $29.6
million; 2001: increase of $129.8 million). Approximately $119.7 million of the
valuation allowance at 31 December 2003 is expected to be applied directly to
contributed capital under U.S. GAAP when deferred tax assets associated with
certain stock option exercises are recognised. The Company has adjusted its net
operating losses to reflect the amounts expected to be realised on a probable
basis.

At 31 December 2003 certain U.S. subsidiaries had net operating loss carryovers
for federal income tax purposes of approximately $333.7 million and for state
income tax purposes of approximately $33.8 million. The federal net operating
losses will expire from 2007-2023 and the state net operating losses, from 2004
to 2022, to the extent they are not utilised. In addition, at 31 December 2003,
certain U.S. subsidiaries had federal research and orphan drug credit
carryovers of $58.0 million which will expire from 2019 through 2022 and state
credit carryovers of $25.9 million, mostly research credits, of which $23.0
million can be carried to subsequent tax years indefinitely, and $2.9 million
will expire from 2004 to 2008 to the extent they are not utilised. The Company
may have had "changes in ownership" as described in the U.S. Internal Revenue
Code Section 382. Consequently, utilisation of federal and state net operating
losses and credits may be subject to certain annual limitations.

At 31 December 2003 certain non-U.S. subsidiaries of Elan had net operating
loss carryovers for income tax purposes of $1,067.0 million. Approximately $1
billion of these losses arose in Ireland and can be carried forward
indefinitely but are limited to the same trade/trades. The remaining loss
carryovers have arisen in a number of different tax jurisdictions and as such
are subject to various local restrictions. These remaining loss carryovers are
also subject to varying expiration dates beginning in 2004, with approximately
$15 million of the remaining losses carrying forward indefinitely.

No taxes have been provided for the unremitted and untaxed earnings of the
Group's overseas subsidiaries as these are, in the main, considered permanently
employed in the business of these companies. Cumulative unremitted earnings of
overseas subsidiaries and related undertakings totalled approximately $1,046.8
million at 31 December 2003. Unremitted earnings may be liable to overseas
taxes and/or Irish taxation if they were to be distributed as dividends. It is
impracticable to determine at this time the potential amount of additional tax
due upon remittance of earnings.

34 AMENDMENTS TO THE CONSOLIDATED FINANCIAL STATEMENTS

The following amendments have been made to the Consolidated Financial
Statements included in the original Annual Report and Form 20-F filed with the
Securities and Exchange Commission on 29 April 2004.

These Amendments include:

(a)  A restatement to the segment information set out in Note 2 to the
     Consolidated Financial Statement for all periods presented to reflect the
     new segment structure under which the Company operates, which was effected
     subsequent to December 31, 2003. Irish GAAP requires such restatement when
     previsouly issued financial statements are reissued when a change in a
     reporting entity's operating segments has been effected subsequent to the
     original issuance of the entity's financial statements. This restatement
     does not have any effect on previously reported net income or equity under
     Irish GAAP.

(b)  A restatement to the amounts classified as discontinued operations as set
     forth in the Company's Consolidated Financial Statements for all periods
     presented to include in such classification certain operations that have
     been disposed of in 2004, but which did not qualify for classification as
     discontinued operations in the Consolidated Financial Statements included
     in our Form 20-F as filed on April 29, 2004. Irish GAAP requires such
     restatement when previously issued financial statements are reissued and
     additional operations that meet the definition of discontinued operations
     have been discontinued subsequent to the original issuance of the entity's
     financial statements. This restatement does not have any effect on
     previously reported net income or equity under Irish GAAP; however, it does
     result in offsetting differences in amounts reported in continuing and
     discontinuing operations. Additionally similar offsetting differences
     between continuing and discontinuing operations are reflected in the
     US GAAP information set forth in Note 33 to the Company's Consolidated
     Financial Statements.

(c)  A restatement to the 2003 reconciliation of net loss under Irish GAAP to
     the net loss determined under US GAAP set forth in Note 33 to the
     Consolidated Financial Statements to reduce the reported net loss under US
     GAAP by $26.7 million for the year ended December 31, 2003 and to increase
     equity under US GAAP by $26.7 million as of December 31, 2003, following a
     reassessment of the amount of net operating loss carry forwards expected to
     be realized on a "probable" basis.

(d)  Post balance sheet events

     Litigation

     During the first half of 2004, ELAN recorded a provision of $55 million
     (Net of insurance coverage) in relation to a fine expected to arise from
     the Class action and SEC investigation proviously disclosed in note 25,
     Since the timing and Final resolution of the class action and SEC
     investigation remains uncertain, Elan's unable to predict or determine the
     outcome of the class action or SEC investingation with certainty.

     Zonegran and Frova

     The sale of Zonegran was completed in the second quarter of 2004 on the
     terms set out in Note 29. In August 2004, Elan completed the disposal of
     Frova on the terms set out in Note 29 other than Elan accepted $44 million
     as full payment.

--------------------------------------------------------------------------------
178

SELECTED FINANCIAL DATA
--------------------------------------------------------------------------------

SELECTED FINANCIAL DATA

The selected financial data set forth below as of and for the years ended 31
December 2003, 2002, 2001, 2000 and 1999 have been derived from Elan's audited
Consolidated Financial Statements. The selected financial data should be read
in conjunction with the Consolidated Financial Statements of the Company and
the Notes thereto, which are included elsewhere in this Annual Report and Form
20-F.

GROUP FINANCIAL RECORD--IRISH GAAP(1)

                                                          YEAR ENDED           YEAR ENDED
                                                         31 DECEMBER          31 DECEMBER
                                                                2003                 2002
-------------------------------------------------------------------------------------------
                                                         ($M, EXCEPT PER SHARE DATA)
-------------------------------------------------------------------------------------------

 PROFIT AND LOSS ACCOUNT DATA:
 Total revenue                                             762.1              1,333.0
 Operating (loss)/profit                                  (935.1)(2)         (2,290.8)(3)
 Retained (loss)/profit                                   (815.4)(6)         (3,615.1)(7)
 Basic (loss)/earnings per Ordinary Share(10)         $    (2.29)(6)     $     (10.34)(7)
 Diluted (loss)/earnings per Ordinary Share(10)       $    (2.29)(6)     $     (10.34)(7)

                                                            YEAR ENDED        YEAR ENDED   YEAR ENDED
                                                           31 DECEMBER       31 DECEMBER  31 DECEMBER
                                                                  2001              2000         1999
-----------------------------------------------------------------------------------------------------
                                                              ($M, EXCEPT PER SHARE DATA)
-----------------------------------------------------------------------------------------------------

 PROFIT AND LOSS ACCOUNT DATA:
 Total revenue                                            1,740.7             1,302.0        1,007.8
 Operating (loss)/profit                                   (829.7)(4)           296.3(5)       309.5
 Retained (loss)/profit                                    (887.2)(8)           342.1(9)       335.9
 Basic (loss)/earnings per Ordinary Share(10)         $     (2.64)(8)      $     1.19(9)   $    1.26
 Diluted (loss)/earnings per Ordinary Share(10)       $     (2.64)(8)      $     1.10(9)   $    1.19
-----------------------------------------------------------------------------------------------------

                                           AT            AT            AT            AT           AT
                                  31 DECEMBER   31 DECEMBER   31 DECEMBER   31 DECEMBER  31 DECEMBER
                                         2003          2002          2001          2000         1999
                                ------------- ------------- ------------- ------------- ------------
                                                      ($M, EXCEPT SHARE DATA)
                                --------------------------------------------------------------------

 BALANCE SHEET DATA:
 Working capital                        302.0         (97.4)      1,223.5         940.7        753.7
 Total assets                         3,171.4       4,771.1       9,439.6       8,096.8      4,674.2
 Long term liabilities                1,509.1       1,716.6       3,048.2       2,157.6      1,550.9
 Total shareholders' equity             825.4       1,460.0       5,054.5       5,315.5      2,687.6
 Number of shares outstanding           386.2         350.4         349.8         322.5        269.1

1.   For information on discontinued operations under Irish GAAP, please refer
     to Note 6 to the Consolidated Financial Statements.

2.   After exceptional items of $576.7 million primarily relating to the
     purchase of royalty rights from Pharma Operating, a write-down of goodwill
     and product intangibles, asset write-downs, severance/relocation and
     similar costs.

3.   After exceptional items of $1,796.3 million primarily relating to a
     write-down of goodwill and product intangibles, acquired intellectual
     property, asset write-downs, severance, rationalisation, integration and
     similar costs, product rationalisations and disposals.

4.   After exceptional items of $957.8 million primarily relating to a
     write-down of acquired intellectual property, asset write-downs, severance,
     rationalisation, integration and similar costs and product
     rationalisations.

5.   After exceptional items of $79.3 million primarily relating to severance,
     rationalisation, integration and similar costs, a product withdrawal and
     asset write-downs.

6.   After exceptional items of $317.1 million primarily relating to the
     purchase of royalty rights from Pharma Operating, business disposals,
     write-down of goodwill and product intangibles, investment write-downs,
     asset write-downs, severance/relocation and similar costs.

7.   After exceptional items of $2,949.4 million primarily relating to a
     write-down of goodwill and product intangibles, acquired intellectual
     property, asset write-downs, business disposals, investment write-downs,
     severance, rationalisation, integration and similar costs and product
     rationalisations and disposals.

8.   After exceptional items of $931.9 million primarily relating to a
     write-down of acquired intellectual property, asset write-downs, investment
     write-downs, severance, rationalisation, integration and similar costs and
     product rationalisations.

9.   After exceptional items of $113.6 million primarily relating to severance
     and rationalisation costs, a product withdrawal and asset write-downs.

10.  Earnings per share is based on the weighted average number of outstanding
     Ordinary Shares and the effect of potential dilutive securities including
     options, warrants and convertible securities.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     179

SELECTED FINANCIAL DATA
--------------------------------------------------------------------------------

GROUP FINANCIAL RECORD--U.S. GAAP

                                                           YEAR ENDED
                                                          31 DECEMBER           YEAR ENDED
                                                        2003 (12)(13)          31 DECEMBER
                                                           (RESTATED)            2002 (12)
---------------------------------------------------------------------------------------------
                                                         ($M, EXCEPT PER SHARE DATA)
---------------------------------------------------------------------------------------------

 INCOME STATEMENT DATA:
 Total revenue                                             685.6             1,093.1
 Operating (loss)/income                                   (363.2)(1)         (612.6) (2)
 Net (loss)/income from continuing operations              (477.2)           (2,173.7)
 Net (loss)/income from discontinued operations             (31.5)             (188.6)
 Cumulative effect of accounting change                        --                  --
 Net (loss)/income                                         (508.7)(6)        (2,362.3) (7)
 Basic (loss)/earnings per Ordinary Share(11)
  from continuing operations                           $    (1.34)      $       (6.21)
  from discontinued operations                         $    (0.09)      $       (0.54)
  from cumulative effect of accounting change                  --                  --
 Total basic (loss)/earnings per Ordinary Share        $    (1.43)      $       (6.75)
 Diluted (loss)/earnings per Ordinary Share(11)
  from continuing operations                           $    (1.34)      $       (6.21)
  from discontinued operations                         $    (0.09)      $       (0.54)
  from cumulative effect of accounting change                  --                  --
 Total diluted (loss)/earnings per Ordinary Share      $    (1.43)      $       (6.75)
---------------------------------------------------------------------------------------------

                                                           YEAR ENDED             YEAR ENDED       YEAR ENDED
                                                          31 DECEMBER            31 DECEMBER      31 DECEMBER
                                                            2001 (12)              2000 (12)        1999 (12)
----------------------------------------------------------------------------------------------------------------
                                                                    ($M, EXCEPT PER SHARE DATA)
----------------------------------------------------------------------------------------------------------------

 INCOME STATEMENT DATA:
 Total revenue                                             1,576.3               1,307.3            1,230.7
 Operating (loss)/income                                     265.0(3)              (64.8)(4)          272.1(5)
 Net (loss)/income from continuing operations                281.4                  62.7              303.8
 Net (loss)/income from discontinued operations              (20.3)                (13.2)              (0.4)
 Cumulative effect of accounting change                        7.8                (344.0)               --
 Net (loss)/income                                           268.9(8)            (294.5)(9)           303.4(5)
 Basic (loss)/earnings per Ordinary Share(11)
  from continuing operations                            $      0.84          $     0.22          $     1.02
  from discontinued operations                          $     (0.06)         $    (0.06)         $       --
  from cumulative effect of accounting change           $      0.02          $    (1.10)                 --
 Total basic (loss)/earnings per Ordinary Share         $      0.80(10)      $    (0.94)(10)     $     1.02
 Diluted (loss)/earnings per Ordinary Share(11)
  from continuing operations                            $      0.79          $     0.20          $     0.97
  from discontinued operations                          $     (0.06)         $    (0.04)         $       --
  from cumulative effect of accounting change           $      0.02          $    (1.10)                 --
 Total diluted (loss)/earnings per Ordinary Share       $      0.75(10)      $    (0.94)(10)     $     0.97
----------------------------------------------------------------------------------------------------------------

                                                 AT            AT            AT            AT           AT
                                        31 DECEMBER   31 DECEMBER   31 DECEMBER   31 DECEMBER  31 DECEMBER
                                               2003          2002          2001          2000         1999
------------------------------------------------------------------------------------------------------------
                                                              ($M, EXCEPT SHARE DATA)
------------------------------------------------------------------------------------------------------------

 BALANCE SHEET DATA:
 Cash, cash equivalents and marketable
  investment securities                     1,156.9       1,464.5       2,542.7       1,250.1       1,285.6
 Total assets                               3,011.0       4,015.5       6,828.3       4,653.0       3,871.7
 Long term liabilities                      1,500.9       1,046.3       2,227.4       1,375.6       1,586.0
 Total shareholders' equity                   599.1         826.9       3,198.9       2,276.9       1,751.1
 Number of shares outstanding                 386.2         350.4         349.8         322.5         298.8
------------------------------------------------------------------------------------------------------------

1.   After other charges of $404.8 million primarily relating to asset
     write-down costs, severence, rationalisation, integration and similar
     costs. After $269.4 million gain on sale of businesses and repurchase of
     debt.

2.   After other charges of $581.7 million primarily relating to asset
     write-down costs, severance, rationalisation, integration and similar
     costs. After $37.7 million gain on repurchase of debt.

3.   After other charges of $323.3 million primarily relating to asset
     write-down costs, severance, rationalisation, integration and similar
     costs.

4.   After other charges of $424.9 million primarily relating to the acquisition
     of IPR&D, merger costs, rationalisation, integration and similar costs.

5.   After other charges of $88.6 million primarily relating to the acquisition
     of IPR&D.

6.   After other charges of $404.8 million, after $269.4 million gain on sale of
     businesses and repurchase of debt; and after charges primarily relating to
     investments and guarantees issued to the noteholders of EPIL II of $136.5
     million.

7.   After other charges of $581.7 million; after $37.7 million gain on
     repurchase of debt; and after charges primarily relating to investments and
     the guarantee issued to the noteholders of EPIL II of $1,443.0 million.

8.   After other charges of $323.3 million primarily relating to asset
     write-down costs, severance, rationalisation, integration and similar
     costs; after charges relating to impairment of investments of $24.5
     million; and after $7.8 million relating to the cumulative catch up
     adjustment for the implementation of SFAS No. 133.

9.   After other charges of $424.9 million primarily relating to the acquisition
     of IPR&D, merger costs, rationalisation, integration and similar costs and
     after $344.0 million relating to the cumulative adjustment for the
     implementation of SAB 104.

10.  Basic and diluted earnings/(loss) per share for 2001 would have been $0.89
     and $0.83, respectively, if goodwill was not amortised for that year. Basic
     and diluted (loss) per share for 2000 would have been $(0.88) if goodwill
     was not amortised for that year. This disclosure is provided as SFAS No.
     142, which has been adopted for 2002 onwards, no longer requires the
     amortisation of goodwill.

11.  Earnings per share is based on the weighted average number of outstanding
     Ordinary Shares and the effect of potential dilutive securities including
     options, warrants and convertible securities.

12.  Subsequent to 31 December 2003, Elan disposed of products which have been
     recorded as discontinued operations under U.S. GAAP. All prior period
     financial information has been amended to reflect these discontinued
     operations (see Note 34 to Elan's Consolidated Financial Statements).

13.  Subsequent to Elan's filing of its Annual Report and Form 20-F in April
     2004, the Company has performed additional verification procedures
     concerning net operating loss carryforwards. These are expected to be
     realised on a probable basis. As such, a change of $26.7 million originally
     recorded in 2003 has been reversed. See Note 34 to Elan's Consolidated
     Financial Statements.

--------------------------------------------------------------------------------
180

SHAREHOLDERS' INFORMATION
--------------------------------------------------------------------------------

Elan has not paid cash dividends on its Ordinary Shares in the past. The
declaration of any cash dividends will be at the recommendation of Elan's board
of directors. The recommendations of Elan's board of directors will depend upon
the earnings, capital requirements and financial condition of Elan and other
relevant factors. Although Elan does not anticipate that it will pay any cash
dividends on its Ordinary Shares in the foreseeable future, Elan expects that
its board of directors will review Elan's dividend policy on a regular basis.
Dividends may be paid on Elan's Executive Shares and "B" Executive Shares at a
time when no dividends are being paid on the Ordinary Shares. For additional
information regarding the Executive Shares and "B" Executive Shares, please
refer to Note 17 to the Consolidated Financial Statements.

NATURE OF TRADING MARKET

The principal trading markets for Elan's Ordinary Shares are the Irish Stock
Exchange and the London Stock Exchange. Elan's ADSs, each representing one
Ordinary Share and evidenced by one American Depositary Receipt ("ADR"), are
traded on the NYSE under the symbol "ELN". The ADR depositary is The Bank of
New York.

The following table sets forth the high and low sales prices of the Ordinary
Shares during the periods indicated, based upon mid-market prices at close of
business on the Irish Stock Exchange and the high and low sales prices of the
ADSs, as reported in published financial sources.

                               (eurodollar)0.05                  AMERICAN
                                ORDINARY SHARES        DEPOSITORY SHARES(1)
--------------------------------------------------------------------------------
                                HIGH          LOW         HIGH          LOW
--------------------------------------------------------------------------------

 YEAR ENDED 31 DECEMBER           (eurodollar)                  ($)
 1999                           40.00        22.35        43.63        21.25
 2000                           66.75        26.35        60.13        26.00
 2001                           73.80        44.60        65.00        39.35
 2002                           50.27         1.23        45.18         1.03
 2003                            7.25         2.33         9.02         2.25
 CALENDAR YEAR
 2002
 Quarter 1                      50.27        14.50        45.18        12.01
 Quarter 2                      15.80         5.85        13.97         5.30
 Quarter 3                       5.00         1.55         5.65         1.31
 Quarter 4                       2.95         1.23         3.09         1.03
 2003
 Quarter 1                       4.40         2.33         4.98         2.25
 Quarter 2                       7.25         2.60         9.02         2.70
 Quarter 3                       5.60         3.88         6.46         4.05
 October                         4.95         4.25         5.97         4.72
 November                        4.71         4.21         5.64         4.85
 December                        5.55         4.45         7.07         5.46
 MONTH ENDED
 January 2004                    7.20         5.40         9.15         6.88
 February 2004                  11.35         6.40        14.66         7.90
 March 2004                     16.70        11.90        21.02        14.12
--------------------------------------------------------------------------------

(1)  An American Depository Share represents one Ordinary Share, par value 5
     Euro cents.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     181

SHAREHOLDERS' INFORMATION
--------------------------------------------------------------------------------

A total of 388,695,832 Ordinary Shares of Elan were issued and outstanding at
31 March 2004, of which 4,847 Ordinary Shares were held by holders of record in
the United States, excluding shares held in the form of ADRs. 342,621,984
Ordinary Shares were represented by Elan ADSs, evidenced by ADRs, issued by The
Bank of New York, as depositary, pursuant to a deposit agreement. At 31 March
2004, the number of holders of record of Ordinary Shares was 7,874, which
includes 11 holders of record in the United States, and the number of
registered holders of ADRs in the United States was 4,817. Because certain of
these Ordinary Shares and ADRs were held by brokers or other nominees, the
number of holders of record or registered holders in the United States is not
representative of the number of beneficial holders or of the residence of
beneficial holders.

American Depositary Warrant Shares ("ADWSs") representing warrants to purchase
Elan ADSs, were traded on the NYSE under the symbol "ELNWSA" ("A-Series
Warrants"). These warrants expired on 31 December 2001. The ADWSs representing
A-Series Warrants were evidenced by American Depositary Warrant Receipts issued
by The Bank of New York, as depositary, under a deposit agreement. Each
A-Series Warrant was exercisable for two Elan ADSs at an exercise price of
$37.54.

A second series of ADWSs, representing warrants to purchase Elan ADSs, traded
on the NYSE under the symbol "ELNWSB" ("B-Series Warrants"). These warrants
expired on 14 January 2003. The ADWSs representing B-Series Warrants were
evidenced by American Depositary Warrant Receipts issued by The Bank of New
York, as depositary, under a deposit agreement. Each B-Series Warrant was
exercisable for two Elan ADSs at an exercise price of $65.01.

The following table sets forth the high and low sales prices per ADWS
representing both A-Series Warrants and B-Series Warrants on the NYSE Composite
Tape for the periods indicated as reported in published financial sources.

                            A-SERIES WARRANTS         B-SERIES WARRANTS
--------------------------------------------------------------------------------
                            HIGH          LOW         HIGH          LOW
                               $            $            $            $
--------------------------------------------------------------------------------

 2001 -- Quarter 1         78.50        51.38        60.00        37.56
     -- Quarter 2          92.50        61.24        68.40        45.00
     -- Quarter 3          87.50        48.30        63.19        34.00
     -- Quarter 4          63.55        42.50        47.50        29.50
 2002 -- Quarter 1            --           --        34.20         1.20
     -- Quarter 2             --           --         1.80         0.25
     -- Quarter 3             --           --         0.40         0.01
     -- Quarter 4             --           --         0.20         0.03
 2003 -- January              --           --         0.03         0.01
--------------------------------------------------------------------------------

In connection with the acquisition of Dura, Elan acquired two additional series
of warrants to purchase Elan ADSs, trading on Nasdaq under the symbols "ELANZ"
("Z-Series Warrants"), formerly traded under the symbol "DURAZ", and "ELANW"
("W-Series Warrants"), formerly traded under the symbol "DURAW". Each Z-Series
Warrant is exercisable for 0.1276 of an Elan ADS at an exercise price of $26.72
per Elan ADS. The Z-Series warrants expire on 31 August 2005. Each W-Series
Warrant was exercisable for 0.1679 of an Elan ADS at an exercise price of
$81.67 per Elan ADS. The W-Series Warrants expired on 31 December 2002.

In connection with the acquisition of Liposome, Elan issued Contingent Value
Rights ("CVRs"). The CVRs began trading on 15 May 2000. CVRs traded on the
Nasdaq under the symbol "LCVRZ". The CVRs were delisted from the Nasdaq on 25
September 2002 for failure to comply with the minimum market value of publicly
traded units requirement of the Nasdaq Marketplace Rules. The CVRs expired on
the termination of the Contingent Value Rights Agreement on 31 March 2003.

The table on the following page sets forth the high and low sales prices for
Z-Series Warrants, W-Series Warrants and for CVRs for the periods indicated as
reported in published financial sources.

--------------------------------------------------------------------------------
182

--------------------------------------------------------------------------------

                             Z-SERIES                W-SERIES                  CVRS
---------------------------------------------------------------------------------------------
                           HIGH         LOW        HIGH         LOW        HIGH         LOW
                              $           $           $           $           $           $
---------------------------------------------------------------------------------------------

2002 -- Quarter 1          3.60        0.35        0.22        0.01       0.14         0.02
     -- Quarter 2          0.64        0.25        0.05        0.01       0.07         0.01
     -- Quarter 3          0.49        0.01        0.04        0.01       0.02         0.01
     -- Quarter 4          0.24        0.03        0.12        0.01       0.01       0.0007
2003 -- Quarter 1          0.70        0.10          --          --      0.005       0.0001
     -- Quarter 2          0.42        0.10          --          --         --           --
     -- Quarter 3          0.23        0.10          --          --         --           --
     -- October            0.25        0.10          --          --         --           --
     -- November           0.32        0.08          --          --         --           --
     -- December           0.32        0.15          --          --         --           --
2004 -- January            0.27        0.17          --          --         --           --
     -- February           1.09        0.20          --          --         --           --
     -- March              2.38        0.55          --          --         --           --

EXCHANGE CONTROLS AND OTHER LIMITATIONS AFFECTING SECURITY HOLDERS

Irish exchange control regulations ceased to apply from and after 31 December
1992. Except as indicated below, there are no restrictions on non-residents of
Ireland dealing in domestic securities, which includes shares or depositary
receipts of Irish companies such as Elan. Except as indicated below, dividends
and redemption proceeds also continue to be freely transferable to non-resident
holders of such securities. The Financial Transfers Act, 1992 gives power to
the Minister for Finance of Ireland to make provision for the restriction of
financial transfers between Ireland and other countries and persons. Financial
transfers are broadly defined and include all transfers which would be
movements of capital or payments within the meaning of the treaties governing
the member states of the EU. The acquisition or disposal of ADSs or ADRs
representing shares issued by an Irish incorporated company and associated
payments falls within this definition. In addition, dividends or payments on
redemption or purchase of shares and payments on a liquidation of an Irish
incorporated company would fall within this definition. At present the
Financial Transfers Act, 1992 prohibits financial transfers involving Iraq, the
Federal Republic of Yugoslavia, the Republic of Serbia, Zimbabwe, the Taliban
of Afghanistan, Osama bin Laden and Al-Qaeda, Burma/Myanmar, Slobodan
Milosevic, and countries that harbour certain terrorist groups, without the
prior permission of the Central Bank of Ireland.

Any transfer of, or payment in respect of, an ADS involving the government of
any country which is currently the subject of United Nations sanctions, any
person or body controlled by any of the foregoing, or by any person acting on
behalf of the foregoing, may be subject to restrictions pursuant to such
sanctions as implemented into Irish law. The following countries and persons
are currently the subject of such sanctions: Federal Republic of Yugoslavia,
Republic of Serbia, Iraq, Liberia, Burma/Myanmar, Zimbabwe, the Taliban of
Afghanistan, Osama bin Laden and Al-Qaeda and Slobodan Milosevic. Elan does not
anticipate that orders under the Financial Transfers Act, 1992, or United
Nations sanctions implemented into Irish law will have a material effect on its
business.

IRISH TAXATION

The following is a general description of Irish taxation inclusive of certain
Irish tax consequences to U.S. Holders (as defined below) of the purchase,
ownership and disposition of Elan ADSs or Ordinary Shares. As used herein,
references to the Ordinary Shares include Elan ADSs representing such Ordinary
Shares, unless the tax treatment of the Elan ADSs and Ordinary Shares has been
specifically differentiated. This description is for general information
purposes only and does not purport to be a comprehensive description of all the
Irish tax considerations that may be relevant in a U.S. Holder's decision to
purchase, hold or dispose of Ordinary Shares. It is based on the various Irish
Taxation Acts, all as in effect on 31 March 2004 and all of which are subject
to change (possibly on a retroactive basis). The Irish tax treatment of a U.S.
Holder of Ordinary Shares may vary depending upon such holder's particular
situation, and holders or prospective purchasers of Ordinary Shares are advised
to consult their own tax advisors as to the Irish or other tax consequences of
the purchase, ownership and disposition of Ordinary Shares.

For the purposes of this tax description, a "U.S. Holder" is a holder of
Ordinary Shares that is: (i) a citizen or resident of the United States; (ii) a
corporation or partnership created or organised in or under the laws of the
United States or of any political subdivision thereof;

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     183

SHAREHOLDERS' INFORMATION
--------------------------------------------------------------------------------

(iii) an estate, the income of which is subject to U.S. federal income taxation
regardless of its source; or (iv) a trust, if a U.S. court is able to exercise
primary supervision over the administration of such trust and one or more U.S.
persons have the authority to control all substantial decisions of such trust.

TAXATION OF CORPORATE INCOME

Elan is a public limited company incorporated, and resident for tax purposes,
in Ireland. Under current Irish legislation, a company is regarded as resident
for tax purposes in Ireland if it is centrally managed and controlled in
Ireland, or, in certain circumstances, if it is incorporated in Ireland. The
Taxes Consolidation Act, 1997, provides that a company which is resident in
Ireland and which is not resident elsewhere shall be entitled to have any
income from a qualifying patent disregarded for taxation purposes. The
legislation does not provide a termination date for this relief. A qualifying
patent means a patent in relation to which the research, planning, processing,
experimenting, testing, devising, designing, developing or similar activities
leading to the invention which is the subject of the patent were carried out in
Ireland. Income from a qualifying patent means any royalty or other sum paid in
respect of the use of the invention to which the qualifying patent relates,
including any sum paid for the grant of a licence to exercise rights under such
patent, where that royalty or other sum is paid, for the purpose of activities
which would be regarded under Irish law as the manufacture of goods (to the
extent that the payment does not exceed an arms-length rate), or by a person
who is not connected with Elan. Accordingly, Elan's income from such qualifying
patents is disregarded for taxation purposes in Ireland. Any Irish
manufacturing income of Elan and its subsidiaries is taxable at the rate of 10%
in Ireland until 31 December 2010. Income arising from qualifying activities in
Elan's Shannon-certified subsidiary is taxable at the rate of 10% in Ireland
until 31 December 2005. From 1 January 2006, it is anticipated, based on Irish
legislation currently enacted, that such income will be taxable at a rate of
12.5%. Any trading income of Elan which does not qualify for the patent
exemption or the 10% rate of tax is taxable at the Irish corporation tax rate
of 12.5% in respect of trading income for the years 2003 et seq. Non-trading
income is taxable at 25%.

TAXATION OF CAPITAL GAINS AND DIVIDENDS

A person who is neither resident nor ordinarily resident in Ireland and who
does not carry on a trade in Ireland through a branch or agency will not be
subject to Irish capital gains tax on the disposal of Ordinary Shares. Unless
exempted, all dividends paid by Elan other than dividends paid out of exempt
patent income, will be subject to Irish withholding tax at the standard rate of
income tax in force at the time the dividend is paid, currently 20%. An
individual shareholder resident in a country with which Ireland has a double
tax treaty, which includes the United States, or in a member state of the EU,
other than Ireland (together, a "Relevant Territory"), will be exempt from
withholding tax provided he or she makes the requisite declaration.

Corporate shareholders who: (i) are ultimately controlled by residents of a
Relevant Territory; (ii) are resident in a Relevant Territory and are not
controlled by Irish residents; (iii) have the principal class of their shares,
or of a 75% parent, traded on a stock exchange in a Relevant Territory; or (iv)
are wholly owned by two or more companies, each of whose principal class of
shares is substantially and regularly traded on one or more recognised stock
exchanges in a Relevant Territory or Territories, will be exempt from
withholding tax on the production of the appropriate certificates and
declarations.

Holders of Elan ADSs will be exempt from withholding tax if they are
beneficially entitled to the dividend and their address on the register of
depositary shares maintained by the depositary is in the United States,
provided that the depositary has been authorised by the Irish Revenue
Commissioners as a qualifying intermediary and provided the appropriate
declaration is made by the holders of the ADSs. Where such withholding is made,
it will satisfy the liability to Irish tax of the shareholder except in certain
circumstances where an individual shareholder may have an additional liability.
A charge to Irish social security taxes and other levies can arise for
individuals. However, under the Social Welfare Agreement between Ireland and
the United States, an individual who is liable for U.S. social security
contributions can normally claim exemption from these taxes and levies.

IRISH CAPITAL ACQUISITIONS TAX

A gift or inheritance of Ordinary Shares will be and, in the case of Elan
warrants or ADWSs representing such Elan warrants, may be, within the charge to
Irish capital acquisitions tax, notwithstanding that the person from whom the
gift or inheritance is received is domiciled or resident outside Ireland.
Capital acquisitions tax is charged at the rate of 20% above a tax free
threshold. This tax free threshold is determined by the relationship between
the donor and the successor or donee. It is also affected by the amount of the
current benefit and previous benefits taken since 5 December 1991 from persons
within the same capital acquisitions tax relationship category. Gifts and
inheritances between spouses are not subject to capital acquisitions tax.

The Estate Tax Convention between Ireland and the United States generally
provides for Irish capital acquisitions tax paid on inheritances in Ireland to
be credited against tax payable in the United States and for tax paid in the
United States to be credited against tax payable

--------------------------------------------------------------------------------
184

--------------------------------------------------------------------------------

in Ireland, based on priority rules set forth in the Estate Tax Convention, in
a case where Elan warrants, Elan ADWSs, Elan ADSs or Ordinary Shares are
subject to both Irish capital acquisitions tax with respect to inheritance and
U.S. Federal estate tax. The Estate Tax Convention does not apply to Irish
capital acquisitions tax paid on gifts.

IRISH STAMP DUTY

Under current Irish law, no stamp duty, currently at the rate and on the amount
referred to below, will be payable by U.S. Holders on the issue of Elan ADSs,
Ordinary Shares or Elan ADWSs. Under current Irish law, no stamp duty will be
payable on the acquisition of Elan ADWSs or Elan ADSs by persons purchasing
such Elan ADWSs or Elan ADSs or any subsequent transfer of an Elan ADWS or Elan
ADS. A transfer of Ordinary Shares, whether on sale, in contemplation of a sale
or by way of gift will attract duty at the rate of 1% on the consideration
given or, where the purchase price is inadequate or unascertainable, on the
market value of the shares. Similarly, any such transfer of a warrant may
attract duty at the rate of 1%. Transfers of Ordinary Shares which are not
liable to duty at the rate of 1% are exempt unless the transfer is by way of
security, in which event there is a potential maximum charge of Euro 630. The
person accountable for payment of stamp duty is the transferee or, in the case
of a transfer by way of gift or for a consideration less than the market value,
all parties to the transfer. Stamp duty is normally payable within 30 days
after the date of execution of the transfer. Late or inadequate payment of
stamp duty will result in a liability to pay interest penalties and fines.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     185

RISK FACTORS
--------------------------------------------------------------------------------

RISK FACTORS

You should carefully consider all of the information set forth in this Annual
Report and Form 20-F, including the following risk factors, before investing in
our securities. The risks described below are not the only ones we face.
Additional risks not currently known to us or that we presently deem immaterial
may also impair our business operations. We could be materially adversely
affected by any of these risks. This Annual Report and Form 20-F also contains
forward-looking statements that involve risks and uncertainties. Any
forward-looking statements are not guarantees of future performance and actual
results; developments and business decisions may differ materially from those
contemplated by such forward-looking statements as a result of certain risks
and uncertainties, including those described below. For additional information,
please refer to "Cautionary Factors That May Affect Future Results ".

WE AND CERTAIN OF OUR CURRENT AND FORMER OFFICERS AND DIRECTORS HAVE BEEN NAMED
AS DEFENDANTS IN A PUTATIVE CLASS ACTION AND WE ARE THE SUBJECT OF AN SEC
INVESTIGATION; AN ADVERSE OUTCOME OR RESOLUTION IN THE ACTION OR THE
INVESTIGATION COULD RESULT IN SUBSTANTIAL PAYMENTS BY US AND COULD HAVE A
MATERIAL ADVERSE EFFECT ON US.

Elan and certain of its current and former officers and directors are named as
defendants in a putative class action in the U.S. District Court for the
Southern District of New York, which consolidated several class actions that
were filed in early 2002. The amended and consolidated complaint filed on 24
January 2003 in the action, or the Complaint, alleges claims under the U.S.
federal securities laws, including that our financial statements were not in
accordance with generally accepted accounting principles and that the
defendants disseminated materially false and misleading information concerning
our business and financial results, our investments in certain business
ventures and business venture parents, and the licence fees and research
revenues received by us from the business ventures; the accounting for proceeds
from our sale of certain product lines and disclosure concerning those sales;
the accounting for certain risk-sharing arrangements that we entered into and
disclosure concerning those arrangements; the accounting for certain qualifying
special purpose entities and disclosure concerning those entities; the
disclosure of compensation of certain of our officers; and certain alleged
related party transactions. The Complaint seeks compensatory damages and other
relief that the court may deem proper. We are also the subject of an ongoing
investigation by the SEC's Division of Enforcement commenced on or about 12
February 2002, which we believe relates primarily to the issues raised in the
actions described above. We are unable to predict or determine the outcome of
the action or the investigation or reasonably estimate the amount or range of
loss, if any, with respect to the resolution of the actions or the
investigation. In addition, the timing and final resolution of the action and
the investigation is uncertain. The Company continues to believe that it has
prepared its financial statements in accordance with applicable GAAP, (subject
to the 2001 restatement relating of EPIL III under U.S. GAAP, described on
pages 150 to 154). The findings and outcome of the investigation may adversely
affect the course of the action. The possible outcome or resolution of these
proceedings could require us to make substantial payments. Any amendment or
restatement of our previously filed financial statements, any substantial
payment required to be made by us in connection with the resolution of the
investigation and any adverse determination in the actions could have a
material adverse effect on us. Further, we are unable to predict or determine
the impact, if any, that the 2001 restatement may have on the outcome of the
shareholder litigation.

We are generally obliged to indemnify our current and former officers and
directors who are also named as defendants in the action, to the extent
permitted by Irish law.

Please refer to Note 25 to the Consolidated Financial Statements for further
information on the SEC investigation and these actions.

--------------------------------------------------------------------------------
186

--------------------------------------------------------------------------------

OUR FUTURE SUCCESS IS DEPENDENT UPON THE CONTINUED ACCEPTANCE OF OUR EXISTING
PRODUCTS AND UPON THE SUCCESSFUL DEVELOPMENT AND COMMERCIALISATION OF
ADDITIONAL PRODUCTS, INCLUDING ANTEGREN.

Our future success will depend upon the continued acceptance of our existing
products and, to a larger extent, upon the successful development and
commercialisation of additional products, including Antegren. We commit
substantial resources to our research and development activities, including
collaborations with third parties such as Biogen Idec for the development of
Antegren. We expect to commit significant cash resources to the development and
the commercialisation of Antegren and to the other products in our development
pipeline. We cannot assure you that these investments will result in a
proportional increase in revenues or income.

In the pharmaceutical industry, the research and development process is lengthy
and involves a high degree of risk and uncertainty. This process is conducted
in various stages and, during each stage, there is a substantial risk that
products in our research and development pipeline, including Antegren, Prialt
and product candidates from our AD research programmes, will experience
difficulties, delays or failures. For example, in 2002, Wyeth and Elan
suspended all clinical dosing with AN-1792, an experimental immunotherapeutic
under development for the treatment of AD which was in a Phase IIa clinical
study. On 1 March 2002, the companies decided not to resume further dosing of
AN-1792. A number of factors could affect our ability to successfully develop
and commercialise products, including our ability to:

 o obtain and protect necessary intellectual property for new technologies,
 products and processes;
 o establish sufficient safety and efficacy of new drugs or biologics;
 o recruit patients in clinical trials;
 o complete clinical trials on a timely basis;
 o observe applicable regulatory requirements;
 o receive and maintain required regulatory approvals;
 o obtain competitive/favourable reimbursement coverage for developed products
   on a timely basis;
 o manufacture sufficient commercial quantities of products at reasonable
   costs;
 o effectively market developed products; and
 o compete successfully against alternative products or therapies.

Even if we obtain positive results from preclinical or clinical trials, we may
not achieve the same success in future trials. Earlier stage trials are
generally based on a limited number of patients and may, upon review, be
revised or negated by authorities or by later stage clinical results.
Historically, the results from preclinical testing and early clinical trials
have often not been predictive of results obtained in later clinical trials. A
number of new drugs and biologics have shown promising results in initial
clinical trials, but subsequently failed to establish sufficient safety and
effectiveness data to obtain necessary regulatory approvals. Data obtained from
preclinical and clinical activities are subject to varying interpretations,
which may delay, limit or prevent regulatory approval. Clinical trials may not
demonstrate statistically sufficient safety and effectiveness to obtain the
requisite regulatory approvals for product candidates.

Elan and Biogen Idec are conducting two, two-year Phase III trials evaluating
Antegren in MS patients with relapsing-remitting forms of the disease. We have
announced that we plan to file applications with the FDA and European
regulatory agencies, in each case for approval to market Antegren as a
treatment for MS. Our plans to submit the applications and to obtain regulatory
approvals could fail if unexpected data arises from the clinical trials or if
other difficulties, delays or failures occur. In the event of our failure to
successfully develop and commercialise Antegren, we could be materially
adversely affected.

RESTRICTIVE COVENANTS IN OUR DEBT INSTRUMENTS RESTRICT OR PROHIBIT OUR ABILITY
TO ENGAGE IN OR ENTER INTO A VARIETY OF TRANSACTIONS, WHICH COULD ADVERSELY
AFFECT US.

The agreements governing some of our outstanding indebtedness contain various
restrictive covenants that limit our financial and operating flexibility. In
particular, these agreements restrict our ability to, among other things:

 o incur additional indebtedness (including intercompany indebtedness);
 o create liens and other encumbrances;
 o enter into transactions with related parties;
 o sell or otherwise dispose of assets and merge or consolidate with another
   entity;
 o amend, modify or supplement our existing debt instruments;
 o retire indebtedness prior to its scheduled final maturity; and
 o pay dividends or redeem, purchase or otherwise acquire any of our
   outstanding capital stock.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     187

RISK FACTORS
--------------------------------------------------------------------------------

We do not currently have the ability to incur any additional indebtedness
(including intercompany indebtedness) under some of these agreements, which has
adversely affected our financial flexibility. In addition, some of these
agreements require us to maintain certain financial ratios. These covenants and
ratios could have an adverse effect on us by limiting our operating flexibility
and our ability to fund our operations. The breach of any of these covenants
and ratios would result in a default under the applicable agreement which could
result in the indebtedness under the agreement becoming immediately due and
payable. Any such acceleration would result in a default under our other
indebtedness subject to cross-acceleration provisions. If this were to occur,
we might not be able to pay our debts or obtain sufficient funds to refinance
them on reasonable terms or at all.

WE HAVE SUBSTANTIAL FUTURE CASH NEEDS AND POTENTIAL CASH NEEDS AND WE MAY NOT
BE SUCCESSFUL IN GENERATING OR OTHERWISE OBTAINING THE FUNDS NECESSARY TO MEET
THOSE NEEDS.

At 31 December 2003, we had approximately $2,214 million of contractual future
cash payments and approximately $11 million of potential future cash payments,
excluding expected capital expenditures on plant and equipment, and future
investments in financial assets such as investments in business ventures. At
such date, we had cash and liquid resources of approximately $828 million. We
estimate that we have sufficient cash, liquid resources and realisable assets
and investments to meet our near-term liquidity requirements. In making this
estimate, we have not assumed any material payments in connection with our
pending litigations during that period. Any material adverse legal judgements,
fines, penalties or settlements arising from our pending litigations or
investigations could require us to obtain additional funds. Although we expect
to incur an operating loss for fiscal 2004, in making our liquidity estimates,
we have also assumed a certain level of operating performance. Our future
operating performance will be affected by general economic, financial,
competitive, legislative, regulatory and business conditions and other factors,
many of which are beyond our control. If our future operating performance is
less than anticipated, including as a result of our failure to timely obtain
marketing approval for Antegren, we could be required to obtain additional
funds. If our estimates are incorrect or are not consistent with actual future
developments, and we are required to obtain additional funds, we may not be
able to obtain those funds on commercially reasonable terms, or at all, which
would have a material adverse effect on us.

OUR INDUSTRY AND THE MARKETS FOR OUR PRODUCTS ARE HIGHLY COMPETITIVE.

The pharmaceutical industry is highly competitive. Our principal pharmaceutical
competitors consist of major international companies, many of which are larger
and have greater financial resources, technical staff, manufacturing, research
and development and marketing capabilities than Elan. Other competitors consist
of smaller research companies and generic drug manufacturers.

A drug may be subject to competition from alternative therapies during the
period of patent protection or regulatory exclusivity and, thereafter, it may
be subject to further competition from generic products. The price of
pharmaceutical products typically declines as competition increases.

Generic competitors may also challenge existing patent protection or regulatory
exclusivity. Generic competitors do not have to bear the same level of research
and development and other expenses associated with bringing a new branded
product to market. As a result, they can charge much less for a competing
version of our product. Managed care organisations typically favour generics
over brand name drugs, and governments encourage, or under some circumstances
mandate, the use of generic products, thereby reducing the sales of branded
products that are no longer patent protected. Governmental and other pressures
toward the dispensing of generic products may rapidly and significantly reduce,
or slow the growth in, the sales and profitability of any of our products not
protected by patents or regulatory exclusivity and may adversely affect our
future results and financial condition. For example, generic forms of Zanaflex
were launched in the second quarter of 2002. As a result, product revenue from
Zanaflex declined from $53.7 million in the first quarter of 2002 to $0.8
million in the first quarter of 2003. Product returns for Zanaflex during 2003
exceeded the Company's best estimate of returns at 31 December 2002, resulting
in net negative revenues of $(5.1) million for 2003. The launch of competitor
products, including generic versions of Elan's products, may materially
adversely affect us.

Our competitive position depends, in part, upon our continuing ability to
discover, acquire and develop innovative, cost-effective new products, as well
as new indications and product improvements protected by patents and other
intellectual property rights. We also compete on the basis of price and product
differentiation and through our sales and marketing organisation that provides
information to medical professionals and launches new products. If we fail to
maintain our competitive position, we may be materially adversely affected.

--------------------------------------------------------------------------------
188

--------------------------------------------------------------------------------

IF WE ARE UNABLE TO SECURE OR ENFORCE PATENT RIGHTS, TRADE SECRETS OR OTHER
INTELLECTUAL PROPERTY, WE COULD BE MATERIALLY ADVERSELY AFFECTED.

Because of the significant time and expense involved in developing new products
and obtaining regulatory approvals, it is very important to obtain patent and
intellectual property protection for new technologies, products and processes.
Our success depends in large part on our continued ability to obtain patents
for our products and technologies, maintain patent protection for both acquired
and developed products, preserve our trade secrets, obtain and preserve other
intellectual property such as trademarks and copyrights, and operate without
infringing the proprietary rights of third parties.

The degree of patent protection that will be afforded to technologies, products
and processes, including ours, in the United States and in other markets is
dependent upon the scope of protection decided upon by patent offices, courts
and legislatures in these countries. There is no certainty that our existing
patents or, if obtained, future patents, will provide us substantial protection
or commercial benefit. In addition, there is no assurance that our patent
applications or patent applications licensed from third parties will ultimately
be granted or that those patents that have been issued or are issued in the
future will prevail in any court challenge. Our competitors may also develop
products, including generic products, similar to ours using methods and
technologies that are beyond the scope of our patent protection, which could
adversely affect the sales of our products.

Our two primary retained products, Maxipime and Azactam, are covered by U.S.
basic patents which expire in 2007 and 2005, respectively. Two formulation U.S.
patents covering Maxipime expire in 2008. Elan's basic U.S. patent for its
development drug, Antegren, which covers the humanised antibody and it its use
to treat MS, expires in 2015. Additional U.S. patents covering the use of
Antegren to treat irritable bowel disease and to inhibit brain inflammation
expire in 2012 and 2017, respectively. In the event that Antegren is approved
by the FDA, one of the patents would qualify for a patent term extension of up
to 5 years.

Although we believe that we make reasonable efforts to protect our intellectual
property rights and to ensure that our proprietary technology does not infringe
the rights of other parties, we cannot ascertain the existence of all
potentially conflicting claims. Therefore, there is a risk that third parties
may make claims of infringement against our products or technologies. In
addition, third parties may be able to obtain patents that prevent the sale of
our products or require us to obtain a licence and pay significant fees or
royalties in order to continue selling our products.

There has been, and we expect there to continue to be, significant litigation
in the industry regarding patents and other intellectual property rights.
Litigation and other proceedings concerning patents and other intellectual
property rights may be protracted, expensive and distracting to our management.
Our competitors may sue us as a means of delaying the introduction of our
products. Any litigation, including any interference proceedings to determine
priority of inventions, oppositions to patents or litigation against our
licensors may be costly and time consuming and could adversely affect us. In
addition, litigation may be necessary in some instances to determine the
validity, scope and/or noninfringement of patent rights claimed by third
parties to be pertinent to the manufacture, use or sale of our products. The
outcome of this litigation could adversely affect the validity and scope of our
patents or other intellectual property rights and hinder or delay the marketing
and sale of our products.

If we are unable to secure or enforce patent rights, trademarks, trade secrets
or other intellectual property, our business, financial condition and results
of operations could be materially adversely affected.

IF WE EXPERIENCE SIGNIFICANT DELAYS IN THE MANUFACTURE OF OUR PRODUCTS OR IN
THE SUPPLY OF RAW MATERIALS FOR OUR PRODUCTS, SALES OF OUR PRODUCTS COULD BE
MATERIALLY ADVERSELY AFFECTED.

Our retained products, Maxipime and Azactam, are currently manufactured by
third parties. In addition, in the event that Antegren is approved by the FDA
for the treatment of MS, Antegren will be manufactured by Biogen Idec. Our
dependence upon third parties for the manufacture of our products may result in
unforeseen delays or other problems beyond our control. For example, if our
third party manufacturers are not in compliance with cGMP or other applicable
regulatory requirements, the supply of our products could be materially
adversely affected. If we are unable to retain or obtain replacements for our
third party manufacturers or if we experience delays or difficulties with our
third party manufacturers in producing our products, sales of these products
could be materially adversely affected. In this event, we may be unable to
enter into alternative manufacturing arrangements on commercially reasonable
terms, if at all.

We require supplies of raw materials for the manufacture of our products.
Currently, we do not have dual sourcing of our required raw materials. Our
inability to obtain sufficient quantities of required raw materials could
materially adversely affect the supply of our products.

If any of these events occur, we could be materially adversely affected.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     189

RISK FACTORS
--------------------------------------------------------------------------------

BUYING PATTERNS OF WHOLESALERS AND DISTRIBUTORS MAY CAUSE FLUCTUATIONS IN OUR
QUARTERLY RESULTS, WHICH MAY ADVERSELY AFFECT OUR PROFITABILITY.

Our product revenue may vary from quarter to quarter due, in part, to the
variance in buying patterns by wholesalers and distributors, which represent a
substantial portion of our sales. In the event that wholesalers and
distributors determine, for any reason, to limit purchases of our products,
sales of those products would be adversely affected. For example, wholesalers
and distributors may order products in larger than normal quantities prior to
anticipated price increases for those products. This excess purchasing in any
quarter could cause sales of those products to be lower than expected in
subsequent quarters.

WE ARE SUBJECT TO PRICING PRESSURES AND UNCERTAINTIES REGARDING HEALTHCARE
REIMBURSEMENT AND REFORM.

In the U.S., many pharmaceutical products and biologics are subject to
increasing pricing pressures, including pressures arising from recent Medicare
reform. Our ability to commercialise products successfully depends, in part,
upon the extent to which health care providers are reimbursed by third party
payors, such as governmental agencies, including the Centers for Medicare and
Medicaid Services, or CMS, private health insurers and other organisations,
such as health maintenance organisations, or HMOs, for the cost of such
products and related treatments. In addition, if current or any future level of
Medicare reimbursement for our products is not viewed favourably by health care
providers, then they may not prescribe our products. Third party payors are
increasingly challenging the pricing of pharmaceutical products by, among other
things, limiting the pharmaceutical products that are on their formulary list.
As a result, competition among pharmaceutical companies to place their products
on these formulary lists has reduced product prices. If reasonable
reimbursement for our products is unavailable or if significant downward
pricing pressures in the industry occurs, we could be materially adversely
affected.

Recent reforms in Medicare added a prescription drug reimbursement beginning in
2006 for all Medicare beneficiaries. In the meantime, a temporary drug discount
card programme is being established for Medicare beneficiaries. The U.S.
federal government, through its purchasing power under these programmes, is
likely to demand discounts from pharmaceutical and biotechnology companies that
may implicitly create price controls on prescription drugs. In addition,
Managed Care Organisations, or MCOs, HMOs, Preferred Provider Organisations, or
PPOs, institutions and other government agencies continue to seek price
discounts. MCOs, HMOs and PPOs and private health plans will administer the
Medicare drug benefit, leading to managed care and private health plans
influencing prescription decisions for a larger segment of the population. In
addition, certain states have proposed and certain other states have adopted
various programmes to control prices for their seniors' and low income drug
programmes, including price or patient reimbursement constraints, restrictions
on access to certain products, importation from other countries, such as
Canada, and bulk purchasing of drugs.

We encounter similar regulatory and legislative issues in most other countries.
In the European Union and some other international markets, the government
provides health care at low direct cost to consumers and regulates
pharmaceutical prices or patient reimbursement levels to control costs for the
government-sponsored health care system. This price regulation may lead to
inconsistent prices and some third-party trade in our products from markets
with lower prices. Such trade exploiting price differences between countries
could undermine our sales in markets with higher prices.

WE ARE SUBJECT TO EXTENSIVE GOVERNMENT REGULATION, WHICH MAY ADVERSELY AFFECT
OUR ABILITY TO BRING NEW PRODUCTS TO MARKET AND MAY AFFECT OUR ABILITY TO
MANUFACTURE AND MARKET OUR EXISTING PRODUCTS.

The pharmaceutical industry is subject to significant regulation by state,
local, national and international governmental regulatory authorities. In the
United States, the FDA regulates the design, development, preclinical and
clinical testing, manufacturing, labelling, storing, distribution, import,
export, recordkeeping, reporting, marketing and promotion of our pharmaceutical
products, which include drugs, biologics and medical devices. Failure to comply
with regulatory requirements at any stage during the regulatory process could
result in, among other things, delays in the approval of applications or
supplements to approved applications, refusal of a regulatory authority to
review pending market approval applications or supplements to approved
applications, warning letters, fines, import and/or export restrictions,
product recalls or seizures, injunctions, total or partial suspension of
production, civil penalties, withdrawals of previously approved marketing
applications or licences, recommendations by the FDA or other regulatory
authorities against governmental contracts, and criminal prosecutions.

We must obtain and maintain approval for our products from regulatory
authorities before such products may be sold in a particular jurisdiction.
Currently, we are researching, developing and pursuing approval for a number of
products from a number of regulatory

--------------------------------------------------------------------------------
190

--------------------------------------------------------------------------------

authorities, including Prialt and Antegren in the United States and the
European Union. The submission of an application to a regulatory authority with
respect to a product does not guarantee that approval to market the product
will be granted. Each authority generally imposes its own requirements and may
delay or refuse to grant approval, even though a product has been approved in
another country. In our principal markets, including the United States, the
approval process for a new product is complex, lengthy, expensive and subject
to unanticipated delays. We cannot be sure when or whether approvals from
regulatory authorities will be received or that the terms of any approval will
not impose significant limitations that could negatively impact upon the
potential profitability of the approved product. Even after a product is
approved, it may be subject to regulatory action based on newly discovered
facts about the safety and efficacy of the product, on any activities which
regulatory authorities consider to be improper or on changes in regulatory
policy. Regulatory action may have a material adverse effect on the marketing
of a product, require changes in the product's labelling or even lead to the
withdrawal of the regulatory marketing approval of the product.

All facilities and manufacturing techniques used for the manufacture of
products and devices for clinical use or for sale in the United States must be
operated in conformity with current good manufacturing practices, or cGMPs, the
FDA's regulations governing the production of pharmaceutical products. There
are comparable regulations in other countries. Any finding by the FDA or other
regulatory authority that we are not in substantial compliance with cGMP
regulations or that we or our employees have engaged in activities in violation
of these regulations could interfere with the continued manufacture and
distribution of the affected products, up to the entire output of such
products, and, in some cases, might also require the recall of previously
distributed products. Any such finding by the FDA or other regulatory agency
could also affect our ability to obtain new approvals until such issues are
resolved. The FDA and other regulatory authorities conduct scheduled periodic
regulatory inspections of our facilities to ensure compliance with cGMP
regulations. Any determination by the FDA or other regulatory authority that
we, or one of our suppliers, are not in substantial compliance with these
regulations or are otherwise engaged in improper or illegal activities could
have a material adverse effect on us.

In May 2001, Elan's wholly owned subsidiary, Elan Holdings, and Donal J.
Geaney, then chairman and chief executive officer of Elan, William C. Clark,
then president operations, and two then employees of Elan Holdings, Hal Herring
and Cheryl Schuster, entered into a consent decree of permanent injunction with
the U.S. Attorney for the Northern District of Georgia, on behalf of the FDA,
relating to alleged violations of cGMP at Elan's Gainesville facility. The
facility manufactured and continues to manufacture, verapamil hydrochloride
controlled-release tablets for the treatment of high blood pressure. The
consent decree does not represent an admission by Elan Holdings or the officers
or employees named above of any of the allegations set forth in the decree.
Under the terms of the consent decree, which will continue in effect until at
least May 2006, Elan Holdings is permanently enjoined from violating cGMP
regulations. In addition, Elan Holdings is required to engage an independent
expert, subject to FDA approval, to conduct inspections of the facility at
least annually through May 2004 in order to ensure the facility's compliance
with cGMP. The first of these inspections was completed and reported upon by
the independent expert to the FDA on 3 September 2002. A corrective action plan
was prepared and sent to the FDA in response to this inspection. A second
independent consultant audit occurred in May 2003 and was reported upon by the
independent expert to the FDA on 14 August 2003. In response to the inspection,
a corrective action plan was prepared and sent to the FDA. During the term of
the consent decree, Elan expects that the facility will be subject to increased
FDA inspections and, under the terms of the consent decree, Elan will be
required to reimburse the FDA for its costs related to these inspections.

OUR BUSINESS EXPOSES US TO RISKS OF ENVIRONMENTAL LIABILITIES.

We use hazardous materials, chemicals and toxic compounds in our product
development programmes and manufacturing processes which could expose us to
risks of accidental contamination, events of non-compliance with environmental
laws, regulatory enforcement and claims related to personal injury and property
damage. If an accident occurred or if we were to discover contamination caused
by prior operations, we could be liable for cleanup obligations, damages or
fines, which could have an adverse effect on us.

The environmental laws of many jurisdictions impose actual and potential
obligations on us to remediate contaminated sites. These obligations may relate
to sites that we currently own, sites that we formerly owned or operated or
sites where waste from our operations was disposed. These environmental
remediation obligations could significantly reduce our operating results. In
particular, our accruals for these obligations could prove to be insufficient
if the assumptions underlying the accruals prove incorrect or if we are held
responsible for additional contamination.

Stricter environmental, safety and health laws and enforcement policies could
result in substantial costs and liabilities to us, and could subject our
handling, manufacture, use, reuse or disposal of substances or pollutants to
more rigorous scrutiny than is currently the case. Consequently, compliance
with these laws could result in significant capital expenditures, as well as
other costs and liabilities, which could materially adversely affect us.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     191

RISK FACTORS
--------------------------------------------------------------------------------

IF WE FAIL TO COMPLY WITH OUR REPORTING AND PAYMENT OBLIGATIONS UNDER THE
MEDICAID REBATE PROGRAMME OR OTHER GOVERNMENTAL PRICING PROGRAMMES, WE COULD BE
SUBJECT TO ADDITIONAL REIMBURSEMENTS, PENALTIES, SANCTIONS AND FINES WHICH
COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS.

We participate in the U.S. Federal Medicaid rebate programme established by the
U.S. Omnibus Budget Reconciliation Act of 1990, as well as several state
supplemental rebate programmes. Under the Medicaid rebate programme, we pay a
rebate to each state Medicaid programme for our products that are reimbursed by
those programmes. The amount of the rebate for each unit of product is set by
law as a minimum 15.1% of the average manufacturer price, or AMP, of that
product, or if it is greater, the difference between AMP and the best price
available from us to any customer. The rebate amount also includes an inflation
adjustment, if necessary.

As a manufacturer currently of single source, innovator multiple source and
non-innovator multiple source products, rebate calculations vary among products
and programmes. The calculations are complex and, in certain respects, subject
to interpretation by us, governmental or regulatory agencies and the courts.
The Medicaid rebate amount is computed each quarter based on our submission to
the Centers for Medicare and Medicaid Services at the U.S. Department of Health
and Human Services of our current AMP and best price for each of our products.
The terms of our participation in the programme impose an obligation to correct
the prices reported in previous quarters, as may be necessary. Any such
corrections could result in an overage or underage in our rebate liability for
past quarters, depending on the direction of the correction. In addition to
retroactive rebates (and interest, if any), if we were found to have knowingly
submitted false information to the government, the statute provides for civil
monetary penalties in the amount of $100,000 per item of false information.
Governmental agencies may also make changes in programme interpretations,
requirements or conditions of participation, some of which may have
implications for amounts previously estimated or paid. Based upon our past
practice and experience, to the extent that we were required to correct prices
reported in previous quarters, we would not expect such corrections to have a
material adverse affect on us.

U.S. Federal law requires that any company that participates in the Medicaid
rebate programme extends comparable discounts to qualified purchasers under the
Public Health Services, or PHS, pharmaceutical pricing programme. The PHS
pricing programme extends discounts comparable to the Medicaid rebates to a
variety of community health clinics and other entities that receive health
services grants from the PHS, as well as hospitals that serve a
disproportionate share of poor patients.

WE ARE SUBJECT TO CONTINUING POTENTIAL PRODUCT LIABILITY, WHICH COULD HARM OUR
BUSINESS.

Risks relating to product liability claims are inherent in the development
manufacturing and marketing of our products. Any person who is injured as a
result of using one of our products may have a product liability claim against
us. Since we distribute and sell our products to a wide number of end users,
the risk of such claims could be material. Product liability claims could also
be brought by persons who took part in clinical trials involving our products.

We currently maintain product liability insurance in the amount of $200 million
in aggregate claims, including $25 million of self-insured retention. However,
the level and breadth of any insurance coverage may not be sufficient to cover
fully all, or at all, potential claims.

We may not be able to maintain product liability coverage on acceptable terms
if our claims experience results in higher rates, or if product liability
insurance otherwise becomes costlier because of general economic, market or
industry conditions. If sales of our products increase materially, or if we add
significant products to our portfolio, we will require increased coverage and
may not be able to secure such coverage at reasonable rates.

OUR STOCK PRICE IS VOLATILE, WHICH COULD RESULT IN SUBSTANTIAL LOSSES FOR
INVESTORS PURCHASING SHARES.

The market prices for our shares and for securities of other companies engaged
primarily in biotechnology and pharmaceutical development, manufacture and
distribution are highly volatile. The market price of our shares likely will
continue to fluctuate due to a variety of factors, including:

 o material public announcements by us;
 o the timing of new product launches by us and others;
 o events related to our marketed products and those of our current and future
   competitors;
 o regulatory issues affecting us;

--------------------------------------------------------------------------------
192

--------------------------------------------------------------------------------

 o availability and level of third party reimbursement;
 o developments relating to patents and other intellectual property rights;
 o results of clinical trials with respect to our products under development
   and those of our competitors;
 o political developments and proposed legislation affecting the pharmaceutical
   industry;
 o economic and other external factors;
 o hedge and/or arbitrage activities by holders of our 6.5% Convertible Notes;
 o period-to-period fluctuations in our financial results or results which do
   not meet or exceed analyst expectations; and
 o market trends relating to or affecting stock prices across our industry,
   whether or not related to results or news regarding us or our competitors.

CERTAIN PROVISIONS OF AGREEMENTS TO WHICH WE ARE A PARTY MAY DISCOURAGE OR
PREVENT A THIRD PARTY FROM ACQUIRING US AND COULD PREVENT SHAREHOLDERS FROM
RECEIVING A PREMIUM FOR THEIR SHARES.

We are a party to agreements which contain provisions that may discourage a
takeover attempt that might be viewed as beneficial to shareholders who wish to
receive a premium for their shares from a potential bidder. For example:

 o our collaboration agreement with Biogen Idec provides Biogen Idec with an
   option to buy the rights to Antegren in the event that we undergo a change of
   control, which may limit our attractiveness to potential acquirers;

 o until June 20, 2010, Biogen Idec and its affiliates are, subject to limited
   exception, restricted from, among other things seeking to acquire or
   acquiring control of us; and

 o under the terms of the indenture governing our 6.5% Convertible Notes any
   acquirer would be required to repurchase the 6.5% Convertible Notes for cash
   in connection with a change of control occurring on or after March 16, 2006.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     193

MEMORANDUM AND ARTICLES OF ASSOCIATION
--------------------------------------------------------------------------------

OBJECTS

The Company's objects, which are detailed in its Memorandum of Association
include, but are not limited to, manufacturing, buying, selling and
distributing pharmaceutical products. The Company's registered number is 30356.

DIRECTORS

Subject to certain limited exceptions, directors may not vote on matters in
which they have a material interest. In the absence of an independent quorum,
the directors may not vote compensation to themselves or any member of the
board of directors. Directors are entitled to remuneration as shall, from time
to time, be voted to them by ordinary resolution of the shareholders and to be
paid such expenses as may be incurred by them in the course of the performance
of their duties as directors. Directors who take on additional committee
assignments or otherwise perform additional services for the Company, outside
the scope of their ordinary duties as directors, shall be entitled to receive
such additional remuneration as the board may determine. The directors may
exercise all of the powers of the Company to borrow money. These powers may be
amended by special resolution of the shareholders. One-third of the board shall
retire at each Annual General Meeting. A director is not required to retire at
any set age and may offer themselves for re-election at any meeting where they
are deemed to have retired by rotation. There is no requirement for a director
to hold shares.

MEETINGS

The Annual General Meeting shall be held in such place and at such time as
shall be determined by the board, but no more than 15 months shall pass between
the dates of consecutive Annual General Meetings. Directors may call
Extraordinary General Meetings at any time. Extraordinary General Meetings may
also be requisitioned by the members in accordance with the Company's Articles
of Association and Irish company law. Notice of an Annual General Meeting (or
any special resolution) must be given at least 21 clear days prior to the
scheduled date and, in the case of any other general meeting, with not less
than 14 clear days notice.

RIGHTS, PREFERENCES AND DIVIDENDS ATTACHING TO SHARES

All unclaimed dividends may be invested or otherwise made use of by the
directors for the benefit of the Company until claimed. All of the shareholders
entitled to attend and vote at the Annual General Meeting are likewise entitled
to vote on the re-election of directors. The Company is permitted under its
Memorandum and Articles of Association to issue redeemable shares on such terms
and in such manner as the shareholders may determine by special resolution. The
liability of the shareholders to further capital calls is limited to the
amounts remaining unpaid on shares.

ACTIONS NECESSARY TO CHANGE THE RIGHTS OF SHAREHOLDERS

The rights attaching to the different classes of shares may be varied by
special resolution passed at a class meeting of that class of shareholders. The
additional issuance of further shares ranking pari passu with, or subordinate
to, an existing class shall not, unless specified by the Articles or the
conditions of issue of that class of shares, be deemed to be a variation of the
special rights attaching to that class of shares.

LIMITATIONS ON THE RIGHT TO OWN SHARES

There are no limitations on the right to own shares in the Memorandum and
Articles of Association. However, there are some restrictions on financial
transfers between Ireland and other specified countries, more particularly
described in the section on "Exchange Controls and Other Limitations Affecting
Security Holders" on page 183.

--------------------------------------------------------------------------------
194

--------------------------------------------------------------------------------

OTHER PROVISIONS OF THE MEMORANDUM AND ARTICLES OF ASSOCIATION

There are no provisions in the Memorandum and Articles of Association:

 o Delaying or prohibiting a change in control of the Company that operate only
   with respect to a merger, acquisition or corporate restructuring;
 o Discriminating against any existing or prospective holder of shares as a
   result of such shareholder owning a substantial number of shares; or
 o Governing changes in capital, where such provisions are more stringent than
   those required by law.

The Company incorporates by reference all other information concerning its
Memorandum and Articles of Association from the section entitled "Description
of Ordinary Shares" in the Registration Statement on Form F-3 (No. 333-1313001)
of the Company and Athena Finance filed with the SEC on 6 February 2001.

DOCUMENTS ON DISPLAY

The Company is subject to the reporting requirements of the Exchange Act. In
accordance with these requirements, the Company files Annual Reports on Form
20-F with, and furnishes Reports of Foreign Issuer on Form 6-K to, the SEC.
These materials, including the Company's Annual Report on Form 20-F for the
fiscal year ended 31 December 2003 and the exhibits thereto, may be inspected
and copied at the SEC's Public Reference Room at 450 Fifth Street, N.W.,
Washington D.C. 20549 and at the SEC's regional offices at 500 West Madison
Street, Suite 1400, Chicago, Illinois 60661-2511, and 233 Broadway, New York,
New York 10274. Copies of the materials may be obtained from the Public
Reference Room of the SEC at 450 Fifth Street, N.W., Washington, D.C. at
prescribed rates. The public may obtain information on the operation of the
SEC's Public Reference Room by calling the SEC in the United States at
1-800-SEC-0330. As a foreign private issuer, all documents which were filed or
submitted after 4 November 2002 on the SEC's EDGAR system are available for
retrieval on the website maintained by the SEC at http://www.sec.gov. These
filings and submissions are also available from commercial document retrieval
services.

Copies of the Company's Memorandum and Articles of Association may be obtained
at no cost by writing or telephoning the Company at its principal executive
offices. The Company's Memorandum and Articles of Association are filed with
the SEC as Exhibit 4.1 of the Company's Registration Statement on Form F-3,
Registration No. 333-100252, filed with the SEC on 1 October 2002. You may also
inspect or obtain a copy of the Company's Memorandum and Articles of
Association using the procedures prescribed above.

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     195

DIRECTORS, SENIOR MANAGEMENT AND OTHER INFORMATION
--------------------------------------------------------------------------------

BOARD OF DIRECTORS
Garo H. Armen, PhD

Brendan E. Boushel

Laurence G. Crowley

William F. Daniel

Alan R. Gillespie, C.B.E. PhD

Ann Maynard Gray

John Groom

Kelly Martin

Kieran McGowan

Kevin M. McIntyre, MD

Kyran McLaughlin

Dennis J. Selkoe, MD

The Honorable Richard L. Thornburgh

Daniel P. Tully

SENIOR MANAGEMENT

Kelly Martin(1)
President and chief executive officer

Paul Breen
Executive vice president, global services and operations

Nigel Clerkin
Senior vice president, finance and group controller

Shane Cooke(1)
Executive vice president and chief financial officer

William F. Daniel(1)
Executive vice president and company secretary

Jean Duvall(1)
Executive vice president and general counsel

Lars Ekman, MD, PhD
Executive vice president and president, global R&D and corporate strategy

Arthur Falk, PhD
Executive vice president, corporate compliance

Jack Laflin
Executive vice president, global core services

Ivan Lieberburg, MD, PhD
Executive vice president and chief medical officer

(1) member of executive management committee

--------------------------------------------------------------------------------
196

TRADEMARKS
--------------------------------------------------------------------------------

The following trademarks appearing in this publication are owned by or licensed
to Elan:

o   Antegren (Trade Mark)  (natalizumab)

o Azactam (Trade Mark)  (aztreonam) injectable

o Maxipime (Trade Mark)  (cefepime hydrochloride) injectable

o NanoCrystal (Trade Mark)  technology

o  Prialt (Trade Mark)  (ziconotide) solution

Third party marks appearing in this publication are:

o Abelcet (Trade Mark)  (amphotericin B lipid complex) injectable

o Actiq (Trade Mark)  (oral transmucosal fentany citrate) lozenges

o Adalat (Trade Mark) CC (nifedipine) tablets

o Avinza (Trade Mark)  (morphine sulfate extended-release) capsules

o Ceclor (Trade Mark)  CD (cefaclor extended-release) tablets

o Diastat (Trade Mark)  (diazepam) rectal gel

o Entex (Trade Mark)  (phenylpropanolamine hydrochloride) capsules

o Frova (Trade Mark)  (frovatriptan succinate) tablets

o Furadantin (Trade Mark)  (nitrofurantoin) suspension

o LYONs (Trade Mark)  (Liquid Yield Option Notes)

o MEDIPAD (Trade Mark)  device

o Midrin (Trade Mark)  capsules

o Myambutol (Trade Mark)  (ethambutal hydrochloride) tablets

o Myobloc (Trade Mark) /Neurobloc (botulinum toxin type B) injectable solution

o Myocet (Trade Mark)  (Liposome encapsulated doxorubicin citrate complex)
  injectable

o Mysoline (Trade Mark)  (primidone) tablets

o Naprelan (Trade Mark)  (naproxen sodium controlled-release) tablets

o Nasalide (Trade Mark)  (flunisolide) solution

o Nasarel (Trade Mark)  (flunisolide) solution

o Oramorph (Trade Mark)  SR (morphine sulfate sustained-release) tablets

o Permax (Trade Mark)  (pergolide mesylate)

o Ritalin LA (Trade Mark)  (methylphenidate)

o Roxicodone (Trade Mark)  (oxycodone hydrochloride) tablets

o Skelaxin (Trade Mark)  (metaxalone) tablets

o Sonata (Trade Mark)  (zaleplon) capsules

o Zanaflex (Trade Mark)  (tizanidine hydrochloride) tablets

o Zelapar (Trade Mark)  (selegiline)

o Zonegran (Trade Mark)  (zonisamide) capsules

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     197

SHAREHOLDER SERVICES
--------------------------------------------------------------------------------

Elan's ADSs are listed on the NYSE (Symbol ELN). The Ordinary Shares of the
Company are listed on the Official Lists of the London and Irish Stock
Exchanges.

DEPOSITARY FOR ADSS   REGISTRAR FOR ORDINARY SHARES

Bank of New York      Computershare Services (Ireland) Ltd
101 Barclay Street    Heron House
New York, NY 10011    Sandyford Industrial Estate
Tel: 888-269-2377     Dublin 18
Tel: 610-312-5315     Tel: 353-1-216-3100
Fax: 212-815-3050     Fax: 353-1-216-3151

DUPLICATE MAILINGS

When several shareholders live at the same address, they may receive more
copies of quarterly and annual reports than they need. The excess can be
eliminated by writing to:

INVESTOR RELATIONS

Elan Corporation, plc
Lincoln House
Lincoln Place
Dublin 2, Ireland

INVESTOR RELATIONS

Security analysts and investment professionals should direct their enquiries
to:

Emer Reynolds
Vice President, Investor Relations
Tel: 353-1-709-4080
  00800 28352600
Fax: 353-1-709-4018
Email: emer.reynolds@elan.com

MEDIA RELATIONS

Contact person:
Anita Kawatra
Vice President, Global Media Relations
Tel: 212-407-5740
Fax: 212-755-1043
Email: anita.kawatra@elan.com

INTERNET WEBSITE

Information on Elan is available online via the Internet at Elan's website,
http://www.elan.com. Information on Elan's website does not constitute part of
this Annual Report and Form 20-F.

--------------------------------------------------------------------------------
198

CROSS REFERENCE TO FORM 20-F
--------------------------------------------------------------------------------

This Annual Report is prepared under Irish GAAP. A reconciliation from Irish
GAAP to U.S. GAAP financial results is provided on pages 154 to 178 in
accordance with SEC requirements. Information required by Form 20-F is
cross-referenced to this document below. Only information in this document
actually cross-referenced to Form 20-F shall be deemed to comprise part of the
Form 20-F and filed with the SEC for all purposes.

ITEM                                                                                             PAGES
------------------------------------------------------------------------------------------------------

3 KEY INFORMATION
  A. Selected financial data                                                                  179-180
  D. Risk factors                                                                             186-193

4 INFORMATION ON THE COMPANY
  A.      History and development of the Company                   4, 16-23, 62-63, 116, 129-130, 145
  B.     Business overview                                                            4-30, 55, 96-99
  C.     Organisational structure                                                      4, 70, 149-150
  D.      Property, plants and equipment                                      27-28, 30, 116, 130-131

5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS
  A-D                                                                5-10, 11, 28-29, 31-69, 125-129,
                                                                                     130-131, 145-147

6 DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
  A.     Directors and senior management                                                        74-75
  B.     Compensation                                                    71-73, 75-77, 81-82, 141-144
  C.     Board practices                                                                 74-77, 79-82
  D.     Employees                                                                            30, 114
  E.     Share ownership                                                        71-72, 81-82, 124-125

7 MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
  A.     Major shareholders                                                               76, 181-183
  B.     Related party transactions                                                    76-77, 139-141

8 FINANCIAL INFORMATION
  A.     Consolidated statements and other financial information                           70, 85-180
  B.     Significant changes                                                                      145

9 THE OFFER AND LISTING
  A4.     Price history of stock listed                                                       181-183
  C.     Markets                                                                              181-183

10 ADDITIONAL INFORMATION
  B.     Memorandum and articles of association                                               194-195
  C.     Material contracts                                                                5-8, 16-23
  D.     Exchange controls                                                                        183
  E.     Taxation                                                                             183-185
  H.     Documents on display                                                                     195
  I.     Subsidiary information                                                               149-150

11 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                          67-68, 125-129

13 DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES                                     60-62, 119-122

15 CONTROLS AND PROCEDURES                                                                      79-82

16 RESERVED
  A.     Audit committee financial expert                                                       79-80
  B.     Code of ethics                                                                            79
  C.     Principal accountant fees and services                                            79-80, 109

18 FINANCIAL STATEMENTS                                                                        85-178

--------------------------------------------------------------------------------
ELAN CORPORATION, PLC 2003 ANNUAL REPORT AND FORM 20-F                     199

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]